,id,ticker,title,category,content,date,provider,url,article_id
147041,368557,CI,Cigna teams up with Oscar in small business health insurance,news,"Cigna  NYSE CI  has agreed to exclusively partner with tech driven health insurer Oscar to jointly offer commercial health solutions to small businesses  The effort will branded as  Cigna   Oscar  
Features 
Integrated medical  behavioral  and pharmacy services 
Broad access to high performing networks of doctors and hospitals 
Support from a dedicated concierge team assigned to individual members to help them understand their benefits and find care 
Digital first support  featuring 24 7 telemedicine at no charge  easy ID card access  an overview of copay details and benefits  deductible tracking  lab results and individual health history 
Easy to use search tools to help review health care providers  book appointments  find facilities and check prescriptions 
Leading broker  business and provider portals for seamless enrollment and management 
The companies will equally share risk under a reinsurance agreement  Limited launch should commence this year ",2020-01-13,Seeking Alpha,https://invst.ly/phjd8,2058415
147043,368559,CI,Loneliness is on the rise and younger workers and social media users feel it most  Cigna survey finds,news,Three out of every five adults  or 61   report that they sometimes or always feel lonely   according to the Cigna U S  Loneliness Index Among workers aged 18 22   73  report sometimes or always feeling alone  up from 69  a year ago There is a greater feeling of loneliness among people who use social media more frequently  the study found At work  men appear to feel much more isolated than women ,2020-01-23,CNBC,https://invst.ly/plub3,2065836
147044,368560,CI,Top 5 Things to Know in the Market on Thursday  6th February,news,"By Geoffrey Smith 
Investing com    China said it will cut tariffs on some U S  imports  sparking further gains in global stocks  The spread of the coronavirus appears to be slowing  according to the latest data on deaths and new infections  Oil markets reacted cautiously to reports that OPEC and its allies may cut another 600 000 barrels a day to bring the world oil market back into balance  Christine Lagarde warned the European parliament that the ECB is running out of road for further policy stimulus  And of course there s a whole load more corporate earnings coming down the track later  Here s what you need to know in financial markets on Thursday  6th February 
1  China cuts tariffs on U S  imports
China said it will cut tariffs on an annual  75 billion worth of U S  imports from Friday  reciprocating the partial roll back in U S  tariffs on Chinese goods that the two sides agreed last month 
Although the step was as expected and hardly moved the price of commodities that were affected such as soybeans and oil  it cements the recent truce between the two and supports hopes that the biggest drag on the global economy will fade this year 
The news overshadowed hints elsewhere from the Chinese press that the government may seek to use the coronavirus outbreak as an excuse not to buy the full volume of U S  goods it agreed to in January 
Elsewhere  China s biggest buyer of gas CNOOC reportedly declared force majeure on contracts to import liquefied natural gas  a reflection of the collapse in industrial demand following the extended shutdown of Chinese factories due to the outbreak 
2  Global markets extend risk rally  mostly
The headlines on the tariff cuts were still all that was needed to justify another move up in global stock markets overnight  Major Chinese stock indices rose by between 1 4  and 2 8   while the Euro Stoxx 600 hit a new all time high before retracing its gains 
However  commodities and emerging market currencies were less impressed   Crude futures gave up early gains after reports that China is also looking to cut purchases of Saudi Arabian oil due to the coronavirus impact on local demand  amidst reports that refineries have slashed throughput 
Copper futures also could only drift sideways  while there were better bids for haven metals Gold and Silver than for industrial ones such as Aluminum and Nickel 
The virus itself continues to spread  although both the incidence of new cases and the death toll are rising more slowly than at any time so far during the outbreak   The trend rate of increase is slowing   said Ian Shepherdson  chief economist at Pantheon Economics in London 
3  OPEC  officials reportedly recommend further oil output cuts
The world s biggest oil exporters look set to cut their production even more deeply in order to restore balance to an oversupplied global market suffering from the impact of the coronavirus 
Newswire reports suggested that the technical experts from the Organization of Petroleum Exporting Countries and allies including Russia would recommend additional supply cuts of 600 000 barrels a day  That compares with an estimate from   BP    LON BP  earlier this week that the virus could hit destroy an average of 400 000 b d over the whole year 
However  it wasn t clear whether Russia s government would support the action  Russia has argued that U S  shale producers should take more of the strain in balancing the market  having ramped up their output considerably at the cartel s expense last year  
Crude markets reacted cautiously  U S  crude futures were up 0 9  at  51 88 a barrel  while Brent was up 0 2  at  55 38  but both blends were off intra day highs posted earlier 
4  Stocks set to open higher  Qualcomm  NASDAQ QCOM  disappoints  Philip Morris  NYSE PM   Uber  NYSE UBER  earnings due
U S  stock markets are set to open modestly higher after another big jump on Wednesday  helped by the continuation of the rally in overseas markets 
By 6 30 AM ET  1130 GMT   Dow 30 futures were up 112 points  or 0 4   with the Nasdaq 100 futures contract rising in parallel and the S P 500 contract lagging only slightly  up 0 3 
After the bell on Wednesday  chipmaker Qualcomm  NASDAQ QCOM  had lowered its guidance range the year through September  citing the potential impact of the coronavirus  Yum China Holdings  NYSE YUMC  had also said it had temporarily closed over 30  of its 9 000 outlets due to the outbreak 
The day s earnings roster is led by Philip Morris  NYSE PM  and Bristol Myers Squibb  NYSE BMY   with updates also due from Cigna  NYSE CI   S P Global   NYSE SPGI     Estee Lauder    NYSE EL  and T Mobile US  Uber and Wynn Resorts report after the closing bell 
5  Lagarde warns on further easing scope  German orders fall
European Central Bank President Christine Lagarde told the EU parliament that the current environment of low interest rates has left the bank with  reduced scope  to provide further support to the economy with monetary policy 
Her words mark a change in emphasis from predecessor Mario Draghi  who never failed to talk up the possibility of further easing  even as outside analysts cast doubt on the diminishing returns of its extraordinary stimulus measures 
Lagarde s comments came after a surprising 2 1  drop in German factory orders in December  leaving them down over 8  on the year and suggesting that the manufacturing slump in the euro zone s largest economy still hasn t run its course  The euro stayed stuck at  1 1000 ",2020-02-06,Investing.com,https://www.investing.com/news/economy/top-5-things-to-know-in-the-market-on-thursday-6th-february-2077730,2077730
147045,368561,CI,Stocks making the biggest moves in the premarket  Twitter  Cigna  Dunkin  Brands  Tapestry   more,news,Twitter  TWTR    Twitter earned an adjusted 25 cents per share for the fourth quarter  4 cents a share below estimates  Revenue came in above forecasts  however  and monetizable active daily users jumped 21  from a year ago to a record Cigna  CI    The insurance company reported quarterly profit of  4 31 per share  11 cents a share above estimates  Revenue also exceeded analysts  projections  helped by growth in its pharmacy benefits unit as well as expense controls Dunkin  Brands  DNKN    The company s fourth quarter earnings came in at 73 cents per share  3 cents a share above estimates  Revenue was below forecasts  however  as is its full year adjusted earnings forecast of  3 16 to  3 21 per share  The restaurant operator also announced a 7  dividend increase to 40 25 cents per share Estee Lauder  EL    The cosmetics company beat estimates by 21 cents a share  with quarterly earnings of 2 11 per share  Revenue also beat Wall Street forecasts  Estee Lauder said it will see a negative impact from the coronavirus  most especially in tourist destination markets and localities most impacted by the outbreak Bristol Myers Squibb  BMY    The drugmaker earned  1 22 per share for the fourth quarter  Revenue came in well above consensus  helped by the acquisition of Celgene  The deal closed in November Tapestry  TPR    The fashion accessories company earned an adjusted  1 10 per share for its fiscal second quarter  11 cents a share above estimates  Revenue also came in above forecasts  Tapestry warned of a potential sales and earnings impact from the coronavirus outbreak  Separately  Tapestry named new leaders for its Kate Spade and Stuart Weitzman brands Becton Dickinson  BDX    The maker of medical products beat estimates on the top and bottom lines  but the stock is under pressure on lower than expected earnings guidance  The forecast reflects an anticipated loss of sales for its Alaris infusion system  which was the subject of a recall last July on concerns that the system might deliver medication faster than expected or unintentionally  Becton Dickinson is continuing to work with the Food and Drug Administration to address concerns and said it stands behind the safety of the system Cardinal Health  CAH    The drug distributor beat consensus by 30 cents a share  with adjusted quarterly earnings of  1 52 per share  Revenue also came in above estimates and Cardinal Health raised its full year earnings forecast amid strength across its pharmaceutical segment Yum Brands  YUM    The parent of KFC  Taco Bell  and Pizza Hut missed estimates by 13 cents a share  with quarterly earnings of  1 00 per share  Revenue came in above forecasts  Same store sales growth was slightly short of consensus  hurt by the performance of Pizza Hut Yum China  YUMC    Yum China reported quarterly earnings of 25 cents per share  6 cents a share above estimates  The restaurant operator s revenue matched forecasts  however the company warned of a significant hit to sales due to the coronavirus outbreak GrubHub  GRUB    GrubHub lost 5 cents per share for its latest quarter  a penny a share more than analysts had been expecting  The food delivery service s revenue came in above estimates  GrubHub is spending more to recruit new customers  a strategy it said is paying off Peloton  PTON    Peloton reported a quarterly loss of 20 cents per share  smaller than the consensus estimate of a 36 cents a share loss  The exercise bike maker s revenue also beat forecasts  but the company gave a smaller than expected current quarter sales outlook Qualcomm  QCOM    Qualcomm beat estimates by 14 cents a share  with quarterly profit of 99 cents per share  with the chipmaker s revenue also above analyst forecasts  Qualcomm did say that the coronavirus outbreak could impact manufacturing and sales for the entire mobile phone industry  Qualcomm is the world s biggest supplier of chips that connect devices to wireless data networks Fox Corp   FOXA    Fox reported a quarterly profit of 10 cents per share  compared to a consensus estimate of a 2 cents per share loss  The media company s revenue also came in above forecasts  thanks in large part to a surge in ad sales Toyota Motor  TM    Toyota raised its annual profit forecast by 4 2   helped by better than expected vehicle sales and favorable currency rates  The automaker warned  however  it had not yet factored in any potential impact from the coronavirus outbreak Casper Sleep  CSPR    Casper priced its initial public offering at  12 per share  at the bottom end of the already slashed range of  12 to  13 per share  The mattress retailer s shares will begin trading today on the New York Stock Exchange PPD  PPD    PPD priced its initial public offering at  27 per share  at the top of the expected range of  24  27 per share  The drug research firm s offering is the biggest of 2020 so far  and its shares will begin trading today on the Nasdaq ,2020-02-06,CNBC,https://invst.ly/prywq,2077867
147046,368562,CI,Cigna  3  on Q4 beat,news,"Cigna  CI  3   Q4 results  Revenues   36 538M   165 7    Health Services   25 570M   671 8    Integrated Medical   9 208M   11 0   
Net Income   977M   EPS   2 60  non GAAP Net Income   1 620M   150 4    non GAAP EPS   4 31   75 2   
CF Ops   9 5B 
2020 guidance   154B   156B vs   148 35B S P Capital IQ Consensus  non GAAP net income   6 8B   7 0B  non GAAP EPS   18 00   18 60 vs   18 60 S P Capital IQ Consensus 
Previously  Cigna EPS beats by  0 11  beats on revenue  Feb  6 ",2020-02-06,Seeking Alpha,https://invst.ly/pr-gn,2077993
147049,368565,CI,Cigna s Express Scripts Acquisition Continues to Pay Off With Its Q4 Earnings Beat,news,"Cigna Corporation  NYSE CI  took investors on a wild ride in 2019  The stock plunged more than 20   only to make a big comeback toward the end of the year  Cigna ultimately delivered a gain of nearly 8  and entered 2020 with strong momentum 
That momentum was put to the test when the global health service company announced its 2019 fourth quarter and full year results before the market opened on Thursday  But it looks as if Cigna passed that test  Here are the highlights from the company s Q4 update 

By the numbers
Cigna announced Q4 revenue of  38 2 billion  a huge 167  increase from the  14 3 billion reported in the same quarter of the previous year  This result easily beat the average analysts  revenue estimate of  35 1 billion 
The company reported net income in the fourth quarter of  977 million  or  2 60 per share  based on generally accepted accounting principles  GAAP   This reflected significant improvement from Cigna s net income of  144 million  or  0 55 per share  generated in the prior year period 
Cigna s adjusted non GAAP bottom line also looked good in the fourth quarter  The company announced Q4 adjusted earnings per share of  4 31  up 75  year over year  The consensus Wall Street estimate was for Cigna to post adjusted EPS of  4 20 
Behind the numbers
There was a simple explanation behind Cigna s tremendous year over year growth  The company acquired pharmacy benefits manager Express Scripts on Dec  20  2018  
Express Scripts is now part of Cigna s health services segment  This segment generated adjusted revenue of  25 6 billion in Q4  Health services made  3 3 billion in revenue in the prior year period 
Cigna s integrated medical segment includes the company s U S  commercial and government insurance products  The integrated medical segment delivered adjusted revenue of  9 2 billion in the fourth quarter  up 11  year over year  This growth stemmed primarily from adding new commercial customers and premium increases 
The company s international markets segment sells supplemental health  life  and accident insurance in countries outside the U S  and provides healthcare benefits for employees of multinational organizations and individuals who travel extensively to other countries  Cigna reported that the international markets segment had adjusted revenue of  1 43 billion in Q4  an increase of 5 5  year over year 
Cigna also sells group long term and short term disability products along with group life  accident  voluntary  and specialty insurance products in its group disability and other operations segment  Adjusted revenue for this segment in the fourth quarter rose nearly 4  year over year to  1 29 billion 
Looking ahead
The company projects adjusted revenues of between  154 billion and  156 billion for full year 2020  Cigna expects that adjusted income from operations for 2020 will be between  6 8 billion and  7 billion  On a per share basis  adjusted earnings for full year 2020 are expected to be between  18 00 and  18 60  
Cigna CEO David Cordani said   Our strong momentum going into 2020 positions us for continued growth  and to deliver sustained value for our customers and clients  as we create greater affordability  predictability and simplicity for their benefit   
There are some factors that could slow Cigna s momentum down this year  The U S  presidential campaign negatively affected some healthcare stocks in 2016 and could do so again in 2020  A nasty flu season and the potential for a wider outbreak of the coronavirus could also drive medical costs higher  eating into Cigna s profits ",2020-02-06,The Motley Fool,https://invst.ly/ps3i4,2078338
147055,368571,CI,Cigna Corp  CI  Q4 2019 Earnings Call Transcript,news,"Cigna Corp  NYSE CI Q4 2019 Earnings CallFeb 6  2020  8 30 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning  Ladies and gentlemen  thank you for standing by for Cigna s Fourth Quarter 2019 Results Review   Operator Instructions  We ll begin by turning the conference over to Mr  Will McDowell  Please go ahead  Mr  McDowell William McDowell    Vice President of Investor RelationsGood morning  everyone  and thank you for joining today s call  I am will McDowell  Vice President of Investor Relations  With me this morning are David Cordani  our President and Chief Executive Officer  and Eric Palmer  Cigna s Chief Financial Officer  In our remarks today  David and Eric will cover a number of topics  including Cigna s full year 2019 interim results as well as our financial outlook for 2020  As noted in the earnings release  when describing our financial results  Cigna uses certain financial measures  adjusted income from operations and adjusted revenues  which are not determined in accordance with accounting principles generally accepted in the United States  otherwise known as GAAP A reconciliation of these measures to the most directly comparable GAAP measures  shareholders net income and total revenues  respectively  is contained in today s earnings release  which is posted in the Investor Relations section of cigna com  We use the term labeled adjusted income from operations and earnings per share on the same basis as our principal measures of financial performance  And our remarks today  we will be making some forward looking statements  including statements regarding our outlook for 2020 and future performance  These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectation  A description of these risks and uncertainties is contained in the cautionary note to today s earnings release and in our most recent reports filed with the SEC Before turning the call over to David  I will cover a few items pertaining to our financial results and disclosures  Regarding our results  in the fourth quarter  we recorded an after tax special item charge of  116 million or  0 31 per share for integration and transaction related costs  We also recorded a special item charge of  162 million or  0 43 per share for severance costs associated with a series of actions we are taking to improve our organizational efficiency  As described in today s earnings release  special items are excluded from adjusted income from operations in our discussion of financial results  Please note that consistent with past practice  when we make prospective comments regarding financial performance including our full year 2020 outlook  we will do so on a basis that excludes the impact of any future share repurchases or prior year development of medical costs Additionally  our outlook for 2020 assumes a full year of earnings from Cigna s Group Disability and Life business  We continue to expect our divestiture of that business to be completed by the third quarter of 2020  I will remind you that  as previously disclosed  beginning in 2020  we will no longer exclude contributions from transitioning clients from our performance measures as the transition for those clients was substantially complete as of December 31  2019  And finally  I would note that this morning  we posted an investor presentation to the Investor Relations section of cigna com that outlines our strategy and track record  the strength of our four growth platforms  2020 operating and capital guidance and details of our longer term outlook  We hope that you will find this a helpful resource With that  I will turn the call over to David David Cordani    President and Chief Executive OfficerThanks  Will  and good morning  everyone  Thank you for joining our call today  In 2019  we delivered consolidated adjusted revenue of  140 billion and grew earnings per share by 20  to  17 05  As a result  we exceeded the guidance that we had already raised each quarter during 2019 for revenue  earnings and EPS as well as cash flow from operations  Today  I ll comment on how we delivered these exceptionally strong results and on the contributions made by each of our four growth platforms  led by Health Services and Integrated Medical segments  I ll also discuss how we are positioned to drive attractive growth in 2020 and achieve our 2021 EPS target of  20 to  21 per share  Finally  I ll highlight a key point of differentiation and a driver of future growth  our focus on being the undisputed partner of choice in healthcare Following my comments  Eric will share more details about our full year 2019 financial results and 2020 outlook  and then we ll take your questions  Let s dive in  At our Investor Day last year  we committed to building on our decade long track record of delivering industry leading cost trends  consistent growth and effective capital stewardship  In 2019  we delivered on each of these commitments  By remaining focused on our customers and patients  we executed well across each of our businesses  deepened our customer relationships and achieved our integration priorities  Together  this fueled our outstanding performance  In Health Services  we delivered market leading customer client retention  including 97  retention for the 2020 selling season and continued strong organic growth in prescriptions  In Commercial  we again delivered industry leading medical cost trend and grew our Commercial medical customers for the tenth consecutive year led by another year of double digit growth in the Select segment  And in our Government business  CMS  most recent Star s ratings position us to have 87  of our Medicare Advantage customers in four star or higher plans for 2021  a reinforcement of our strong customer satisfaction and high levels of clinical quality Additionally  we made significant progress in advancing our five key integration priorities  First and foremost  we kept our promises in the marketplace by ensuring our more than 107 million customer relationships around the world experience ongoing high service quality throughout the year  Second  we delivered medical and pharmacy cost savings for the benefit of our customers and clients  effectively completing their transition to industry leading pharmacy solutions  including Accredo s Specialty Pharmacy and Express Scripts customer friendly home delivery pharmacy  Additionally  more than 95  of our customers have access to SafeGuardRx  an innovative suite of value based programs that improve care and value for customers with challenging medical conditions  Third was our focus on talent  As a health service company  our talent and their engagement is key to our performance and ongoing growth  Our retention and engagement levels today one year into our combination are above our already strong pretransaction levels  Fourth  we made significant progress toward securing base operating expense synergies  The organizational efficiency plan we announced earlier today is another important step toward achieving these targets And finally  we kept our vision top of mind by accelerating marketplace innovations that improve affordability  predictability and simplicity  including our Embarc Benefit Protection program which improves customer access to life changing gene therapies while shielding clients from the price shock of multimillion dollar treatments  our digital health formulary to better carry and generate value from the 300 000 digital health apps in the marketplace today  and our Patient Assurance Program  with insulin dependent patients with diabetes pay a maximum of  25 for a 30 day supply of insulin  As a result of this program  our customers are already realizing significant out of pocket savings  Overall  2019 was an exceptionally strong year for Cigna and gives us considerable momentum for ongoing attractive growth in 2020 and beyond  Our achievements were and continue to be driven by the focus  commitment and passion of our employees who wake up every day to fulfill our mission to improve the health  well being and peace of mind of those we serve  In 2020  we will continue to drive significant growth in customer relationships  revenue  earnings and EPS as well as strong cash flows  In Health Services  we expect adjusted script growth in a range of 20  to 23  over our year end 2019 levels In Integrated Medical  we are on track for continued medical customer growth  highlighted by our Government business  where we expect 13  to 16  customer growth in Medicare Advantage  and we remain positioned for very attractive growth over the next five years  Additionally  after a very successful first year as a combined company  we remain on track to complete our integration activities over the next year  We also expect to close the sale of our Group Disability and Life business to New York Life by the third quarter this year  and we are on track to return our balance sheet to normalized levels of debt by year end 2020  In short  we are on pace to meet the commitments we made when we announced the combination nearly two years ago and meet the commitments we made at our Investor Day in May of 2019  Looking forward  a key point of differentiation and growth driver for Cigna in 2020 and beyond is our orientation toward partnering in order to achieve accelerated innovation  improved affordability  predictability and simplicity and to further expand our distribution reach  Several recent examples demonstrate our proven differentiation  First is our new arrangement with Prime Therapeutics Starting in April 2020  together  we will make pharmacy care more affordable  by enhancing pharmacy networks and pharmaceutical manufacturer value for Prime s 28 million members who are covered by 23 health plans  including employer programs  Medicare and Medicaid  Together  Express Scripts and Prime will help each other to continue to grow in the market across the country by innovating new solutions to improve affordability  increase access to medicine and further improve individual health  This agreement shows our ability to work across healthcare and partner with those who seek to deliver innovative high quality health services and solutions to employers  health plans and governmental agencies for the benefit of customers and patients  A second example of our partnership orientation is our work with emerging and highly innovative companies  A great recent example of this is our partnership with Oscar Health  With Oscar  we will deliver new innovative solutions for small businesses  which all too often are left with limited options that are highly priced  We will offer small businesses access to affordable  fully insured health plans that brought in choice and prioritize whole person health We will focus in four geographies with Oscar later this year and we ll take our proven test and learn framework to accelerate growth over time  A third example is our trusted relationships with healthcare professionals  We have a long history of innovative value based arrangements with healthcare professionals in both our U S  Commercial and Government businesses  including more than 650 collaborative accountable care relationships  Today  more than 65  of Cigna s medical payments are in value based arrangements across our top 40 commercial markets and all our Medicare markets  Importantly  92  of healthcare providers in our programs are delivering differentiated levels of quality and 90  of care providers believe Cigna is the industry leader in this area  These deep partnerships drive our growth  particularly in Medicare Advantage  where we focus on geographies where our commercial business already has aligned high performing collaborative accountable care relationships in place Approximately 25  of medical eligible seniors live in geographies where our Commercial business has deep ties and delivery systems but where we have no Medicare Advantage presence today  That provides a meaningful growth opportunity for our Medicare Advantage business that we have begun to capitalize in 2020 by accelerating our geographic expansion and bringing new PPO solutions to market  This  combined with the fact that 87  of our Medicare Advantage customers are in four star or greater plans in 2021  and our high customer NPS levels which approximate 70 across all of our markets  make us excited about our future customer growth  which we project to be in the range of 10  to 15  on an annualized basis over the next five years Each of these examples gives a clear view of how diverse healthcare stakeholders view Cigna as their best partner for future success and how being the partner of choice in the healthcare marketplace will contribute to our sustained  differentiated growth over time  Now briefly to summarize  At Cigna  we delivered exceptional full year 2019 financial results across our four growth platforms  led by Health Services and our Integrated Medical segments  These results drove strong financial performance in 2019 and provide us with considerable momentum as we step into 2020 with outstanding strategic and financial flexibility  and we remain on track to deliver our EPS goal of  20 to  21 per share in 2021 With that  I ll turn the call over to Eric Eric Palmer    Executive Vice President and Chief Financial OfficerThanks  David  Good morning  everyone  In my remarks today  I will review Cigna s 2019 results and provide our outlook for 2020  Key consolidated financial highlights for 2019 include  adjusted revenue of  140 billion  earnings of  6 5 billion after tax  earnings per share growth of 20  to  17 05  and operating cash flows that more than doubled this year to  9 5 billion  These results reflect strong  consistent execution across our businesses throughout 2019  Regarding our segments  I ll first comment on Health Services  Full year 2019 revenues were  96 4 billion and pre tax earnings were  5 1 billion  Results for 2019 reflect organic growth with outstanding client retention and the addition of 2 7 million pharmacy customers  strong volumes with 1 22 billion adjusted pharmacy scripts fulfilled and growth in Specialty Pharmacy  Overall  Health Services performed well in 2019 with results in line with our expectations and reflecting significant progress across our integration activities Turning to Integrated Medical  2019 revenues grew 11  to  36 5 billion driven by commercial customer growth and expansion of specialty relationships  premium growth  reflecting underlying cost trends  and the inclusion of the Express Scripts Medicare Part D business  We organically grew our global medical customer base to 17 1 million lives  In 2019  we once again delivered double digit organic customer growth in our Select segment with continued enrollment gains in middle market  Full year earnings grew 9  to  3 8 billion  reflecting growth in medical customers and specialty relationships  strong operating expense discipline and continued effective medical cost management  Turning to medical costs  For our total U S  commercial book of business  full year medical cost trend for 2019 was approximately 4   which marks the seventh consecutive year Cigna has delivered an industry leading result  Our full year 2019 total medical care ratio or MCR was 80 8   finishing the year at the low end of our guidance range  Our MCR performance reflects stable trends and focused execution of affordability initiatives across our Commercial and Government businesses and the pricing effect of the health insurance tax suspension Full year 2019 Integrated Medical earnings benefited from  85 million pre tax of favorable net prior year reserve development  For all  Cigna s Integrated Medical segment delivered strong financial results in 2019  In our International Markets business  revenues grew to  5 6 billion  an increase of 8  on a currency adjusted basis  and full year 2019 pre tax earnings grew to  762 million  reflecting continued business growth partially offset by unfavorable foreign currency impacts  For our Group Disability and Other Operations segment  full year 2019 revenues were  5 2 billion  Full year pre tax earnings for this segment were  501 million with strong performance in Life and continued administrative efficiencies partially offset by higher disability claims  For our Corporate segment  the full year 2019 loss was  1 8 billion primarily driven by  1 7 billion of interest costs  As Will mentioned  during fourth quarter  we reported a special item charge of  162 million after tax for severance costs related to our organizational efficiency plan  Under this plan  we will implement efficiency initiatives that we identified primarily through our integration work These actions reflect our commitment to providing affordable quality solutions to the marketplace and the savings associated with this plan are included within the multi year administrative expense synergy targets that we ve previously communicated  Overall  Cigna s 2019 results reflect focused execution across each of our businesses  Before discussing our outlook for continued attractive growth this year  I would remind you of the 2019 earnings per share baseline adjustment that we quantified on our third quarter earnings call  Specifically  Cigna s earnings per share performance in 2019 should be adjusted for the following three items  first   0 12 per share for the tax item we favorably settled in the second quarter of 2019  second   0 18 per share of favorable net prior year reserve development  and finally   0 25 per share associated with the industry tax  which was suspended for 2019 but returns in 2020 for a final year  This impact is increased to reflect the incremental timing effect of the recent repeal of the industry tax  When adjusting for these impacts  Cigna s 2019 earnings per share baseline was  16 50 Turning to our outlook  We have entered 2020 well positioned to drive both continued growth and innovation  We also expect to complete our integration activity associated with Express Scripts combination over the next year  For full year 2020  we expect consolidated adjusted revenues in the range of  154 million to  156 billion  representing growth of 10  to 11   We expect full year 2020 consolidated adjusted income from operations to be  6 8 billion to  7 billion or  18 to  18 60 per share  This represents growth in the range of 9  to 13  over our 2019 baseline  We expect the cadence of earnings per share in 2020 to be approximately 47  in the first half and 53  in the second half of the year  taking into consideration seasonality patterns within our businesses  For 2020  we project an expense ratio in the range of 8 6  to 9 1  and the consolidated adjusted tax rate in the range of 23  to 24   Additionally  our outlook excludes any contribution from future share repurchases and prior year reserve development and assumes a full year of contributions from our Group Disability and Life business  And as previously communicated  in 2020  we will no longer report transitioning client contributions since those transitions were substantially complete as of December 31  2019  I will now discuss our 2020 outlook for our segments For our Health Services business  we expect full year 2020 earnings in the range of  5 3 billion to  5 45 billion  This represents year over year growth in the range of 4  to 7   In Health Services  we expect first quarter 2020 earnings to grow by a mid single digit percentage over first quarter 2019  This outlook reflects solid underlying growth and the benefits of increased year over year administrative expense synergies  I would also note that we expect our first quarter 2020 Health Services SG A expense ratio to be higher than first quarter 2019  reflecting impacts of the client transitions we ve discussed previously and including start up costs associated with our collaboration with Prime Therapeutics  For 2020  we expect adjusted pharmacy scripts in the range of 1 47 billion to 1 50 billion claims  This reflects the impact of completing the insourcing of Cigna pharmacy services  growth associated with the first year of the Prime collaboration and additional organic growth of 25 million to 35 million adjusted pharmacy scripts All in  this represents year over year growth of 20  to 23   For Integrated Medical  we expect full year 2020 earnings in the range of  4 billion to  4 1 billion  which represents growth of 11  to 13  over the 2019 baseline  This outlook reflects strength and growth in our businesses driven by continued benefits from organic customer growth  deepening of customer relationships and effective medical cost management  This outlook also included the benefit of administrative expense synergies  Key assumptions reflected in our Integrated Medical earnings outlook for 2020 include the following  Regarding global medical customers  we expect 2020 growth in the range of 150 000 to 250 000 customers driven by continued organic growth in our Commercial business  led by the Select and Middle Market segments  partially offset by lower National Accounts enrollment  We also expect Medicare Advantage customer growth of 13  to 16   Our growth outlook also includes an expectation of lower enrollment in our U S  individual business and the expected loss of our Texas Medicaid contracts  collectively resulting in a reduction of approximately 90 000 customers Turning to medical costs  For our U S  Commercial Employer book of business  we expect full year 2020 medical cost trend to be in the range of 3 5  to 4 5   We expect the 2020 medical care ratio to be in the range of 80 2  to 81 2   reflecting the return of the health insurance tax in 2020 and continued strong performance of our Commercial and Government businesses offset by the mix impact of new Medicare Advantage lives and normalized margins in our U S  individual business  We also expect strong contributions from our International Markets  Group Disability and Other businesses as they continue to deliver solutions that enhance affordability and predictability and provide a more simplified experience for those we serve  Regarding interest expense  we expect costs of approximately  1 6 billion pre tax in 2020  So all in  for full year 2020  we expect consolidated adjusted income from operations of  6 8 billion to  7 billion or  18 to  18 60 per share  I would also remind you that our outlook excludes the impact of future share repurchases and prior year reserve development and assumes a full year of contributions from our Group Disability and Life business Overall  these expected results represent a very attractive outlook  aided by the strong performance across our differentiated portfolio of businesses  These expected results also position us well to achieve our 2021 earnings per share target of  20 to  21 per share  Now moving to our capital management position and outlook  Our subsidiaries remain well capitalized  and we expect them to continue to drive exceptional cash flow with strong returns on capital even as we continue reinvesting to support long term growth and innovation  In 2019  we deployed  5 2 billion to repay debt  and we repurchased 11 8 million shares of stock for  2 billion  We ended 2019 with a debt to capitalization ratio of 45 2   an improvement of 570 basis points over year end 2018  For 2020  we expect greater than  7 5 billion of cash flow from operations  reflecting the strong capital efficiency of our well performing businesses  As previously discussed  we have a near term focus on accelerated debt repayment and remain on track to return our debt to capitalization ratio to the upper 30s by the end of 2020 In 2020  we expect to deploy  4 5 billion to  5 billion to debt repayment and  1 billion to capital expenditures  As a reminder  our capital priorities remain as follows  reinvestment back into our businesses to drive further innovation and growth  strategic M A on a targeted basis  and returning capital to shareholders  which historically we have done primarily through share repurchase  Year to date  as of February 5  2020  we have repurchased 1 2 million shares for  245 million and we have  3 72 billion of remaining share repurchase authorization  Our balance sheet and cash flow outlook remains strong  benefiting from our highly efficient service based orientation that drives strategic flexibility  strong margins and attractive returns on capital  Now to recap  our full year 2019 consolidated results reflect the considerable strength and momentum across our four growth platforms and continued effective execution of our focused strategy  We are confident in our ability to deliver our full year 2020 earnings outlook  and we remain on track to achieve our  20 to  21 of earnings per share target for 2021  Further  our clear strategic focus  differentiated value proposition across our businesses and outstanding financial flexibility give us continued confidence in our long term targets for growth in revenue  earnings and EPS And with that  I ll turn it over to the operator for the Q A portion of the call OperatorThank you   Operator Instructions  Our first question is from Justin Lake with Wolfe Research  Mr  Lake  your line is open Justin Lake    AnalystThanks  Good morning  Wanted to ask a quick numbers question and then a little bit about the capital deployment  So first  just in terms of the Group Disability sale on numbers  I know you have it in there  Just want to understand how you deploy capital that you receive to keep this earnings neutral for 2020  Wouldn t the company have to begin buying back stock early or do an ASR given the earnings will go away at a moment in time and yet the share capital deployment might take time Eric Palmer    Executive Vice President and Chief Financial OfficerJustin  it s Eric  Thanks for the question on that  So just to step back  So for the Group Disability and Life transaction  as we noted  in December  we entered into that agreement  We expect  5 3 billion of after tax proceeds  and we re on track for that to close in the third quarter  So again  the  5 3 billion  first  will be incremental to our operating cash flow for the year  We ve got flexibility in terms of the timing of how we deploy things that    how we deploy the capital for the year  Our primary focus is on achieving our debt to capitalization ratio of below 40  by the end of the year and we ve got flexibility beyond that and throughout the year to begin to do share repurchase and such  We haven t provided any specific guidance in terms of the exact timing of the share repurchase  but we do have flexibility to get started on that even at the end of the close Justin Lake    AnalystOkay  But will it be earnings neutral to the year  the combination of using the disability and the capital deployment Eric Palmer    Executive Vice President and Chief Financial OfficerThat s our expectation  and that s the guidance that we provided back when we announced the transaction Justin Lake    AnalystOkay  And then if I could just ask a question about the Prime relationship  Congratulations on that  obviously  I wanted to understand two things  One  in terms of the relationship itself  it s somewhat narrow in focus  but it sounds like it could expand over time  How do you kind of look at the risk versus opportunity  the risk being that some of your existing Express Scripts customers  where you have a much broader relationship  move to Prime and  therefore  could be somewhat dilutive versus the opportunities to work with these blues and potentially expand that partnership and kind of offset some of that risk David Cordani    President and Chief Executive OfficerJustin  good morning  It s David  First and foremost  let me just really underscore how pleased we are to have entered that relationship  the validation of our deep commitment to servicing health plans  partnering with health plans and growing those relationships  Two  your ability to retain any relationship  be it commercial  health and otherwise  is based on a couple of basic tenets  a  are you able to drive partnership and alignment  b  deliver differentiated value  c  innovate together  We re committed to doing so  And actually  we view the opposite of the maybe risk that you identified  this further broadens our reach and our opportunity to serve more lives  both individual customers and patients and a broader portfolio of health plans as we go forward  So we re delighted by securing this  and we look forward to beginning to serve that relationship in the second quarter of this year Justin Lake    AnalystThanks for the call OperatorThank you for the question  Our next question is from Kevin Fischbeck with Bank of America  Your line is open  sir Kevin Fischbeck    AnalystOkay  great  Thanks  Actually  this is a quick numbers question first  too  It sounds like you re saying that the guidance basically is similar to what you were saying with Q3  but you ve got another  0 05 drag from HIF being removed in 2021  Do I just have that right that  that s the main change versus Q3 initial outlook Eric Palmer    Executive Vice President and Chief Financial OfficerKevin  it s Eric  Really two small things to think about there  the HIF incremental drag of a few cents that you noted  and we have the benefit of a  0 02 pickup because of the lower share count as we completed repurchase from the time period  So those are the two differences Kevin Fischbeck    AnalystOkay  And then a question being  I think that when you guys provided initial membership guidance at the beginning of this year  that was kind of a little bit disappointing  And I guess  it s clear now that some of it s individuals  some of it s Medicaid  But you  in your presentation  have long term commercial top line growth of 8  to 10   which is a higher number than I think most people think about as far as commercial growth  How much of that is able to be driven by just growth in the Select and Middle Market accounts  Or do you need to be starting to grow National Accounts and Individual to kind of achieve that over the long term  And how do you    if so  how do you turn that around Eric Palmer    Executive Vice President and Chief Financial OfficerKevin  it s Eric  I ll start on that  First of all  those targets are very consistent with the results we ve driven in the commercial markets for a number of years now  And I think of the growth in that    the frames that we target in that business is being driven by really three things  The first category would be around continued customer growth as we continue to grow in the Select and Middle Market segments  We ve got a lot of opportunity to continue to grow in those segments  The next one  I would say  would be on deepening our existing client relationships and so as we work to identify new solutions and deepen our existing solutions in terms of new product sales and  again  for other programs and services  And then the third category to think about would be around working to innovate and to deliver new solutions more broadly  But again  that s the recipe that we ve used for a number of years now  and we see a lot of opportunity to continue on that track in the commercial market Kevin Fischbeck    AnalystAnd you don t need National Accounts growth per se  Or is that part of the growth pipeline David Cordani    President and Chief Executive OfficerKevin  it s David  When you think about National Accounts  put it back in context  we define that segment to remind you much more narrow than maybe the market in total  So for Integrated Medical  it s commercial employers  5 000 or more employees that are multi state  Based on that definition and our strategy  we view that marketplace as a flat to somewhat shrinking marketplace based on our strategy within Integrated Medical  Now Eric s point two and point three reinforce how we continue to actually grow and deepen relationships with National Accounts  Even today  we re able to successfully do that  And then lastly  what we re quite excited about is adding to that  more broadly  off of our Health Services platform the ability to offer broader coordinated services  So we continue to see deepening of relationships and broadening relationships within National Accounts even with the medical membership performance that you re making reference to  And over time  we see the ability to even further accelerate that by leveraging our Health Services portfolio  So that will be a net contributor as well OperatorThank you for your question   Operator Instructions  Our next question comes from Dave Windley with Jefferies  Your line is open  sir Mr  Windley Are you perhaps on mute Dave Windley    AnalystSorry  Thank you  I was on mute  Sorry about that  Thanks for taking my question  On Medicare Advantage  as you look at a double digit growth trajectory here  and I think that s your expectation for multiple years  that larger cohorts can sometimes come in and put a little pressure on margin  I m wondering what your expectations are around that and what kind of platform and resources you have in place to onboard risk or risk assess and get new Medicare Advantage members into programs to mitigate any initial margin pressure David Cordani    President and Chief Executive OfficerIt s David  First and foremost  we re really pleased with the start to 2020  As we indicated in 2019  we expect to grow this platform 10  to 15   and we re on track to do 13  to 16   Just back to reminding you of some of the context  We re well positioned today in 2021  Our Stars rating picks up yet further to 87  of our lives in four star or greater plans  and our Net Promoter Score is tracking at a tad over 70 across our broad portfolio  So our ability to grow both in markets  on platforms  net new geographies  being adjacent counties and new markets we re opening and broadening our PPO platform  will fuel this and drive it on a go forward basis Clearly  the rate and pace of that growth may put a little margin pressure and draw us toward the lower end of our margin range where we are at times maybe a tad below that  We ll balance that in our portfolio as we continue to invest as we are today  but we like the growth outlook  We like the aggregate margin profile  We like the sustainability  The last sub note maybe to have there in terms of the coding and otherwise  Our value based provider relationships and our high engagement programs are well positioned to coordinate the care of the services  etc   as reinforced by the Stars rating and as reinforced by our overall performance  So we feel good about the outlook for this year and the trajectory going forward Dave Windley    AnalystThank you OperatorThank you for your question  Your next question is from Steve Tanal with Goldman Sachs  Your line is open  sir Steve Tanal    AnalystSo I guess I ll ask one in Oscar  It sounds like partnership but trying to understand what elements of their business are difficult or costly for Cigna to build or offer independently  So just trying to really understand what are the functions each of the companies will do in the context of the partnership  And maybe that s it for me David Cordani    President and Chief Executive OfficerSteve  thanks  It s David  So stepping back  as I noted in my prepared remarks  first  at a philosophical level  we view that the notion of partnering and beyond partnering  striving to be the undisputed partner of choice  it s a competitive advantage and something we want to build on  Why  It accelerates pace of innovation  It accelerates value creation  whether it be around affordability  predictability  simplicity  and it could broaden speed and absolute reach within the marketplace  Oscar is a wonderful example of that  And if you take it up to the macro level  you ll recall that Cigna s historically not participated in the smallest end of the employer marketplace  be it under 50 or under 100 depending on where the regulatory lines are drawn from that standpoint  Two  we believe that s an underserved marketplace with less choice and less leverage of some of the most innovative solutions Now to the core of your question  when you re open minded to partnering  you could have both focus and acceleration  in this case  by leveraging Oscar s phenomenal  technological infrastructure  digital first infrastructure and information flow infrastructure  which is similar to our philosophy but we just apply it upmarket in Select  Middle and National  And this is a case where we re philosophically aligned  but the durable infrastructure is there to serve the unique needs of the small employers  and then we re able to pour it over our value based network configurations  our high performing engagement  clinical  behavioral pharmacy capabilities to make one plus one equal a lot more than two  So we re excited about that  And as I noted in my prepared remarks  we re staged to open up four markets toward the latter part of this year and then fuel some growth OperatorThank you for your question  Our next question is from A J  Rice with Credit Suisse  Your line is open  sir A J  Rice    AnalystHi everybody  Just to maybe ask about the 2020 bottom line and 2021 bottom line ranges that you have for    two parts to it  First  Eric made some comments about divisional level seasonality this year and how we might think about that  I know some of your peers have made a bigger deal about the first quarter and the impact of leap day  Perhaps because your business is diversified  it doesn t mean as much to you  but is there anything you d like to say about the seasonal pattern relative to a normal year  And when you think about the range itself  I guess my question is  there s a number    you ve got a number of business lines  You ve got variability around your capital deployment and cost synergy realization  Is that    is there a couple of things in that range that you see as standing out that would particularly move you into the high end or the low end of your forecast given its  0 60 range and  1 range for this year and next  Or is it just the agglomeration of all these different business lines and it falls out  But I guess I m just trying to figure out of there a couple of things that are big variables in your mind as to where you re going to be  say  versus the  20 to  21 next year David Cordani    President and Chief Executive OfficerAll right  On the item related to the leap year and February having an extra day this year  that does move the pattern around a little bit in the Integrated Medical segment  All else equal  that runs the loss ratio up a little bit for the first quarter  it will normalize out over the course of the year  Of course  fully factored into our guidance and such  but that does put a modest amount of pressure on the first quarter that will recover over the balance of the year  nothing that I would call out as particularly significant  As it relates to the range more broadly  there aren t any big items I ve called out other than just the rate and pace of our spending and our investments in terms of future growth  As you know  we have continued to invest in building new capabilities and the like  There s spend every year as we get ready for new clients to come on board and things along those lines  So it would be those types of items that I d think about more than anything else at this point A J  Rice    AnalystOkay  thanks OperatorThank you for your question  Our next question is from Ralph Giacobbe with Citi  Your line is open  sir Ralph Giacobbe    AnalystThanks  Good morning  I want to go to interest expense guidance  So it looks like you re run rating to  1 6 billion  at least as of the fourth quarter  The guidance calls for  1 6 billion of interest cost in 2020 despite the  4 5 billion to  5 billion debt pay down  So is it just timing related  Maybe if you can kind of help reconcile that  And then along those lines  I guess  to Justin s first question  I just want to make sure  That share repo  I mean  to the extent that you re doing it and accelerating it early on as an offset for the Group Disability and Life  does that mean any upside  essentially  in the first half of the year  essentially  it s not going to carry through to the EPS line simply because of the timing again Eric Palmer    Executive Vice President and Chief Financial OfficerRalph  it s Eric  So on the interest expense  really nothing in particular I d call out other than and maybe looking out to the decimal point a little bit further and the timing throughout the year  Obviously  to the extent we were to extinguish that earlier  the interest expense will go down  but again  our current expectation would be for  1 6 billion  as I noted in my prepared remarks  In terms of the timing on the capital deployment  the mechanics are consistent with what I outlined to Justin s question  We do have flexibility in terms of the timing at which we would deploy  Our expectation is that we would fully offset the absence of the group transition by reducing the share count through share repurchase  and we ll approach that as we go through the course of the coming months and quarters here OperatorThank you for your question  Our next question from Sarah James with Piper Sandler  Ma am  your line is open Sarah James    AnalystThank you  Looking at the five year Medicare growth strategy  There s a shift to focus on PPO  Wondering what dynamics changed in the market to make PPO more attractive  And why not focus on Group  given your large National Account base  Your peers have had good success on retiree accounts  So why is that not a strategy Cigna s pursuing David Cordani    President and Chief Executive OfficerSarah  it s David  So first and foremost  I wouldn t view it as a shift  We didn t go from something and away from something to something  So the individual HMO continues to be a bedrock of the platform and  in fact  is a major driver of our growth in 2020 as an example of that  We sought to add the individual PPO platform to our portfolio  invested to do so  stood it up and have the arrangements with the dollar based provider community to be able to offer that  So it s expanding choice and building on a successful platform and track record  And as we both enter new markets and expand in counties  we will make our decisions in terms of individual HMO  individual PPO or both on a go forward basis We just see it as an end and a natural extension of our portfolio  Additionally  to your important point  we view that the employer marketplace is also a very attractive addressable market  And as you know  beyond National Accounts  our broad  well performing commercial portfolio of employee relationships presents another opportunity for that  and it s on our growth trajectory  We re just very disciplined as it relates to building the momentum  So going from the proven HMO to adding the PPO  expanding geographies  and you should expect us over time to come back and talk with you about the very attractive additional growth opportunities that exist in the employer marketplace for us as well Sarah James    AnalystThank you OperatorThank you for your question  Our next question is from Gary Taylor with JPMorgan  Your line is open  sir Gary Taylor    AnalystHi  good morning  Two quick numbers questions  The first one is to Eric on the 80 basis point impact on the MLR from the HIF recurring next year  Just wondering when you derive that  do you just presume that on MA there s no impact because there s no explicit growth up there  which is kind of a yes no question  My other question was on the PBM  So for next year  you ve got like 5  at the midpoint pre tax growth on like 22  script growth  Obviously  the Prime scripts are coming in at breakeven  you ve told us  We know that the Optum scripts coming over are lower profitability per script  So when we just think about the core and the organic growth in script  should we assume that organic EBITDA margins are similar  those new organic scripts are coming in at similar margins and the sort of dilution and profitability per script is purely being driven by Optum and Prime Eric Palmer    Executive Vice President and Chief Financial OfficerGary  it s Eric  On the first part of your question  I think the short answer is yes  Think of that as not having a specific impact in terms of the quantification  given there s not a way to specifically build that into how you bid for MA  On the second portion of your question  I think also the answer is yes  The dynamics you outlined are really the biggest pieces here  When you adjust for the Prime volumes  and you adjust for the Cigna transition volumes  I think of the core side on those items as being consistent Gary Taylor    AnalystGreat  Thank you OperatorThank you for your question  Our next question is from Matthew Borsch with BMO Capital Markets  Your line is open  sir Matthew Borsch    AnalystThank you  You guys just asked about the commercial market  maybe a little bit about what you ve seen from  I guess  what you call your Select segment in terms of preference to shift to alternate funding away from risk and if you ve got any sense for how that may be affecting the risk pools  I m asking the question partly in light of another company that spoke to seeing some deterioration in the remaining underwriting risk David Cordani    President and Chief Executive OfficerMatthew  it s David  So specific to the commercial marketplace  and I think you re going into the Select segment  recall that we offer choice in that marketplace  The choice is heavily oriented around a well configured  integrated value proposition with the medical  the pharmacy  the behavioral  the care management programs  etc   and building choice around funding options  Today  think about  from a new business standpoint  it s tracking about 50 50  About 50  of the new business we re writing right now is risk  About 50  of it is ASO stop loss  plus or minus  and that vacillates in any given year a little bit more one  a little bit more of the other  and we re delighted with that  We re delighted to be able to be in position to offer it in that way I d also remind you from prior conversations  one of our strengths when you offer that choice is oftentimes  you re literally offering that choice side by side  And it s a good validation for the purchaser  in this case the client  of our conviction to the ASO proposition when you re able to put the guaranteed cost side by side  But today  think about it  the new business is running about 50 50 and I wouldn t describe any difference we re seeing in terms of your terminology from a risk pool standpoint of performance  It s performing really well for us Matthew Borsch    AnalystThank you OperatorThank you for your question  Our next question is from Josh Raskin with Nephron Research  Your line is open  sir Josh Raskin    AnalystThanks  Good morning  I m going to ask a little bit about capital deployment  and you re talking about getting your debt to cap under 40  by the end of this year  You ve got another  5 3 billion of proceeds from Disability and Life and  7 5 billion of available deployable cash next year  You think about adding all these numbers up and it s approaching 20  of the market cap  And I understand the priorities  but is there a little bit more urgency from a capital deployment perspective rather than sort of sitting on cash that s dilutive to returns  Do you think about more aggressive buybacks  Is there a dividend increase  things like that  I m just curious if you re starting to feel a little bit more pressure in terms of that deployment Eric Palmer    Executive Vice President and Chief Financial OfficerJosh  It s Eric  Appreciate where you framed that up  Obviously  we re very excited about the capital generation that we ve got  the cash flow from operations visibility that we ve got for 2020 and into 2021  and that gives us a lot of flexibility  I think we ve got a really good track record of not  to use your word  sitting on cash  We will deploy the capital in a way that s effective and aligned with our shareholders  interest and such versus just accumulating  to be clear  But again  the overall history we ve got from    and track record we ve got from an effectiveness of capital deployment and managing our capital  coupled up with the visibility and flexibility that we ve got coming with the capital available for us  is an exciting combination  David  I don t know what else you ll add on that David Cordani    President and Chief Executive OfficerI ll just reinforce    Josh  I appreciate your question  Recall from the    our strategic positioning  pre combination  aided to by the combination  etc   our ability to generate a significant amount of operating cash flow is a critical competency and we believe a strategic advantage with  9 5 billion in 2019  at least  7 5 billion in 2020 and at least  8 5 billion in 2021  so quite deliberate  And as Eric said  we note the importance of that responsibility  not something we take lightly  but our effective capital stewardship responsibility will be clear as we go forward  and we have tremendous value creation opportunity in front of us right now OperatorThank you for your question  Our next question is from Lance Wilkes with Bernstein  Your line is open  sir Lance Wilkes    AnalystGreat  Just had a question on the individual business line and the strategy and appetite in that business going forward  And then maybe also if you can comment on the SG A increase in Health Services for the fourth quarter and maybe what drove that David Cordani    President and Chief Executive OfficerLance  it s David  I ll take the first question and I ll ask Eric to take the second part of your question  Individual business line  I m presuming you re referencing the individual exchange  Just to remind everybody  the individual exchange marketplace  we took a very focused  deliberate posture on that  in that marketplace in 2014 and have stayed steady within that marketplace  systematically but slowly growing our posture  We re in 10 markets today  Think about the positioning of being in 10 markets highly oriented around leveraging our value based provider relationships  and that marketplace has performed pretty darn well in the last couple of years Going forward  we ll monitor the competitive landscape  but we see the ability to continue to grow that reasonably over time with fair returns  Cornerstone to our value proposition  though  is ensuring that in those states  we go down to sub MSA level and make sure we re building the value prop or the offering around our highest performing physician relationships and getting the requisite alignment with the delivery system  And thus far  that s performed well for us  And we look forward to year in  year out making individual decisions of additional market expansion  Eric  I ll ask you to address the SG A comment Eric Palmer    Executive Vice President and Chief Financial OfficerYes  Lance  it s Eric  On the Health Services  fourth quarter  really two items that I ll have you think about on that front  One  as we noted throughout both David and my prepared remarks  continue to spend to invest in terms of building new and additional capabilities and such  Additionally  we re spending on facilitating and effectuating the transitions associated with the full reinsourcing of the Cigna volumes and the like  The other item I would just note that we ve provided some commentary throughout the year last year around the effect of the transitioning client going away  sometimes the volumes in our transitioning clients wound down  that s added cost back into the core  if you will  and we re well on track to extinguish that as we work through 2020 Lance Wilkes    AnalystPerfect OperatorThank you for your question  Our next question is from Peter Costa with Wells Fargo Securities  Your line is open  sir Peter Costa    AnalystThank you  I d like to follow up with    on Dave s question earlier about margins in Medicare  and in particular  timing of when that will start to add to your earnings from a perspective of    first off  how are you getting the members that you re getting today  Are they coming electronically  Are you setting up broker networks  And can you talk a little bit about the channel and how that s going to evolve going forward  And then also in 2021 with ESRD patients coming on  how do you expect that to impact your margins in the Medicare business David Cordani    President and Chief Executive OfficerPeter  it s David  First  broadly speaking  just to reiterate  we re really pleased with the positioning we have in our existing MSAs and expanding into new markets  Our individual HMO platform is the lead offering still in the lead part of the growth chassis  aided by the new market entrees as well as the PPO platform  Specifically  to your question of how we go to market  think about that as an end proposition  So it s a multi channel approach relative to captive partnered and otherwise and expect that to continue to expand over time  Specific to the margins  as I mentioned to the prior question  the margins  we would expect to be at the lower end of the range that we put out as a long term range as we accelerate our growth trajectory over the near term potentially ticking below that Having said that  with the growth  we would have earnings growth that  that brings along with it  And finally  relative to ESRD  as we flagged in the past when asked a question  it will be a smaller impact on our aggregate franchise  We will manage the final ESRD posture  MSA by MSA  benefit offering by benefit offering in alignment with our value based physicians  And we ll be well positioned to manage that to the extent the final changes transpire as currently proposed from that standpoint  Net net  taken together  attractive growth  even at the lower end of the margin range  we will be experiencing earnings expansion while simultaneously investing for growth going forward Peter Costa    AnalystThank you OperatorThank you for your question  Our next question is from Frank Morgan with RBC Capital Markets  Your line is open  sir Frank Morgan    AnalystThank you  Two real quick questions  Any thoughts on last night  CMS proposed rule around 2021 MA rate update  And then any update on the Cigna  Anthem litigation David Cordani    President and Chief Executive OfficerFrank  it s David  Specific to the rate notice  as you might imagine  we re digesting the detail of it given the magnitude of it  It s the preliminary notice  You know the process in terms of getting to the final rate notice  Big picture  I would suggest to you we re macro in line with the aggregation of what that rate notice indicates  And when we think about the posture of that rate notice  the expansion of our charge proposition for 2021  we ll be in good shape for 2021  More to follow  but big picture  our impact is  broadly speaking  in line with what the rate notice speaks to  As it relates to the    you asked specifically about the Cigna  Anthem litigation  That is on course to resolve itself by the end of this calendar month Frank Morgan    AnalystAny other color you can share on that  What gives you confidence it will be wrapped up this month and would that result in a settlement payment David Cordani    President and Chief Executive OfficerNo comment in specificity relative to litigation other than I would reinforce  we feel very strong about our position relative to our contractual responsibility and contractual ability to collect our break fee  and the court is on track to resolve that by the end of this calendar month Frank Morgan    AnalystThank you OperatorThank you for your question  Our next question is from George Hill with Deutsche Bank  Sir  your line is open George Hill    AnalystGood morning  guys  And thanks for taking the question  I guess  David  you talked a lot about the partnership strategy and maybe digging a little bit more into Prime    the Prime deal  I guess  can you talk about the network component of it and I guess  where do you guys see the most significant points of operating leverage that delivered through to earnings beyond 2020  Is it more on the rebate side  Or is it more on the network side  And kind of can you talk a little bit about the strength that each side brought to the relationship David Cordani    President and Chief Executive OfficerYes  I m not going to go through the micro pieces of the components of the relationship  I d rather just reframe what we re trying to achieve together  This is a wonderful example of two organizations identifying philosophical alignment and strategic alignment and then pursuing leverage that results in additional value for customers and clients  That s the end of and the net net of this  which is improved affordability  potentially improve coordinated access and then clinical program leverage on a go forward basis  We will continue to work with Prime in terms of the best ways in which we could add additional value for them There s 28 million individual relationships that our customers and members that are within the Prime relationship  And we ll be guided by the components that they feel we could create the most value for  We ll make value added suggestions and evolve that over time  all with the objective of creating more value for their members and clients and  therefore  getting some benefit for Cigna as well over time  So we re delighted with it and it s another validation of our ability to work with other like minded partners to create mutual value George Hill    AnalystMaybe a quick follow up then is  how do we think about you guys effectively strengthening a competitor at the margin or kind of enabling their competition against you in the PBM business David Cordani    President and Chief Executive OfficerWe don t    I appreciate the question  We think about it the exact opposite way  It s a dynamic marketplace and those who create the most valuable win  those who try to preserve or regress to control value will lose over time  So big picture  we re more oriented around a perpetual innovation cycle and continue to drive more value  And we like to do that with others and create mutual value and we have a long track record  The legacy of ESI has that  The legacy of Cigna has that  and we re fueling more of it  So this is an opportunity to create more value for 28 million more customers starting in 2020 and further improve affordability and further improve quality from that standpoint  that s a great outcome  Each organization has to continue to innovate  Each organization has to deliver value  and there s ample growth opportunity in front of both organizations going forward  and we ll align to mutually identified beneficial opportunities for both organizations to grow  but the cornerstone is innovation and more value delivery  So we view it as upside and not downside OperatorThank you for your question  Our next question is from Ricky Goldwasser with Morgan Stanley  Your line is open  sir Ricky Goldwasser    AnalystYes  Hi  good morning  As we start thinking about 2021 selling season for the PBM business  can you give us some sense of the size of the book that s up for renewal in also any    what are    what s the size of the opportunities you re seeing that s up in the market from the other PBMs  And then my second question is on the MA growth guidance  Obviously  you came in    the guidance you gave based in January  I think it was ahead of your initial goal  at least near term goals  So maybe you can share with us what really resonated in the marketplace  And what do you think drove the above expectations performance or at least its materializing earlier David Cordani    President and Chief Executive OfficerRicky  it s David  Specific to the 2021 PBM selling season  break it up into two components  health plan relationships  corporate relationships  As we sit here today  the health plan relationships  as you would expect  drew out a closure or completion sooner given the size  shape and scope of those relationships  They re substantially completed through the renewal cycle  and we feel great about the outcome  So that would be the picture I gave you for 2021  continued strength from that standpoint  The corporate part of the relationships are getting into full steam right now  We think we re going to have another very good year from that standpoint  and our value proposition is resonating very well in the marketplace  specifically relative to the    our value proposition and some of the new innovations that we put into the marketplace  be it the patient insurance program  be it Health Connect 360  etc  Put a circle around it  in aggregate  think about the size of the book moving or up to move about    from a normal standpoint As it relates to Medicare Advantage  pleased that you re calling out the fact that we re a bit ahead of the market we put down before  Remind you  we said 10  to 15  on average over time  We said in our first year  we would expect it to be at the lower end of the range as we re stepping into that new result  There s no one driver of what moved us to the 13  to 16   I would call out a bit higher retention  so what we had initially put into our projection  Our retention is even higher  We love that  And as I noted in my prepared remarks  we re sitting at an NPS right now just in excess of 70 across the aggregate book of business that we have and the vast majority of our customers in this space are in value based arrangements  So I wouldn t call out anything else  Our existing platforms drove the majority of it  Our new markets contributed  and we had a bit higher retention rate Ricky Goldwasser    AnalystThank you OperatorThank you for your question  Our next question is from Scott Fidel with Stephens  Your line is open  sir Scott Fidel    AnalystHi guys  Good morning  A question just on hospital volumes  And there s been a little bit of debate on whether those have been picking up or not over the course of the year  And just interested from your perspective across both the Commercial and Medicare books  what you saw in terms of hospital volumes in the fourth quarter and how those trended relative to your expectations Eric Palmer    Executive Vice President and Chief Financial OfficerScott  it s Eric  Overall  nothing that I would call out as particularly notable  We finished the year with a trend of about 4   which is right in the middle of our expectations  Again  nothing that I would call out as a particular change in trajectory in either the Commercial or in the Government business Scott Fidel    AnalystOkay  thanks OperatorThank you for your question  Our next question is from Steven Valiquette with Barclays  Your line is open  sir Steven Valiquette    AnalystAll right  Great  Thanks  Good morning  Dave and Eric  Thanks for taking my question  So I have two just somewhat interrelated questions on pharmacy  I guess  first  are you able to provide a little more color on your drug procurement strategy going forward for the PBM mail order operations  There s been some conjecture you may be changing one of your buying group relationships  I m not sure if you be able to comment on that or not  And then secondarily  in pharmacy  for the 3 5  to 4 5  commercial medical cost trend that you re expecting for 2020  are you able to discuss whether this includes any incremental pharmacy savings and maybe a lower pharmacy trend this year versus prior years  which obviously may be tied to further integration David Cordani    President and Chief Executive OfficerIt s David  I ll take the first question  I ll ask Eric to take the second question  We don t get into individual actions we re taking relative to our supply chain and procurement strategy  I would just step back and say we have a broad portfolio of tools  solutions and capabilities and we re going to continue to dynamically manage those to get the best possible value for existing and prospective customers and clients going forward  Beyond that  we re not going to comment on any individual actions we re taking in the supply chain activity  Eric  I ll ask you to comment on the trend Eric Palmer    Executive Vice President and Chief Financial OfficerYes  Steve  on the trend piece  we ve had pharmacy trend in that low  to mid single digits range for some time now  I mean  that would be the expectation we d have going into 2020 as well  Just to remind you  gosh  Express Scripts delivered in 2018 a 0 4  commercial trend  We ll be publishing our Express Scripts client  our drug trend report later this month and expect another really attractive result there  but typically  nothing else I would call out OperatorThank you for your question  Our last question will be from Charles Rhyee with Cowen  Your line is open Charles Rhyee    AnalystYes  Hi  thanks for squeezing me in here  Maybe I can ask about the    if you look at the chart here in your presentation  and obviously  over the last 10 years  you ve really driven your medical cost trend down and you re guiding here 3 5  to 4 5   If I m not mistaken  that s sort of the same range you gave last year  I know you ve talked about trying to get toward CPI  Anything in the short term that might be keeping you in this range  Can you talk about what are the factors that you re seeing that s going to help you to get lower from here  And sort of how should we think about the pacing of that David Cordani    President and Chief Executive OfficerCharles  first  to your point  we re delighted with the fact that we have seven years now and going into a plus in terms of delivering the lowest medical cost trend in the industry  And our clients and customers benefit from that immediately  especially given the profile of our business  highly ASO oriented from that standpoint  and we ll continue to drive exceptional value for our clients and customers  Two  I appreciate you calling out the CPI level goal and objective  A couple of years ago  we put forward the strategic objective which said we strive to deliver a level of medical cost trend approximating CPI by 2021  We view that as indicative of a sustainable trend that the system and society could tally and manage on a go forward basis and indicative of a responsible trend I would note that today  we feel like we re well on our way to that journey  and I would underscore that with the fact that many of our clients today  we have established relationships with us and are leveraging our most advanced consumer engagement  health improvement and value based relationships  are benefiting from CPI or a better trend from that standpoint  So there s a toolkit we have that we ll continue to innovate and evolve around how do we get engagement in support of the consumer in their life journey  how do we evolve the precision and speed of the health improvement programs  especially as we continue to expand in the whole personal health arena on an accelerated basis with our market leading behavioral health and pharmacy capabilities and then just further deepening the activation of and value based care delivery platforms that we have in the marketplace  And we re already able to deliver  as I indicated  CPI or better for many of our clients  So we re going to see further expand that in 2020 and beyond  I appreciate your question OperatorThank you for your question  I will now turn the conference over to David Cordani for closing remarks David Cordani    President and Chief Executive OfficerThank you  To wrap up  I d like to highlight just some    a few key points from today s conversation  First  to remind you  Cigna delivered exceptional full year 2019 financial results across our four growth platforms  led by our Health Services and Integrated Medical segments  We exceeded the guidance we had already raised each quarter for 2019 for revenue  earnings and EPS as well as for cash flow from operations  Looking forward  our 2019 performance gives us considerable momentum for attractive growth in 2020 and beyond  In 2020  we will continue to drive significant growth in customer relationships  revenue  earnings  EPS  as well as continued strong operating cash flow  We are on track to complete our integration activities associated with our combination with Express Scripts over the next year  We expect to close the sale of our Group Disability Life business to New York Life in the third quarter  We re on track to return our balance sheet to normalized levels of debt and be in a position to provide exceptional strategic financial flexibility moving forward just as we committed to when we announced our combination two years ago  and we re well positioned to drive attractive growth beyond 2020 and on track to deliver our 2021 EPS target of  20 to  21 per share  We thank you for joining our call today  and we look forward to our future conversations OperatorLadies and gentlemen  this concludes Cigna s fourth quarter 2019 results review  Cigna Investor Relations will be available to respond to additional questions shortly  A recording of this conference will be available for 10 business days following this call  You may access the recorded conference by dialing 800 867 1930 or 203 369 3371  No passcode is required  Thank you for participating  We will now disconnect Questions and Answers Duration  71 minutesCall participants William McDowell    Vice President of Investor RelationsDavid Cordani    President and Chief Executive OfficerEric Palmer    Executive Vice President and Chief Financial OfficerJustin Lake    Wolfe Research    AnalystKevin Fischbeck    Bank of America    AnalystDave Windley    Jefferies    AnalystSteve Tanal    Goldman Sachs    AnalystA J  Rice    Credit Suisse    AnalystRalph Giacobbe    Citi    AnalystSarah James    Piper Sandler    AnalystGary Taylor    JPMorgan    AnalystMatthew Borsch    BMO Capital Markets    AnalystJosh Raskin    Nephron Research    AnalystLance Wilkes    Bernstein    AnalystPeter Costa    Wells Fargo Securities    AnalystFrank Morgan    RBC Capital Markets    AnalystGeorge Hill    Deutsche Bank    AnalystRicky Goldwasser    Morgan Stanley    AnalystScott Fidel    Stephens    AnalystSteven Valiquette    Barclays    AnalystCharles Rhyee    Cowen    Analyst
More CI analysis
All earnings call transcripts",2020-02-06,The Motley Fool,https://invst.ly/ps4k8,2078425
147056,368572,CI,Cigna CEO on Express Scripts deal   We re proving the combination works ,news, We re proving the combination works  We re growing the company  as you noted   Cigna CEO David Cordani said of the company s  54 billion merger with Express Scripts in 2018  We increased our revenue guidance and our earnings guidance each of the last quarters of 2019 and we ended the year with another beat   he said in a  Mad Money  interview  Then we re stepping into 2020 with a 10  revenue growth outlook and another double digit earnings outlook in front of us   he said ,2020-02-06,CNBC,https://invst.ly/ps6m6,2078679
147057,368573,CI,Everything Jim Cramer said about the stock market on  Mad Money   including market comeback  Cigna and McCormick executives,news,CNBC s Jim Cramer explained why he thinks the stock market continues to rise  despite fears and uncertainty surrounding the coronavirus outbreak  The  Mad Money  host checked in with Cigna CEO David Cordani to get insight into how its multi billion dollar merger with Express Scripts is panning out  Later in the show  he sat down with McCormick   Company CEO Lawrence Kurzius to understand why the situation in China could impact the company s bottom line ,2020-02-06,CNBC,https://invst.ly/ps72v,2078711
147064,368580,CI,Healthcare In Retirement  Personal Finance 101,opinion,"Like all retirement related things  healthcare is very important to plan for  financially and emotionally   And like many medical related things  healthcare in your nest egg years can still be complicated and overwhelming 
There are many things retirees will have to take into consideration  from buying a Medicare Advantage plan  figuring out how to pay for prescription drugs  and whether or not to purchase Medigap  a supplemental insurance plan  Retirees also must think aboutbuying long term care coverage  since the older you are  the more expensive coverage will become 
Buying private health insurance is also an option for retirees  and you can purchase plans from insurance providers like UnitedHealth   NYSE UNH    Cigna   NYSE CI    and Anthem   NYSE ANTM   
Healthcare  where to get it and how to pay for it  is one of the biggest worries for retirees and almost retirees  But if you plan ahead and take stock of yourself and your health  you ll be one step closer to a great retirement 
Personal Finance 101 is a video series that aims to help you take control of your money  It s hosted by Zacks Editor Madeleine Johnson  and covers a wide range of personal finance related topics  To watch more video content from Zacks  subscribe to  today 
A Simple Way to Build Wealth
No matter what your financial goals are  investing in quality stocks is an option worth considering  Stocks have produced better returns than other kinds of investments over the years and generated significant wealth for shareholders  If you re interested in stocks but you re nervous about picking the right ones  Zacks can help  Our research team makes it simple to find long term buys with long term wealth building potential  Starting today  you can see our private selection of stocks priced under  10  Warren Buffett style value picks  dividend stocks and more ",2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/healthcare-in-retirement-personal-finance-101-200500711,200500711
147065,368581,CI,Here s Why You Should Add BioDelivery Stock To Your Portfolio,opinion,"BioDelivery Sciences International  Inc    NASDAQ BDSI   is focused on the development and commercialization of treatments in the areas of pain management and drug addiction  The company s portfolio consists of three marketed products   Bunavail  buprenorphine naloxone buccal film   opioid dependence   Symproic  opioid induced constipation  and Belbuca  buprenorphine HCl buccal film   chronic pain   Belbuca is the major revenue generator for the company 
Here we discuss five reasons why adding BioDelivery stock to one s portfolio may prove to be beneficial in 2020 
Favorable Share Price Movement  Strong performance of BioDelivery s marketed drugs has enabled the company to outperform the   Shares of the company have rallied 56 2  in the past six months compared with the industry s growth of 6 7  

 
Strong Performance of Belbuca  The drug generated  69 3 million in sales in the first nine months of 2019  representing a year over year growth of almost 130   Moreover  sales of the drug grew sequentially in the last three reported quarters  The company expects the growth momentum to get reflected in the fourth quarter results 
It expects full year sales for the drug to be at the upper end of  105  110 million  suggesting an increase of more than 139  from 2018  Sales growth is also expected to continue in 2020 as well 
The sales growth can be attributed to the company s efforts to increase accessibility to Belbuca for covered patients in the United States  The company has several commercial agreements with Medicare insurers in the country  including Cigna Corp    NYSE CI    and has brought more than 165 million patients under coverage for Belbuca  Notably  it re acquired all rights to the drug from Endo International   NASDAQ ENDP   in 2017 
Acquisition of Constipation Drug Symproic  In April 2019  BioDelivery acquired U S  commercial rights to Symproic from Japan based Shionogi  The drug is approved as treatment for opioid induced constipation in adult patients with chronic non cancer pain  The acquisition seems encouraging as the drug has demonstrated rapid growth 
During the third quarter of 2019  total Symproic prescriptions were 15 686  an all time high  and represented more than 39  growth from the prior year period  The company expects Symproic to generate sales of  7  9 million in 2019  The company is also focusing on placing the drug on preferred formulary position of pharmacy benefit managers 
It has brought more than 40 million commercially covered lives with expanded access to the drug so far  These efforts should drive sales higher in the coming quarters 
Encouraging Guidance for 2020  BioDelivery expects total sales for 2020 to be between  165 million and  175 million  This indicates nearly 60  growth at mid point compared to full year sales expectation for 2019  primarily driven by Belbuca  The company expects 2020 sales for the drug to be in the range of  150  160 million 
Rising Estimates  BioDelivery s earnings estimates for 2020 have increased 7 1  in the past 90 days  In fact  the company came up with impressive earnings performances and exceeded expectations in three of the trailing four quarters  It recorded an average positive earnings surprise of 159 38  
Conclusion
Belbuca and Symproic are likely to be key drivers for the company s top line going forward  However  we note that performance of BioDelivery s third marketed drug  Bunavail  has been lackluster  The drug is facing significant competition from generics of London based Indivior s opioid treatment drug  Suboxone  Moreover  Belbuca also targets a highly genericized  crowded and competitive market and faces competition from Butrans and opioid drug abuse deterrent formulations  which include Pfizer s   NYSE PFE   Embeda 
Nevertheless  BioDelivery sports a Zacks Rank  1  Strong Buy  and looks like a good investment now  You can see  BioDelivery Sciences International  Inc  Price
 

    
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained an impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  
This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-biodelivery-stock-to-your-portfolio-200501965,200501965
147066,368582,CI,Cigna  CI  Earnings Expected To Grow  Should You Buy ,opinion,"Cigna  CI  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 6  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  4 19 per share in its upcoming report  which represents a year over year change of  70 3  
Revenues are expected to be  35 30 billion  up 156 7  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 03  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cigna 
For Cigna  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 31  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Cigna will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cigna would post earnings of  4 37 per share when it actually produced earnings of  4 54  delivering a surprise of  3 89  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cigna doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-earnings-expected-to-grow-should-you-buy-200503260,200503260
147067,368583,CI,Cigna  CI  Q4 Earnings And Revenues Beat Estimates  Rise Y Y,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings of  4 54 per share in fourth quarter 2019  surpassing the Zacks Consensus Estimate by 2 9   Quarterly earnings were up 75  year over year Cigna s revenues of  36 6 billion beat the Zacks Consensus Estimate by 3 7   Revenues grew 167  year over year owing to the acquisition of Express Scripts  NASDAQ ESRX  Among the revenue components  pharmacy revenues were  25 6 billion compared with  3 3 billion in the year ago quarter  premiums were up 9 8  year over year to  10 billion while fees increased 50 2  to  2 2 billion  The growth in pharmacy revenues was backed by the acquisition of pharmacy benefit manager Express Scripts The company s medical enrollment grew by 184 000 lives from the prior year quarter to 17 15 million customers  driven by growth in Commercial and International markets Cigna Corporation Price  Consensus and EPS Surprise    Segment DetailsHealth Services   Adjusted revenues of  25 6 billion were up from  3 3 billion in the year ago quarter  primarily due to the acquisition of Express Scripts completed in December 2018 Integrated Medical   Adjusted revenues of  9 2 billion were up 11  year over year  driven by increase in Commercial customer as well as premium growth International Markets   Adjusted revenues of  1 43 billion were up 5 5  year over year  reflecting continued business growth Capital PositionCigna s debt to capitalization ratio improved to 45 2  as on Dec 31  2019  from 50 9  as of Dec 31  2018 Shareholders  equity as of Dec 31  2019 was  45 3 billion  up 10 5  year over year 2020 GuidanceThe company expects earnings per share in the range of  18  18 6  adjusted revenues in the range of  154 billion to  156 billion  Medical customers are projected to grow between 150 000 and 250 000 Medical care ratio is expected in the range of 80 2 81 2  Cigna carries a Zacks Rank  2  Buy  
You can see  Some other stocks in the healthcare space that have reported fourth quarter earnings so far  UnitedHealth Group Inc    NYSE UNH   and Humana Inc    NYSE HUM   beat earnings estimates by 3 45  and 3 64   respectively  while Centene Corp    NYSE CNC   missed the same by 1 4   More Stock News  This Is Bigger than the iPhone                    It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020    
 ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q4-earnings-and-revenues-beat-estimates-rise-yy-200505312,200505312
147076,368592,CI,Is Cigna s Stock a Buy ,news,"Healthcare provider Cigna  NYSE CI  was having a lackluster 2019 until the past three months  since then  its stock has been soaring more than 35   soundly outperforming the S P 500 s 11  returns over that time  At a market cap of  76 billion and trading near its 52 week high  the stock s seen lots of bullishness of late  but whether it can continue that into 2020 is by no means a sure thing 
Let s take a close look at what it s been up to as well as the risks the company is facing to determine whether the stock is a good investment today 
The Express Scripts merger is paying off
Cigna s stock began soaring in October after hovering around its 52 week low  An attractive buy  it became even hotter when the company released its third quarter results at the end of the month  which benefited from the acquisition of Express Scripts  In December 2018  Cigna finalized its purchase of Express Scripts  valued at  54 billion in a cash and stock deal for the pharmacy benefits manager  the deal has proven to be worth it thus far  

In Q3  Cigna s sales of  38 6 billion increased 237  from the prior year quarter  when the company recorded just  11 5 billion in revenue  The increase comes primarily from pharmacy revenue  which is due to the merger with Express Scripts  A year ago  Cigna recorded just  747 million in pharmacy sales for Q3  but this past quarter that number s soared to  26 billion  It s now the company s largest segment and accounted for more than two thirds of Cigna s top line  The results trickled down to the bottom line as well  with Cigna s net income nearly doubling from  774 million in the prior year quarter to  1 4 billion in Q3 2019 
The company beat expectations and also raised its forecast for adjusted earnings for 2019  bumping up its projections from a range of  16 60 to  16 90 per share up to  16 80  17  The company also expects earnings per share to rise from 10  to 13  in 2020  which is also the annual goal the company has  over the long term   
Healthcare uncertainty could weigh on the stock
One of the risks for healthcare stocks as a whole is the potential that greater transparency in the industry could put more scrutiny on insurers and hospitals  leading to lower prices  President Trump signed an executive order in November relating to the secrecy that exists in the industry  stating that  We believe the American people have a right to know the price of services before they go to visit the doctor   
The new law would allow patients to see the rates that hospitals and insurers have negotiated  It would give patients the ability to shop around before going to a particular hospital  which could impact the revenue that healthcare providers like Cigna are able to generate  While the law may not come into effect until 2021 and will likely face opposition along the way  it s a risk that investors need to be aware of  Healthcare could become a key issue in the upcoming federal election  with a particular focus being on bringing down costs  That could have an adverse impact on Cigna being able to meet its long term growth targets 
Why Cigna is a good buy despite the risks ahead
Although there is uncertainty ahead for the industry  Cigna remains a solid healthcare stock for investors to add to their portfolios  With Express Scripts having such a positive contribution to the company s results thus far  there s plenty of reason to be optimistic  Although Cigna is trading near its high  at just 16 times earnings and 1 7 times book value  the stock is a good value buy  a low PEG ratio of 0 91 confirms that 
Management s strong outlook for the future should give investors plenty of hope that the stock can continue building on its recent results and that its value will continue to climb  That growth and a reasonable valuation make Cigna a good stock to buy today ",2020-01-04,The Motley Fool,https://invst.ly/pdk05,2052415
147084,368600,CI,Cigna  Oscar Team Up To Offer Health Aids To Small Businesses,opinion,Cigna Corporation   NYSE CI   has entered into a collaboration with Oscar  a tech driven health insurance company  to offer feasible commercial health solutions to small businesses Both companies reached a consensus to share risks in equal proportion under a reinsurance agreement for services delivered through this alliance  The partners will launch the solutions in specified markets during 2020 and gradually grow their partnership over time  However  the agreement is subject to closing conditions Services under the Cigna   Oscar brand catering to small group market include integrated medical  behavioral and pharmacy solutions  wide accessibility to doctors and hospitals  solid support from a dedicated concierge team  digital first assistance that includes 24 7 telemedicine at zero cost  ID card availability  deductible tracking  etc Moreover  individuals would benefit from user friendly search tools to review healthcare providers  get appointments as well as spot the leading broker  business and provider portals for helping them with convenient enrollment Rationale Behind the MoveIn 2018  small businesses created more than 40  of total jobs  proving to be the backbone of American economy With this solution  Cigna expects to aid in cost management of small businesses besides extending network and product choice  This booming space with above 500 000 new companies starting out every month is a great market to tap into  Small group health plans cater to 15 million people in the United States today and this new service would provide entrepreneurs with an affordable  simple to use choice  which in turn  would keep their employees in good health This Cigna   Oscar initiative is another indicator of lending a significant boost to the healthcare sector for wider payment structures  This innovative alliance will further dispense more robust medical treatment Shares of this Zacks Rank  3  Hold  company have gained 3 5  in a year s time  underperforming its  s growth of 10 7   The stock price uptick looks subdued in comparison to the returns of Anthem  Inc    NYSE ANTM    WellCare Health Plans  Inc    NYSE WCG   and UnitedHealth Group Incorporated   NYSE UNH    which have rallied 16 3   32 7   15 2   respectively  over the same time frame  You can see But we expect all these measures to bode well for the long haul and boost the company s share price rise Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ,2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/cigna-oscar-team-up-to-offer-health-aids-to-small-businesses-200498675,200498675
147085,368601,CI,UnitedHealth  UNH  Q4 Earnings Beat On Revenue Growth,opinion,"UnitedHealth Group Inc  s   NYSE UNH   fourth quarter 2019 earnings of  3 90 per share surpassed the Zacks Consensus Estimate by 3 4   Earnings were up 19  year over year Higher revenues  strength in both segments   UnitedHealthcare and Optum   plus membership growth led to this outperformance UnitedHealth has a tradition of guiding conservatively and then surpassing its own estimates to surprise investors  The reported quarter was not an exception UnitedHealth Group Incorporated Price  Consensus and EPS Surprise   Strong Operating PerformanceUnitedHealth posted revenues of  60 9 billion  which came in line with the Zacks Consensus Estimate  Revenues were up 3 8  year over year  led by double digit growth at UnitedHealthcare Medicare   Retirement  OptumRx and OptumHealth Total operating cost of  55 8 billion was up 3 5  year over year  due to higher medical costs and operating cost     2019 ResultsRevenues of  242 billion grew 7  year over year  Earnings per share of  15 11 grew 17 3  year over year and came in ahead of the company s earlier provided guidance of  14 90  15 Strong Performance Across SegmentsIn the reported quarter  the company s health benefits segment  UnitedHealthcare  generated revenues of  48 2 billion  up 4 3  year over year  Revenue growth was driven by higher enrollment and increase in pricing The company s business groups   Employer and Individual  Medicare and Retirement   contributed to the growth  Earnings from operations were up 15 5  year over year to  2 1 billion  led by revenue growth Revenues from Optum improved 8 3  year over year to  29 8 billion  reflecting strong contributions from the sub segments  OptumHealth  up 30 2   and OptumInsight  14 4    Earnings from operations jumped 12  year over year to  3 billion Increase in Membership EnrollmentThe company served 49 15 million people in the quarter  up 0 2  year over year  It was led by growth in members  served in the Commercial and Medicare Advantage and partially offset by lower Medicaid and International membership Capital Position UpdateDuring the year  cash flow from operations increased 17 5  year over year to  18 46 billion Cash and short term investments at quarter end were  14 24 billion  down 0 6  year over year 2020 Guidance UpdateThe company affirmed its recently issued earnings outlook for 2020  including net earnings of  15 45 to  15 75 per share and adjusted net earnings of  16 25 to  16 55 per share Our Take    UnitedHealth s vast and diversified business operations  spanning from health benefit to health services  and a number of accretive acquisitions that have driven its performance over the years  will be growth catalysts this year too Moreover  a solid balance sheet will enable acquisitions that should drive inorganic growth  Good command on controlling medical cost should aid its margins Zacks Rank and Stocks That Warrant a LookUnitedHealth has a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare space are The Joint Corp    NASDAQ JYNT    WellCare Health Plans  Inc    NYSE WCG   and Cigna Corp    NYSE CI     While The Joint Corp sports a Zacks Rank  1  Strong Buy   Cigna and WellCare carry a Zacks Rank  2  Buy   You can see  The Joint Corp   WellCare and Cigna are expected to reported earnings growth in the to be reported quarter of 33 3   33 7  and 70 3   respectively Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2020-01-14,Zacks Investment Research,https://www.investing.com/analysis/unitedhealth-unh-q4-earnings-beat-on-revenue-growth-200498959,200498959
147086,368602,CI,Why Is Hold Strategy Appropriate For CNO Financial  CNO  Now  ,opinion,CNO Financial Group  Inc    NYSE CNO   has been in investors  good books on the back of healthy revenue stream  decreasing expenditure and strong financial strength The company is well poised for progress  evident from its favorable  of B  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors Now let s see what makes the company an investor favorite CNO Financial has been witnessing growing revenues over the past several years  This upside was backed by the company s higher premiums  net investment income and a sturdy balance sheet  Although the metric dipped to some extent in the first nine months of 2019  analysts expect this trend to continue on the back of the company s solid fundamentals This industry player s Washington National business has been contributing well since 2011  In 2018  total premiums from this segment grew 4 6  year over year  This was mainly owing to several growth initiatives introduced in the past couple of years  such as portfolio diversification and a geographic expansion program  We expect this momentum to continue  riding on the company s key growth endeavors CNO Financial has been undertaking measures to curb its overall costs  In the first nine months of 2019  the metric declined 27 5  year over year  The company will pursue further strategic actions to lower costs and enhance its earnings profile  On the back of its constant efforts  we expect the company s expenses to fall The company also invested in technology to boost its agent productivity plus sales and advertising  This move will in turn  improve online customer experience and ramp up productivity  With added technology  CNO Financial can now easily access employer partners  which was earlier impossible due to dearth of a sophisticated benefits platform CNO Financial deepens its focus on bettering its capital and debt position  It has also been hiking its quarterly dividend since 2013  which should retain investor confidence in the stock  Additionally  frequently taken up share repurchase programs have been a major capital deployment strategy for the company  It witnessed a steady cash flow for the past several years as well  Moreover  its balance sheet strength  which assists in efficient capital management  should attract investors  attention However  the company s high leverage continues to be bothersome  Its debt to equity ratio that has been rising over the last few quarters now stands at 57 8   worse than the industry average of 41 6   In the first nine months of 2019  interest expenses rose 6 4  year over year  This raises financial risk in turn For 2020  the Zacks Consensus Estimate for earnings per share stands at  2 10 on  3 77 billion revenues  implying a respective 16  and 0 7  increase from the prior year reported numbers Shares of this Zacks Rank  3  Hold  company have gained 3 3  in a year s time  underperforming its  s rise of 8 5    Stocks to ConsiderInvestors interested in the insurance industry might look into some better ranked stocks like Cigna Corporation   NYSE CI    MetLife  Inc    NYSE MET   and MGIC Investment Corporation   NYSE MTG    each carrying a Zacks Rank  2  Buy   You can see Cigna provides insurance and related products and services in the United States and internationally  For the trailing four quarters  the company s earnings beat is 5 2   on average MetLife engages in insurance  annuities  employee benefits and asset management businesses  The company has a positive surprise of 3 3   on average  for the preceding four quarters MGIC Investment Corporation offers private mortgage insurance  other mortgage credit risk management solutions  and ancillary services to lenders and government sponsored entities in the United States  The company came up with a positive surprise of 12 6   on average  for the previous four quarters Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-hold-strategy-appropriate-for-cno-financial-cno-now-200499319,200499319
147102,368618,CI,White House kills rule aimed at ending Medicare drug rebates,news,"By Caroline Humer and Bryan Pietsch NEW YORK WASHINGTON  Reuters    The Trump administration on Thursday scrapped one of its most ambitious proposals for lowering prescription medicine prices  backing down from a policy aimed at health insurers and raising the possibility of new measures focused on drugmakers   The abandoned proposal would have required health insurers to pass billions of dollars in rebates they receive from drugmakers to Medicare patients  The decision represents a new setback to U S  President Donald Trump s efforts to deliver on a pledge to lower drug prices for consumers before the November  2020 election  when Republicans want to capitalize on voter concern over high healthcare costs   It allows companies like  Cigna Corp   NYSE CI  and CVS Health Corp  NYSE CVS   which negotiate rebates with drugmakers on behalf of the government s Medicare program  to continue to benefit from those discounts   Shares of Cigna rose 9   CVS gained 5  and UnitedHealth Group Inc  NYSE UNH  was up 6    Pharmaceutical company shares fell  with Merck   Co off 4   Bristol Myers Squibb  NYSE BMY  Co down 3  and  Pfizer  Inc  NYSE PFE  off 2   Baird analyst Eric Coldwell said Trump was likely refocusing his reform efforts on the pharmaceutical companies themselves   There are still many headwinds for the supply chain  but    pharma and biotech seem to have drawn the ire of the administration more recently   said Coldwell  noting the industry s successful legal challenge of a rule that would have required drugmakers to include list prices in TV ads for their medicines   Shelving the rebate reform initiative  which pharma strongly supported  feels like payback   Coldwell added  The White House first floated the idea of ending the rebates last year as part of a drug pricing  blueprint  aimed at bringing down costs  Several Democratic presidential hopefuls have also seized on drug pricing as a key issue for the 2020 elections  Legislators  including House Speaker Nancy Pelosi  are pushing for new laws to allow the government to negotiate drug prices directly with manufacturers   A senior administration official  speaking on the condition of anonymity  said the rule was too costly and could have hurt chances for bipartisan legislation   The decision was made that    it was not prudent to go forward with the rule right now  that it would be too disruptive  that the risk was probably too high  and that it might upset a legislative deal  which is our primary focus   he said  The rebate rule would have forced companies like Cigna and CVS either to forgo the discounts or pass them onto Medicare patients enrolled in their health insurance plans and drug plans  They argued that such a change would force them to raise monthly premiums and had been pressing the administration to consider its impact on Medicare  which includes people aged 65 and older and the disabled  and instead focus on drugmakers   Only drug manufacturers have the power to set drug prices  We believe that the key to lowering drug costs is to enact policies that encourage greater competition   JC Scott  chief executive of industry lobbyist Pharmaceutical Care Management Association  said in a statement  PhRMA  the main pharmaceutical industry lobby group  disagreed  saying in a statement that the move ended the only government proposal that would have provided immediate savings at the pharmacy counter for patients   UNINTENDED WINDFALL PROFITS  FOR DRUGMAKERS  The Trump administration is considering a proposed rule that aims to bring some U S  drug prices in the Medicare program in line with lower prices paid by other countries  U S  Department of Health and Human Services Secretary Alex Azar said on Thursday that Americans overpay for medicines  subsidizing socialist European systems  Most European countries pay for citizens  healthcare and directly negotiate drug prices  Azar also said that he and Trump are working on allowing the importation of cheaper drugs from other countries  a move Trump has endorsed but which drugmakers have long opposed  The rebate rule was estimated by the nonpartisan Congressional Budget Office to cost the government  177 billion over the next 10 years  The CBO also said it was likely drugmakers would not cut their prices because of the rule  The government had hoped that by eliminating rebates of 15 percent to 30 percent  or more  of a drug s listed price  the prices would fall  JP Morgan analyst Gary Taylor said in a note that political momentum had been building against the rebate rule  due to the perceived unintended windfall profits that might have accrued to pharmaceutical manufacturers    Politico first reported the planned scrapping of the rebate rule on Thursday and the White House confirmed the decision to Reuters    Based on careful analysis and thorough consideration  the President has decided to withdraw the rebate rule   White House spokesman Judd Deere said in an emailed statement  
In recent weeks  Politico and other publications reported that the White House and Azar had disagreed over the rule  Azar said on Thursday that he planned to stay in his job as long as Trump wanted him there ",2019-07-11,Reuters,https://www.investing.com/news/stock-market-news/white-house-kills-rule-aimed-at-ending-medicare-drug-rebates-1920965,1920965
147106,368622,CI,Is Cigna Corporation  CI  A Solid Value Investor Pick Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Cigna Corporation   NYSE CI   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Cigna Corporation has a trailing twelve months PE ratio of 13 18  as you can see in the chart below  This level actually compares favorably with the market at large  as the PE for the S P 500 stands at about 19 5  If we focus on the long term PE trend  Cigna Corporation s current PE level puts it below its midpoint of 15 70 over the past five years  with the number having risen rapidly over the past few months  However  the current level stands below the highs for the stock  suggesting that it can be a solid entry point  Moreover  the stock s PE also compares favorably with the Zacks Finance Market sector s trailing twelve months PE ratio  which stands at 14 37  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that Cigna Corporation has a forward PE ratio  price relative to this year s earnings  of 12 04  so it is fair to say that a slightly more value oriented path may be ahead for Cigna Corporation s stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value  focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Cigna Corporation has a P S ratio of about 0 59  This is much lower than the S P 500 average  which comes in at 3 37 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years  Broad Value OutlookIn aggregate  Cigna Corporation currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Cigna Corporation a solid choice for value investors For example  the PEG ratio for Cigna Corporation is just 1 03  a level that is lower than the industry average of 1 18  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Clearly  CI is a solid choice on the value front from multiple angles What About the Stock Overall Though Cigna Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of A and Momentum Score of F  This gives CI a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at the best  The current year has seen 12 upward revisions in the past sixty days compared to no downward revisions  while the full year 2020 estimate has seen three upward revision compared to eight downward revisions in the same time period The current year consensus estimate increased 0 95  in the past two months  whereas the full year 2020 estimate fell 0 43   You can see the consensus estimate trend and recent price action for the stock in the chart below Cigna Corporation Price and Consensus   Owing to such bearish estimate trends  the stock has a Zacks Rank  3  Hold   which is why we are looking for in line performance from the company in the near term Bottom LineCigna Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 34  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  the broader industry has underperformed the market at large  as you can see below  So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-26,Zacks Investment Research,https://www.investing.com/analysis/is-cigna-corporation-ci-a-solid-value-investor-pick-now-200488378,200488378
147116,368632,CI,Anthem beats earnings estimates  raises 2019 profit forecast,news," Reuters    Anthem  NYSE ANTM  Inc s first quarter profit beat Wall Street estimates on Wednesday as it reined in expenses  and the U S  health insurer raised its earnings forecast for the year  Shares of the Indiana based company rose 2 7 percent to  257 39 before the opening bell  Last year  the health insurance sector experienced its biggest shake up in years  as rivals Aetna  NYSE AET  and  Cigna Corp   NYSE CI  closed deals with the biggest U S  pharmacy benefits managers   Anthem  which operates Blue Cross Blue Shield plans in 14 states  also overhauled its pharmacy benefits business after years of relying on Express Scripts  NASDAQ ESRX  to handle those operations  Its new company  IngenioRx  is expected to be launched during the second quarter with the help of CVS Health Corp  NYSE CVS   For 2019  Anthem said it expects adjusted earnings to be above  19 20 per share  higher than its prior estimate of more than  19 00  Members in the company s health plans rose by 1 2 million to 40 8 million  helped by growth in the government business that provides Medicare health plans for people aged 65 and older and Medicaid plans for the poor  The company gained market share across its commercial  Medicare and Medicaid businesses and its earnings forecast for the year beat the average Wall Street estimate of  19 17  implying consensus estimates will move higher  Stephens Inc analyst Scott Fidel said  Anthem s benefit expense ratio   the percentage of premiums taken in that are paid out for medical services   worsened to 84 4 percent in the quarter from 81 5 percent a year earlier  partly due to a one year waiver of the health insurance tax in 2019  Analysts on average had expected 84 percent  according to IBES data from Refinitiv  The company said certain states in which it runs Medicaid plans saw higher medical costs  Net income rose 18 2 percent to  1 55 billion  or  5 91 per share  in the quarter ended March 31  Excluding items  the company earned  6 03 per share  ahead of the average analyst estimate of  5 81  
Total revenue rose 9 4 percent to  24 67 billion  beating analysts  estimates of  24 28 billion  helped by membership growth across the company s businesses and premium rate increases ",2019-04-24,Reuters,https://www.investing.com/news/stock-market-news/anthem-beats-earnings-estimates-raises-2019-profit-forecast-1844229,1844229
147117,368633,CI,The obscure advisory committees at the heart of the U S  drug pricing debate,news,"By Caroline Humer CHICAGO  Reuters    Expectations were high last year for three new migraine drugs hitting the market from  Amgen Inc   NASDAQ AMGN   Eli Lilly  NYSE LLY  and Co and Teva Pharmaceutical Industries  NYSE TEVA    Priced around  7 000 each  the drugmakers called them  breakthrough  treatments designed to prevent migraines when taken year round  and estimated that millions of patients could benefit  The U S  Food   Drug Administration said Amgen s Aimovig   the first of the three drugs approved   was an  important addition  to available treatments  But a small group of external medical experts who quietly advise U S  health insurers on new drugs was not impressed  according to a private meeting held at UnitedHealth  NYSE UNH  Group s OptumRx offices in Chicago that was attended by Reuters   They concluded that all three medicines offered no clear benefit over drugs already on the market and that insurers could consider them optional when it came to health coverage  They advised putting limits into place on their use   While these experts do not discuss drug costs  their view of the clinical value of the new migraine drugs emboldened OptumRx  which manages prescription drug benefits  to demand steep discounts from the three manufacturers  Similar  pharmacy and therapeutics   P T  committees at rivals CVS Health Corp  NYSE CVS  and Cigna  NYSE CI  Inc s Express Scripts  NASDAQ ESRX  came to the same conclusion   The impact of their rulings will be on display on Tuesday  when Amgen  which co markets the drug with Novartis AG  and Lilly report on their quarterly financial performance   When asked by Reuters about the OptumRx committee decision  the three drugmakers said the new therapies represent an important advance to patients who are not helped by existing treatments  or who have struggled to stay on their medications  They stress that for some patients  the new migraine drugs cut by half the number of days they experience headaches each month   These relatively unknown expert committees have been involved in drug coverage decisions for decades  Their identities are kept secret due to federal regulations aimed at preventing pharmaceutical industry interference  The committees make their decisions based on a drug s clinical value  independent of cost  pharmacy benefit managers say  But their power has grown more recently with the consolidation of most of the U S  pharmacy benefits business under OptumRx  CVS and Express Scripts  Taken together  their three advisory committees now guide drug coverage for more than 90 million Americans   P T committees also hold sway over record numbers of novel and expensive medicines introduced into the U S  market each year  more often with less evidence of effectiveness or safety than in the past   New drugs that may fall under their scrutiny in the next year include potentially life saving therapies for spinal muscular atrophy and Duchenne muscular dystrophy as well as oral treatments for migraine  diabetes and multiple sclerosis   Their decisions have new consequences as the pharmacy benefits companies they advise are more likely to exclude a new treatment from coverage if it is deemed on par with existing therapies  Or they can demand discounts   or rebates   from drugmakers in exchange for the coverage    If the committee says  a treatment  is no better than the existing drug  there is a very decent possibility that it might get a less preferred status or not be included  for reimbursement  said Jack Hoadley  a health policy expert at Georgetown University   OptumRx s ability to call the shots on drug coverage for more than 30 million people make it a formidable negotiator for clients like Ben Johnson  a pharmacy director for a health plan in Utah that covers about 20 000 railroad union workers  Johnson once relied on his own P T committee to determine whether a drug was effective and worth the price   Now he is often among the dozens of OptumRx clients and consultants invited to observe the quarterly P T committee meetings in Chicago  Handing that role to OptumRx has tripled the value of rebates that his plan receives  Johnson said   FROM  BREAKTHROUGH  TO  OPTIONAL   Drugmakers say pharmacy benefit managers such as OptumRx are middlemen that take too great a cut of the discounts they negotiate and ultimately drive prices higher   U S  Congress and President Donald Trump have taken up that criticism  and the administration has proposed banning rebates in government health programs unless benefits managers hand over the savings to patients   OptumRx  Express Scripts and CVS say that their method of reviewing a drug s benefit and subsequent price negotiations has lowered prescription drug costs  and that 95 to 98 percent of the discounts they receive are passed on to their clients   In the case of the migraine drugs  Amgen  Lilly and Teva were quick to advertise the potential benefits directly to U S  consumers once they were approved  months before the pharmacy benefits companies made decisions on how to cover the drugs   Television commercials from the drugmakers highlighted how some patients had their headache days cut in half  or more  The manufacturers offered the drugs to commercially insured migraine sufferers for free for up to a year or even longer to entice people to try them  Their primary competition is older  cheaper generic drugs  Migraines affect more than 39 million Americans  mostly women  and Amgen estimated 8 million could be candidates for the preventative therapies  which are delivered by injection every month or few months  Analysts forecast  4 billion in annual sales by 2026 in major global markets   OptumRx convened its advisory committee of a dozen doctors and pharmacists last November to review the new migraine drugs  These experts pointed to clinical trial data showing that patients taking the new drugs experienced an average of 1 to 2 5 fewer migraine days a month than those treated with a placebo  and said that was on par with existing therapies  though there were no clinical studies directly comparing the two groups of medicines   The committee acknowledged that some patients saw a much bigger benefit from the new drugs  but said the data did not show who might be helped the most  They questioned the limited safety data and the unknown long term effects on the body    Let s be cautious and see how it all plays out  but we need to look at these studies with a jaundiced eye   one of the members said  The committee s verdict  All three drugs should be considered  optional  treatments that provide no unique benefit  OptumRx Chief Medical Officer Sumit Dutta said the decision  based on available clinical data  provided balance to the drugmakers  claims    There are plenty of examples of drugs that have a lot of enthusiasm in the beginning   but that later turned out to be problematic  Dutta said   Because OptumRx could choose not to cover any of the new migraine drugs  it could push aggressively for discounts  On February 1  it began to cover Amgen s Aimovig and Lilly s Emgality  Teva s Ajovy would only be covered if patients did not benefit from the other two drugs   Leerink biotech analyst Ami Fadia estimates manufacturer rebates on the drugs are as high as 50 percent   Amgen said 200 000 U S  patients have been prescribed Aimovig  with about half of prescriptions being filled for free  Teva and Lilly have not provided figures on patient use  Teva said in February it expects 2019 sales for Ajovy of  150 million   
For its part  Express Scripts estimates that only 128 000 of its covered patients will be good candidates for the new therapies  and has a program to closely manage who receives them  OptumRx and CVS declined to provide similar forecasts ",2019-04-29,Reuters,https://www.investing.com/news/stock-market-news/the-obscure-advisory-committees-at-the-heart-of-the-us-drug-pricing-debate-1849446,1849446
147119,368635,CI,Day Ahead  Top 3 Things to Watch,news,"Investing com   Here s a preview of the top 3 things that could rock markets tomorrow 
1  More Jobs Numbers Ahead of Friday s Payrolls
More employment numbers arrive tomorrow as the big April jobs report gets nearer 
At 7 30 AM ET  11 30 GMT   outplacement firm Challenger  Gray   Christmas releases its job cuts report for April 
At 8 30 AM ET  the Labor Department issues its weekly initial jobless claims figures  Claims for first time unemployment benefits are expected to drop to 220 000  according to economists  forecasts compiled by Investing com 
Meanwhile  the Commerce Department will release its report on March factory orders at 10 00 AM ET  Economists  on average  are predicting that orders rebounded to rise 1  for the month 
2  Cigna  Shell to Report Results 
In sheer numbers  this is among the heaviest weeks of the earning season 
Among the most import reports due 
Cigna  NYSE CI   one of the largest health insurance companies  reports before the bell  Analysts polled by Investing com expect the company to report earnings of  3 78 a share in the first quarter  down from  4 11 a year ago 
Revenue is forecast at  42 69 billion  That s not comparable to a year ago because Cigna acquired pharmacy benefits manager Express Scripts  NASDAQ ESRX  last year in a  67 billion deal  The shares are down 14 7  this year 
Royal Dutch Shell  NYSE RDSa   the Anglo Dutch oil giant  is expected to report  1 11 per American Depositary Unit in the quarter  down 13  from a year ago  Revenue is forecast at  84 65 billion  down 5 1  from a year ago  The ADRs are up 7 6  this year  in part because of rising oil prices 
Broadcaster CBS  NYSE CBS  is expected to report  1 39 a share postmarket  up from  1 34 a share a year ago  according to analysts polled by Investing com  Revenue is projected at  4 31 billion  up 14 6  from a year ago 
The shares are up nearly 17  this year  The company has contended with changes in broadcasting and intense management stress  In addition  the company and Viacom  NASDAQ VIAB  are talking about combining again 
Also after the bell   Tableau Software   NYSE DATA   which builds visualization software sold for desktops or on the cloud  is expected to report a loss of a cent a share in the first quarter on revenue of  287 25 million  according to analysts polled by Investing com 
That would be up from a loss of 19 cents a share a year ago and up 32  from year ago revenue of  217 85 million  The shares are off 0 6  this year but were up 73  in 2018 
3  Market Now Looking at December Rate Cut  Barely 
Investors expressed their post Fed disappointment today  selling into the close as Fed Chief Jerome Powell poured cold water on expectations for a rate cut 
The FOMC kept rates steady in the range of 2 25  to 2 5  
 We do think our policy stance is appropriate right now  We don t see a strong case for moving in either direction   Powell said during his news conference 
Now the market will be watching Treasuries and fed funds futures for hints of where longer term monetary policy is heading  The market was pricing more than a 50  chance that a rate cut would come in September before the decision  But that has been pushed out until December  with a 54 5  chance rates are lower after that meeting  according to Investing com s Fed Rate Monitor Tool 
The 10 Year Treasury hovered around 2 5   down slightly in late trading ",2019-05-01,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-1853250,1853250
147128,368644,CI,Cigna  CI  Q3 Earnings   Revenues Beat Estimates  View Up,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings of  4 54 per share in third quarter 2019  surpassing the Zacks Consensus Estimate by 3 84   Quarterly earnings were up 18  year over year Cigna s revenues of  35 8 billion beat the Zacks Consensus Estimate by 5   Revenues grew 214  year over year owing to the acquisition of Express Scripts  NASDAQ ESRX  Among the revenue components  pharmacy revenues were  25 9 billion compared with  747 million in the year ago quarter  premiums were up 10 5  year over year to  9 9 billion while fees increased 68  to  2 3 billion  The growth in pharmacy revenues was backed by the acquisition of pharmacy benefit manager Express Scripts Cigna Corporation Price  Consensus and EPS Surprise    The SG A expense ratio was 9 2  for third quarter 2019  down from 23 8  in the year ago quarter  The decline was mainly led by business mix changes resulting from the Express Scripts combination and the health insurance tax suspension The company s medical enrollment grew by 212 000 lives from the prior year quarter to 17 07 million customers  driven by growth in Government  Commercial and International markets  Moreover  the acquisition of Express Scripts  completed last December  led to an increase in Pharmacy and Medicare Part D members Cigna s debt to capitalization ratio improved to 46 4  as on Sep 30  2019  from 50 9  as of Dec 31  2018 2019 GuidanceFor 2019  the company expects earnings per share in the range of  16 8  17 compared with the previous guidance of  16 6  16 9 Total revenues are expected to be  138 billion  versus  136  137 billion expected earlier  and medical customers are projected to grow by approximately 200 000 Medical care ratio is expected in the range of 80 8 81 2  versus previous estimate of 80 5 81 5  2020 GuidanceFor 2020  the company projects Health Services  retention rate of 97  for the 2019 selling season for pharmacy services  Health Services  adjusted pharmacy scripts are expected to grow between 25 million and 35 million organically in 2020 Our TakeCigna is well poised for the long term due to its recent acquisition of pharmacy benefit manager  Express Scripts  which provides a nice diversification to its existing businesses  namely administrative services  international operations  and disability and life insurance The combination of Express Scripts  pharmacy benefit business and Cigna s health insurance business will help control drug pricing cost to a large extent  which is one of the biggest components of soaring medical costs  The company has better control over its medical cost compared with other players in the industry  The decline in medical costs should further aid its margins Another distinguishing feature of the company is the international business  which provides additional diversification opportunities  Its strong balance sheet is another positive Zacks Rank and Other ReleasesCigna currently carries a Zacks Rank  3  Hold  
You can see  Other players in the medical space that have reported third quarter earnings so far are UnitedHealth Group  Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Wellcare Health Plans  Inc    NYSE WCG    each beating the Zacks Consensus Estimate by 3 47   0 62  and 39 95   respectively Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q3-earnings--revenues-beat-estimates-view-up-200480670,200480670
147129,368645,CI,Options Players  Analysts Lean Bullish Ahead Of Cigna Earnings,opinion,"Health services stock  Cigna Corp   NYSE CI  has been in rally mode since its one month low of  146 50  hit earlier this month  Since then  the stock has ended higher during all but three sessions  set to clock over a 16  monthly gain    its biggest in 10 years  A run in with its 320 day moving average has the stock pulling back from yesterday s three month high of  178 13  however  down 0 8  today at  176 69  as traders gear up for the company s third quarter earnings report  due out before tomorrow s open 




 
Looking back  CI s last three post earnings moves have been negative  More broadly speaking  the stock s earnings reactions over the past two years have been mixed  with an average next day move of 1 7  in either direction  This time around  the options market is pricing in an even bigger move of 5 9   
While recent earnings history doesn t bode particularly well for the security  Cigna  NYSE CI  has done well in November  historically speaking  The equity just showed up as one of the  next month  per data from Schaeffer s Senior Quantitative Analyst Rocky White  boasting a 90  positive return rate over the past 10 years  and averaging a 4 6  monthly pop 
Drilling deeper  sentiment among the options pits has been unusually bullish lately  On the International Securities Exchange  ISE   Cboe Options Exchange  CBOE   and NASDAQ OMX PHLX  PHLX   3 32 calls have been picked up for every put over the past 10 days  This ratio sits higher than 88  of all other readings from the past year  too  suggesting a much bigger than usual appetite for calls over puts in recent weeks  
Echoing this  CI s Schaeffer s put call open interest ratio  SOIR  of 0 51 sits in the 6th percentile of its annual range  This suggests short term options players have rarely been more call heavy during the past 12 months  
The brokerage bunch has favored the insurance name  too  Currently  17 of the 20 in coverage have given Cigna  NYSE CI  a  strong buy  rating  In the same vein  the consensus 12 month price target of  209 73 represents a level the equity hasn t hit since late last year ",2019-10-31,Schaeffer's Investment Research,https://www.investing.com/analysis/options-players-analysts-lean-bullish-ahead-of-cigna-earnings-200480543,200480543
147130,368646,CI,Cigna  CI  Beats Q3 Earnings And Revenue Estimates,opinion,"Cigna  CI  came out with quarterly earnings of  4 54 per share  beating the Zacks Consensus Estimate of  4 37 per share  This compares to earnings of  3 84 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 89   A quarter ago  it was expected that this health insurer would post earnings of  3 73 per share when it actually produced earnings of  4 30  delivering a surprise of 15 28  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Cigna  which belongs to the Zacks Insurance   Multi line industry  posted revenues of  35 83 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 5 08   This compares to year ago revenues of  11 45 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cigna shares have lost about 7 1  since the beginning of the year versus the S P 500 s gain of 21 5  
What s Next for Cigna 
While Cigna has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cigna was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 23 on  34 82 billion in revenues for the coming quarter and  16 77 on  136 71 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Insurance   Multi line is currently in the bottom 17  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-beats-q3-earnings-and-revenue-estimates-200480629,200480629
147134,368650,CI,Wall St  edges lower in choppy session,news,"By Sin ad Carew NEW YORK  Reuters    Wall Street s three major indexes fell slightly after a choppy session on Tuesday as investors eyed mixed U S  economic data and corporate news and waited for clarity on issues such as the U S  China trade talks  Weaker than expected housing data contrasted with a rosy consumer confidence report  while  Home Depot  Inc  NYSE HD  was among the biggest drags on the benchmark S P 500 index after the home improvement retailer blamed bad weather for missed Wall Street forecasts  Federal Reserve Chairman Jerome Powell told a U S  Senate Banking Committee that the central bank would remain  patient  in deciding on further interest rate hikes and that rising risks and recent soft data should not prevent solid growth for the economy this year  The indexes have already been bolstered in recent weeks by trade optimism and dovish signals from the Fed  with the S P 500 s session high just 4 7 percent away from its record closing high in September   Investors are a little tentative as far as chasing the market higher  They re waiting for better prices or better news   said Michael O Rourke  chief market strategist at JonesTrading in Greenwich  Connecticut  He cited issues such as a need for specifics on U S  China trade relations after President Donald Trump said on Sunday he would delay an increase in U S  tariffs on Chinese goods after  productive  trade talks  Sameer Samana  senior global market strategist at  Wells Fargo   NYSE WFC  Investment Institute in St  Louis  also cited uncertainty over reports that Trump s former personal attorney Michael Cohen would tell lawmakers this week that Trump asked him about a proposed skyscraper project in Moscow long after he had secured the Republican presidential nomination   You ve higher uncertainty today relative to yesterday   said Samana   The economic data was mixed  We ve had a market rally going on for about two months  All those things together suggest this would be a good time to take some profits  It s not wholesale selling but profit taking around the edges   The Dow Jones Industrial Average fell 33 97 points  or 0 13 percent  to 26 057 98  the S P 500 lost 2 21 points  or 0 08 percent  to 2 793 9 and the Nasdaq Composite dropped 5 16 points  or 0 07 percent  to 7 549 30   Seven of the 11 major S P sectors ended lower with industrials providing the biggest drag with a 0 3 percent drop  The benchmark s biggest boost was the technology index  which closed up 0 2 percent   The healthcare index declined 0 3 percent after a U S  congressional hearing on the prices of medicines wrapped up in Washington  Declines in shares of health insurers  Cigna Corp   NYSE CI  and UnitedHealth Group  NYSE UNH   both of which operate major pharmacy benefit managers  were big drags on the sector   The S P s biggest losing stock was JPMorgan Chase   Co  NYSE JPM   which closed down 0 8 percent after it warned of rising costs for deposits  a key part of its business  and slowing global economic growth   Caterpillar  Inc  NYSE CAT  fell 2 4 percent and also depressed the benchmark after brokerage UBS downgraded the stock to  sell  from a  buy  rating  U S  homebuilding tumbled to a more than two year low in December as construction of both single and multifamily housing declined  the latest sign that the economy had lost momentum in the fourth quarter  But the Conference Board s consumer confidence index rose more than expected in February  Declining issues outnumbered advancing ones on the NYSE by a 1 29 to 1 ratio  On Nasdaq  a 1 56 to 1 ratio favored decliners  The S P 500 posted 16 new 52 week highs and one new low  The Nasdaq Composite recorded 45 new highs and 21 new lows  
Volume on U S  exchanges was 7 05 billion shares  compared to the 7 3 billion average for the last 20 trading days ",2019-02-26,Reuters,https://www.investing.com/news/stock-market-news/home-depot-caterpillar-weigh-on-stock-futures-fed-testimony-awaited-1790628,1790628
147135,368651,CI,Amazon  Berkshire  JPMorgan healthcare company to be called Haven,news,"NEW YORK  Reuters    Amazon com Inc  NASDAQ AMZN   Berkshire Hathaway  NYSE BRKa  Inc and JPMorgan Chase   Co  NYSE JPM  on Wednesday said their joint healthcare company would be called Haven and will focus on better primary care access  simpler insurance benefits and more affordable prescription drugs for their employees  Haven will be tasked with improving healthcare for the three companies  1 2 million employees and family members in the United States  but will also share its findings with outsiders  according to its website  launched on Wednesday  Haven did not say when the changes would be in place for employees  The three companies announced plans for a new venture in January of 2018  shaking the shares of health insurance companies like UnitedHealth Group Inc  NYSE UNH  and  Cigna Corp   NYSE CI  that manage large corporate benefits on worries that Amazon would disrupt the traditional insurance and drug benefit businesses  Haven Chief Executive Atul Gawande  who has been running the company since July  said in a news release that the company plans to start small and expand  Haven said it is  interested in working with clinicians and insurance companies to improve the overall health care system   according to the website  
Haven is based in Boston and has offices in New York ",2019-03-06,Reuters,https://www.investing.com/news/stock-market-news/amazon-berkshire-jpmorgan-healthcare-company-to-be-called-haven-1799881,1799881
147136,368652,CI,Apps let more women  swipe right  to find friends,news,"By Jillian Kitchener NEW YORK  Reuters    Women have long relied on dating apps to find romantic partners  but many now are going online to seek another special someone  a friend  Friend finding apps such as Bumble BFF and GirlCrew are becoming more popular with women  many of whom work remotely or move around the globe for career pursuits   Cindy wasn t my first   said Priya Vedhara  35  smiling as she sat next to Cindy Santos  39  another Brooklyn resident whom she met through Bumble BFF  Two months later they are friends who share a glass of wine as well as life s complaints and comforts   I swiped and we matched   said Vedhara  a regional manager for a hair loss consultancy who said an initial volley of online messages revealed their shared sense of humor  The first time they met in person  they shared a  hilarious  night on a dance floor  recalled Santos  a child welfare project manager  who moved to New York from Philadelphia in March 2017   Very quickly I thought to myself   Yeah  this could be a good girlfriend for me    said Vedhara  who recently moved to New York from London  Both women had previously used dating apps to meet men  But they met each other on a break from romance to focus instead on cultivating platonic friendships with women to better weather the ups and downs of living in New York City    Having a very strong group of female friends in the UK is something I deeply missed here   Vedhara said   I found I couldn t enjoy the city without some good girlfriends   Making friends can be more challenging as people grow older  especially at a time when remote employment and independent freelance work have become the norm  experts said   Loneliness is a global challenge  Nearly half of Americans say they sometimes or always feel alone or left out  according to a 2018 Cigna  NYSE CI  and Ipsos study  Britain last year appointed a minister for loneliness to address the social isolation felt by more than one in 10 people in the country   Friendship carries both mental and physical benefits  said Ali Mattu  clinical psychologist at Columbia University Irving Medical Center   Going from not knowing each other to identifying shared interests is one of the first steps in making a new friend and apps  online communities  the internet can fast track that   Mattu said   They make it a lot easier to get over that first big step   Bumble BFF  which the dating app Bumble launched worldwide in 2016  counts among its friendship successes an Atlanta based group of baseball loving women who go to Braves games together  said Bumble Chief Brand Officer Alex Williamson  
GirlCrew s 100 000 members in more than 50 cities across seven countries include women who may want to team up for an afternoon of axe throwing or hiking or a pottery class  said co CEO Pamela Newenham ",2019-03-08,Reuters,https://www.investing.com/news/technology-news/apps-let-more-women-swipe-right-to-find-friends-1800431,1800431
147137,368653,CI,Cigna Shares Hit 52 Week Low on Trump Bid to Kill ACA ,news,"Investing com   The Trump Administration wants the entire Affordable Care Act  also known as Obamacare  declared unconstitutional and Cigna  NYSE CI  shares fell back Tuesday as a result 
The shares were down 1 8  Tuesday afternoon and hit a 52 week low of  160 37  The shares are off 29  since peaking on Dec  3 and down more than 15  this year 
The administration s position came in a letter sent to the Fifth Circuit Court of Appeals  The court is hearing an appeal of a Texas court decision that declared the entire ACA unconstitutional 
The administration told the appeals court that  it is not urging that any portion of the district court s judgment be reversed    
Health insurance stocks generally were lower on Tuesday 
UnitedHealth Group  NYSE UNH   off 1 6   was the worst performer among the 30 stocks in the Dow Jones Industrial Average  and Molina Healthcare  NYSE MOH  was off 9 5  
Critics of the Administration s current position  who include the health insurance industry  say gutting the ACA entirely will take away insurance coverage from as many as 100 million Americans and cause chaos for consumers  healthcare providers and health insurance companies 
The case will likely be appealed to the Supreme Court no matter who wins on the appeal  It will also likely be a political issue for the 2020 election 
Cigna earned  2 46 a share in the fourth quarter on revenue of  14 3 billion  Both beat estimates from analysts polled by Investing com  The stock has been weak since December in part because of the uncertainty created by the Texas ACA decision 
Cigna will be spending much of this year digesting its  67 billion acquisition pharmacy benefit manager Express Scripts  NASDAQ ESRX  
Its 2019 results won t be comparable to 2018 because the Express Scripts deal  The current Investing com consensus is earnings of  3 76 a share on revenue of  34 1 billion 
The Express Scripts deal is part of an industry trend for health insurers and pharmacy management operations to combine in hopes of cutting prices  But the deals will also intensify competition  United Health  which owns Optum Rx and drugstore chain CVS Health  NYSE CVS   bought Aetna  NYSE AET  in a  70 billion deal in late 2018 ",2019-03-26,Investing.com,https://www.investing.com/news/stock-market-news/cigna-shares-hit-52week-low-on-trump-bid-to-kill-aca-1818713,1818713
147138,368654,CI,U S  Health insurer Centene to buy smaller rival WellCare for  15 3 billion,news,"By Michael Erman and Tamara Mathias  Reuters    U S  health insurer  Centene   NYSE CNC  Corp on Wednesday said it would buy smaller rival WellCare Health Plans Inc for  15 27 billion in stock and cash  in a move to bulk up its government backed Medicare and Medicaid businesses while reducing exposure to Obamacare healthcare exchanges  Shares of WellCare jumped 9 8 percent to  253 98  Centene shares fell about 7 5 percent to 50 71  The announcement comes days after the Trump administration stepped up its opposition to former President Barack Obama s signature healthcare law  The Department of Justice  DOJ  on Monday said it believes the Affordable Care Act  ACA   popularly known as Obamacare  violated the U S  Constitution and that the law should be struck down  Centene relies on its Obamacare business for about 40 percent of its earnings  making it among the most vulnerable companies should the law be overturned  according to SVB Leerink analyst Ana Gupte  The combined company will have 22 million members  up from around 14 million for Centene at the end of 2018   The more we can grow in this area  the better the recipients are  the better for the investors     And there are other very large competitors out there   Centene Chief Executive Michael Neidorff said on a conference call  Neidorff will remain CEO of the combined company  It will have a Medicaid business in 22 states  covering more than 11 million lives  according to Jefferies data  That represents a more than 50 percent increase for Centene   Since the beginning of 2014  when Obamacare s Medicaid expansion began taking effect on a significant scale  shares of both companies have surged  Centene s shares are up around 272 percent  while WellCare shares rose around 228 percent  The two companies Medicaid businesses currently have significant overlap in Illinois  Florida  Georgia and Missouri  according to Jefferies  The deal is expected to close in the first half of 2020  the companies said  They forecast around  500 million in cost savings from the deal in the second year after it closes   The deal  including debt  was valued at  17 3 billion  The offer price of  305 39 per share represents a premium of about 32 percent to WellCare s closing price on Tuesday  Under its terms  WellCare shareholders will get 3 38 shares of Centene common stock and  120 for each WellCare share  giving them about 29 percent ownership of the new company  Centene s planned acquisition of WellCare continues a wave of consolidation in U S  healthcare  coming after two large health insurers combined with the two largest U S  pharmacy benefit managers in deals that closed last year  
In those deals  CVS Health Corp  NYSE CVS  bought  Aetna Inc   NYSE AET  for  69 billion  while  Cigna Corp   NYSE CI  acquired Express Scripts  NASDAQ ESRX  Holding Co for  54 billion ",2019-03-27,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-centene-to-buy-smaller-rival-wellcare-for-1527-billion-1819307,1819307
147144,368660,CI,Options Traders Expect Huge Moves In Cigna  CI  Stock,opinion,Investors in Cigna Corporation   NYSE CI   need to pay close attention to the stock based on moves in the options market lately  That is because the Oct 11  2019  162 50 Put had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for Cigna shares  but what is the fundamental picture for the company  Currently  Cigna is a Zacks Rank  2  Buy  in the Insurance   Multi line industry that ranks in the Top 43  of our Zacks Industry Rank  Over the last 30 days  no analysts have increased their earnings estimates for the current quarter  while two have dropped their estimates  The net effect has taken our Zacks Consensus Estimate for the current quarter from  4 35 per share to  4 37 in that period Given the way analysts feel about Cigna right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Check out the simple yet high powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple digit winners  In addition to impressive profit potential  these trades can actually reduce your risk ,2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/options-traders-expect-huge-moves-in-cigna-ci-stock-200472202,200472202
147145,368661,CI,Will UnitedHealth s  UNH  Benefits Business Aid Q3 Earnings ,opinion,"UnitedHealth Group Inc  s   NYSE UNH   health service segment UnitedHealthcare is likely to have performed well in the third quarter  which may reflect on the quarterly results  slated for release on Oct 15 UnitedHealthcare benefits business has been a major contributor to the company s top line growth In the last reported quarter  revenues from UnitedHealthcare grew 6 1  year over year  Revenue growth was driven by higher enrollment and increase in pricing  All the business groups   Employer and Individual  Medicare and Retirement and Community and State contributed to the growth  Earnings from operations were up 12 1  year over year to  2 6 billion  led by revenue growth and cost control  to know how the company s overall third quarter performance is expected to be Let s Delve DeeperUnitedHealthcare has consistently witnessed balanced growth  serving increasingly diverse markets  Among these growing market segments are Medicaid  including people needing long term services and support and dual eligible individuals  seniors  including Medicare Advantage and Part D plans  as well as employer sponsored retiree groups  large national employers  along with medium and small employer groups  and emerging markets  like global health benefits  social services  personalized wellness and caregiver services The segment is likely to have seen an increase in membership in the third quarter  primarily as a result of acquisitions and growth in services to self funded employers and seniors Within UnitedHeathcare  fee based commercial group business should have benefitted from an acquisition Revenues from Medicare Advantage business is likely to show an increase due to growth in people served through individual and employer sponsored group Medicare Advantage plans UnitedHealthcare Community   State revenues should have gained from growth in people served with higher acuity needs The segment s operating earnings should have benefitted from operating cost management Zacks Rank   Key Picks
Currently  UnitedHealth carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader healthcare sector include Molina Healthcare  Inc    NYSE MOH    Cigna Corp    NYSE CI   and HCA Healthcare  Inc    NYSE HCA    While Molina sports a Zacks Rank  1  Strong Buy   Cigna and HCA Healthcare carry a Zacks Rank of 2  Buy   You can see  Long term earnings growth for Molina Healthcare  Cigna and HCA Healthcare is currently projected at 9 6   11 7  and 11 3   respectively Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/will-unitedhealths-unh-benefits-business-aid-q3-earnings-200473113,200473113
147151,368667,CI,UnitedHealth profit beats on strength in Optum  insurance units,news," Reuters    UnitedHealth Group Inc  N UNH  beat Wall Street estimates for fourth quarter profit on Tuesday  helped by growth in services business as well as its mainstay health insurance plans  The largest U S  health insurer kicked off earnings season for the sector  reporting  46 23 billion in sales in its insurance business  an 11 1 percent rise from a year earlier  Revenue from Optum  which includes a pharmacy benefits management business  grew 13 percent to  27 56 billion in the quarter  benefiting from growth in care delivery  behavioral health and health financial services  the company said   UnitedHealth and its Optum unit are set to face tough competition this year  as health insurer rivals  Cigna Corp   N CI  and  Aetna Inc   NYSE AET  entered into separate deals with large benefit managers  UnitedHealth s 2018 medical care ratio  or the percentage of premiums paid out for medical services  improved to 81 6 percent from 82 1 percent last year  The health insurer also affirmed its 2019 profit forecast    Despite the beat  management did not increase its 2019 guidance  This is not surprising to us  Over the years  UnitedHealth has typically been conservative   Cantor Fitzgerald analyst Steven Halper said in a client note  calling the results a  solid finish  to 2018   Net earnings attributable to shareholders fell 16 percent to  3 04 billion  or  3 10 per share  in the quarter ended Dec  31  Excluding items  the company earned  3 28 per share  Total revenue rose about 12 percent to  58 42 billion  Analysts on average were expecting earnings of  3 21 per share and revenue of  58 01 billion  according to IBES data from Refinitiv   
Shares of the Hopkins  Minnesota based company rose 1 6 percent to  252 in light trading before the opening bell ",2019-01-15,Reuters,https://www.investing.com/news/stock-market-news/unitedhealth-fourthquarter-profit-drops-16-percent-1747079,1747079
147152,368668,CI,CVS  Walmart resolve pharmacy contract impasse,news," Reuters    Walmart Inc  N WMT   the world s largest retailer  will remain part of CVS Health Corp s  N CVS  network for commercial and Medicaid pharmacy customers  the companies said on Friday  breaking a contract impasse disclosed earlier this week   The companies did not provide financial terms of the new contract  On Tuesday  CVS said the companies had failed to agree on pricing and that Walmart was leaving the pharmacy network for prescription drug plans that CVS manages for companies and health insurers and for the government run Medicaid program for low income people  Walmart and CVS also said on Tuesday they were still in discussions   CVS shares gained 1 6 percent to  64 76 in premarket trading  recouping some of the stock s losses on Tuesday    We view the agreement positively for CVS   Cantor Fitzgerald analyst Steven Halper said in a research note  explaining that the loss of Walmart pharmacies could have negatively impacted CVS  ability to sign up customers for its 2020 prescription drug plans  Evercore ISI analyst Ross Muken said the speed at which the dispute was resolved likely points to the negotiating strength of pharmacy benefit managers in contract discussions  Consumers historically move to where their insurance is accepted  and Walmart likely would have lost out on the estimated 15 million to 20 million prescriptions it receives from CVS customers  Muken said  In 2012  Walgreens Boots Alliance  O WBA  and pharmacy benefit manager Express Scripts  NASDAQ ESRX   now part of  Cigna Corp   N CI   failed to come to contract terms  Walgreens sales fell as it stopped filling prescriptions for Express Scripts customers  and the two companies reached a new agreement in the middle of the year that put Walgreens back in its network  In addition to its retail pharmacies and stores  CVS is one of the country s biggest pharmacy benefit managers and  after buying Aetna  NYSE AET   one of its top health insurance companies  Its prescription plans for those on the government run Medicare program were unaffected by the contract dispute as was its Sam s Club agreements  
Sean Slovenski  a Walmart senior vice president  described the terms as  fair and equitable  in a press release ",2019-01-18,Reuters,https://www.investing.com/news/stock-market-news/cvs-walmart-reach-new-agreement-for-pharmacy-network-1750797,1750797
147154,368670,CI,Exclusive  CVS to cover migraine drugs from Teva  Lilly  excludes Amgen,news,"By Caroline Humer and Deena Beasley NEW YORK  Reuters    CVS Health Corp  NYSE CVS   a top U S  manager of pharmacy benefits  has added new migraine drugs from Teva Pharmaceutical Industries  NYSE TEVA  and Eli Lilly  NYSE LLY  and Co to its list of covered drugs  excluding a rival treatment from  Amgen Inc   NASDAQ AMGN   a CVS spokeswoman told Reuters on Friday   CVS s decision represents a setback for sales of Amgen s Aimovig  as many patients who rely on the coverage list will now have easier access to the rival Teva and Lilly drugs  Inclusion on the preferred drugs lists by the largest pharmacy benefit managers  PBMs  and health insurers is seen as critically important for sales of new medicines  About 39 million Americans suffer from migraine headaches  according to the Migraine Research Foundation  and global migraine drug sales could reach  8 7 billion by 2026  according to analytics firm GlobalData  Shares of Amgen fell 1 3 percent to  198 27  Teva shares traded in New York were up 1 3 percent at  19 60  while Lilly was off 0 5 percent at  114 36  An Amgen spokeswoman said the company was disappointed by the CVS decision and that it would work toward Aimovig being a preferred brand on CVS coverage lists  The move by CVS is a positive development for Teva  whose drug was initially excluded from the list of covered drugs by Express Scripts  NASDAQ ESRX   another large U S  PBM  Its status recently changed and it may appear on some coverage lists  but likely with a higher out of pocket cost  Express Scripts said on Friday  Teva s Ajovy and Lilly s Emgality will be available to members who have tried and failed to be helped by other preventive migraine treatments  CVS spokeswoman Christine Cramer said in an emailed statement  The treatments belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines  and whose prices were backed as cost effective by the Institute for Clinical and Economic Review  Cramer said  ICER is a non partisan research organization that reviews the clinical and economic value of medicines  Cramer did not provide a reason for why the company had excluded Amgen   PBMs typically extract discounts from drugmakers in return for favorable placement on their list of covered drugs  such as through a low co payment  or coinsurance payment  for their members   A Teva spokeswoman said in a statement that 60 percent of commercial patients now have access to Ajovy through covered drug lists and that discussions are continuing with other national and regional payers  All three migraine drugs have a list price of  575 a month  or  6 900 a year  Those prices do not reflect rebates and discounts drugmakers typically provide to PBMs  who design and negotiate benefits for employers and insurers  All three companies have said that they are providing a limited duration supply of these drugs at no cost directly to patients in addition to other assistance programs  Amgen was the first of the three companies to launch a drug in the new class  The rival drugs from Teva and Lilly  which work in a similar manner  came on the market soon after  CVS  policy is similar to that of Express Scripts  which requires patients first try two older preventive therapies and a triptan  a family of generic drugs used to treat acute migraine  Express is now part of  Cigna Corp   NYSE CI   
Lilly did not respond to a request for comment ",2019-01-25,Reuters,https://www.investing.com/news/stock-market-news/exclusive-cvs-to-cover-migraine-drugs-from-teva-lilly-excludes-amgen-1758291,1758291
147157,368673,CI,Bill Gross Is a Cautionary Tale for Any Future Bond Kings,news," Bloomberg Opinion     Six months ago  I asked if  it s worth stepping back to wonder whether we re witnessing the end of the line  for Bill Gross  There s no need to wonder any longer 
Gross is retiring from Janus Henderson Group Plc  the firm announced Monday  more than four years after leaving his perch atop the bond market world at Pacific Investment Management Co  His stint running the Janus Henderson Global Unconstrained Bond Fund should serve as a cautionary tale for fixed income investors who think they re smarter than the rest of the market 
The issue that plagued Gross was that he was too unconstrained for his own good at Janus  His fund topped out at about  2 2 billion of assets   not an insignificant sum  but a far cry from the almost  300 billion that he ran at Pimco  That huge pool of money meant he was the market  which explains why bond traders used to hang on his every word  Being the world s largest mutual fund also restrained his investing because by and large there wasn t enough for him to buy aside from the more traditional fixed income securities 
During his time at Janus  however  he was nimble enough to invest like a hedge fund manager  He made a big bet on the convergence of U S  and German 10 year yields at precisely the wrong time  with the Federal Reserve raising interest rates while the European Central Bank remained on hold  The effective duration of his fund somehow fell to minus 4 58 years at one point  even though the prospectus on Janus s website says the  fund s average portfolio duration may range from negative 4 years to plus 6 years   What s more  it went against what Gross was saying publicly   that the bond bear market would be  relatively mild   hardly an environment to take a big bet on rising rates  Most recently  he appeared to employ a  merger arbitrage  strategy  a long position in shares of Express Scripts  NASDAQ ESRX  Holding Co  and a short position in those of  Cigna Corp   NYSE CI  
This experiment didn t end well for Gross or for those who entrusted their money with him   The unconstrained strategy Mr  Gross manages has underperformed its three month Libor benchmark since Mr  Gross joined Janus Henderson in late 2014   according to the press release announcing his retirement  Just over the past year  the fund fell 4 86 percent  It gained 2 43 percent in 2017 and 5 26 percent in 2016  which trailed its peer group  according to data compiled by Bloomberg  In 2015  when the fund fell 0 43 percent  it did better than its counterparts 
Gross  for his part  seems to understand that he may have miscalculated with his unconstrained fund  
 Maybe I should have stuck to total return and been a little more constrained   he said in an interview with Tom Keene on Bloomberg Television  He said he managed some total return accounts at Janus and they outperformed  like the old days  
Gross said that the idea of total return investing  in his mind  was  based on measured risk taking   He didn t heed that advice  and that was his downfall  He seemed contemplative during the interview with Keene  comparing his big bet on Treasuries versus bunds in terms of blackjack  saying he put too many chips on the table with that trade  Of course  Gross was briefly a blackjack success in Las Vegas   turning  200 into  10 000 over four months  raising the tuition for his MBA at UCLA   which only added to his mystique as a bond savant  
By now  it should be clear that there is no such thing  Not when a fund manager is able to  go anywhere   unshackled by any sorts of guidelines or parameters  Gross learned that the hard way  After all  much of his own money was at stake  Anyone else who wants to stake their reputation on running an unconstrained strategy   or investing in one   should do so at their own risk ",2019-02-04,Bloomberg,https://www.investing.com/news/stock-market-news/bill-gross-is-a-cautionary-tale-for-any-future-bond-kings-1768500,1768500
147161,368677,CI,Sanofi and Regeneron cut list price of cholesterol drug by 60 percent,news,"By Michael Erman NEW YORK  Reuters    Sanofi  PA SASY  SA and Regeneron Pharmaceuticals Inc  NASDAQ REGN  said on Monday that they will slash the U S  list price of their potent but expensive cholesterol fighter Praluent by 60 percent  as the drugmakers follow a similar move by rival  Amgen Inc   NASDAQ AMGN  in hopes of increasing use of the drug  The new list price for Praluent will be  5 850 a year  matching the price Amgen set when it lowered the list of its competing drug  Repatha  in October  Sanofi and Regeneron said they expect the lower priced Praluent to be available for pharmacies to order in early March  They said the new price should improve patient access and result in lower out of pocket costs for U S  consumers  Praluent and Repatha belong a class of injectable biotech drugs called PCSK9 inhibitors that dramatically lower bad LDL cholesterol and reduce the risk of heart attacks and death  Sales of both have been severely constrained by onerous roadblocks to patient access put up by insurers looking to limit spending on the expensive drugs  They were approved in 2015 with initial list prices of more than  14 000 a year  In March of last year  Regeneron and Sanofi said that they would be willing to charge less for their drug if insurers agreed to reduce barriers for high risk heart patients  A few months later they struck a deal with Express Scripts  NASDAQ ESRX   now part of  Cigna Corp   NYSE CI   to make the drug available to that company s customers at a price in the range of  4 500 to  6 600 a year  The United States  which leaves drug pricing to market competition  has higher prices than in other developed countries  where governments directly or indirectly control costs  That makes it by far the world s most lucrative market for manufacturers  Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for U S  consumers  particularly since Democrats took over the House of Representatives in January  Executives from at least six drugmakers plan to testify at a Senate hearing on rising prescription drug prices later this month  
Drug pricing is also a top priority of the administration of President Donald Trump  who had made it a central issue of the 2016 presidential campaign ",2019-02-11,Reuters,https://www.investing.com/news/stock-market-news/sanofi-and-regeneron-cut-list-price-of-cholesterol-drug-by-60-percent-1775627,1775627
147166,368682,CI,Can Cigna  CI  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Cigna  CI   which belongs to the Zacks Insurance   Multi line industry  could be a great candidate to consider 
When looking at the last two reports  this health insurer has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 9 78   on average  in the last two quarters 
For the most recent quarter  Cigna was expected to post earnings of  3 73 per share  but it reported  4 30 per share instead  representing a surprise of 15 28   For the previous quarter  the consensus estimate was  3 74 per share  while it actually produced  3 90 per share  a surprise of 4 28  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Cigna  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Cigna has an Earnings ESP of  2 20  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  2  Buy   it shows that another beat is possibly around the corner  The company s next earnings report is expected to be released on October 31  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-03,Zacks Investment Research,https://www.investing.com/analysis/can-cigna-ci-keep-the-earnings-surprise-streak-alive-200470745,200470745
147167,368683,CI,Cigna  CI  Outpaces Stock Market Gains  What You Should Know,opinion,"Cigna  CI  closed the most recent trading day at  150 74  moving  1 43  from the previous trading session  The stock outpaced the S P 500 s daily gain of 1 42   Meanwhile  the Dow gained 1 42   and the Nasdaq  a tech heavy index  added 1 4  
Coming into today  shares of the health insurer had lost 1 58  in the past month  In that same time  the Finance sector gained 1 72   while the S P 500 gained 0 38  
Investors will be hoping for strength from CI as it approaches its next earnings release  which is expected to be October 31  2019  On that day  CI is projected to report earnings of  4 37 per share  which would represent year over year growth of 13 8   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  34 02 billion  up 197 23  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  16 77 per share and revenue of  136 55 billion  which would represent changes of  17 93  and  183 82   respectively  from the prior year 
Any recent changes to analyst estimates for CI should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 01  higher  CI currently has a Zacks Rank of  2  Buy  
Valuation is also important  so investors should note that CI has a Forward P E ratio of 8 86 right now  This valuation marks a discount compared to its industry s average Forward P E of 10 42 
Investors should also note that CI has a PEG ratio of 0 76 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Insurance   Multi line was holding an average PEG ratio of 1 16 at yesterday s closing price 
The Insurance   Multi line industry is part of the Finance sector  This industry currently has a Zacks Industry Rank of 106  which puts it in the top 42  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-10-04,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-outpaces-stock-market-gains-what-you-should-know-200470829,200470829
147175,368691,CI,Anthem profit beats as insurer reins in costs,news," Reuters    Anthem Inc  N ANTM  reported quarterly profit that beat Wall Street estimates on Wednesday  helped by lower costs at its commercial insurance business and the company raised its full year adjusted earnings forecast  The insurer s benefit expense ratio   an insurer s spending on claims against the premiums it earns   narrowly missed the consensus estimate of 84 7 percent by brokerage Evercore ISI   However  the ratio improved to 84 8 percent in the quarter from 87 percent in the year ago period   Anthem said it now expects the ratio for the full year to be around 84 2 percent  an improvement from its prior forecast of 84 4 percent  Evercore analyst Michael Newshel said in a note that any worries about the small miss in ratio for the quarter could be tempered by the lowered forecast for benefit expense   As the health insurance industry doubles down on ways to tighten spending  Anthem s rivals  Aetna Inc   N AET  and  Cigna Corp   N CI  have separately signed multi billion dollar deals to merge with pharmacy benefit managers  However  Anthem has decided to take its pharmacy benefits business in house in 2020  when it will start managing billions of dollars of patient prescriptions in a bid to cut costs   In the third quarter  total membership fell by 753 000 members from 40 3 million members in the year ago period  as the company continues to exit its Obamacare business and lost out on members buying its Medicaid health plans for low income members  However  membership in its Medicare business  which caters to the elderly and people with disabilities  rose nearly 18 percent to 1 77 million from a year earlier  boosted by Anthem s acquisitions of health insurers HealthSun and America s 1st Choice   Anthem said it now expected full year adjusted earnings forecast to be more than  15 60 per share  up from the prior forecast of over  15 40 per share   Net income rose to  960 million  or  3 62 per share  in the third quarter ended September 30  Excluding items  the company earned  3 81 per share  beating the average analyst estimate of  3 70 per share  according to Refinitiv data  
Total revenue rose 3 7 percent to  23 25 billion  beating the analyst average estimate of  22 94 billion ",2018-10-31,Reuters,https://www.investing.com/news/stock-market-news/anthem-quarterly-profit-beats-estimates-raises-2018-forecast-1667397,1667397
147176,368692,CI,Cigna profit beats on strength in commercial health plan unit,news," Reuters     Cigna Corp   N CI  on Thursday posted a better than expected third quarter profit as the health insurer earned more in premiums and added more members to its commercial health plans  The company also raised its earnings forecast for the year and now expects full year adjusted income of  14 20 to  14 40 per share  compared with its prior forecast of  13 60 to  13 90 per share  Cigna s commercial medical loss ratio   the amount it spends on medical claims compared to income from premiums   improved to 76 3 percent in the third quarter  from a year ago ratio of 78 6 percent   The commercial business  which saw a 3 percent rise in membership to 15 8 million  benefited from corporate and individual health plans sold  Net income for Cigna shareholders rose to  772 million  or  3 14 per share  in the third quarter ended Sept  30  from  560 million  or  2 21 per share  a year earlier   Excluding items  Cigna earned  3 84 per share  above the average analyst estimate of  3 44 per share  according to Refinitiv data  
Cigna  which is buying pharmacy benefit manager Express Scripts Holding Co  O ESRX  in a  52 billion deal  said total revenue rose 9 2 percent to  11 46 billion ",2018-11-01,Reuters,https://www.investing.com/news/stock-market-news/cignas-thirdquarter-profit-rises-driven-by-lower-medical-costs-1669559,1669559
147177,368693,CI,Health Care Stocks Sink Midday After Obamacare Ruling,news,"Investing com   Health care stocks were lower in midday trading after a judge in Texas ruled late Friday that the Affordable Care Act is unconstitutional 
The S P 500 Health Care index fell about 1  
The decision late on Friday argued that the health care law can t stand on its own since Congress repealed the individual mandate last year  which imposed a tax penalty on those who were not insured 
The lawsuit is expected to be appealed and possibly heard by the Supreme Court  but does not go into immediate effect  If upheld  it would mean fewer customers for insurance companies and fewer insured patients for hospitals 
 Centene   NYSE CNC  fell 6    Universal Health Services   NYSE UHS  dipped 1 4  and Cigna  NYSE CI  lost 1 5  
Anthem  NYSE ANTM  declined 2   while WellCare Health Plans  NYSE WCG  inched down 0 9   UnitedHealth Group  NYSE UNH  slipped 1 2  ",2018-12-17,Investing.com,https://www.investing.com/news/stock-market-news/health-care-stocks-sink-midday-after-obamacare-ruling-1723770,1723770
147181,368697,CI,Cigna closes  54 billion purchase of Express Scripts,news,By Caroline Humer NEW YORK  Reuters     Cigna Corp   N CI  on Thursday closed its  54 billion deal to buy Express Scripts  NASDAQ ESRX  Holding Co  creating one of the biggest providers of pharmacy benefits and insurance plans in the United States  a combination it says will help it improve healthcare coordination and cut costs  Cigna s deal puts it in direct competition with two other healthcare companies set up the same way   Aetna  NYSE AET  with CVS Health Corp  N CVS  and UnitedHealth Group Inc  N UNH  with Optum  Cigna s deal has already passed antitrust scrutiny  Cigna will start offering new products next year to its corporate health insurance customers  including access to Express Scripts  specialty pharmacy  which has cost savings programs in treatment areas such as cancer  its top executive said in an interview on Thursday  Prescription drugs that require special handling and are delivered to a doctor s office or patient home by specialty pharmacies are a growing part of employer healthcare spending and rising U S  drug costs  Many new drugs costs tens of thousands of dollars when they are launched and drugmakers raise the price of older drugs once or twice a year  The company will also try to improve products and services by integrating healthcare data  he said   There s a lot of data available today but it s either not aggregated in a singular place or coalesced in a way that s intuitive   Cigna Chief Executive Officer David Cordani said in an interview ,2018-12-20,Reuters,https://www.investing.com/news/stock-market-news/cigna-closes-its-54-billion-purchase-of-express-scripts-1727867,1727867
147186,368702,CI,Magellan Healths Growth Measures Aid Investors  Confidence ,opinion,"Magellan Health  Inc  s   NASDAQ MGLN   strategic initiatives to rake in growth seems to be slowly taking off  Though the company has sustained declining earnings and revenues for the first nine months of 2019  investors  have been cognizant of the green shoots appearing in its Pharmacy Management business and greater clarity for its overall business performance 
Increased visibility for business growth in the second half of 2019 have supported the stock price gain of 7 8  compared with the  s decline of 5 4   In 2018  the stock slid 41  due to its disappointing performance 

 
During June 2018  sources reported that Magellan Health was mulling its possible sale to private equity firm Centerbridge Partners  after it came under pressure  due to its prolonged underperformance  from activist hedge fund Starboard Value  which owned nearly 10  stake in the company 
The second quarter earnings provide a clearer visibility into second half earnings performance  Though the company anticipates year over year decline in top line for 2019  it expects new business wins and lower costs to support overall results 
Magellan Health expects earnings growth in the Pharmacy Management segment  which contributed nearly 40  of total revenues in 2018  This should be driven on the back of improvement in cost of goods sold  addition of a new business in 2019  and a normal seasonality in the fourth quarter 
Also  Healthcare segment  which made up nearly 60  of the company s revenues in 2018  should see higher earnings from the normalization of utilization and finalization of New York reimbursement rates 
The sale of Magellan Health has become deadlocked  Thus  it is focusing on business growth 
Magellan Health carries a Zacks Rank  3  Hold   Some better ranked players in the same space are Molina Healthcare    NYSE MOH    UnitedHealthcare Group  Inc    NYSE UNH   and Cigna Corp    NYSE CI    Each of these stocks carries a zacks rank  2  Buy  You can see  
Cigna has surpassed earnings estimates in three of the four reported quarters by 7 02   UnitedHealth and Molina Health have surpassed the same in each of the four reported quarters by 3 37  and 66 93   respectively 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/magellan-healths-growth-measures-aid-investors-confidence-200459571,200459571
147187,368703,CI,Here s Why Cigna  CI  Is An Attractive Investment Option Now,opinion,The stock of Cigna Corp    NYSE CI   witnessed the Zacks Consensus Estimate for current year earnings being revised 1 4  upward over the last 30 days  This shows analyst s optimism over the company s favorable performance  driven by the recently closed acquisition of Express Scripts  NASDAQ ESRX  The addition of Express Scripts has provided diversification to Cigna s existing businesses   administrative services  international operations  and disability and life insurance  which are already performing well  For the first nine months of 2019  the company s revenues and EBITDA grew 196  and 77   respectively  mainly due to accretion from the acquisition of Express Scripts Following its second quarter performance  management raised its earnings outlook for 2019  representing 17 19  EPS growth over the company s strong 2018 performance It expects to deliver  20 to  21 of EPS in 2021 and 10  to 13  average annual EPS growth over the long term The combination of Express Scripts  pharmacy benefit business with Cigna s health insurance business will help control drug pricing costs to a large extent  which is one of the biggest components of soaring medical costs  Notably  Cigna has a better control over its medical costs than other players in the industry  The decline in medical costs should further aid its margins Another distinguishing feature of the company is its international business  which provides additional diversification opportunities  Other than Cigna  only UnitedHealth Group  Inc    NYSE UNH   has a growing international business Cigna s international business  which includes India  Hong Kong  Turkey and the Middle East  among others  has overall recorded double digit revenue and earnings growth for the past seven years  The biggest international market for Cigna is South Korea  where it has been operating for more than three decades Moreover  the company has a large chunk of revenues coming from the administrative services only   ASO   business  which though has lower profitability  is growing in size and provides opportunities for cross selling Another positive for Cigna is its strong capital position  Its cash flow from operations has been increasing consistently over the years   An increasing cash flow provides scope for investment in business  Though the company s leverage levels have increased due to the purchase of Express Scripts  the same should moderate over time as it repays debt Year to date  the stock is down 22  compared with the  s decline of 8   This fall in the stock price makes it an attractive buy  The stock also looks undervalued with its 12 month forward price to earnings ratio of 8 2 compared with 13 1 for the industry   Cigna currently carries a Zacks Rank  2  Buy   Some other top ranked stocks are Molina Healthcare  Inc    NYSE MOH   and Anthem inc    NYSE ANTM    both sporting a Zacks Rank  1  Strong Buy  at present  Molina Healthcare and Anthem surpassed estimates in each of the four reported quarters  the average positive surprise being 66 93  and 4 6   respectively You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/heres-why-cigna-ci-is-an-attractive-investment-option-now-200459925,200459925
147188,368704,CI,The Zacks Analyst Blog Highlights  First Horizon National  Cigna  Ally Financial And Och Ziff Capital Management,opinion,For Immediate ReleaseChicago  IL   August 29  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  First Horizon National Corp    NYSE FHN    Cigna Corp    NYSE CI    Ally Financial Inc    NYSE ALLY   and Och Ziff Capital Management Group Inc    NYSE OZM   Here are highlights from Wednesday s Analyst Blog  Are Investors Wrong Selling These 4 Finance Stocks Now Several macroeconomic concerns have been hurting investor sentiments of late  These matters have led to a bearish stance toward the overall stock markets  with the Finance sector not untouched Issues like the inversion of the yield curve along with the escalating U S  China trade war have been negatively impacting investor sentiments over the past several days  Moreover  other concerns like continued protests in Hong Kong  uncertainty related to Brexit and slump in the Eurozone economy among others have made investors apprehensive Thus  over the past month  the S P 500 Index has lost nearly 5  and the S P 500 Financials  Sector  Index has dipped more than 8   Moreover  the Zacks Finance Sector has lost nearly 6  over the same period While these concerns are weighing on investors  minds  leading to sell off in finance stocks  the sector still has growth potential The fundamental strength of the companies in the finance sector is expected to support performance in the upcoming quarters Finance companies are making efforts to streamline operations and expand business  organically and inorganically  to diversify footprint and revenue base  In fact  lower corporate tax rates along with the easing of stringent regulations are likely to keep supporting profitability Moreover  several finance sector companies are undertaking measures to align their businesses for technology driven clients  They are spending substantially on technology to upgrade and add advanced features  This is expected to lower costs and improve operating efficiency In fact  the U S  economy is growing against expectations of a slowdown  With the health of the nation being the main driving factor for finance companies  profitability  this will continue to provide support Choosing the Winning StocksBased on the above mentioned positives  we can say that investors are not correct in selling all the finance stocks right away With the help of the Zacks Stock Screener  we have selected finance stocks that investors can consider based on fundamental strength and solid prospects  While the stocks have declined more than 5  over the past month  these have current year earnings growth expectation of 12  or more Further  all these stocks have a Zacks VGM Score of A or B and currently carry a Zacks Rank  1  Strong Buy  or 2  Buy   You can see the complete list of today s Zacks  1 Rank stocks here Here are four stocks worth considering Headquartered in Memphis  TN  First Horizon National Corp  is a financial services company  which offers banking as well as investment and advisory services  It has a VGM Score of A and has lost 5 7  over the past month  The company s earnings are expected to grow 12 8  in 2019  It currently carries a Zacks Rank of 2 Cigna Corp  also carries a Zacks Rank  2 at present  This insurance provider  based in Bloomfield  CT  has a VGM Score of B  The company s current year earnings are projected to increase 17 8   Its shares have declined 15 1  over the past month Shares of Ally Financial Inc  have lost 8 8  over the past month  The Detroit  MI based company is a diversified financial services provider of a broad array of financial products and services primarily to automotive dealers and their customers  Its earnings are expected to grow 12  in 2019  The company has a VGM Score of B and a Zacks Rank of 2 at present Och Ziff Capital Management Group Inc  is an investment management company based in New York  Its shares have lost 12 2  over the past month  The stock has a VGM Score of B  The company s earnings are expected to jump more than 100  in 2019  The stock currently sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look See the pot trades we re targeting  Media ContactZacks Investment Research800 767 3771 ext  9339    Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-first-horizon-national-cigna-ally-financial-and-ochziff-capital-management-200460011,200460011
147189,368705,CI,Why Is Cigna  CI  Down 8 1  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Cigna  CI   Shares have lost about 8 1  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Cigna due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Cigna s Q2 Earnings and Revenues Beat EstimatesCigna came up with adjusted earnings of  4 3 per share in second quarter 2019  surpassing the Zacks Consensus Estimate by 15 3   Quarterly earnings were up 10 5  year over year Cigna posted revenues of  34 4 billion and beat the Zacks Consensus Estimate by 3   Revenues grew 198  year over year on the acquisition of Express Scripts  NASDAQ ESRX  Among the revenue components  pharmacy revenues were  26 3 billion compared with  750 million in the year ago quarter  premiums were up 8 9  year over year to  9 8 billion while fees increased 76  to  2 39 billion  The growth in pharmacy revenues was due to the acquisition of pharmacy benefit manager Express Scripts The SG A expense ratio was 9  for second quarter 2019  down from 23 5  in the year ago quarter  The decline was mainly led by business mix changes resulting from the Express Scripts combination and the health insurance tax suspension The company s medical enrollment grew by 207 000 lives from the prior year quarter to 16 99 million customers  driven by growth in Government  Commercial and International markets  Moreover  the acquisition of Express Scripts  completed last December  led to an increase in Pharmacy and Medicare Part D members Cigna s debt to capitalization ratio improved to 47 2  as on Jun 30  2019 from 50 9  as of Dec 31  2018 2019 Guidance UpdateFor 2019  the company expects earnings per share in the range of  16 6  16 9  up from the prior range of  16 25  16 65 Total revenues are expected in the range of  136  137 billion  versus  132 5  134 5 billion expected earlier  and medical customers are projected to grow by approximately 200 000 Medical care ratio is expected in the range of 80 5 81 5   
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month 
VGM Scores
At this time  Cigna has an average Growth Score of C  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Cigna has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/why-is-cigna-ci-down-81-since-last-earnings-report-200460484,200460484
147190,368706,CI,Cigna  CI  Moves To Buy  Rationale Behind The Upgrade,opinion,"Investors might want to bet on Cigna  CI   as it has been recently upgraded to a Zacks Rank  2  Buy   An upward trend in earnings estimates    one of the most powerful forces impacting stock prices    has triggered this rating change 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
The power of a changing earnings picture in determining near term stock price movements makes the Zacks rating system highly useful for individual investors  since it can be difficult to make decisions based on rating upgrades by Wall Street analysts  These are mostly driven by subjective factors that are hard to see and measure in real time 
As such  the Zacks rating upgrade for Cigna is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  The influence of institutional investors has a partial contribution to this relationship  as these big professionals use earnings and earnings estimates to calculate the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
Fundamentally speaking  rising earnings estimates and the consequent rating upgrade for Cigna imply an improvement in the company s underlying business  Investors should show their appreciation for this improving business trend by pushing the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Cigna
This health insurer is expected to earn  16 77 per share for the fiscal year ending December  2019  which represents a year over year change of 17 9  
Analysts have been steadily raising their estimates for Cigna  Over the past three months  the Zacks Consensus Estimate for the company has increased 1 2  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Cigna to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-moves-to-buy-rationale-behind-the-upgrade-200468351,200468351
147202,368718,CI,Icahn ratchets up pressure against Cigna Express Scripts deal,news," Reuters    Activist investor Carl Icahn fired the latest salvo against Cigna Corp s  N CI  deal to buy pharmacy benefit manager Express Scripts  saying drug rebates that PBMs receive from drugmakers will ultimately be eliminated  dealing a blow to the industry  Icahn  who has a 0 56 percent stake in Cigna  on Tuesday made public his opposition to the health insurer s  52 billion purchase of Express Scripts Holding Co  O ESRX   citing regulatory hurdles and the growing threat from Amazon  NASDAQ AMZN    
 Everyone wants drug prices lower   it is a bipartisan issue  I have little doubt that legislation will ultimately be passed to do away with rebates   Icahn said in a letter ",2018-08-09,Reuters,https://www.investing.com/news/stock-market-news/icahn-ratchets-up-pressure-against-cignaexpress-scripts-deal-1567361,1567361
147204,368720,CI,Day Ahead  Top 3 Things to Watch,news,"Investing com   Here s a preview of the top 3 things that could rock markets tomorrow 
1  Consumer Inflation on Tap
Investors will get a look at some more inflation numbers before many hit the road to get a jump on the weekend 
The consumer price index  CPI  comes out at 8 30 AM ET  12 30 GMT  
Economists expect that the CPI rose 0 2  in July  compared with June  and the year over year gain will be 3   The core CPI  which excludes volatile food and energy prices  is forecast to have risen 0 2  month on month  The year on year core CPI gain is expected to be 2 3  
Wholesale inflation numbers out Thursday were encouraging for the stock market  coming in flat  The core PPI was up 0 1  for the month  up less than anticipated 
Those numbers will give the Fed a lot of room to breathe when it comes to hiking interest rates 
2  M A Hits Speed Bumps
Mergers and acquisitions  or the termination thereof  are gaining market attention 
Rite Aid  NYSE RAD  and Albertson s called off their  24 billion merger  Institutional Shareholder Services advised shareholders last month to vote against the deal because Rite Aid would not get a fair ownership interest 
Rite Aid ended the day down about 12  
Ad Tribune Media  NYSE TRCO  walked away from its deal to be acquired by Sinclair  NASDAQ SBGI  for  3 9 billion  Tribune also sued Sinclair for being too aggressive with regulators  The deal looked already in trouble as the FCC voiced opposition on competition grounds 
Look for more comments tomorrow about Cigna  NYSE CI  proposed  54 billion takeover of Express Scripts  NASDAQ ESRX   Carl Icahn recently expressed his opposition to the deal  calling it a  folly  
Glenview Capital s Larry Robbins hit back today  supporting the deal 
3  Oil Rig Data Caps a Busy Week for Oil
Oil prices continue to have an impact on the market and energy stocks have been particularly active this past week 
The Baker Hughes U S  oil rig count comes out tomorrow at 1 PM ET  17 00 GMT   Data on Wednesday showed U S  oil output fell to 10 8 million barrels a day last week 
 Some traders swooped in and picked up oil as it is relatively cheap today  but there is still a lot of uncertainty surrounding its prospects   said David Madden at CMC Markets 
 The Energy Information Administration report yesterday  pointed to a fall in U S  demand   Madden said   Traders are also concerned about China s demand  given the country is locked in a trade spat with the U S  ",2018-08-09,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-1568308,1568308
147205,368721,CI,Icahn reverses position on Cigna Express Scripts deal,news," Reuters    Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the  52 billion Cigna Express Scripts deal  a turn around from his position last week when he urged the health insurer s shareholders to vote against it  Icahn s comments come after proxy advisory firms Glass Lewis   Co and Institutional Shareholder Services Inc  ISS   as well as hedge fund Glenview Capital Management  extended their support for the deal   In light of the ISS and Glass Lewis recommendations in favor of the Cigna Express Scripts transaction and the significant stockholder overlap between the two companies  we have informed the SEC  U S  Securities and Exchange Commission  that we no longer intend to solicit proxies to vote against the transaction   Icahn said in a statement  The billionaire investor  who has a long position on Cigna and a short position on Express Scripts  has been vocal in his criticism of the deal and last week said Cigna  N CI  was overpaying for Express Scripts  O ESRX   At the time  he urged Cigna s shareholders to rally against the deal at a vote scheduled for Aug  24  citing regulatory hurdles and the growing threat from Amazon  NASDAQ AMZN   
The proposed deal between Cigna and Express Scripts  announced in March  was outlined as a new way for the companies to hold onto profits as the U S  healthcare industry faces greater scrutiny for rising costs ",2018-08-13,Reuters,https://www.investing.com/news/stock-market-news/icahn-reverses-position-on-cignaexpress-scripts-deal-1572574,1572574
147206,368722,CI,Cigna  Express Scripts shareholders approve  52 billion deal,news," Reuters     Cigna Corp   N CI  shareholders on Friday voted in favor of the health insurer s proposed  52 billion acquisition of pharmacy benefit manager Express Scripts Holding Co  O ESRX   although the deal still needs clearance from antitrust authorities  The vote in favor of the merger was on expected lines after activist investor Carl Icahn walked away last week from his 11th hour attempt to rally shareholders to reject the deal   The U S  Department of Justice is still conducting an antitrust review of the combination that is not expected to close until later this year  According to the preliminary results  about 90 percent of the votes cast were in favor of the merger  the health insurer said  Cigna expects the merger to close by end of 2018  The insurer agreed to buy Express Scripts in March saying the two companies could save more on healthcare costs for clients if they better coordinated medical care with prescriptions   But since then Express Scripts has come under stiffer opposition from the Trump administration  lawmakers and drug makers as being a middleman that drives up drug costs  Icahn had argued that Cigna was overpaying given prospects for reduced profits   He backed down after shareholder advisory groups recommended that shareholders vote for the deal  Express Scripts shareholders also approved the deal  with about 78 percent of outstanding shares of Express Scripts voted for the deal  Cigna s plan for the acquisition comes as Express Scripts  major rival CVS Health  N CVS  and  Aetna Inc   N AET  move forward on their own merger  Cigna s deal to be bought by Anthem Inc  N ANTM  fell apart last year after it failed to pass antitrust review  
Cigna shares slipped 0 10 percent  while Express Scripts rose 0 47 percent ",2018-08-24,Reuters,https://www.investing.com/news/stock-market-news/cigna-shareholders-approve-52-billion-express-scripts-acquisition-1586276,1586276
147210,368726,CI,Summer lull hits U S  loan fees despite Refinitiv deal,news,By Lynn Adler NEW YORK  LPC    Bank fees earned from arranging US syndicated loans fell in the third quarter amid a summer lull as bankers awaited the US 13 5bn financing backing Blackstone s US 20bn buyout of Refinitiv  the biggest buyout deal to test the markets since the financial crisis   A soft third quarter was offset by a move towards new money loans  which offer higher fees than debt refinancings  and by record first half fees on a flurry of mergers and acquisitions  M A  loans  The rush into Refinitiv s loan and bond buyout financing in September resulted in lower pricing  a shift of debt to loans from bonds  and set a more aggressive tone for fourth quarter lending   Blackstone s purchase of 55  of the newly named Refinitiv  which includes LPC and IFR  from Thomson Reuters closed on October 1     Refinitiv was overhanging the market in the summer  Now  there s a risk on attitude among investors after seeing how well the Refinitiv deal did   said Jeff Nassof  a director at Freeman Consulting Services   That will have a big impact on the fee pool  because the fees on new money deals like this are much higher than on refinancings   Total US syndicated lending slumped to US 432bn in the third quarter  the lowest quarterly amount since the first three months of 2016  However  38  was new money lending  which is the highest quarterly share of the loan market in more than two years  LPC data show   The rise of more profitable new money deals   which include loans for acquisitions  loans backing the creation of new companies as units are carved out of existing businesses  and the upsizings of existing credit facilities   helped offset the drop in fees from the drop in overall loan volume   Arranging banks made US 2 5bn of fees from underwriting leveraged loans for highly indebted companies in the third quarter  down 27  from a year earlier  according to Freeman Consulting  which estimates fees based on Refinitiv data  Leveraged loan fees in the first nine months of 2018 of US 8 8bn were roughly flat with the same period of last year  showing a 2 2  decrease   Third quarter lending to leveraged companies of US 177bn was around 40  lower than the third quarter of 2017  even with a post Labor Day rush that also included large buyout loans for chemicals company Akzo Nobel and physician outsourcing services provider Envision Healthcare   ENCOURAGING SIGNS Bank fees earned from lending to blue chip investment grade companies also slid in the third quarter  dropping 22  to US 523m from a year earlier   The first half of the year was dominated by mega mergers  mainly in the healthcare  media and technology sectors  before activity stalled in the third quarter    Companies are still focused on growing by acquisition  and the pace is expected to pick up after a slow summer for corporate marriages  bankers and lawyers said   On the investment grade side  loan fees track M A very closely   said Nassof   Acquirers are still in a pretty aggressive mindset   Prolonged regulatory review periods caused some companies to hesitate before pulling the trigger on big mergers  Concerns about the potential fallout from tariffs  trade wars  and upcoming midterm elections also contributed to the summer slowdown  bankers said  But the logjam seems to have broken now that Cigna  NYSE CI  Corp s US 52bn acquisition of pharmacy benefits manager Express Scripts Holding Co and retail pharmacy CVS Health  NYSE CVS  Corp s US 69bn acquisition of health insurer  Aetna Inc   NYSE AET  appear to be on course for completion    We re very encouraged about Cigna and Express Scripts   it bodes well for deal approvals   a senior banker said   Companies are looking for top line growth  and it s hard to achieve that organically so acquisitions are the way to go   In the first nine months of the year  investment grade lending fees of US 2 07bn were 22  higher than the US 1 70bn earned in the same period last year due to the first half deal wave  according to Freeman  The third quarter drag on US syndicated lending to low  and high rated borrowers has helped pull down the total US investment banking fee pool  Adding bank earnings from equity and bond underwriting  as well as M A advisory to the syndicated loan arrangement fees  the total US investment banking fee pool dropped 18  in the quarter from a year earlier to US 11bn   Year to date  the US 37 4bn earned is down 3 5  from US 38 8bn seen in the first nine months of last year ,2018-10-05,Reuters,https://www.investing.com/news/stock-market-news/summer-lull-hits-us-loan-fees-despite-refinitiv-deal-1634563,1634563
147211,368727,CI,UnitedHealth tops earnings estimates  raises 2018 forecast,news," Reuters    UnitedHealth Group Inc  NYSE UNH  added more members to its health plans in the third quarter  helping it to post a profit well above Wall Street estimates and boost its earnings forecast for the year  The largest U S  health insurer said it now expects full year adjusted earnings per share to approach  12 80  compared with its prior forecast of between  12 50 and  12 75  While other health players including CVS Health  NYSE CVS    Aetna Inc   NYSE AET  and  Cigna Corp   NYSE CI  are embarking on major merger deals  UnitedHealth has doubled down on a strategy of reining in costs and expanding its medical services group  UnitedHealth s insurance business added 2 8 million more members year over year in the third quarter and raked in revenue of  45 94 billion  12 8 percent higher than last year  Net earnings attributable to shareholders rose 28 percent to  3 19 billion  or  3 24 per share  in the quarter ended Sept  30  Excluding items  the company earned  3 41 per share  Total revenue rose 12 4 percent to  56 56 billion  
Analysts on average had expected earnings of  3 29 per share on revenue of  56 34 billion  according to I B E S data from Refinitiv ",2018-10-16,Reuters,https://www.investing.com/news/stock-market-news/unitedhealth-tops-earnings-estimates-raises-2018-forecast-1645677,1645677
147212,368728,CI,Exclusive  Express Scripts covers Amgen  Lilly migraine therapies  excludes Teva drug,news,"By Deena Beasley LOS ANGELES  Reuters    Express Scripts Holding Co  O ESRX   one of the largest U S  prescription benefits managers  will cover new migraine drugs from Eli Lilly  N LLY  and  Amgen Inc   O AMGN   but is excluding a rival medication made by Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  after price negotiations with all three manufacturers  The decision represents a setback for Teva  which is in the midst of a corporate restructuring and had hoped to capture a sizable stake of the multibillion dollar migraine market  Express Scripts is also taking steps to limit use to the patients it says are most likely to benefit from the new Amgen and Lilly migraine drugs   Pharmacy benefits managers like Express Scripts are taking more aggressive action to lower the cost of prescription drugs for their clients  large employers who pay for health benefits for their workers  The new migraine drugs were approved for the U S  market within a few months of each other this year  That gave Express Scripts more leverage in demanding a discount in exchange for putting a therapy on its  formulary   or list of covered drugs   These products are fairly interchangeable   Harold Carter  clinical solutions director at Express Scripts  told Reuters   It comes down to manufacturers providing the best value to be on the formulary   He acknowledged that price rebates played a role in determining coverage status  but declined to comment on the level of rebating  In May  Amgen and marketing partner  Novartis  AG  S NOVN  won U S  regulatory approval for Aimovig  an injected drug designed to interfere with a process that helps kick off migraine headaches  Teva s Ajovy and Lilly s Emgality were approved last month  The three drugs work in a similar manner and represent an improvement over existing treatments  in clinical trials they significantly reduced migraine frequency in about half of patients  Wei Li Shao  vice president of neuroscience at Eli Lilly  told Reuters last month that discounts and rebates for the migraine drug would be negotiated with insurers and other payers  Brendan O Grady  head of Teva s North America commercial operations  declined to comment on talks with payers  while executives at Amgen did not immediately respond to a request for comment  All three drugs have a list price of  575 a month  or  6 900 a year  Geoffrey Porges  biotech analyst at Wall Street investment bank Leerink Partners  told Reuters he expects the drugmakers will need to offer rebates of at least 30 percent for the new migraine class to be covered by insurance  Express Scripts already lists Amgen s Aimovig as a preferred treatment on its largest formulary  but requires that patients first try two older preventive therapies and a triptan  a family of generic drugs used to treat acute migraine  Lilly s Emgality will be covered under the same terms  Amgen and Lilly will also begin next April to refund part of the drug cost if a migraine patient stops treatment within 90 days  indicating that the medication does not work for them or causes too many side effects  That refund  between 25 and 30 percent of the drugs  list price  would be returned to clients of Express Scripts  and comes in addition to the rebates the pharmacy benefit manager has already negotiated  
39 MILLION MIGRAINE SUFFERERS  Everyone in the chain is taking some accountability for the cost of the drug   Carter said  adding that the refund means the manufacturers are sharing financial risk if the drugs do not work as well as claimed  Around 39 million Americans suffer from migraine headaches  according to the Migraine Research Foundation  Worldwide migraine drug sales could reach  8 7 billion by 2026  according to analytics firm GlobalData  But Carter estimated that only about 128 000 of the 83 million people who get their prescription drug benefits through Express Scripts will be good candidates for the migraine prevention drugs  Under the Migraine Care Value program that will launch next April  Express Scripts will have its specially trained pharmacists  nurses and other staff assess appropriate care and access to therapies for patients  The pharmacy benefit manager  which is being acquired by  Cigna Corp   N CI   created a similar program in 2015 that sharply limited the use of two novel  and expensive  cholesterol drugs   from Amgen and partners Regeneron Pharmaceuticals  O REGN  and Sanofi SA  PA SASY   For the new migraine drugs  the challenges will likely be right out of the gate  seeing if patients are responding to the therapy   Carter said  The drugmakers have already tried to pre empt efforts to limit access to the new migraine treatments  Amgen and Lilly are providing two months  supply of the drug for free directly to patients  All three companies have plans to pay nearly all of an individual s out of pocket costs under a commercial insurance plan  In addition  Amgen and Lilly have temporary programs to supply the treatments to patients who are covered by commercial insurance  but are still having trouble getting reimbursed  Some large health insurers  such as Anthem Inc  N ANTM   have similar coverage terms for Aimovig  requiring patients to document how they suffer from a defined number of headaches each month  and show that they have tried older migraine drugs first  Others  including Blue Cross Blue Shield plans in states like Pennsylvania and Kansas  only cover prescriptions for the new drugs from   or in consultation with   a neurologist or headache specialist  and not a primary care doctor  Some plans have not yet determined coverage terms  meaning each prescription has to go through a lengthy review process ",2018-10-17,Reuters,https://www.investing.com/news/stock-market-news/exclusive-express-scripts-covers-amgen-lilly-migraine-therapies-excludes-teva-drug-1647668,1647668
147214,368730,CI,Should Value Investors Buy Cigna  CI  Stock ,opinion,"While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks  we also know that investors tend to develop their own individual strategies  With this in mind  we are always looking at value  growth  and momentum trends to discover great companies 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
One stock to keep an eye on is Cigna  CI   CI is currently sporting a Zacks Rank of  2  Buy   as well as an A grade for Value 
Investors will also notice that CI has a PEG ratio of 0 81  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  CI s PEG compares to its industry s average PEG of 0 98  Within the past year  CI s PEG has been as high as 1 16 and as low as 0 69  with a median of 0 83 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  Some people prefer this metric because sales are harder to manipulate on an income statement  This means it could be a truer performance indicator  CI has a P S ratio of 0 61  This compares to its industry s average P S of 1 07 
Value investors will likely look at more than just these metrics  but the above data helps show that Cigna is likely undervalued currently  And when considering the strength of its earnings outlook  CI sticks out at as one of the market s strongest value stocks ",2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-cigna-ci-stock-200450762,200450762
147215,368731,CI,Buy CVS Health  CVS  Ahead Of Q2 Earnings ,opinion,"CVS Health   NYSE CVS   will be reporting their second quarter performance before the opening bell on Wednesday  The company hasn t been able to stay in the green this year  down 17 9  year to date  Furthermore  the broader retail drug stores market has struggled as a whole this year  down 20 7  
The company is coming off earnings and revenue beats in Q1 and is looking to repeat this in Q2  The ongoing issue of Medicare For All has made the pharmacy and drug market volatile in recent months  Can CVS kickstart its second half of 2019 with a strong Q2 report  Let s see how Zacks estimates have the company performing in Q2 
Overview and Q1 Performance 
The company is based out of Woonsocket  Rhode Island  and changed its name to CVS Health from CVS Caremark to better reflect its health commitment  In November 2018  CVS Health acquired insurance giant Aetna  NYSE AET  for  70 billion  The company reports in four segments  Pharmacy Services  Retail LTC  Health Care Benefits  and Corporate Other  The company s pharmacy services segment provides pharmacy benefit mangers  PBM  solutions  The company recently benefited from the Trump administration s decision to withdraw its proposal to eliminate rebates from government drug plans  The plan would have effectively lowered the prices of drugs for consumers by hindering the profits of PBM 
In Q1  CVS Health brought in  61 6 billion in revenue and reported earnings of  1 62 per share  beatings estimates by 8  and 1 9   respectively  In addition  the reported bottom line was a jump of 9 5  and the top line was a surge of 34 8   Net income was  1 43 billion for a 42 99  gain from Q1 2018  The company s pharmacy services segment jumped 3 11  to  33 56 billion while the retail LTC segment generated  21 1 billion for a jump of 3 3   The health care benefits segment reported  17 87 billion in Q1 which was primarily driven by the Aetna acquisition 
Q2 Outlook 
Consensus estimates are calling for CVS to report EPS of  1 70 and total revenue of  62 61 billion for a jump of 0 59  and 34 05   respectively  Key Company Metric estimates are forecasting pharmacy services to post  34 18 billion in revenue for a 2 79  jump  The retail LTC segment is predicted to gain 2 77  to  21 24 billion  The pharmacy network that is within the pharmacy services segment is projected to jump 5 65  to  21 73 billion  Mail choice  also within pharmacy services  is projected to jump 5 22  to 75 65 million  In the retail segment  prescriptions filled is expected to increase 5 86  to 349 million  The total number of stores is expected to add 45 to the Q1 number  bringing it to 9 945 
CVS Health is highly optimistic about the merger with Aetna  They believe Aetna s analytics and CVS s  touch of humanity  on the health care side provides a platform to better serve consumers  Over the last few quarters  the retail LTC segment registered positive revenue growth after several quarters of sluggish performances  The 3 3  growth in Q1 was driven by continued adoption of patient care programs and collaborations with PBM  The increasing demand for PBM and specialty pharmacy  along with continued growth in the retail segment  will bode well for CVS 
Additionally  PBMs being clear from federal regulation for the moment also sit well for CVS and other companies like Cigna   NYSE CI   and UnitedHealth   NYSE UNH    CVS Health is listed as a Zacks Rank  3  Hold  with a Style Score of A in Value  CVS has historically traded at a discount relative to its industry for the better part of 3 years 

The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/buy-cvs-health-cvs-ahead-of-q2-earnings-200451901,200451901
147216,368732,CI,Zacks Industry Outlook Highlights  Joint  Anthem  Centene And UnitedHealth,opinion,For Immediate ReleaseChicago  IL   August 8  2019   Today  Zacks Equity Research discusses Health Insurance  including The Joint Corp    NASDAQ JYNT    Anthem Inc    NYSE ANTM    Centene Corp    NYSE CNC   and UnitedHealth Group  Inc    NYSE UNH   Industry  Health InsuranceLink  The Health Maintenance Organization  HMO  industry comprises entities  either private or public  that take care of the basic and supplemental health services of its subscribers  Companies in this space primarily assume the risks involved and assign premiums for health and medical insurance policies  Industry participants also provide administrative and managed care services for self funded insurance Services are generally provided by a network of approved care providers  called in network   which include primary care physicians  clinical facilities  hospitals and specialists  However  out of network exceptions are made in emergencies or when medically necessary  Health insurance plans can be availed by ways such as private purchase  social insurance or social welfare programs such as Medicare and Medicaid  funded by the government Let us take a look at the industry s three major themes      As life expectancy continues to increase in the United States and seniors account for a higher percentage of the total U S  population  overall demand for health insurance for seniors will increase  According to the 2018 U S  Census  between 2010 and 2030  the number of individuals aged 65  is projected to nearly double from 39 million to 73 million  a growth rate nearly 5 times faster than the 17  increase expected for the total population  The census estimates this group to grow from 13  to 21  by 2030   one of the fastest growing within U S  population      The HMO industry is rapidly consolidating with mergers and acquisitions  The most common takeovers in recent years have been in the nature of horizontal expansion in the areas of Medicare and Medicaid as the players seek to garner a greater share of the attractive MA market  Lately  however  the companies have shown interest in expanding vertically and add capabilities to its supply chain through mergers and acquisitions  The mega mergers of Aetna  NYSE AET  with CVS Health Corp   NYSE CVS  and Cigna Corp   NYSE CI  with Express Scripts  NASDAQ ESRX  are the best examples of inter industry deals that led to the union of a health insurer and a pharmacy benefit manager      The industry has also witnessed development in ancillary business to diversify revenue sources in the wake of tough regulations laid  via the ACA  on health insurance business   These businesses  mostly in the form of health care services  are growing rapidly  opening up new avenues of growth and forming an increased proportion of the industry s total revenues  Health services business is an important growth area for HMOs as these provide unregulated cash flows and enable players to become comprehensive healthcare providers  Ample opportunities of growth exist in the health service business and continued investments are being made in this area  A poster child for the same is UnitedHealth s Optum  which provides a range of healthcare related services Zacks Industry Rank Indicates Bright ProspectsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates upbeat prospects in the near term  The Zacks   which is an 11 stock group within the broader Zacks  sector  currently carries a Zacks Industry Rank  25  which places it at the top 10  of 255 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  In a year s time  the industry s earnings estimate for the current year has gone up by 4 6  Industry Return Underperformed S P 500  and its SectorThe Zacks Medical HMO industry has underperformed both the Zacks S P 500 composite and its own sector over the past year We see that the stocks in this industry have collectively lost 5 7  over the past year  while the Zacks S P 500 composite and Zacks Medical Sector have rallied 1 8  and 11 4   respectively HMO Industry s Current ValuationOn the basis of forward 12 month price to earnings  P E  ratio  which is commonly used for valuing HMO stocks  the industry is currently trading at 14 53X compared with the S P 500 s 16 39X and the sector s 19 32X Over the past five years  the industry has traded as high as 20 53X  as low as 14 27X and at a median of 16 21X Bottom LineDespite earnings outperformance by the companies  the industry has underperformed in a year s time due to various regulatory issues and the uncertainty in policy changes if new a president gets elected  These may have kept investors away from the industry   Shrugging aside the intermittent political disruptions  players in the industry will continue to ride on technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions  and a healthy balance sheet HMO Stocks to Buy NowFour stocks in the Zacks Medical HMO space currently carry a Zacks Rank  2  Buy  You can see  The Joint Corp    The stock has surpassed earnings estimates in two of the last four quarters with an average positive surprise of 190  Anthem Inc   The stock has surpassed earnings estimates in each of the trailing four quarters with an average positive surprise of 4 57   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings has gone up 0 3  over the past 30 days Centene Corp   The Zacks Consensus Estimate for 2019 bottom line of this Louisville  KY based company has been raised 0 7  over the past 30 days  The stock has surpassed earnings estimates in each of the last four quarters with an average positive surprise of 4 56  UnitedHealth Group  Inc   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings has gone up 0 6  over the past 30 days  The stock has surpassed earnings estimates in each of the trailing four quarters with an average positive surprise of 3 37  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-08-07,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-joint-anthem-centene-and-unitedhealth-200453171,200453171
147217,368733,CI,BioDelivery  BDSI  Earnings   Sales Beat Estimates In Q2,opinion,"BioDelivery Sciences International  Inc    NASDAQ BDSI   recorded adjusted earnings of 6 cents per share for second quarter 2019 against the Zacks Consensus Estimate of a loss of 6 cents  In the year ago quarter  the company had incurred an adjusted loss of 12 cents per share Revenues totaled  29 7 million  up 143 44  from the year ago period figure and 50  sequentially  The uptick was mainly driven by higher sales of Belbuca  The top line also outpaced the Zacks Consensus Estimate of  25 3 million So far this year  shares of BioDelivery have gained 8 9  against the  s 2 5  decrease Quarter in DetailBioDelivery s marketed portfolio includes three drugs   Belbuca for chronic pain  Bunavail  for treating opioid dependence and Symproic for opioid induced constipation   The company added Symproic to its portfolio by  U S  commercial rights to the drug from Japanese pharma company  Shionogi Net product sales were up 161  year over year to  28 1 million BioDelivery s chronic pain drug  Belbuca  generated revenues of  24 1 million in the quarter  up 29  sequentially  On a year over year basis  the top line surged 147   Sales of the drug have witnessed a strong uptrend since 2018  The momentum continued into the first half of 2019  This trend is likely to continue in the rest of the year  Notably  the company re acquired worldwide rights to Belbuca in early 2017 from Endo International   NASDAQ ENDP   Symproic sales in the second quarter  the first quarter after the acquisition and launch of the drug in May  added  3 2 million to the top line Sales of Bunavail  indicated for the treatment of opioid dependence  were  0 82 million in the second quarter  reflecting a decline of 19 5  year over year Meanwhile  operating expenses increased 47 6  to  22 million and 29 4  sequentially  The increase was due to continued investment in commercialization efforts for Belbuca and acquisition of Symproic Belbuca UpdateBioDelivery recorded all time high prescription volumes of almost 80 000 prescriptions for Belbuca in the second quarter  Prescription volume for Belbuca expanded 23  sequentially and 125  year over year  The company added approximately 6 579 new patients to Belbuca treatment during the quarter  an all time high  In the first quarter  it had added 1 260 new patients  Management seems confident about Belbuca s strong performance in the second half of 2019  Moreover  the settlement of the patent litigation with Teva Pharmaceuticals   NYSE TEVA   in 2018 will keep generic competition at bay till mid 2027 BioDelivery has been expanding the preferred coverage for Belbuca by adding it to the list of several pharmacy benefit managers  In July  the company announced that several prominent regional U S  insurance plans enhanced Belbuca s coverage to preferred status or initiated coverage for the drug  These enhancements have brought additional six million patients under coverage with access to Belbuca  These deals along with the addition of Belbuca to a preferred formulary of Cigna Healthcare   the managed care division of Cigna Corporation   NYSE CI     in February gave more than 165 million covered patients  representing 90  of the U S  commercial insurance market  access to Belbuca Please note that in 2017  Aquestive Therapeutics had filed a complaint for patent infringement by Belbuca  Earlier this month  United States District Court for the Eastern District of North Carolina ruled in favor of BioDelivery in the litigation related to Belbuca  However  the ruling allows Aquestive to re file a similar complaint against Belbuca  This ruling may have led to a decline in share price in pre market trading 2019 GuidanceBioDelivery raised its 2019 guidance for total revenues to the range of  101  105 million from  92  100 million predicted earlier  This upside can be attributed to the strong demand for Belbuca and addition of Symproic to the company s commercial portfolio Following the encouraging performance of Belbuca in the second quarter  the company again raised guidance for the drug s sales  Sales of Belbuca are expected to be between  90 million and  93 million compared with  83 million and  88 million anticipated earlier  Symproic sales guidance was maintained in the  7  9 million band Furthermore  the company anticipates combined sales of Belbuca and Symproic to reach  425    500 million over the long term BioDelivery Sciences International  Inc  Price  Consensus and EPS Surprise
    Zacks RankBioDelivery currently carries a Zacks Rank  3  Hold   You can see  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-bdsi-earnings--sales-beat-estimates-in-q2-200453708,200453708
147218,368734,CI,Are Investors Wrong In Selling These 4 Finance Stocks Now ,opinion,Several macroeconomic concerns have been hurting investor sentiments of late  These matters have led to a bearish stance toward the overall stock markets  with the Finance sector not untouched Issues like the inversion of the yield curve along with the escalating U S  China trade war have been negatively impacting investor sentiments over the past several days  Moreover  other concerns like continued protests in Hong Kong  uncertainty related to Brexit and slump in the Eurozone economy among others have made investors apprehensive Thus  over the past month  the S P 500 Index has lost nearly 5  and the S P 500 Financials  Sector  Index has dipped more than 8   Moreover  the  has lost nearly 6  over the same period While these concerns are weighing on investors  minds  leading to sell off in finance stocks  the sector still has growth potential The fundamental strength of the companies in the finance sector is expected to support performance in the upcoming quarters Finance companies are making efforts to streamline operations and expand business  organically and inorganically  to diversify footprint and revenue base  In fact  lower corporate tax rates along with the easing of stringent regulations are likely to keep supporting profitability Moreover  several finance sector companies are undertaking measures to align their businesses for technology driven clients  They are spending substantially on technology to upgrade and add advanced features  This is expected to lower costs and improve operating efficiency In fact  the U S  economy is growing against expectations of a slowdown  With the health of the nation being the main driving factor for finance companies  profitability  this will continue to provide support Choosing the Winning StocksBased on the above mentioned positives  we can say that investors are not correct in selling all the finance stocks right away With the help of the   we have selected finance stocks that investors can consider based on fundamental strength and solid prospects  While the stocks have declined more than 5  over the past month  these have current year earnings growth expectation of 12  or more Further  all these stocks have a Zacks  of A or B and currently carry a Zacks Rank  1  Strong Buy  or 2  Buy   You can see  Here are four stocks worth considering Headquartered in Memphis  TN  First Horizon National Corporation   NYSE FHN   is a financial services company  which offers banking as well as investment and advisory services  It has a VGM Score of A and has lost 5 7  over the past month  The company s earnings are expected to grow 12 8  in 2019  It currently carries a Zacks Rank of 2 Cigna Corporation   NYSE CI   also carries a Zacks Rank  2 at present  This insurance provider  based in Bloomfield  CT  has a VGM Score of B  The company s current year earnings are projected to increase 17 8   Its shares have declined 15 1  over the past month Shares of Ally Financial Inc    NYSE ALLY   have lost 8 8  over the past month  The Detroit  MI based company is a diversified financial services provider of a broad array of financial products and services primarily to automotive dealers and their customers  Its earnings are expected to grow 12  in 2019  The company has a VGM Score of B and a Zacks Rank of 2 at present Och Ziff Capital Management Group Inc    NYSE OZM   is an investment management company based in New York  Its shares have lost 12 2  over the past month  The stock has a VGM Score of B  The company s earnings are expected to jump more than 100  in 2019  The stock currently sports a Zacks Rank  1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/are-investors-wrong-in-selling-these-4-finance-stocks-now-200459378,200459378
147228,368744,CI,Icahn  with sizable stake in Cigna  to oppose Express Scripts acquisition  WSJ,news,"By Michael Erman and Caroline Humer  Reuters    Billionaire investor Carl Icahn has a sizable stake in health insurer Cigna  N CI  and plans to vote against its planned  52 billion acquisition of pharmacy benefits manager Express Scripts  O ESRX   the Wall Street Journal reported  on Wednesday  Icahn believes Cigna is paying too high a price for Express Scripts  the Journal reported  citing people familiar with the matter   The Journal said Icahn s stake was less than 5 0 percent of Cigna s shares  Cigna shareholders are scheduled to vote on the deal on Aug  24  The two companies hope the deal will help them hold onto profits despite scrutiny for rising healthcare costs   Cigna s shares closed up 2 0 percent on Wednesday afternoon  while Express Scripts  stock slid nearly 7 0 percent  Express Scripts shares have been trading well below the value of Cigna s bid   The arbitrage spread of the deal  which measures that difference  widened to more than 25 percent from 18 percent after Icahn s stake was revealed  suggesting investor skepticism the deal can close    Clearly there had been shareholder disappointment and discontent post the transaction announcement   Evercore ISI analysts Mike Newshel and Ross Muken said in a research note Express Scripts business model is in question  and on its own would likely be worth  57 to  62 a share  they said   Cigna would be better off doing a share buyback of  7 billion to  10 billion  buying smaller pharmacy benefit managers  and increasing its government paid business  they said   Leerink Research analyst Ana Gupte doesn t believe investors will vote the deal down  noting that Icahn would need to get other large investors on board    I don t know if he could do that   she said  Neither Icahn nor Cigna immediately responded to Reuters  requests for comment  Express Scripts spokesman Brian Henry said the deal would  deliver significant value to shareholders   Cigna announced the deal in March  looking for new ways to boost profits as the industry faces greater scrutiny for rising healthcare costs   They say the deal could generate  600 million in savings per year and help Cigna more closely manage how costly drugs are prescribed and delivered to patients  But headwinds for the companies have strengthened since the deal was announced   Pharmacy benefits managers  PBMs  like Express Scripts have been in the crosshairs of the Trump administration  which is looking at scaling back or eliminating rebates from drug purchases that are diverted to middlemen like PBMs  Amazon com Inc  O AMZN  has also purchased an online pharmacy that Wall Street analysts say can help it undercut traditional prescription drug sales   
The deal followed the  69 billion merger announced in December between CVS Health Corp  N CVS  and health insurer  Aetna Inc   N AET   Shareholders from those companies approved the CVS Aetna tie up in March  but they are still awaiting antitrust approval ",2018-08-01,Reuters,https://www.investing.com/news/stock-market-news/icahn-with-sizable-stake-in-cigna-to-oppose-express-scripts-acquisition--wsj-1556043,1556043
147229,368745,CI,ETFs To Shine As Trump Tosses Drug Rebate Curb Plan,opinion,The Trump administration recently faced another setback in its effort to lower prescription drug prices  Recently  requiring drug manufacturers to reveal list prices of medicines in television commercials  This time   to block rebates and discounts from drug makers  This is considered a hard blow to Trump s election campaign propaganda to bring down drug prices Responding to the news  shares of a few pharmacy benefit managers like Cigna Corporation   NYSE CI    UnitedHealth Group   NYSE UNH   and CVS Health   NYSE CVS    Proposed Rule at a GlanceThe proposed rule  which was considered one of the most effective tools up Trump administration s sleeve to control prescription drug prices   and rebates to pharmacy benefit managers or directly to insurers for getting the drug included in a list or formulary of drugs covered by health plans   pharmacy benefit managers a flat fee and pass on the benefits to consumers Why Was it Dropped that manufacturers kept the price high intentionally and it was a sheer requisite to have middlemen to negotiate discounts to control the cost of drugs  Moreover  administration and congressional budget analysts opposed the proposed rule saying that if rebates are blocked  drug makers will keep most of the savings instead of passing them onto end users It was argued that insurance premiums and government spending will rise in the absence of middlemen  In fact  that there might have been a rise in Medicare premiums just ahead of the 2020 elections  if the rule was implemented  Moreover  the rule would have resulted  who spend substantially on medication  The Congressional Budget Office projected that the rule would  ETFs to ConsiderAgainst this backdrop we discuss certain ETFs that can benefit from the latest decision iShares U S  Healthcare Providers ETF The fund tracks investment results that correspond generally to the price and yield performance of Dow Jones U S  Select Healthcare Providers Index  read     The fund consists of 47 holdings in its basket  Pharmacy benefit managers and health insurers make most of the top 10 holdings  Accordingly  IHF gained 3 8  on Jul 11 following the dropping of key proposal by the Trump administration AUM   898 8 millionExpense Ratio  0 43 YTD Return  8 6 iShares Evolved U S  Healthcare Staples ETF This actively managed fund seeks to provide access to U S  companies with healthcare staples exposure  The fund consists of 160 holdings in its basket  United Health Group weighing 11 06  makes the top holding of the fund  IEHS gained 1 5  on Jul 11 following the dropping of key proposal by the Trump administration AUM   7 4 millionExpense Ratio  0 18 YTD Return  14 3 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-07-12,Zacks Investment Research,https://www.investing.com/analysis/etfs-to-shine-as-trump-tosses-drug-rebate-curb-plan-200439415,200439415
147230,368746,CI,Icahn going public with opposition to Cigna Express Scripts deal    WSJ,news,Calling the deal a   60B folly   Carl Icahn  NYSE IEP  intends to send an open letter on Thursday urging his fellow Cigna  NYSE CI  owners to vote against the acquisition of Express Scripts  NASDAQ ESRX   writes Cara Lombardo in the WSJ  Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks on several fronts    says Icahn  referencing Amazon  NASDAQ AMZN  s possible entry into the PBM market Icahn owns about 0 56  of Cigna  or more than  250M worth The experts say the odds of winning this battle are against Icahn  in part because the August 24 vote means not very much time to rally shareholders to his side ESRX down 1 1  in after hours action Previously  ESRX  7 6   CI  4 2  on report Icahn opposing deal  Aug  1 Now read ,2018-08-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/icahn-going-public-with-opposition-to-cignaexpress-scripts-deal---wsj-1562677,1562677
147231,368747,CI,Stocks Rise On Fed Hopes   But Likely Due For A Breather ,opinion,"Summary 

The S P 500  SPX  rose 18 points last week to 3013  an increase of 0 6  
Our projection is for the S P 500 to chop around this week  and then move lower as the current short term market cycle moves in to a small corrective period 

The stock market continued its upward drive last week  as investors remained jubilant about a new round of easing by the Federal Reserve  as I pointed out in the latest Market Week show 
During the previous week   good news was bad news   as hopes rate cut were dashed by strong payroll data  But Fed Chair Jerome Powell flipped this around in his testimony to Congress  He continued to voice concerns about weakness in the world economy and trade relations  ultimately hinting at the possibility of new rate cuts 
S P 500  SPX  Daily Chart 
Our approach to technical analysis uses market cycles to project price action  Our analysis of the S P 500 is for choppy price action that may rise as high as 3032 but is likely to slip lower with the dominant larger cycle  Our short term support zone is between 2950 and 2971 
Let s also take a look at an individual stock that moved significantly last week  Cigna  NYSE CI  rose by 9 6  to over  179  This occurred after the Trump administration let go of its plan to cancel rebates related to Medicare and Medicaid 
Cigna  CI  Stock Weekly Chart 
Based on its market cycles  CI is either still in the rising phase of its current minor cycle  or has already started the rising phase of its next minor cycle  In either case  the stock is now in a Fibonacci resistance zone  Having just made a new low in April  and showing weak technical patterns  we are not optimistic about the intermediate term future of Cigna or the HMO group 
For a more detailed analysis of both of these charts  check out the latest episode of the askSlim Market Week show ",2019-07-14,Steve Miller,https://www.investing.com/analysis/stocks-continued-to-rise-on-fed-hopes--but-likely-due-for-a-breather-200439481,200439481
147232,368748,CI,Icahn to send letter to oppose Cigna Express Scripts deal  WSJ,news," Reuters    Investor Carl Icahn will send an open letter to the shareholders of insurer  Cigna Corp   N CI  asking them to vote against the company s  52 billion Express Scripts Holding Co  O ESRX  buyout  the Wall Street Journal reported on Monday  citing a draft of the letter   Icahn and his affiliates own about 0 56 percent of Cigna  which is worth over  250 million as of Monday s market close  the Journal reported  citing people familiar with the matter    Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks on several fronts   said the letter  which the newspaper reported would be made public on Tuesday   Express Scripts spokesman Brian Henry told Reuters on Monday that the company remained confident in the deal  Cigna and a representative for Icahn did not respond to a request for comment outside regular business hours   
Investors have expressed concern over the Cigna Express Scripts deal because of the growing presence of Amazon com  O AMZN  in the healthcare sector and U S  President Donald Trump s push to cut rebates from drugmakers to pharmacy benefit managers ",2018-08-06,Reuters,https://www.investing.com/news/stock-market-news/icahn-to-send-letter-to-oppose-cignaexpress-scripts-deal-wsj-1562476,1562476
147233,368749,CI,Analysts Estimate Cigna  CI  To Report A Decline In Earnings  What To Look Out For,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when Cigna  CI  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on August 1  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  3 73 per share in its upcoming report  which represents a year over year change of  4 1  
Revenues are expected to be  33 39 billion  up 190 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 03  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cigna 
For Cigna  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 01  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Cigna will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cigna would post earnings of  3 74 per share when it actually produced earnings of  3 90  delivering a surprise of  4 28  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cigna doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-cigna-ci-to-report-a-decline-in-earnings-what-to-look-out-for-200445072,200445072
147234,368750,CI,Icahn urges Cigna shareholders to vote against Express Scripts deal,news,"By Ankur Banerjee  Reuters    Activist investor Carl Icahn on Tuesday urged  Cigna Corp   N CI  shareholders to vote against the health insurer s  52 billion purchase of Express Scripts Holding Co  O ESRX   citing regulatory hurdles and the growing threat of Amazon  The Cigna Express Scripts deal has drawn investor skepticism over concerns that Amazon com Inc s  O AMZN  entry into healthcare will upend the sector at a time when President Donald Trump has made a push to lower drug prices  The Trump administration has proposed a rule that will scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers  PBMs   Icahn said the proposed rule  which came after the Cigna Express Scripts deal agreement  is a clear shot across the bow for the PBM industry   We believe this is the start of a concentrated effort to reform drug pricing and eliminate the highly flawed rebate system   Icahn wrote in a letter to Cigna shareholders  adding that the industry will likely move to an entirely fee based model over time  Icahn also highlighted the rising threat of Amazon  which in June bought small online pharmacy PillPack  putting the world s biggest online retailer in direct competition with drugstore chains  drug distributors and PBMs   When Amazon starts to compete as we believe they will  with their 100 million Prime users and scale distribution system  they will have no trouble breaking into the so called ecosystem   Icahn said  The billionaire investor  who has a long position on Cigna and a short position on Express Scripts  said in the letter titled  Cigna s  60 billion folly   that the insurer was overpaying for Express Scripts  Icahn said Cigna should instead repurchase its shares and pursue partnership with existing pharmacy benefit managers  including Express Scripts  Icahn owns 1 36 million shares  representing about 0 56 percent of the outstanding shares of Cigna  Express Scripts  shares fell last week after the news of Icahn s stake and his opposition to the deal first emerged  Cigna on Thursday said it was confident of winning shareholder approval for its Express Scripts deal  The shareholder vote is due on Aug  24  Express Scripts  shares were up 1 percent in early trading  while Cigna shares were up 0 34 percent   We believe we are well positioned for growth and remain confident in the deal   Express Scripts spokesman Brian Henry said  Cigna was not immediately available for comment  Analysts do not expect shareholders to support Icahn  noting that few shareholders have questioned the strategic rationale of the deal  
Leerink analyst Ana Gupte said a majority of current shareholders are likely to vote in favor of the deal  given a large shareholder overlap between the two companies ",2018-08-07,Reuters,https://www.investing.com/news/stock-market-news/icahn-urges-cigna-shareholders-to-vote-against-express-scripts-deal-1562890,1562890
147235,368751,CI,Cigna  CI  Beats On Q2 Earnings And Revenues  Guides Up,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings of  4 3 per share in second quarter 2019  surpassing the Zacks Consensus Estimate by 15 3   Quarterly earnings were up 10 5  year over year Cigna posted revenues of  34 4 billion and beat the Zacks Consensus Estimate by 3   Revenues grew 198  year over year on the acquisition of Express Scripts  NASDAQ ESRX  Among the revenue components  pharmacy revenues were  26 3 billion compared with  750 million in the year ago quarter  premiums were up 8 9  year over year to  9 8 billion while fees increased 76  to  2 39 billion  The growth in pharmacy revenues was due to the acquisition of pharmacy benefit manager Express Scripts Cigna Corporation Price  Consensus and EPS Surprise   The SG A expense ratio was 9  for second quarter 2019  down from 23 5  in the year ago quarter  The decline was mainly led by business mix changes resulting from the Express Scripts combination and the health insurance tax suspension The company s medical enrollment grew by 207 000 lives from the prior year quarter to 16 99 million customers  driven by growth in Government  Commercial and International markets  Moreover  the acquisition of Express Scripts  completed last December  led to an increase in Pharmacy and Medicare Part D members Cigna s debt to capitalization ratio improved to 47 2  as on Jun 30  2019 from 50 9  as of Dec 31  2018 2019 Guidance UpdateFor 2019  the company expects earnings per share in the range of  16 6  16 9  up from the prior range of  16 25  16 65 Total revenues are expected in the range of  136  137 billion  versus  132 5  134 5 billion expected earlier  and medical customers are projected to grow by approximately 200 000 Medical care ratio is expected in the range of 80 5 81 5  Our TakeCigna is well poised for the long term due to its recent acquisition of pharmacy benefit manager  Express Scripts  which provides a nice diversification to its existing businesses  namely administrative services  international operations  and disability and life insurance The combination of Express Scripts  pharmacy benefit business and Cigna s health insurance business will help control drug pricing cost to a large extent  which is one of the biggest components of soaring medical costs  The company has better control over its medical cost compared with other players in the industry  The decline in medical costs should further aid its margins Another distinguishing feature of the company is the international business  which provides additional diversification opportunities  Its strong balance sheet is another positive Zacks Rank and Other Releases
Cigna currently carries a Zacks Rank  3  Buy   You can see  
Other players in the medical space that have reported second quarter earnings so far are UnitedHealth Group  Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Wellcare Health Plans  Inc    NYSE WCG    each beating their Zacks Consensus Estimate by 4 1   0 65  and 5 12   respectively 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-07-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-beats-on-q2-earnings-and-revenues-guides-up-200449067,200449067
147236,368752,CI,Cigna  CI  Q2 Earnings And Revenues Beat Estimates,opinion,"Cigna  CI  came out with quarterly earnings of  4 30 per share  beating the Zacks Consensus Estimate of  3 73 per share  This compares to earnings of  3 89 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 15 28   A quarter ago  it was expected that this health insurer would post earnings of  3 74 per share when it actually produced earnings of  3 90  delivering a surprise of 4 28  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Cigna  which belongs to the Zacks Insurance   Multi line industry  posted revenues of  34 38 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 2 96   This compares to year ago revenues of  11 50 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cigna shares have lost about 10 5  since the beginning of the year versus the S P 500 s gain of 18 9  
What s Next for Cigna 
While Cigna has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cigna was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 52 on  33 19 billion in revenues for the coming quarter and  16 52 on  133 77 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Insurance   Multi line is currently in the bottom 42  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q2-earnings-and-revenues-beat-estimates-200448832,200448832
147263,368779,CI,U S  antitrust official says worries over limiting vertical deals  misplaced ,news,"By Liana B  Baker NEW YORK  Reuters    A top antitrust official at the U S  Justice Department attempted to reassure investors on Thursday that worries that regulators would crack down on proposed combinations of two companies on a supply chain    known as vertical mergers    were overblown  Makan Delrahim  the assistant attorney general for antitrust  said that most proposed transactions were either good for consumers or neutral  But the department s decision in November to sue to stop AT T Inc  N T   which owns DirecTV  from buying  Time Warner  Inc  N TWX  made investors question whether other vertical deals might also meet with skepticism from antitrust enforcers   Delrahim said that was overblown   I understand that some journalists and observers have recently expressed concern that the antitrust division no longer believes that vertical mergers can be efficient and beneficial to competition and consumers   he said  Delrahim said that some of these point at the decision to sue to try to stop AT T from buying Time Warner  as a supposed bellwether   he said   Rest assured these concerns are misplaced   
Two other vertical deals under review are Cigna Corp s  N CI  plan to buy Express Scripts Holding Co  O ESRX  for  52 billion and CVS Health Corp s  N CVS  planned merger with  Aetna Inc   N AET  for  69 billion ",2018-06-07,Reuters,https://www.investing.com/news/stock-market-news/us-antitrust-official-says-worries-over-limiting-vertical-deals-misplaced-1485015,1485015
147264,368780,CI,AT T  Justice Department await decision that could determine future of media,news,By Diane Bartz WASHINGTON  Reuters    AT T Inc  N T   which owns DirecTV  awaits a court ruling on Tuesday that will determine if it can buy  Time Warner  Inc  N TWX   a decision that could prompt a cascade of pay TV companies buying television and movie makers and the first big test of the Trump administration s antitrust teams  Judge Richard Leon of the U S  District Court for the District of Columbia is expected to rule at 4 p m  ET  2000 GMT  on whether the  85 billion deal may go forward more than 1 1 2 years after it was announced  The government argued in a six week trial this spring that AT T s ownership of DirecTV  which has 20 million subscribers  would become too powerful if combined with Time Warner  which owns Turner s sports and CNN news  That power would allow the company to raise prices for pay TV rivals and online streaming services  the government said  AT T said the deal was legal  and pre emptively offered to take any disputes with pay TV rivals to arbitration while refraining from withholding content  or  going dark   during the arbitration  If AT T wins  the Justice Department may rethink whether to sue to stop other deals where a company buys a supplier  known as a  vertical merger    It depends on the scope of the ruling  If it s narrow  like  I don t think Time Warner content is that must have   that may have implications in a similar merger in the telecommunications space but may not have a drastic effect in other vertical mergers   said Caroline Holland  who was in the Antitrust Division during the administration of former President Barack Obama  A big win for the Justice Department would send shudders down the spines of M A bankers pursuing deals where a company seeks to merge with a supplier  Already one deal depends on the ruling  Comcast Corp  O CMCSA  said in May that it was preparing a higher  all cash offer for most of the media assets of Twenty First Century Fox  O FOXA   but sources say it will only proceed if AT T wins its case  Two other vertical deals under review are Cigna Corp s  N CI  plan to buy Express Scripts Holding Co  O ESRX  for  52 billion and CVS Health Corp s  N CVS  planned merger with  Aetna Inc   N AET  for  69 billion  Ahead of the court ruling  a top antitrust official at the Justice Department urged investors not to read too much into the decision to sue to stop AT T from buying Time Warner  Most proposed transactions were either good for consumers or neutral  said Makan Delrahim  the assistant attorney general for antitrust   I understand that some journalists and observers have recently expressed concern that the antitrust division no longer believes that vertical mergers can be efficient and beneficial to competition and consumers   he said   Rest assured these concerns are misplaced  ,2018-06-12,Reuters,https://www.investing.com/news/technology-news/att-justice-department-await-decision-that-could-determine-future-of-media-1489225,1489225
147265,368781,CI,Four ways to prevent loneliness from wrecking your retirement,news,"By Chris Taylor NEW YORK  Reuters    When Monica Dwyer of West Chester  Ohio thinks of retirement  her mind wanders to her family friend Paul  Paul had a wife and kids  and a good job at Procter   Gamble  But his wife died 15 years before he did  and  over time  his social circles started shrinking  along with his finances  Eventually  Paul  barely had money to eat   Dwyer said  He kept his thermostat at 55 Fahrenheit  13 Celsius   even in frigid Ohio winters  He could not drive  surviving on  1 McDonald s hamburgers  and was alienated from his children  before he died   He was a forgotten soul   Dwyer said  You might not hear of stories like Paul s very often  but they are out there  A study  released last month by health services company Cigna  N CI  found that nearly half of Americans report feeling lonely sometimes or always  which the study concluded is a national  epidemic    We had been hearing from customers that they are feeling more disconnected and lonely  so we wanted to do some research to understand the state of loneliness across the U S    said Dr  Doug Nemecek  Cigna s chief medical officer for behavioral health   What we found was astounding   The emotional impact of loneliness in retirement is obvious   feelings of being isolated and misunderstood  with social interactions that lack meaning  But loneliness turns out to have financial ramifications as well  Take healthcare costs  for instance   People who feel lonely are less healthy   Nemecek said   There are many studies linking loneliness to worsening heart disease  cancer  diabetes  depression and substance abuse  In fact  healthwise  loneliness is comparable to smoking 15 cigarettes a day   If you are strategic and determined  there are multiple defenses against social isolation as you get older  Here are four tips from financial planners  MOVE TO A RETIREMENT COMMUNITY Society likes to poke fun at retiree developments  like the elder Seinfelds buying their condo in Del Boca Vista  But at larger senior communities like The Villages and Sun City Center  both in Florida   you could participate in a group activity nearly every hour of every day   said Holly Donaldson  a financial planner in Seminole  Florida   Retirement communities are a powerful alternative to retiring  in place  in your own home  Staying in your home may initially sound appealing because of the comfort level with your surroundings  but it could eventually leave you very alone indeed  especially if you are struggling with physical disability  KEEP WORKING If you enjoy working  and your employer does not have any mandated retirement age  then by all means keep showing up at the office  The first benefit is cognitive  keeping you alert and active and maintaining that social circle in the workplace  The second benefit is financial  Just a couple of years of additional work means you are actively building up your 401 k  assets  not drawing anything down  and boosting your Social Security payments by delaying taking them  That alone is enough to create a robust retirement outlook  VOLUNTEER Volunteers live longer  have lower levels of disability and higher levels of well being  according to data analysis by the Corporation for National   Community Service  CNCS   a federal agency  One surprising fact  volunteerism has a greater impact on well being than other factors like income  education or marriage  Volunteering also assembles a new social circle to hold you up in dark times  Intuitively  many seniors know this already  More than 21 million older Americans provide 3 3 billion hours of service every year  according to the CNCS  CREATE SOCIAL CHECKS AND BALANCES Retirees are highly susceptible to financial abuse  thanks to social isolation  The losses amount to an estimated  36 5 billion every year to fraud  scams and exploitation  according to a study by True Link Financial  a financial services company aimed at retirees  with the vast majority of financial abuse not even being reported  The sad fact is that 90 percent of financial abuse comes at the hands of someone in a position of trust  like a family member  according to the non profit National Adult Protective Services Association  The best way to defend against being at the mercy of one person is by having multiple people in your corner  If you have church friends  childhood friends  extended family and volunteering friends   all looking out for you   it will be less likely you will be taken advantage of  
 I always recommend having duplicate financial statements sent to someone you trust   advises Brett Anderson  a planner with St  Croix Advisors in Hudson  Wisconsin ",2018-07-02,Reuters,https://www.investing.com/news/economy-news/four-ways-to-prevent-loneliness-from-wrecking-your-retirement-1514589,1514589
147268,368784,CI,Is Cigna  CI  Stock Undervalued Right Now ,opinion,"Here at Zacks  we focus on our proven ranking system  which places an emphasis on earnings estimates and estimate revisions  to find winning stocks  But we also understand that investors develop their own strategies  so we are constantly looking at the latest trends in value  growth  and momentum to find strong companies for our readers 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
One company to watch right now is Cigna  CI   CI is currently sporting a Zacks Rank of  2  Buy   as well as an A grade for Value  The stock is trading with P E ratio of 9 38 right now  For comparison  its industry sports an average P E of 9 56  CI s Forward P E has been as high as 14 12 and as low as 8 44  with a median of 11 53  all within the past year 
We also note that CI holds a PEG ratio of 0 77  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  CI s PEG compares to its industry s average PEG of 1 04  Over the past 52 weeks  CI s PEG has been as high as 1 16 and as low as 0 69  with a median of 0 93 
Another valuation metric that we should highlight is CI s P B ratio of 1 47  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  CI s current P B looks attractive when compared to its industry s average P B of 1 54  Over the past year  CI s P B has been as high as 3 52 and as low as 1 30  with a median of 1 85 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  This is a prefered metric because revenue can t really be manipulated  so sales are often a truer performance indicator  CI has a P S ratio of 0 82  This compares to its industry s average P S of 1 07 
These are just a handful of the figures considered in Cigna s great Value grade  Still  they help show that the stock is likely being undervalued at the moment  Add this to the strength of its earnings outlook  and we can clearly see that CI is an impressive value stock right now ",2019-07-07,Zacks Investment Research,https://www.investing.com/analysis/is-cigna-ci-stock-undervalued-right-now-200437696,200437696
147269,368785,CI,Cigna  CI  Jumps  Stock Rises 9 2 ,opinion,Cigna Corporation   NYSE CI   was a big mover last session  as the company saw its shares rise more than 9  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  156 07 to  164 83 in the past one month time frame The company has seen one negative estimate revision in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Cigna currently has a Zacks Rank  3  Hold  while its  is negative Cigna Corporation Price   Investors interested in the Insurance   Multi line industry may consider Kemper Corporation   NYSE KMPR    which has a Zacks Rank  1  Strong Buy   You can see Is CI going up  Or down  Predict to see what others think Up or DownThe Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-jumps-stock-rises-92-200439281,200439281
147270,368786,CI,Company News For Jul 12  2019,opinion,Shares of Cigna Corporation   NYSE CI   rose 9 2  after the Trump administration decided to scrap its drug rebate planDelta Air Lines  Inc  s   NYSE DAL   shares increased 1 2  after the air transportation provider reported 8 7  revenue growth to  12 5 billion in Q2 from a year agoShares of Bed Bath   Beyond Inc    NASDAQ BBBY   dropped 3  after the home goods retailer reported hefty losses because of  401 million in impairment charges in the fiscal first quarterFastenal Company s   NASDAQ FAST   shares dropped 2 9  after its Q2 earnings of  0 36 per share missed the Zacks Consensus Estimate of  0 37 per share,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jul-12-2019-200439338,200439338
147271,368787,CI,Drug Pricing Woes Linger On Repealing Drug Rebate Proposal,opinion,Major pharma industry players were in the red on Jul 11 following the scrapping of the Trump administration s proposal to eliminate rebates offered by the drug companies to pharmacy benefits managers  PBMs   The proposal was part of the government s efforts to control drug pricing PBMs act as intermediaries to negotiate with drugmakers for rebates on the listed price of their branded drugs to lower the costs on behalf of small buyers and insurers  PBMs retain a percentage of the rebate offered and sell drugs to the buyers insurers  However  these rebates and discounts were rarely passed down to the buyers aka pharmacies  The proposal stated that drugmakers will instead pay a certain fee to PBMs in return for placing the drugs on co pay or medicare beneficiary list and the rebates will be directly delivered to buyers pharmacies Following the Trump regime s decision not to proceed with the proposal for revoking rebates to PBMs  shares of PBM like Cigna Corporation   NYSE CI   rose while those of pharma companies declined  The committees overseeing this proposal remained wary of the fact that it could lead to rise in medicare premiums  The experts also suggested that the implementation of the rule will cost the federal government almost  177 billion over the next decade The proposal to remove rebates offered by drug makers to the PBMs prompted the pharma players to put the onus of skyrocketing drug prices on PBMs  shoulders  However  the Trump administration s announcement to withdraw the proposal has brought the drugmakers in focus again  Moreover  the decision also spurs uncertainty for the pharma industry as the government is hell bent on curbing the exorbitant drug prices  Investors remain skeptical about the next step from the administration and also expect drugmakers to bear the brunt of the same  This misgiving has caused the large pharma shares to crash down with Merck   NYSE MRK    Bristol Myers   NYSE BMY    Eli Lilly   NYSE LLY   and Pfizer   NYSE PFE   stocks registering a dip of 3 4  on Jul 11 Drug pricing controversy has plagued the industry since the last presidential campaign  Time and again  Trump has criticized drugmakers for escalating drug prices ever since he assumed office  He remains committed to take on the industry bigwigs on pricing issue and the opposition  Democrats  also supported this cause  making the situation more challenging for the pharma industry In 2018  several large pharma companies deferred their plans to increase the drug prices or decreased the same amid a strong opposition from the government  Earlier this year  senators grilled the respective management of these companies over the drug pricing issue and blamed the American patent system for perking up the prices by almost monopolizing the markets for drugs Notably  the Trump administration is planning an executive order   favorable nations clause   which will restrict drugmakers to charge the lowest price for a drug in any global market  If passed  the burden will be on the pharma companies to suffer the loss due to price decline  which will likely dent the industry s profits Meanwhile  a judge in the United States District Court in the District of Columbia  in favour of the pharma companies related to the disclosure of wholesale prices of the drugs in television advertising by the drugmakers  The federal court ordained that the pharma companies are not required to reveal the price tags in television adverts Every government has vowed to keep the drug prices under control  However  there has been little progress  As a matter of fact  drug prices have been touching staggering levels over the past decade  piling up pressure on patients in the United States with rising healthcare costs  Moreover  it is argued that PBMs prefer branded drugs over the generic versions due to better margins  which can induce high costs for customers  Meanwhile  the pharma companies argue that the high costs of drugs reflect high cost of research and development We expect the tussle between pharma companies and the government over drug pricing issue to persist in 2019  This raises volatility for the whole pharma biotech drug market While Merck has a Zacks Rank  2  Buy   Bristol Myers  Pfizer and Lilly carry a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/drug-pricing-woes-linger-on-repealing-drug-rebate-proposal-200439377,200439377
147272,368788,CI,The Dow Breaks 27 000 For The First Time Ever After Powell Testimony,opinion,"The Dow Jones Industrial Average rallied to a record high on Thursday  led by UnitedHealth  NYSE UNH  shares  after testimony by Federal Reserve Chair Jerome Powell that signaled easier monetary policy could be implemented later this month 
The 30 stock average broke above 27 000 for the first time in its history  before trading just below that level  The Dow was up 0 5   or 132 points  around 9 50 a m  ET 
Meanwhile  the S P 500 rose 0 2  to trade back above 3 000 while the NASDAQ Composite gained 0 2  
UnitedHealth shares surged more than 4  after the White House dropped a proposal to eliminate drug rebates  CVS Health  NYSE CVS  and Cigna  NYSE CI  also jumped on the news  gaining 7  and 14   respectively 
Delta Air Lines  NYSE DAL  rose 0 9  on better than expected earnings  Amazon  NASDAQ AMZN  traded 0 7  higher  bringing its market cap back above  1 trillion 
In testimony to the House Financial Services Committee on Wednesday  Powell said business investments across the U S  have slowed  notably  recently as uncertainties over the economic outlook linger  As a result  expectations of an upcoming rate cut grew 
Original Post",2019-07-12,Alfonso Esparza,https://www.investing.com/analysis/the-dow-breaks-27000-for-the-first-time-ever-200439126,200439126
147288,368804,CI,UnitedHealth profit beats and it raises 2018 outlook,news," Reuters    UnitedHealth Group Inc  N UNH   the largest U S  health insurer  on Tuesday posted quarterly profit that beat estimates as it kept medical costs within expectations despite the added demand for services due to a strong flu season and raised its 2018 outlook  Shares of UnitedHealth rose 2 9 percent to  237 in premarket trading  ISI Evercore analyst Michael Newshel said in a research note that he believed the earnings beat came from the Optum business  which includes its pharmacy benefit manager  data analysis and physician groups  UnitedHealth has added more doctors  urgent care centers and surgery centers through a series of acquisitions   UnitedHealth s medical care ratio  or the percentage of premiums paid out for medical services  improved to 81 4 percent from 82 4 percent a year earlier  The company raised its full year adjusted earnings forecast to a range of  12 40 to  12 65 per share from a range of  12 30 to  12 60   The health insurance sector has gone through a number of big takeover deals in the past year as companies consider how to stay competitive  Recent deals include insurer Aetna Inc s  N AET   69 billion merger with CVS Health Corp  N CVS  and smaller rival  Cigna Corp   N CI  acquisition of Express Scripts Holding Co  O ESRX   the largest U S  independent pharmacy benefit manager  for  54 billion  UnitedHealth s net earnings rose to  2 84 billion  or  2 87 per share  in the first quarter ended March 31 from  2 17 billion  or  2 23 per share  a year earlier  Excluding items  the company earned  3 04 per share  Total revenue rose 13 3 percent to  55 19 billion  
Analysts  on average  expected earnings of  2 89 per share on revenue of  54 86 billion  according to Thomson Reuters I B E S ",2018-04-17,Reuters,https://www.investing.com/news/stock-market-news/unitedhealths-quarterly-profit-beats-estimates-1398041,1398041
147289,368805,CI,Express Scripts targets new migraine drugs to change U S  pricing dynamic,news,"By Deena Beasley LOS ANGELES  Reuters    The largest U S  manager of prescription benefits is telling drugmakers that the current pricing model is broken  and taking aim at  Amgen Inc   NASDAQ AMGN  and other makers of new migraine medicines to try and fix it  Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U S  list price  then lowering the cost for health plans through hefty rebates  It is also seeking a refund if the drugs don t work within a defined timeframe  The shift could help Express Scripts and other pharmacy benefits managers  PBMs  bring prices down  and deflect growing criticism of their role as  middlemen  in the drug supply chain   The Trump administration and members of Congress have demanded that PBMs pass on more of the rebates they receive to consumers outraged over rising costs at the pharmacy counter  Many Americans now have health plans with higher deductibles or co payments  making them responsible for more of their medical costs  Express Scripts is advising drugmakers to take that shift into account as they launch a new class of migraine drugs   If your expectation is that you are not going to actually get that high list price  then don t do that to patients who have high co pays   Chief Medical Officer Steve Miller said in an interview  describing his message to Amgen and its rivals   Let s be more balanced  Let s get back to where gross to net is not so different   Amgen s Aimovig is expected to be approved next month  followed by similar drugs from Teva Pharmaceutical Industries  NYSE TEVA  Ltd and Eli Lilly   Co that the companies say could benefit up to 4 million people in the United States   The injected therapies interfere with the function of a molecule involved in the processes that kick off a migraine  such as dilation of blood vessels in the brain  Wall Street analysts expect Amgen to announce a list price of up to  10 000 per year for Aimovig once it is approved  setting the tone for competitors  But Express Scripts and other PBMs restrict access to new drugs they deem too expensive  asking doctors to provide detailed evidence of why a specific patient may benefit  requiring the use of other drugs for a period of time or favoring cheaper rivals when available  Drugmakers could face similar issues with the new migraine treatments  Miller said   Should they price these things too high they will probably not be able to achieve much market share   Express Scripts is also pushing Amgen and its peers to refund two thirds of the cost of a migraine drug if a patient stops treatment within 90 days because it didn t work or caused major side effects   Such guarantees are becoming more prevalent for older drugs with competing products on the market  including diabetes and hepatitis C therapies  It would be unusual to introduce them for the first drug in an entirely new class of therapy  Amgen  which will market Aimovig in partnership with Novartis  declined to comment on talks with Express Scripts  Research chief Sean Harper said in a recent interview that payers share blame for the current pricing model   Their demands for ever larger rebates has forced manufacturers to use higher list prices as a benchmark  he said    It is a ridiculous situation that we are in   Harper said   No one is paying the list price  but patients are exposed for a period of time  until they pay off their insurance deductible  TAKING OUT COSTS  Rising U S  healthcare costs  the most expensive worldwide  are straining budgets for families  employers and government agencies  That has created new pressures within the industry to control costs   To that end  Express Scripts has agreed to a buyout from health insurer  Cigna Corp   NYSE CI   while PBM rival CVS Health Corp  NYSE CVS  plans to buy insurer  Aetna Inc   NYSE AET     In interviews with Reuters  smaller PBM Abarca Health and insurer Highmark Health said they were adopting similar tactics to Express Scripts in negotiating coverage for the migraine drugs  CVS declined comment   Teva said it was evaluating the pricing environment for its migraine drug  Officials at Lilly did not respond to a request for comment   The stakes are high for Amgen  which has struggled to grow revenue in recent years   The biotech company s last potential blockbuster  high priced cholesterol treatment Repatha  has been stymied by PBMs who questioned its value compared to generic statins that cost  100 per year   Repatha and rival Praluent  sold by Sanofi  PA SASY  and Regeneron Pharmaceuticals  launched in 2015 at list prices near  14 000 a year and were expected to be billion dollar products  But Express Scripts and other payers have rejected most prescriptions written for the new medicines while awaiting proof that they lower the risk of death  As a result  Repatha sales totaled  319 million last year  while Praluent had sales of  195 million    If Amgen and Sanofi had it to do over again  I think they would have priced at half the list price and made a whole lot more money   said Jason Borschow  chief executive officer at Miami based Abarca   Aimovig is far more effective at preventing migraines than current treatments  mainly low cost generic drugs  Recent studies have shown that Aimovig reduces episodic migraines by at least half in around 50 percent of patients   The Food and Drug Administration is expected to decide on Aimovig by May 17  The agency s decision on Teva s treatment fremanezumab had been expected in June  but that may be delayed due to manufacturing issues  A ruling on Lilly s galcanezumab is expected later in the year  
Amgen will report quarterly results on Tuesday afternoon ",2018-04-24,Reuters,https://www.investing.com/news/stock-market-news/express-scripts-targets-new-migraine-drugs-to-change-us-pricing-dynamic-1410052,1410052
147290,368806,CI,Express Scripts targets Amgen  Lilly migraine drugs in pricing shift,news,By Deena Beasley LOS ANGELES  Reuters    The largest U S  manager of prescription benefits is telling drugmakers that the current pricing model is broken  and taking aim at  Amgen Inc   O AMGN   Eli Lilly and Co  N LLY  and other makers of new migraine medicines to try and fix it  Express Scripts  O ESRX  told Reuters it is pressing them to forego the usual strategy of setting a high U S  list price  then lowering the cost for health plans through hefty rebates  It is also seeking a refund if the drugs don t work within a defined timeframe The shift could help Express Scripts and other pharmacy benefits managers  PBMs  bring prices down  and deflect growing criticism of their role as  middlemen  in the drug supply chain   The Trump administration and members of Congress have demanded that PBMs pass on more of the rebates they receive to consumers outraged over rising costs at the pharmacy counter  Many Americans now have health plans with higher deductibles or co payments  making them responsible for more of their medical costs  Express Scripts is advising drugmakers to take that shift into account as they launch a new class of migraine drugs   If your expectation is that you are not going to actually get that high list price  then don t do that to patients who have high co pays   Chief Medical Officer Steve Miller said in an interview  describing his message to Amgen and its rivals   Let s be more balanced  Let s get back to where gross to net is not so different  Amgen s Aimovig is expected to be approved next month  followed by similar drugs from Teva Pharmaceutical Industries  NYSE TEVA  Ltd and Lilly that the companies say could benefit up to 4 million people in the United States   Lilly has been pushing PBMs  for years  to create contracts that take drug performance into account  Chief Executive David Ricks said when analysts asked about the Reuters story on a conference call to discuss quarterly earnings  Ricks said he was happy that Express Scripts  is now changing their view and support this kind of construct  We ll be happy to work with them on it   The new injected therapies interfere with the function of a molecule involved in the processes that kick off a migraine  such as dilation of blood vessels in the brain  Wall Street analysts expect Amgen to announce a list price of up to  10 000 per year for Aimovig once it is approved  setting the tone for competitors  But Express Scripts and other PBMs restrict access to new drugs they deem too expensive  asking doctors to provide detailed evidence of why a specific patient may benefit  requiring the use of other drugs for a period of time or favoring cheaper rivals when available  Drugmakers could face similar issues with the new migraine treatments  Miller said   Should they price these things too high they will probably not be able to achieve much market share   Express Scripts is also pushing Amgen and its peers to refund two thirds of the cost of a migraine drug if a patient stops treatment within 90 days because it didn t work or caused major side effects  Such guarantees are becoming more prevalent for older drugs with competing products on the market  including diabetes and hepatitis C therapies  It would be unusual to introduce them for the first drug in an entirely new class of therapy Amgen  which will market Aimovig in partnership with  Novartis   S NOVN   declined to comment on talks with Express Scripts  Research chief Sean Harper said in a recent interview that payers share blame for the current pricing model   Their demands for ever larger rebates has forced manufacturers to use higher list prices as a benchmark  he said   It is a ridiculous situation that we are in   Harper said   No one is paying the list price  but patients are exposed for a period of time  until they pay off their insurance deductible  Shares of Amgen  which will report quarterly results on Tuesday afternoon  fell 1 percent in midday trading  Lilly declined 0 5 percent   TAKING OUT COSTS Rising U S  healthcare costs  the most expensive worldwide  are straining budgets for families  employers and government agencies  That has created new pressures within the industry to control costs   To that end  Express Scripts has agreed to a buyout from health insurer  Cigna Corp   N CI   while PBM rival CVS Health Corp  N CVS  plans to buy insurer  Aetna Inc   N AET    In interviews with Reuters  smaller PBM Abarca Health and insurer Highmark Health said they were adopting similar tactics to Express Scripts in negotiating coverage for the migraine drugs  CVS declined comment   Teva said it was evaluating the pricing environment for its migraine drug  The stakes are high for Amgen  which has struggled to grow revenue in recent years   The biotech company s last potential blockbuster  high priced cholesterol treatment Repatha  has been stymied by PBMs who questioned its value compared to generic statins that cost  100 per year  Repatha and rival Praluent  sold by Sanofi  PA SASY  and Regeneron Pharmaceuticals  O REGN   launched in 2015 at list prices near  14 000 a year and were expected to be billion dollar products  But Express Scripts and other payers have rejected most prescriptions written for the new medicines while awaiting proof that they lower the risk of death  As a result  Repatha sales totaled  319 million last year  while Praluent had sales of  195 million   If Amgen and Sanofi had it to do over again  I think they would have priced at half the list price and made a whole lot more money   said Jason Borschow  chief executive officer at Miami based Abarca  Aimovig is far more effective at preventing migraines than current treatments  mainly low cost generic drugs  Recent studies have shown that Aimovig reduces episodic migraines by at least half in around 50 percent of patients  The Food and Drug Administration is expected to decide on Aimovig by May 17  The agency s decision on Teva s treatment fremanezumab had been expected in June  but that may be delayed due to manufacturing issues  A ruling on Lilly s galcanezumab is expected later in the year ,2018-04-24,Reuters,https://www.investing.com/news/stock-market-news/express-scripts-targets-amgen-lilly-migraine-drugs-in-pricing-shift-1411525,1411525
147291,368807,CI,Premarket analyst action   healthcare,news,Anthem  NYSE ANTM  upgraded to overweight at JPMorgan  NYSE JPM  Lemaitre Vascular  NASDAQ LMAT  downgraded to Hold at Stifel Now read ,2018-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1416163,1416163
147296,368812,CI,3 Reasons Why Growth Investors Shouldn t Overlook Cigna  CI ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a growth stock that can live up to its true potential can be a tough task 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Cigna  CI  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this health insurer a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Cigna is 15 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 16 5  this year  crushing the industry average  which calls for EPS growth of 11 6  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Cigna is 31 5   which is higher than many of its peers  In fact  the rate compares to the industry average of 11 4  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 10 9  over the past 3 5 years versus the industry average of  0 4  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Cigna have been revising upward  The Zacks Consensus Estimate for the current year has surged 0 1  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Cigna a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Cigna is a potential outperformer and a solid choice for growth investors ",2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-growth-investors-shouldnt-overlook-cigna-ci-200432831,200432831
147297,368813,CI,What Makes Cigna  CI  A New Buy Stock,opinion,"Cigna  CI  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank  2  Buy   This upgrade primarily reflects an upward trend in earnings estimates  which is one of the most powerful forces impacting stock prices 
The sole determinant of the Zacks rating is a company s changing earnings picture  The Zacks Consensus Estimate    the consensus of EPS estimates from the sell side analysts covering the stock    for the current and following years is tracked by the system 
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts  since these are mostly driven by subjective factors that are hard to see and measure in real time  In these situations  the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near term stock price movements 
Therefore  the Zacks rating upgrade for Cigna basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price 
Most Powerful Force Impacting Stock Prices
The change in a company s future earnings potential  as reflected in earnings estimate revisions  has proven to be strongly correlated with the near term price movement of its stock  That s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company s shares  An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock  and institutional investors typically buy or sell it  Their transaction of large amounts of shares then leads to price movement for the stock 
For Cigna  rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company s underlying business  And investors  appreciation of this improving business trend should push the stock higher 
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near term stock movements  so it could be truly rewarding if such revisions are tracked for making an investment decision  Here is where the tried and tested Zacks Rank stock rating system plays an important role  as it effectively harnesses the power of earnings estimate revisions 
The Zacks Rank stock rating system  which uses four factors related to earnings estimates to classify stocks into five groups  ranging from Zacks Rank  1  Strong Buy  to Zacks Rank  5  Strong Sell   has an impressive externally audited track record  with Zacks Rank  1 stocks generating an average annual return of  25  since 1988  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here      
Earnings Estimate Revisions for Cigna
For the fiscal year ending December  2019  this health insurer is expected to earn  16 57 per share  which is a change of 16 5  from the year ago reported number 
Analysts have been steadily raising their estimates for Cigna  Over the past three months  the Zacks Consensus Estimate for the company has increased 0 9  
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations  the Zacks rating system maintains an equal proportion of  buy  and  sell  ratings for its entire universe of more than 4000 stocks at any point in time  Irrespective of market conditions  only the top 5  of the Zacks covered stocks get a  Strong Buy  rating and the next 15  get a  Buy  rating  So  the placement of a stock in the top 20  of the Zacks covered stocks indicates its superior earnings estimate revision feature  making it a solid candidate for producing market beating returns in the near term 
You can learn more about the Zacks Rank here    
The upgrade of Cigna to a Zacks Rank  2 positions it in the top 20  of the Zacks covered stocks in terms of estimate revisions  implying that the stock might move higher in the near term ",2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/what-makes-cigna-ci-a-new-buy-stock-200435184,200435184
147298,368814,CI,MetLife  MET  To Sell Hong Kong Unit To Streamline Business,opinion,MetLife  Inc    NYSE MET    the leading U S  multiline insurer  might sell its Hong Kong unit to FWD Insurance  per multiple sources  However  financial terms of the transaction are not disclosed Notably  this buyout complements FWD s several transactions closed in the region  This deal will further add to its strategy to form an advanced pan Asian life insurance platform It also reflects the strength of Hong Kong s insurance businesses  which is further evident from FWD s life and health insurance premium to GDP ratio of 17 94  in 2017  according to insurer Swiss Re FWD plans to rebrand and rename the Hong Kong unit of MetLife  Post the completion of the above deal  the acquirer would continue to honor the current MetLife Hong Kong policies Earlier  MetLife attempted to sell this business to a mainland Chinese buyer  This divestment is in line with the company s aim to streamline its business to focus more on the areas with growth potential and in fixing or exiting operations that do not create value One of the most significant steps taken in this direction was the separation of its U S  Retail business  BrightHouse Financial  The split up happened in 2018  This business required MetLife to hold a huge capital buffer  thereby placing it at a massive competitive disadvantage  The strategic move thus freed MetLife from a capital intensive business  It also saved the company from exposure to interest rate and equity market volatility related to the discontinued business MetLife also concluded the shutdown of its UK Wealth Management business  which was enduring low interest rates  Moreover  the company sold MetLife Afore  S A  de C V   its pension fund management business in Mexico  Though the termination of these businesses will dent its top line growth to some extent  in the coming quarters  in the form of fees and premium loss  over the long term  these strategic measures will transform MetLife into a company with less risk level and more free cash flow to generate higher return on equity Shares of this Zacks Rank  2  Buy  have rallied 14  in a year s time  outperforming its  s growth of 7 2  Other Stocks to ConsiderInvestors interested in the same space might also take a look at some other top ranked stocks like American International Group  Inc    NYSE AIG    Cigna Corporation   NYSE CI   and Kemper Corporation   NYSE KMPR     You can see  American International Group provides insurance products in North America and around the globe  It sports a Zacks Rank  1  In the trailing four quarters  the stock pulled off average positive surprise of 15 61  Cigna provides insurance and related products and services in the United States and around the globe  It came up with average positive surprise of 7 4  over the last four quarters  The stock has a Zacks Rank of 2 Kemper is a diversified insurance holding company  offering property and casualty plus life and health insurance services in the United States  This Zacks  2 Ranked player managed to deliver average trailing four quarter beat of 14 13  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/metlife-met-to-sell-hong-kong-unit-to-streamline-business-200436055,200436055
147299,368815,CI,Centene  CNC  Acquires Additional Stake In Ribera Salud,opinion,Centene Corporation   NYSE CNC   recently announced that it has bought an additional stake in Ribera Salud from Banco Sabadell  The deal was closed on Jun 28  2019  Financial terms of the purchase were not disclosed The transaction boosted Centene s share in the Spanish healthcare company from 50  to 90   Buying this surplus interest positions the company well for enhancing its unique solutions through cutting edge technology  value creation and better customer outcomes In July 2014  the company invested  17 million to purchase a noncontrolling interest in Ribera Slaud  which helped it enter the Spanish market  It further penetrated the space through a few following pacts  In late 2018  Centene also bought a majority stake in a Madrid hospital  It also owns 89  of the University Hospital of Torrej n  which is managed by Ribera Salud The deal is in line with the company s commitment to bolster its international portfolio On the domestic front  Centene is well poised for growth  evident from its  17 3 billion worth pending acquisition of WellCare Health Plans  Inc    NYSE WCG    which was approved by shareholders last month  The merger is estimated to be completed in the first half of 2020  The combined entity will have a wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members  In total  it will have around 22 million members across 50 US states Centene joins its peers UnitedHealth Group Incorporated   NYSE UNH   as well as Cigna Corporation   NYSE CI    which too are establishing their presence outside the United States in evolving markets for driving growth Merger and acquisition activity has led to Centene s inorganic growth  The company targets market expansion and higher Medicaid membership  Certain buyouts like Community Medical Holdings  MHM Services and Fidelis Care have contributed to the company s revenue base and evidently  aided it to consolidate is capabilities  All these strategic initiatives by the company bode well for growth Shares of this Zacks Rank  3  Hold  company have lost around 19 7  in a year  wider than its  s dip of 0 9  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-04,Zacks Investment Research,https://www.investing.com/analysis/centene-cnc-acquires-additional-stake-in-ribera-salud-200437314,200437314
147313,368829,CI,Mizuho weighs in on Cigna Express Scripts tie up,news,In a note  Mizuho Securities considers Cigna s  CI  9 5   proposed  67B takeout of Express Scripts  ESRX  11 8   fairly valued  adding that the multiples for the group are too low and investor sentiment too negative on the perceived risks  i e   potential Amazon  NASDAQ AMZN  entry  drug pricing pressures  changes in the rebate model  Mizuho believes regulators will eventually sign off on the deal  as well as the CVS Aetna tie up  after lengthy review periods Now read ,2018-03-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/mizuho-weighs-in-on-cignaexpress-scripts-tieup-1332304,1332304
147314,368830,CI,Goldman Sachs sees reshaping of industries driving MA,news,"By Svea Herbst Bayliss and Liana B  Baker NEW ORLEANS  Reuters    Major shifts in industries ranging from semiconductors and food to beverages and pharmaceuticals will keep fueling the blistering pace of mergers and acquisitions  one of  Goldman Sachs Group   NYSE GS  Inc s top dealmakers said on Thursday  Gradually rising interest rates  stock market jitters amid concerns over U S  trade policy  and new concerns about U S  regulators moving to thwart mergers have raised questions on Wall Street on whether robust dealmaking activity will continue  However  most transformative mergers and acquisitions are driven by industries that were static for several years and are now in the process of adjusting to changes ranging from the introduction of new technologies to demographic shifts  Goldman Sachs global M A co head Michael Carr told the Tulane Corporate Law Institute conference in New Orleans on Thursday   We are in an environment where entire industries are changing structure and that s causing M A to happen    Transactions beget transactions  Sometimes you need to do something because your neighbor did it    Carr said  Semiconductor company managers  for example  have recognized they are in a race to gain scale  saying to themselves and rivals   I m either in this game or I m a seller   said Carr  U S  merger and acquisition volumes reached  389 billion so far this year  compared with  236 5 billion in the same period a year ago  as more mega deals were announced  according to Thomson Reuters data  including U S  health insurer Cigna  NYSE CI  Corp s  52 billion agreement to buy pharmacy benefits manager Express Scripts Holding Co and Keurig Green Mountain s more than  21 billion deal to combine with soda maker  Dr Pepper Snapple  Group Inc  NYSE DPS   Given the strategic reasons companies are exploring mergers  Carr downplayed the risk of rising debt financing costs and soaring corporate valuations weighing on M A activity  However  he acknowledged that U S  President Donald Trump s administration has increased regulatory uncertainty for deals  especially those involving China   The relationship between the White house and Beijing is far from great   Carr said   With the Trump administration s tax reform set  companies will have more cash to put to work  The U S  corporate tax rate was cut to 21 percent from 35 percent at the start of the year  Also  billions of dollars will be brought back to the United States now that companies face a one time tax on profits stock piled abroad  
 Right now this feels like a bit of a juggernaut    this is going to continue until people do stupid deals   Carr said ",2018-03-15,Reuters,https://www.investing.com/news/stock-market-news/goldman-sachs-sees-reshaping-of-industries-driving-ma-1344081,1344081
147316,368832,CI,Cigna  CI  Down 6 5  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Cigna  CI   Shares have lost about 6 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Cigna due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Cigna Beats Q1 Earnings Estimates  Raises 2019 ViewCigna Corp  came up with adjusted earnings of  3 9 per share in first quarter 2019  surpassing the Zacks Consensus Estimate by 4 3   However  the same was down 5 1  year over year Cigna posted revenues of  33 43 billion and missed the Zacks Consensus Estimate by 1 5   Revenues grew 192  year over year on the acquisition of Express Scripts  NASDAQ ESRX  Premiums were up 11  year over year to  10 billion while fees increased 79  to  2 45 billion The SG A expense ratio was 9 3  for first quarter 2019  down from 23 5  for the first quarter of 2018  The decline was mainly led by business mix changes  resulting from the Express Scripts combination  and the health insurance tax suspension The company s medical enrollment grew by 224 000 lives from the prior year quarter to 16 99 million customers  driven by growth in Government  Commercial and International markets  Moreover  the acquisition of Express Scripts  completed last December  led to an increase in Pharmacy and Medicare Part D members Strong Segmental PerformanceHealth Services  Operating revenues of  22 4 billion were up from  1 07 billion in the year ago quarter owing to the acquisition of Express ScriptsAdjusted operating earnings were  994 million  up from  83 million in the year ago quarter  driven by organic growth in pharmacy customers since the beginning of the year  and strong adjusted pharmacy script volumes and performance in specialty pharmacy care Integrated Medical  Operating revenues of  9 2 billion were up 12 8  year over year due to organic growth in Commercial and Government business Operating income increased 15 6  from the year ago quarter to  1 2 billion due to strong medical and specialty contributions and continued effective medical cost performance International Markets  Operating revenues of  1 39 billion were up 4  year over year  reflecting continued business growth  partially offset by some impact from unfavorable foreign currency movements Adjusted operating income decreased 5 1  year over year to  206 million due to unfavorable foreign currency impact Global Disability and Life  Operating revenues of  1 3 billion were up 2  year over year  However  operating income decreased 28  year over year to  84 million  due to unfavorable disability claims  partly offset by strong life results Cigna s debt to capitalization ratio improved to 48 8  at Mar 31  2019  from 50 9  at the end of Dec 31  2018 2019 Guidance UpdateFor 2019  the company expects earnings per share in the range of  16 25  16 65  up from the prior range of  16  16 50 Total revenues are expected in the range of  132 5  134 5 billion  versus  131 5  133 5 billion earlier  and medical customers are projected to grow within 0 3 0 4 million lives Medical care ratio is expected in the range of 80 5 81 5  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Cigna has a nice Growth Score of B  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Cigna has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-down-65-since-last-earnings-report-can-it-rebound-200427413,200427413
147317,368833,CI,3 Reasons Why Cigna  CI  Is A Great Growth Stock,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a great growth stock is not easy at all 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Cigna  CI  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this health insurer is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Cigna is 15 7   investors should actually focus on the projected growth  The company s EPS is expected to grow 16 3  this year  crushing the industry average  which calls for EPS growth of 11 6  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Cigna is 31 5   which is higher than many of its peers  In fact  the rate compares to the industry average of 11 4  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 10 9  over the past 3 5 years versus the industry average of  0 4  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for Cigna have been revising upward  The Zacks Consensus Estimate for the current year has surged 0 7  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Cigna a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Cigna is a potential outperformer and a solid choice for growth investors ",2019-06-03,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-cigna-ci-is-a-great-growth-stock-200427742,200427742
147318,368834,CI,Why It Is Worth Betting On Cigna Stock For Your Portfolio,opinion,Cigna Corporation   NYSE CI   is well placed for growth on the back of its strategic acquisitions  strong international business and a rising top line Estimates for the stock have been revised upward over the past 30 days  reflecting analysts  optimism on the stock  The stock has seen the Zacks Consensus Estimate for 2019 earnings move 0 2  north over the same time frame The company even boasts a favorable earnings surprise history  having exceeded the Zacks Consensus Estimate in three of the trailing four quarters  the average beat being 7 4   This also highlights the company s operating excellence The stock carries an impressive  of B  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors   Its return on equity   a profitability measure   stands at 14 2   better than its industry s average of 7 9  The company looks well poised for 2019 with the buyout of Express Scripts  NASDAQ ESRX   the pharmacy benefits manager  The merged company is now a one stop shop for customers  healthcare needs  ranging from the sale of drugs to insurance cover  Consumers will also gain traction from this consolidation as this is expected to improve treatments and lower medical costs The combined entity will be able to rise in ranks in the health insurance industry  thereby strengthening its competitive edge  This transaction would lead to total cost synergies of  650 million and a double digit accretion to earnings in 2019 The company has also been putting in efforts to expand its international operations  which have been contributing to its top  and bottom line growth for the past many years  The company has its global businesses in places like India  Turkey  Hong Kong  etc  with the largest operation being in South Korea where it has been active for more than three decades Cigna s revenue stream has been pretty impressive as is evident from its 2010 2018 CAGR of 11   This growth can be attributable to the company s specific acquisitions  its operating performance and provision of quality products and services Following solid results  the company provided a strong guidance  which should instill investors  confidence in the stock  For 2019  Cigna expects earnings per share in the range of  16 25  16 65  up from the prior range of  16  16 50  Total revenues are projected in the  132 5  134 5 billion band  earlier estimate was  131 5  133 5 billion  The company s long term growth rate is pegged at 12 2   higher than the industry s average of 11 5   which remains a positive for the company The Zacks Consensus Estimate for current year earnings per share is pegged at  16 57  suggesting a rise of 16 5  on 178 1  higher revenues of  133 83 billion from the year ago reported figures For 2020  the Zacks Consensus Estimate for earnings per share stands at  18 58 on  141 56 billion revenues  implying a respective 12 2  and 5 8  from the prior year reported numbers Shares of this Zacks Rank  2  Buy  company have lost 9  in a year s time against its  s growth of 2  Other Key PicksInvestors interested in the medical sector can also take a look at some other top ranked stocks like WellCare Health Plans  Inc    NYSE WCG    HCA Healthcare  Inc    NYSE HCA   and Molina Healthcare  Inc   NYSE MOH    You can see  WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 13 52  in the preceding four quarters  It holds a Zacks Rank of 2 HCA Healthcare provides health care services  In the last four quarters  the company delivered average beat of 15 74   It is a Zacks  2 Ranked player Molina Healthcare is a multi state healthcare organization  In the trailing four quarters  the company came up with average beat of 88 17   It sports a Zacks Rank  1  Strong Buy  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/why-it-is-worth-betting-on-cigna-stock-for-your-portfolio-200432950,200432950
147321,368837,CI,CIGNA beats by  0 05  beats on revenue,news,CIGNA  NYSE CI   Q4 EPS of  1 94 beats by  0 05 Revenue of  10 51B   6 4  Y Y  beats by  210M Press ReleaseNow read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/cigna-beats-by-005-beats-on-revenue-1180830,1180830
147323,368839,CI,U S  to extend skimpy health insurance outside of Obamacare,news,"By Yasmeen Abutaleb and Caroline Humer WASHINGTON NEW YORK  Reuters    The U S  government on Tuesday proposed extending the availability of skimpy health insurance plans to millions of Americans in another Trump administration move aimed at undercutting the requirements of the Affordable Care Act  often called Obamacare  The U S  Department of Health and Human Services issued a proposed rule that such plans  now available only for periods of three months or less  will be available for up to 12 months  The agency is considering whether these plans will be renewable   The plans will not include the benefits that define the insurance created under Democratic former President Barack Obama  including required health benefits such as maternity coverage and the guarantee of insurance regardless of health   Obamacare currently allows for such short duration plans  but they are limited to three months  The agency said it expects 100 000 to 200 000 people to shift from an Obamacare plan to such insurance in 2019 when the rule would go into effect  but that millions more people who have no insurance will likely sign up  Health and Human Services Secretary Alex Azar  who began serving in his post less than a month ago  said in his first media briefing on Tuesday that the proposed rule marked  an important first step   He said the administration is working on additional policies aimed at providing cheaper health insurance options for consumers  America s Health Insurance Plans  the biggest U S  health industry lobby  said it was concerned the expansion would make it more expensive to cover the sicker people  particularly those with pre existing conditions  who remain on the Obamacare marketplace  About 10 million people are enrolled in Obamacare plans that are eligible for income based subsidies  Evercore ISI analyst Michael Newshel said in a research note that while the magnitude of the new rule s impact is debatable  directionally it is  another negative more for the stability of the individual insurance market   Even so  there were no new negatives in the government rule proposal  Newshel said  Shares in insurers which sell these plans were mixed   Centene  Corp  N CNC  gained 82 cents  or less than 1 percent  to  101 04  Molina Healthcare  N MOH  rose 55 cents or less than 1 percent to  72 67  Anthem Inc  N ANTM  fell 70 cents or about 0 3 percent to  234 33 and  Cigna Corp   N CI  fell 84 cents or 0 4 percent to  192 97  The premiums on the plans have been rising each year since the marketplace was launched and increased in the double digits in 2018  reflecting a costly pool of members  fewer insurers and less competition  and the government decision to pull back billions of dollars in payments to insurers  Republican President Donald Trump last year issued an executive order requiring the agency  which oversees the Obamacare individual market  to propose such a rule as part of its goal to make health insurance more affordable  The order also required an extension of association based health plans that do not comply with Obamacare and more use of tax free health savings accounts  
U S  health officials said they did not expect the introduction of the plans to contribute to a rise in premiums in the ACA marketplace ",2018-02-20,Reuters,https://www.investing.com/news/politics-news/us-to-extend-skimpy-health-insurance-outside-of-obamacare-1279501,1279501
147331,368847,CI,Cigna  CI  Beats Q1 Earnings Estimates  Raises 2019 View,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings of  3 9 per share in first quarter 2019  surpassing the Zacks Consensus Estimate by 4 3   However  the same was down 5 1  year over year Cigna posted revenues of  33 43 billion and missed the Zacks Consensus Estimate by 1 5   Revenues grew 192  year over year on the acquisition of Express Scripts  NASDAQ ESRX  Premiums were up 11  year over year to  10 billion while fees increased 79  to  2 45 billion The SG A expense ratio was 9 3  for first quarter 2019  down from 23 5  for the first quarter of 2018  The decline was mainly led by business mix changes  resulting from the Express Scripts combination  and the health insurance tax suspension The company s medical enrollment grew by 224 000 lives from the prior year quarter to 16 99 million customers  driven by growth in Government  Commercial and International markets  Moreover  the acquisition of Express Scripts  completed last December  led to an increase in Pharmacy and Medicare Part D members Cigna Corporation Price  Consensus and EPS Surprise    Strong Segmental Performance
Health Services  Operating revenues of  22 4 billion were up from  1 07 billion in the year ago quarter owing to the acquisition of Express ScriptsAdjusted operating earnings were  994 million  up from  83 million in the year ago quarter  driven by organic growth in pharmacy customers since the beginning of the year  and strong adjusted pharmacy script volumes and performance in specialty pharmacy care Integrated Medical  Operating revenues of  9 2 billion were up 12 8  year over year due to organic growth in Commercial and Government business Operating income increased 15 6  from the year ago quarter to  1 2 billion due to strong medical and specialty contributions and continued effective medical cost performance International Markets  Operating revenues of  1 39 billion were up 4  year over year  reflecting continued business growth  partially offset by some impact from unfavorable foreign currency movements Adjusted operating income decreased 5 1  year over year to  206 million due to unfavorable foreign currency impact Global Disability and Life  Operating revenues of  1 3 billion were up 2  year over year  However  operating income decreased 28  year over year to  84 million  due to unfavorable disability claims  partly offset by strong life results Cigna s debt to capitalization ratio improved to 48 8  at Mar 31  2019  from 50 9  at the end of Dec 31  2018 2019 Guidance UpdateFor 2019  the company expects earnings per share in the range of  16 25  16 65  up from the prior range of  16  16 50 Total revenues are expected in the range of  132 5  134 5 billion  versus  131 5  133 5 billion earlier  and medical customers are projected to grow within 0 3 0 4 million lives Medical care ratio is expected in the range of 80 5 81 5  Our TakeWe remain bullish on Cigna due to its recent acquisition of pharmacy benefit manager  Express Scripts  which provides a nice diversification to the company s existing businesses  namely administrative services  international operations  and disability and life insurance  which are already performing strongly The combination of Express Scripts  pharmacy benefit business with Cigna s health insurance business will help control drug pricing cost to a large extent  which is one of the biggest components of soaring medical cost  The company has a better control over its medical cost compared with other players in the industry  The decline in medical costs should further aid its margins Another distinguishing feature of the company is the international business  which provides additional diversification opportunities  Its strong balance sheet is another positive Zacks Rank and Other ReleasesCigna currently carries a Zacks Rank  2  Buy   You can see  Among the other players from the healthcare industry that have reported first quarter earnings  the bottom line of Anthem  Inc    NYSE ANTM    Centene Corporation   NYSE CNC   and UnitedHealth Group Incorporated   NYSE UNH   beat the Zacks Consensus Estimate by 2 9   5 3  and 3 6   respectively Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-beats-q1-earnings-estimates-raises-2019-view-200415576,200415576
147333,368849,CI,Cigna  CI  Q1 Earnings Top Estimates,opinion,"Cigna  CI  came out with quarterly earnings of  3 90 per share  beating the Zacks Consensus Estimate of  3 74 per share  This compares to earnings of  4 11 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 4 28   A quarter ago  it was expected that this health insurer would post earnings of  2 53 per share when it actually produced earnings of  2 46  delivering a surprise of  2 77  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Cigna  which belongs to the Zacks Insurance   Multi line industry  posted revenues of  33 43 billion for the quarter ended March 2019  missing the Zacks Consensus Estimate by 1 51   This compares to year ago revenues of  11 42 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cigna shares have lost about 14 7  since the beginning of the year versus the S P 500 s gain of 16 6  
What s Next for Cigna 
While Cigna has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cigna was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 89 on  34 41 billion in revenues for the coming quarter and  16 44 on  136 41 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Insurance   Multi line is currently in the top 21  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q1-earnings-top-estimates-200415380,200415380
147334,368850,CI,Are Investors Undervaluing Cigna  CI  Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Of these  value investing is easily one of the most popular ways to find great stocks in any market environment  Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued  leaving room for profits 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
One company value investors might notice is Cigna  CI   CI is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock holds a P E ratio of 9 24  while its industry has an average P E of 9 39  Over the past year  CI s Forward P E has been as high as 14 12 and as low as 8 55  with a median of 12 55 
We also note that CI holds a PEG ratio of 0 75  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  CI s industry has an average PEG of 1 03 right now  Over the past 52 weeks  CI s PEG has been as high as 1 16 and as low as 0 69  with a median of 1 02 
Another notable valuation metric for CI is its P B ratio of 1 47  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  CI s current P B looks attractive when compared to its industry s average P B of 1 74  Within the past 52 weeks  CI s P B has been as high as 3 52 and as low as 1 35  with a median of 2 96 
Value investors also love the P S ratio  which is calculated by simply dividing a stock s price with the company s sales  Some people prefer this metric because sales are harder to manipulate on an income statement  This means it could be a truer performance indicator  CI has a P S ratio of 0 77  This compares to its industry s average P S of 0 99 
These are only a few of the key metrics included in Cigna s strong Value grade  but they help show that the stock is likely undervalued right now  When factoring in the strength of its earnings outlook  CI looks like an impressive value stock at the moment ",2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/are-investors-undervaluing-cigna-ci-right-now-200417312,200417312
147340,368856,CI,Cigna Q3 top line up 5   earnings up 23   shares up 1  premarket,news,Cigna  NYSE CI  Q3 results   M   Revenues  10 382   5 1    Premiums  8 030   5 6   Net Income  560   22 8    Non GAAP Net Income  716   42 3    EPS  2 21   25 6    Non GAAP EPS  2 83   45 9   2017 Guidance  Revenue growth   4   Commercial medical care ratio  80   81   Government medical care ratio  84 5   85 5   Operating expense ratio   21   Global medical customer growth   650K Shares are up 1  premarket on light volume Now read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/cigna-q3-top-line-up-5-earnings-up-23-shares-up-1-premarket-762628,762628
147341,368857,CI,Anthem CEO Joseph Swedish to step down  Gail Boudreaux to succeed  WSJ,news," Reuters    U S  health insurer Anthem Inc s  N ANTM  Chief Executive Joseph Swedish will step down and be succeeded by industry veteran Gail Boudreaux  the Wall Street Journal reported on Friday  citing people with knowledge of the matter  It is unclear how quickly the transition will occur  but the plan is expected to be announced as soon as next week  the publication reported   Anthem  the nation s second largest health insurer by revenue  did not respond to requests for comment  Boudreaux is well known among managed care investors and has served as CEO of United Healthcare  a unit of the largest U S  health insurer UnitedHealth Group Inc  N UNH   Boudreaux  will be the right executive to lead Anthem to its next phase of growth  after CEO Swedish s successful 4 year tenure in turning around a troubled company during the challenging years of Obamacare implementation   Leerink analyst Ana Gupte said in a research note  Swedish was behind the insurer s  54 billion merger proposal with smaller rival  Cigna Corp   N CI   which was ultimately called off due to regulatory issues  That deal would have created the largest U S  health insurer by membership  Healthcare consolidation has been a popular route for insurers and pharmacies  under pressure from the government and large corporations to lower soaring medical costs   Health insurer  Aetna Inc   N AET  and pharmacy operator CVS Health Corp  N CVS  are working toward finalizing merger terms and announcing a deal for more than  70 billion as early as December  according to people familiar with the matter  The deal would combine CVS  one of the largest U S  pharmacy benefits managers and drugstore chains  with Aetna  one of the oldest health insurers  whose far reaching business ranges from employer healthcare to government plans nationwide   Anthem last week reported better than expected quarterly earnings as its Obamacare individual insurance business broke even and forecast a slight 2018 profit for the government plans despite uncertainty about the market s future  Anthem  which runs Blue Cross Blue Shield plans in 14 states  said it had cut in half the number of areas where it will sell individual plans in 2018  which will reduce enrollment by 70 percent next year and help profits   
Through Friday  Anthem shares had climbed about 47 percent this year to  211 80  compared with UnitedHealth s 33 percent rise to  212 87  After hours on Friday  the shares were up 0 6 percent ",2017-11-03,Reuters,https://www.investing.com/news/stock-market-news/anthem-ceo-joseph-swedish-to-step-down-gail-boudreaux-to-succeed-wsj-763894,763894
147343,368859,CI,Cigna  CI  Expected To Beat Earnings Estimates  What To Know Ahead Of Q1 Release,opinion,"Cigna  CI  is expected to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on May 2  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  3 74 per share in its upcoming report  which represents a year over year change of  9  
Revenues are expected to be  33 89 billion  up 196 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cigna 
For Cigna  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  5 14  
On the other hand  the stock currently carries a Zacks Rank of  1 
So  this combination indicates that Cigna will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cigna would post earnings of  2 53 per share when it actually produced earnings of  2 46  delivering a surprise of  2 77  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cigna appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release-200411016,200411016
147344,368860,CI,Is A Beat In Store For Cigna  CI  This Earnings Season ,opinion,"Cigna Corp  s   NYSE CI   first quarter 2019 results  scheduled on May 2  should reflect growth in contributions across each of its businesses including strong retention levels  the continued expansion and deepening of its customer and client relationships  and solid growth across the company s portfolio 
The Zacks Consensus Estimate for earnings is pegged at  3 74 per share  down 9  year over year  on revenues of  33 9 billion  up 197   
Factors Affecting Q1 Results
In the company s Integrated Medical segment  we expect to see rise in commercial customers and expansion of specialty relationships as well as premium growth reflecting underlying cost trends  Membership should increase from growth in the company s select  middle market and government segments 
The company expects rise in membership from global medical customers  strong customer and client retention  growth in the commercial business  as well as in Medicare advantage enrollments  partly offset by an expected enrollment decline in the U S  individual business 
The company s Health Service business should reflect solid performance from its mail order pharmacy operations  support from its integrated value proposition and contributions from the Express Scripts  NASDAQ ESRX  business Contribution from the company s International Markets should bear evidence of solid business growth  continued administrative efficiency  and strategic investments for long term growth 
The company expects the 2019 medical care ratio to be in the range of 80 5  to 81 5   indicating continued strong performance of its commercial and government businesses  the impact of the health insurance tax suspension in 2019  as well as changes in business mix   We expect medical care ratio in the first quarter to be around this range We expect to see a year over year increase in interest expenses  due to debt taken  to fund the acquisition of Express Scripts   
However  share repurchases made by the company will provide an additional cushion to its bottom line 
Earnings Surprise
Cigna boasts an impressive earnings surprise history  having surpassed estimates in three of the four reported quarters  with average positive surprise of 11 8  
Cigna Corporation Price and EPS Surprise
   What Our Model Says
Our proven model indicates that chances of Cigna beating the Zacks Consensus Estimate are high as it has the right combination of the two key ingredients   a positive  and a Zacks Rank  3  Hold  or higher  You can uncover the best stocks to buy or sell before they re reported with our  
Earnings ESP  The Earnings ESP of Cigna is  5 14  
Zacks Rank  Cigna currently has a Zacks Rank  1  Strong Buy   which further increases the predictive power of ESP 
Other Stocks to Consider
Here are a few other healthcare stocks worth considering as these too have the right combination of elements to beat on earnings in the upcoming quarterly results 
WellCare Health Plans  Inc    NYSE WCG   has an Earnings ESP of  1  and a Zacks Rank of 3   You can see  
Pfizer Inc    NYSE PFE   has an Earnings ESP of  0 65  and a Zacks Rank of 3 
Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  0 37  and is a Zacks  3 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-cigna-ci-this-earnings-season-200412594,200412594
147358,368874,CI,Aging Demography  Consolidation Brighten HMO Industry Outlook,opinion,"The Health Maintenance Organization  HMO  industry comprises entities  either private or public  that take care of the basic and supplemental health services of its subscribers  Companies in this industry primarily assume the risks involved and assign premiums for health and medical insurance policies  Industry participants also provide administrative and managed care services for self funded insurance Services are generally provided by a network of approved care providers  called in network  which include primary care physicians  clinical facilities  hospitals and specialists  However  out of network exceptions are made in emergencies or when medically necessary  Health insurance plans can be availed by ways such as private purchase  social insurance or social welfare programs such as Medicare and Medicaid  funded by the government Let us take a look at the industry s three major themes      The HMO industry is witnessing aggressive mergers and acquisitions as the players strive to gain market share and build forward and backward capabilities  While the most common takeovers in recent years have been in the areas of Medicare and Medicaid to tap bourgeoning demand from the retiring baby boomer population  mergers between companies from different industries of the healthcare sector were also rampant in 2018  The mega mergers of Aetna  NYSE AET  with CVS Health Corp  NYSE CVS    CVS  and Cigna Corp   CI  with Express Scripts  NASDAQ ESRX  are the best examples of inter industry deals that led to the union of a health insurer and a pharmacy benefit manager and further concentrated the HMO industry  This also points to the fact that the industry participants are trying to expand vertically  in an effort to control medical cost      The industry should also gain from an aging American population  with 10 000 baby boomers entering retiring population every single day  This senior population has fueled demand for Medicare Advantage  the private version of the government Medicare program  These MA plans have proven to be beneficial for all concerned groups   customers government and health insurers  Customers get better coverage and services  the government gains from reduction in cost of care and health insurers find these plans highly profitable and catalysts for revenue growth  Recently  CMS decided to raise the 2020 Medicare Advantage reimbursement rate by 2 53   which is higher than the proposed a hike of 1 59   This is another positive for the HMO players        The industry witnessed development in ancillary business in recent years for diversification of revenue sources in the wake of tough regulations laid by the Accountable Care Act  These businesses  mostly in the form of health care services  are growing rapidly  opening up new avenues of growth and forming an increased proportion of the industry s total revenues Health services business is an important growth area for HMOs  as it provides unregulated cash flows and enables players to become comprehensive health care providers  Ample scope for growth exists in the health service business calling for continued investments Zacks Industry Rank Indicates Solid ProspectsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates bright prospects in the near term  The Zacks   which is an 11 stock group within the broader Zacks  sector  currently carries a Zacks Industry Rank  55  which places it at the top 22  of 247 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is a result of positive earnings outlook for the constituent companies in aggregate  In a year s time  the industry s earnings estimate for the current year has gone up by 3 5  
Before we present a few HMO stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry Return Underperformed S P 500 but Outdid its SectorThe Zacks Medical HMO industry has underperformed both the Zacks S P 500 composite and its own sector over the past year We see that the stocks in this industry have collectively gained 6 8  over the past year  while the Zacks S P 500 composite and Zacks Medical Sector have rallied 7 8  and 4 6   respectively One Year Price PerformanceHMO Industry s Current ValuationOn the basis of forward 12 month price to earnings  P E  ratio  which is commonly used for valuing HMO stocks  the industry is currently trading at 15 39X compared with the S P 500 s 16 97X and the sector s 20 59X Over the past five years  the industry has traded as high as 20 53X  as low as 13 04X and at the median of 16 21X Price to Earnings  P E  Ratio  F12M  Price to Earnings  P E  Ratio  F12M  Bottom LineThe replacement to Obamacare has been pushed back until after the 2020 presidential election  This means no regulatory changes will be made in the meantime  thus restoring stability to the sector which has been exposed to high regulatory conundrum for long Players in the industry will continue to ride on technological investment and upgrade  application of blockchain technology  growth of new business units  international expansion  better claims handling  medical cost management  mergers and acquisitions  and a healthy balance sheet HMO Stocks to Buy NowFour stocks in the Zacks Medical HMO space currently carry a Zacks Rank  2  Buy  You can see   Molina Healthcare Inc   MOH   The Zacks Consensus Estimate for current year earnings of this Long Beach  CA based company has moved 6 6  north over the past 60 days Anthem  NYSE ANTM  Inc   ANTM   The stock surpassed earnings estimates in each of the four quarters  with an average positive surprise of 7 04  Centene  NYSE CNC  Corp   CNC   The Zacks Consensus Estimate for 2019 bottom line of this Louisville  KY based company has been raised 1 4  over the past 60 days WellCare Health Plans  Inc   WCG   The Zacks Consensus Estimate for this Minnetonka  MI based company s 2019 earnings has gone up 0 4  over the past 60 days 
 Today s Best Stocks from Zacks   Would you like to see the updated picks from our best market beating strategies  
 From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3    This outperformance has not just been a recent phenomenon   From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year   ",2019-04-03,Zacks Investment Research,https://www.investing.com/analysis/aging-demography-consolidation-brighten-hmo-industry-outlook-200403995,200403995
147359,368875,CI,Cigna  Express Scripts Join Amazon Alexa For New Voice Skills,opinion,"Cigna Corporation   NYSE CI   along with Express Scripts  NASDAQ ESRX  has collaborated with Amazon  NASDAQ AMZN  Alexa on introducing two voice skills for dispensing more engaging and seamless medical care to customers  With the aid of Alexa skills  selected customers will be able to use the voice technology for managing their own prescriptions  getting involved in the medical improvement programs and tracking their incentives With this deal  Cigna is being able to cater to their customers  needs  irrespective of where they are   at residences or while travelling  etc Notably  the Express Scripts voice skill is now available to patients  who use Express Scripts  prescription home delivery services  Customers can not only check their prescription order status via Alexa but can even get notified of the time when the orders are received  processed and shipped  Customers can save money by getting the maintenance medications shipped to their houses at lower cost  have more privacy and better medication adherence as well In order to drive better health outcomes  Cigna is also piloting Cigna Health Today  an innovative voice skill with the intention of improving proactive health engagement with one of its national clients Eligible staff can even trace their personal wellness incentives  such as redeemable gift dollars and receiving daily wellness tips by using the same Per a study conducted by Cigna on more than 2 00 000 customers over a span of three years  health incentives actually doubled the chances of an individual getting treated and working on their health recovery  Last year  Cigna allocated more than  255 million in cost savings back to customers for the completion of above 4 5 million health goals These new voice skills enhance both Cigna s and Express Scripts  overall voice capabilities  Last March  Cigna unveiled Amazon Alexa skill with an aim to simplify health information  This  Answers by Cigna  solution offers easy responses to more than 250 commonly asked questions and was recently extended to incorporate Medicare related terms Shares of this Zacks Rank  2  Buy  company have lost 3 8  in a year s time against its  s growth of 11 7  Other Stocks to ConsiderInvestors interested in the medical sector can also take a look at some other top ranked stocks like Anthem Inc   NYSE ANTM    Centene Corporation   NYSE CNC   and WellCare Health Plans  Inc    NYSE WCG    each carrying a Zacks Rank of 2 You can see  Anthem and subsidiaries operate as a health benefits company in the United States   In the last four quarters  the company delivered average beat of 7 1  Centene operates as a diversified  multi national healthcare enterprise in the United States  The company came up with average earnings surprise of 4 99  in the trailing four quarters WellCare Health offers managed care services to government sponsored health care programs  The company pulled off average positive surprise of 15 43  in the preceding four quarters 
 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-04,Zacks Investment Research,https://www.investing.com/analysis/cigna-express-scripts-join-amazon-alexa-for-new-voice-skills-200404296,200404296
147360,368876,CI,Bull Of The Day  Centene  CNC ,opinion,Managed care provider Centene  NYSE CNC   CNC  was already in the upper realms of the Zacks Rank after delivering a strong Q4 report and guidance in early February  Analysts responded by raising 2019 revenue estimates to nearly  71 billion for 18  growth and projected EPS of  4 25 for 20  growth  Then we learned on March 27 that the company intends to acquire WellCare  WCG  in a cash and stock deal worth  17 3 billion  So it s time to review the investor and analyst reactions to see if it s still a good time to put money into CNC  Shares had already drifted back below  60 in March  and Wednesday the 27th  deal news came before the open  though Bloomberg got a leak Tuesday night  saw a plunge to  50 on heavy volume of 34 million shares  The transaction is obviously dilutive for CNC shares and thus the drop  Under the terms of the merger agreement  WellCare  WCG  shareholders will receive a fixed exchange ratio of 3 38 shares of Centene  CNC  common stock and  120 in cash for each share of WellCare common stock  Based on Centene s closing stock price on March 26  2019  the implied cash and stock consideration to be received by WellCare shareholders is  305 39 per share  The cash and stock consideration represents an approximately 21 0  premium to WellCare shareholders based on the 30 day volume weighted average closing stock price  or VWAP  of WellCare prior to signing and an approximately 32 1  premium based on the closing stock price of WellCare on March 26  2019  Upon completion of the transaction  Centene shareholders will own approximately 71  of the combined entity  with WellCare shareholders owning approximately 29   The good news is that the stock didn t fall further and recovered quickly back to  53 to close the quarter  And since we ve had plenty of positive investor and analyst reaction since the deal announcement  CNC shares have climbed back to  57 58 on good volume  The bad news is that things were looking so good again for new highs in CNC before this deal  as the stock made a strong run back to  68 from the Dec lows at  54  Why Buy WCG  This is obviously part of the company s long term growth strategy to compete with bigger players like UnitedHealth Group  UNH   Cigna  NYSE CI   and Anthem  NYSE ANTM   ANTM  in the vastly complex  9 trillion healthcare sector  On the surface  the new company would have strengths in Medicare Advantage  MA  and Medicaid  both of which are growing markets  As consolidation continues in the industry  so that economies of scale can handle the turbulent waters of healthcare reform  I had thought the sub  25 billion Centene would be an acquisition target for one of the larger players mentioned above   In the short run  investors face plenty of  uncertainty volatility  that could keep shares below  60  As we saw in Bristol Meyers  BMY   74 billion cash and stock bid for Celgene  CELG  this year  BMY shares fell immediately and that day marked the low  with the stock recovering to fill the down gap and then some  By the end of March  we saw CELG pop and BMY fidget as a key shareholder who had been blocking the deal fell in line  This anecdote doesn t  of course  guarantee anything  And classic  merger arbitrage  will be buffeting the shares of both companies until their shareholders  and the regulators  chime in with  yea  or  nay   But so far  so good  Centene Strategy Amidst ACA Turbulence The day before the deal announcement we learned that the DOJ shifted its stance  backing full invalidation of the Affordable Care Act  In a legal filing March 25 with the U S  Court of Appeals for the 5th Circuit in New Orleans  the Department of Justice revealed a significant shift in its stance and said it now backs a full invalidation of the Affordable Care Act  The DOJ previously has said there were grounds only to strike down the ACA s consumer protections  So Centene s acquisition of WellCare comes just as the White House and Congress seem to be renewing a long running feud over the Affordable Care Act  While ACA survived a 2017 repeal effort by Republicans  20 conservative leaning states sued last year to have it repealed  saying that changes in tax law invalidated it  This week  the Department of Justice backed the effort for a complete repeal   Of course  Centene and WellCare had to have been planning and negotiating this deal for months prior to the DOJ move  And it might be coincidence they announced the same week  But the spotlight is certainly on them about whether this was the right move for long term growth given the legislative turbulence  In an interview on CNBC s Mad Money on the evening of March 27  Centene CEO Michael Neidorff said  The time was right to buy WellCare    When there is uncertainty  that is the time to act    There are a lot of things that need to be strengthened with the ACA    There is an opportunity to make it more affordable  WellCare acquisition made more sense than I ve seen in a long time   And in formal comments that morning in the press release  here s how he described the deal    This transformational combination creates a leading healthcare enterprise that is committed to helping people live healthier lives through a localized approach and provides access to high quality healthcare through a wide range of affordable health solutions  With the addition of WellCare  we expect to bolster and diversify our product offerings  increase our scale and have access to new markets  which will in turn  enable us to continue investing in technology and better serve members with innovative programs designed to meet their needs  Centene has grown significantly by adding capabilities that have increased revenues and enabled margin expansion  The addition of WellCare is the next logical step in our growth strategy and to drive value for our collective shareholders  We have long admired the WellCare organization and together look forward to building on our mission of transforming the health of our communities  one person at a time  Analyst Reaction to Deal Centene might internalize WellCare PBM business  says Wells Fargo  NYSE WFC  Analyst Peter Costa expects Centene to eventually internalize WellCare s pharmacy benefit management  PBM  business  which would likely be another blow to CVS  CVS   WellCare s current PBM  Centene currently has some of its PBM business with CVS and is bringing that business in house to its own internal PBM  while WellCare is planning to rebid its PBM contract this year  He added that this merger would likely mean that contract rebid may not occur and that WellCare would more likely move its estimated  15B  20B in pharmacy spend away from CVS to Centene for 2021  Costa told investors that he does not believe the government would find the overlapping Medicaid markets as problematic from an anti trust point of view  since he believes the government views Medicaid market as a more national market of bidders for state contracts   Stephens   Excellent strategic combination  In a research note before the companies confirmed the deal  based on the early Bloomberg reporting   Stephens analyst Scott Fidel told investors that he would view a Centene WellCare deal as an  excellent strategic combination   While he acknowledged that the transaction could face some political hurdles  the analyst noted that the direct business overlap is  actually less than one might initially suspect   Both companies are in a position of strength as they are each poised to deliver top tier revenue and earnings growth performance in 2019 Fidel concluded  He kept an Overweight rating on both names  Leerink analysts see strong  offensive  play in CNC WCG deal While WCG earnings won t become accretive until year 2 of the merger  some cost synergies will start right away  Leerink analysts attended a reception after the deal was announced with managements from both companies and came away more optimistic about changes in managed care  reiterating their  78 PT    The net upshot for us is that fears that this deal has been inked to offset secular headwinds are unfounded  The combined almost   100 B entity is poised to be a Government powerhouse across Medicare Advantage  Managed Medicaid   Part D  Regulatory risk remains  but unlike MA  the Medicaid plans are price takers and there is no 35  market share ceiling  SunTrust   Powerful combination with opportunity on several fronts  The analysts view the proposed combination as compelling as it further increases scale  expands the Medicaid footprint  accelerates MA growth and provides an attractive opportunity in pharmacy  They noted that  synergies look quite doable  as the deal brings incremental diversification  is expected to be accretive in year 2 and CNC s integration track record provides comfort  They reiterated their Buy rating and  90 PT based on about 21 5X 2019E EPS  Oppenheimer analysts wrote a preliminary note on the morning of March 27 with these thoughts  The deal would expand Centene s leading Medicaid platform and provide a large boost in Medicare Advantage  MA   a business it has targeted  Although the price and equity heavy deal terms represent a hefty premium to Centene s own valuation  the company has done a good job with M A in the past  Since then  the Oppenheimer team has reiterated their Outperform rating and  83 PT  Are any i bank analysts not so enthusiastic about this deal  Yes  Jefferies analysts are far less sanguine  with this title on their report after the deal    CNC for WCG  Strategically Logical  but not Catalytic Jefferies analysts see the logic of the deal in a strong strategic rationale  enhances Medicaid and overall scale  accelerates MA growth agenda  and diversifies HIX exposure   but they see only modest financial benefit  They also think that cost synergies and earnings accretion contemplate divestitures  And regarding the probability of the deal actually getting done  they cite as many as 5 markets likely to be scrutinized by anti trust regulators  The Jefferies analysis of Medicaid market share  focuses on key states where CNC and WCG will have significant share of   30   MO  NE  IL and GA  These are likely to be most problematic since combined share is 60  75  and the states only have 3 4 MCOs in the market  Combined share in IL would be 54   but the market would still have 5 players after the deal closes  Here s how the Jefferies team described the impacts of potential divestitures    If CNC was required to divest the smaller contract in each of those 4 states  they estimate pro forma EPS impact of  15c  lowering year 2 accretion by 2 5 points  FL and NY have many more players  perhaps lowering the divestiture risk in those markets  That said  divesting the smaller contract in FL NY would lower EPS by 11c  Thus  the worst case is 26c of EPS risk across all 6 states  If that happened  the deal would still be accretive by 1 5  in year 2  Another issue is competitive bidders  Other big managed care players may want WCG more than CNC does  Deal  break up  fees increase after May 10  which suggests to the Jefferies team that both parties may be willing to entertain other offers  Bottom line  I remain a buyer of CNC in the low  50s and wait to see where large shareholders  regulators  and potential competitive bidders  stand on the deal  The recent ACA political rumblings are seen by many as mere posturing ahead of the 2020 elections  So the real test of this deal is how compelling it is for an unpredictable landscape  The bias leans toward  size wins  to compete on this bigger  more turbulent field  I should add that I wrote most of this report during the final weekend of March for my subscribers in Healthcare Innovators where we ve been long time CNC shareholders  So it does not include the impacts of April 1 proposals by the Centers for Medicare   Medicaid Services  CMS  in their 2020 Medicare Advantage and Part D Rate Announcement  Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day-centene-cnc-200405814,200405814
147361,368877,CI, Stock Market News For Apr 18  2019,opinion,Wall Street closed lower on Wednesday as stiff loses of the healthcare sector negated the positive impact of strong first quarter earnings results  Moreover  investors waited for special counsel Robert Muller s report to be released on Thursday regarding Russian intervention into the 2016 U S  Presidential election  Market participants remained concerned that the report may generate volatility on Wall Street  All three major stock indexes ended in the red The Dow Jones Industrial Average  DJI  closed at 26 449 54  declining 3 12 points  The S P 500 Index  INX  shaded 0 2  points to close at 2 900 45  However  the Nasdaq Composite Index  IXIC  closed at 7 976 08  losing 0 1   A total of 7 07 billion shares were traded on Wednesday  higher than the last 20 session average of 6 84 billion shares  Decliners outnumbered advancers on the NYSE by 1 39 to 1 ratio  On the Nasdaq  decliners had an edge over advancers by 1 74 to 1 ratio   The CBOE VIX decreased 3 5  to close at 12 60  How Did the Benchmarks Perform The Dow ended in negative territory with 18 stocks of the 30 stockblue chip index finishing in the green while twelve ended in the red  The tech heavy Nasdaq Composite finished in the red due to weak performance by large cap tech stocks  The S P 500 also closed in the red  The Health Care Select Sector SPDR  XLV  declined 2 9    Notably  five out of eleven sectors of the benchmark index closed in the red while six finished in the green Healthcare Stocks Plummet Health care sector suffered stiff losses of Wednesday after UnitedHealth Group Inc  s   NYSE UNH   CEO David Wichmann expressed concerns over the proposed  Medicare for All  bill by several Democrat lawmakers and alarmed investors that the bill is a potential destabilizer of nation s health system Notably  on Apr 10  Democrat Sen  Bernie Sanders introduced a new  Medicare for All  bill  The proposed bill is designed to create a government controlled system to provide health insurance to all citizens of the country As per David Wichmann the newly unveiled bill is destined to  surely jeopardize the relationship people have with their doctors  destabilize the nation s health system and limit the ability of clinicians to practice medicine at their best   Consequently  shares of major healthcare management companies such as UnitedHealth Group  Athem Inc    NYSE ANTM   and Cigna Corp    NYSE CI   plunged 0 4   3 6  and 3 7   respectively  UnitedHealth Group carries a Zacks Rank  2  Buy   You can see  Strong First Quarter Earnings Meanwhile  first quarter 2019 earnings session continued its momentum with better than expected performance  Despite weak trading and investment banking performance  Morgan Stanley s   NYSE MS   first quarter 2019 earnings and revenues topped Zacks Consensus Estimates    PepsiCo Inc    NASDAQ PEP   reported solid first quarter 2019 results  wherein earnings and sales topped estimates  With this  the company reported sales beat in seven of the last nine quarters  Further  it recorded positive earnings surprise in 12 of the last 13 quarters    Consequently  shares of Morgan Stanley and PepsiCo climbed 2 6  and 3 8   respectively Economic Data The Department of Commerce reported that U S  trade deficit declined 3 4  in February to  49 4 billion from a revised figure of  51 1 billion in January  February s trade deficit was better than the consensus estimate of  53 5 billion and marked the lowest level of trade deficit in eight months  Exports jumped 1 1  to a four month high of  209 7 billion while imports rose marginally by 0 2  to  259 1 billion Stocks That Made HeadlineKinder Morgan Inc    NYSE KMI   posted first quarter 2019 adjusted earnings of 25 cents per share  in line with the Zacks Consensus Estimate and up almost 14  from the year ago quarter s 22 cents    Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/stock-market-news-for-apr-18-2019-200408187,200408187
147377,368893,CI,Pfizer files suit against J J over Remicade contracts,news,"By Caroline Humer  Reuters    Drugmaker  Pfizer  Inc  N PFE  on Wednesday filed a lawsuit against Johnson   Johnson  N JNJ   saying its rival s contracts with health insurers for blockbuster rheumatoid arthritis drug  Remicade  were anticompetitive and blocked sales of Pfizer s new biosimilar  Pfizer said in the suit that J J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer s drug from insurance coverage  keeping it out of the hands of patients  J J said in an e mailed statement that the lawsuit was without merit and that the company is competing on value and price    To date Pfizer has failed to demonstrate sufficient value to patients  providers  payers and employers   said Scott White  President of Janssen Biotech Inc  a unit of J J  J J signed exclusionary contracts with health insurers  hospitals and doctor groups after U S  regulators approved it as a reasonable substitute for Remicade in 2016  Pfizer said   The contracts with insurers   including UnitedHealth Group  N UNH   Anthem Inc  N ANTM    Aetna Inc   N AET  and  Cigna Corp   N CI    covered about 70 percent of the commercially insured patients in the United States  the lawsuit said  Both Aetna and Anthem declined to comment  Other U S  insurers contacted for this story did not have an immediate comment  Remicade is an infused treatment for chronic autoimmune disorders and costs about  4 000 per dose  or  26 000 a year  Pfizer said in the suit  Its Inflectra rival is priced 19 percent lower than that list price  But Pfizer said it has not been able to reach customers because of J J s anticompetitive actions  The suit comes at a time when insurers  consumers and the U S  government have pushed for lower drug prices  saying double digit annual price increases are unsustainable  Biosimilars are intended to be lower cost alternatives to expensive biotech medicines  But because they are made from living cells and it is not possible to make an exact copy of the branded medicine  they are not automatically substituted for the existing branded drug the way a generic drug would be  Pfizer said in the lawsuit that J J s contracts with many insurers exclusively pay for Remicade and only pay for Inflectra in limited cases where patients  fail first  on Remicade   In return  Pfizer said  J J pays after market rebates on both new and existing customers  Remicade purchases  To make up for the J J rebates and discounts on this large base of old and new customers  Pfizer said it would need to price Inflectra below its own average variable cost  Pfizer shares were up 1 3 percent  or 45 cents  at  35 90 and J J shares fell 1 6 percent  or  2 10  to  133 11  
The case was filed in the U S  District Court for the Eastern District of Pennsylvania ",2017-09-20,Reuters,https://www.investing.com/news/stock-market-news/pfizer-sues-johnson-amp-johnson-over-remicade-biosimilar-530954,530954
147382,368898,CI,Sanofi Regeneron Cut Price Of PCSK9 Inhibitor Praluent By 60 ,opinion,Sanofi   NASDAQ SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced a 60  cut in the U S  list price of their PCSK9 inhibitor  Praluent  following a similar action last year by rival Amgen  Inc    NASDAQ AMGN   to improve access and affordability of the productSanofi  Regeneron said that beginning in early March both the 75 mg and 150 mg doses of Praluent will be made available at a U S  list price of  5 850 annually  The new price  which is 60  less than the original price  should lower the  out of pocket  costs of Praluent  The companies estimate that out of pocket costs for Medicare patients could decline to approximately  25 to  150 per month  a potential savings of up to  345  depending on patients  insurance plan Sanofi has been actively negotiating with U S  payers to simplify the utilization management criteria and improve access to Praluent  Since March last year  Sanofi and Regeneron have committed to lower Praluent s U S  net price for those payers who agree to reduce access barriers for high risk heart patients  Though these efforts have paid off  the improved access came at the cost of significantly higher rebates  which hurt profits from the drug s sales  Praluent sales were up 56  in 2018 at constant exchange rate as Praluent is gaining category share  mainly owing to its exclusive coverage by Express Scripts  NASDAQ ESRX   now a cart of Cigna Corporation   NYSE CI    Along with the latest release  Regeneron s chief executive officer said that though patient access to Praluent has improved with their efforts  some patients are still unable to afford it due to high co pay costs or co insurance at many Medicare Part D plans  The price cuts should encourage payers to improve access to Praluent  which will encourage use of the drug  It goes without saying that the price cuts will significantly dent Sanofi s profits from the drug In October last year  Amgen announced its decision to cut the U S  list price of its PCSK9 inhibitor Repatha by 60  to improve access and affordability  Earlier this year Amgen informed that all device options of Repatha including pre filled syringe and the Pushtronex system are now available in the United States at a discount of 60   Repatha SureClick autoinjector  the most popular device option of Repatha  has been available at a discounted price since Oct 24 last year  Sales of Repatha rose 62  in 2018 as higher demand offset lower pricing Nonetheless  sales of both these PCSK9 inhibitors have been below expectations since launch in 2015 due to payer restrictions  Amgen has in the past said that despite efforts to improve access to Repatha  patients face significant hurdles due to high co pay expenses  Though lower price may impact Repatha sales in the near term  Amgen management is optimistic about better volume growth in the long term Sanofi s shares have performed in line with the  in the past year  Both have risen 6 9  in the said time frame   In the past year  Regeneron s stock has risen 19 2   largely outperforming the 17 3  decrease of its    Sanofi currently carries a Zacks Rank  3  Hold  while Regeneron has a Zacks Rank  2  Buy   You can  Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ,2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/sanofiregeneron-cut-price-of-pcsk9-inhibitor-praluent-by-60-200386850,200386850
147383,368899,CI,Radian Group  RDN  Looks Good  Stock Adds 7 5  In Session,opinion,Radian Group Inc    NYSE RDN   was a big mover last session  as the company saw its shares rise nearly 8  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 16 3  in the past one month time frame The company has seen one negative estimate revision in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So  make sure to keep an eye on this stock going forward  to see if this recent move higher can last Radian Group currently has a Zacks Rank  3  Hold  while its  is 0 00  Radian Group Inc  Price   Investors interested in the Insurance   Multi line industry may consider Cigna Corporation   NYSE CI    which has a Zacks Rank  1  Strong Buy   You can see the complete list of today s Zacks  1 Rank stocks here Is RDN going up  Or down  Predict to see what others think Up or DownIs Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/radian-group-rdn-looks-good-stock-adds-75-in-session-200389650,200389650
147384,368900,CI,AIG Surges  Stock Moves 5 3  Higher,opinion,American International Group  Inc    NYSE AIG   was a big mover last session  as the company saw its shares rise more than 5  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  40 19  44 18 in the past one month time frame  witnessed a sharp increase yesterday The company has seen three negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last AIG currently has a Zacks Rank  5  Strong Sell  while its  is negative American International Group  Inc  Price   Investors interested in the Insurance   Multi line industry may consider Cigna Corporation   NYSE CI    which has a Zacks Rank  1  Strong Buy   You can see  Is AIG going up  Or down  Predict to see what others think  Up or DownIs Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/aig-surges-stock-moves-53-higher-200389639,200389639
147385,368901,CI,Kemper  KMPR  Stock Rallies 38  In A Year s Time  Here s Why,opinion,Kemper Corporation s   NYSE KMPR   shares have soared nearly 37 6  in a year against the  s decline of 12 9  and the Zacks S P 500 composite s gain of 1 7   With a market capitalization of  5 2 billion  average volume of shares traded in the last three months were 0 2 million What s Behind the Upside Kemper delivered positive earnings surprise in the last four quarters with the average beat being 28 65  The company s earnings and returns improved  with the business growing both organically and inorganically  Adjusted consolidated net operating income surged 175   Earned premiums increased 44  driven by volume growth within Specialty auto business  Operating cash flows increased 125  to  540 million The Specialty P C insurance segment posted double digit growth and policies in force with low 90s combined ratios  The business was strengthened by the acquisition of Infinity Property and Casualty Corporation Kemper s return on equity   a measure of profitability   is 10 1   better than the industry average of 8 1   This reflects the company s prudent usage of its shareholders  funds Kemper carries a favorable  of B  With respect to returning value to shareholders  on Feb 6  the board of directors increased quarterly dividend by 4   marking the first increase since 2011 Kemper currently carries a Zacks Rank  3  Hold   The consensus mark for earnings and revenues indicates year over year improvement in both 2019 and 2020  The Zacks Consensus Estimate for current year earnings per share is pegged at  5 45  indicating a year over year increase of 24 7  on 29 8  increase in revenues to  4 8 billion  For 2020  the estimate is pegged at  6 10  indicating a year over year rise of 11 9  on 6 2  revenue growth to  5 1 billion The company boasts a sturdy portfolio of businesses in Specialty auto  Preferred home and auto  and basic life and supplemental health and accident products  which provides capital diversification benefits  The personal insurance and Life   Health businesses provide Kemper diversified sources of earnings and liquidity The company also has reinsurance programs in place to insulate it from low frequency  high severity catastrophes  Its program for 2019 provides 95  coverage against  225 million of losses arising from a single event in excess of  50 million retention  The company also renewed the homeowners aggregate catastrophe reinsurance program These together should help the stock continue the bull run Stocks to ConsiderSome better ranked stocks from the insurance industry are MGIC Investment Corporation   NYSE MTG    Cigna Corp    NYSE CI   and Arch Capital Group Ltd    NASDAQ ACGL   MGIC Investment provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  It came up with average four quarter beat of 22 88   The stock carries a Zacks Rank  2  Buy   You can see  Cigna provides insurance and related products and services in the United States as well as internationally  It delivered average four quarter beat of 15 74   The stock sports a Zacks Rank of 1 Arch Capital provides property  casualty and mortgage insurance and reinsurance products worldwide  It delivered average four quarter beat of 14 75   The stock sports a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/kemper-kmpr-stock-rallies-38-in-a-years-time-heres-why-200389626,200389626
147386,368902,CI,BioDelivery  BDSI  Q4 Earnings In Line  Sales Beat  Stock Up,opinion,"BioDelivery Sciences International  Inc    NASDAQ BDSI   reported loss of 10 cents per share for fourth quarter 2018  meeting the Zacks Consensus Estimate  In the year ago quarter  the company had recorded a loss of 29 cents per share Revenues were  18 million in the reported quarter  up 44 1  from the year ago period and 27 4  sequentially  The increase in sales was mainly driven by strong demand for Belbuca  which exceeded the company s expectations  The top line beat the Zacks Consensus Estimate of  16 15 million BioDelivery s shares were up 3 9  in after market hours on Mar 15 due to the strong performance of Belbuca as well as future expectations for the drug  Shares of the company have gained 24 8  so far this year compared with the  s 14 4  increase Quarter in DetailBioDelivery s chronic pain drug  Belbuca  continued its strong sequential growth trend of 2018 into the fourth quarter  The company witnessed consistent increase in new patients as well as in total prescription every quarter in 2018  The drug generated revenues of  15 9 million in the quarter  rising 28 3  sequentially  Sales surged 68 3  year over year The company reacquired worldwide rights to Belbuca in early 2017 from Endo International Plc   NASDAQ ENDP   During the quarter  the company recorded all time high prescription volumes of almost 56 000 prescriptions for Belbuca  Prescription volume for Belbuca expanded 27  sequentially and 126  year over year In 2018  the company successfully added Belbuca to the preferred coverage list of several pharmacy benefit managers  In November  the company brought more than 100 million patients under preferred coverage by adding the drug to OptumRx s preferred formulary list  Subsequently in February  the company added the drug to a preferred formulary of Cigna Healthcare  the managed care division of Cigna Corporation   NYSE CI   The company has brought 115 million patients under preferred coverage so far in 2019  having started with 7 million in 2018  It has also expanded its sales force to support the growth and reach of the drugs to eligible or covered patients The company added approximately 1 100 new patients to Belbuca treatment during the quarter  higher than the 900 new patients in the previous two quarters  Management seems confident about Belbuca s continued strong performance in 2019 Moreover  the settlement of the patent litigation with Teva Pharmaceuticals   NYSE TEVA   in early 2018 will keep generic competition at bay till mid 2027 Operating expenses increased 30 3  to  18 5 million due to expansion of commercial and medical teams  However  operating expenses fell 14 4  year over year Full  Year ResultsBioDelivery reported total revenues of  55 6 million in 2018  down 10 2  year over year  The decline was due to  20 million recorded as contract revenues in 2017 related to the termination of the licensing agreement with Endo for Belbuca rights  Excluding contract revenues  total revenues grew 32 5  in 2018 Total sales of Belubca during 2018 were  46 million  up 70 5  year over year For the full year  the company incurred an adjusted loss of 54 cents per share compared with adjusted loss of 67 cents per share in the year ago period The company ended 2018 with  43 8 million in cash and cash equivalents 2019 GuidanceThe company guided total revenues to in the range of  85 million to  90 million for 2019  The guided range is higher than the Zacks Consensus Estimate of  82 15 million The company expects Belbuca sales to be between  80 and  85 million  indicating an almost 80  increase at the mid point of the range  The company expects the drug to achieve annual net sales of  250 million to  300 million over the long term The company anticipates to turn operating cash flow positive in 2019 BioDelivery Sciences International  Inc  Price  Consensus and EPS Surprise
    Zacks RankBioDelivery currently carries a Zacks Rank  2  Buy   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-bdsi-q4-earnings-in-line-sales-beat-stock-up-200398181,200398181
147387,368903,CI,Cigna  CI  Stock Sinks As Market Gains  What You Should Know,opinion,"In the latest trading session  Cigna  CI  closed at  166 46  marking a  1 83  move from the previous day  This change lagged the S P 500 s daily gain of 0 5   Meanwhile  the Dow gained 0 54   and the Nasdaq  a tech heavy index  added 0 76  
Coming into today  shares of the health insurer had lost 11 79  in the past month  In that same time  the Finance sector gained 1 8   while the S P 500 gained 2 53  
Investors will be hoping for strength from CI as it approaches its next earnings release  On that day  CI is projected to report earnings of  3 71 per share  which would represent a year over year decline of 9 73   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  33 55 billion  up 193 94  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  16 41 per share and revenue of  136 25 billion  These totals would mark changes of  15 4  and  183 19   respectively  from last year 
It is also important to note the recent changes to analyst estimates for CI  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 03  higher  CI is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  CI currently has a Forward P E ratio of 10 33  This valuation marks a discount compared to its industry s average Forward P E of 10 61 
Investors should also note that CI has a PEG ratio of 0 84 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Insurance   Multi line was holding an average PEG ratio of 1 09 at yesterday s closing price 
The Insurance   Multi line industry is part of the Finance sector  This group has a Zacks Industry Rank of 180  putting it in the bottom 30  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-stock-sinks-as-market-gains-what-you-should-know-200398313,200398313
147408,368924,CI,Hundreds of counties at risk for no Obamacare insurer in 2018,news,"By Caroline Humer NEW YORK  Reuters    With Republican efforts to dismantle Obamacare in disarray  hundreds of U S  counties are at risk of losing access to private health coverage in 2018 as insurers consider pulling out of those markets in the coming months  Republican senators failed this week to repeal and replace Obamacare  former President Barack Obama s signature healthcare reform law  creating new uncertainty over how the program providing health benefits to 20 million Americans will be funded and managed in 2018  In response  Republican President Donald Trump on Friday again suggested that his administration would let the Obamacare program  implode   He has weakened enforcement of the law s requirement for individuals to buy insurance  threatened to cut off funding and sought to change plan benefits through regulations   Anthem Inc   Cigna Corp   NYSE CI   Health Care Service Corp and Molina Healthcare  four of the biggest health insurers selling Obamacare plans  said they are weighing whether to pull out of more markets for 2018 rather than face financial losses  They have until Sept  27 to finalize their plans   So far  40 U S  counties are expected to have no insurer offering individual coverage next year  but that number could rise by the hundreds  according to U S  government data  Kaiser Family Foundation analysis and insurer disclosures  More than 1 300 counties  primarily in 15 states  currently have only one insurer participating in 2018  Anthem and HCSC are the last man standing in one third of those counties and states   putting those areas in particular at risk   Right now the number of counties at immediate risk of having no insurers in 2018 is small  but it could easily grow significantly if a couple major insurers decide to exit   Larry Levitt  health economist at the Kaiser Family Foundation  said   Many insurers have been waiting for an answer from Trump or lawmakers on whether they will continue to fund  8 billion in annual government subsidies  Without assurances  many insurers plan to raise rates an additional 20 percent by an Aug  16 deadline for premium prices  Others say that the many unknowns will make the business too risky  The last minute drama has left millions of Americans questioning whether they will have medical coverage next year  Julie Grady  a 59 year old small business owner in Carson City  Nevada  is currently covered by Blue Cross Blue Shield of Nevada  part of Anthem  which has already decided to leave the exchanges in her county and most of the state  Carson City will have no insurer on the exchanges next year       Grady s pays a reduced premium of  70 per month and a deductible under  1 000 for her plan  which is part of the Affordable Care Act  commonly called Obamacare  Grady is looking at being uninsured  as she was before the law       I would have to go without health insurance   she said   I would just stay healthy  hike  eat well  I d be in trouble if something catastrophic happened  I would lose everything              ANTHEM CONSIDERING 2018 PLANS      Anthem  the second largest U S  health insurer  sells Blue Cross Blue Shield plans in 14 states  It has already decided to pull out of most individual markets in Nevada  Ohio  Indiana and Wisconsin in 2018  Earlier this week  Chief Executive Officer Joe Swedish said he was still weighing 2018 participation in its other states     In states like Colorado  Georgia  Kentucky  Missouri  and Virginia  Anthem sells plans in more than 250 counties where it is the only insurer  and they could be left  bare  next year  according to government data       Health Care Services Corp is a Blue Cross Blue Shield licensee in five states and is the only Obamacare individual insurer in more than 90 Texas counties  more than 75 Oklahoma counties  and half a dozen Illinois counties  It confirmed on Friday that it has submitted products for its five states but is still weighing next year       We re working through the regulatory filing process and hope to fully participate   in 2018  however no final decisions have been made   HCSC spokeswoman Kristen Cunningham said      Molina  which has more than 1 million members in Obamacare plans  and Cigna  with more than 250 000 participants  have said they need more certainty from the government to decide on 2018 participation and would weigh their decisions up until the late September deadline       State insurance regulators have worked hard in recent months to replace insurers who have left  In Nevada  for instance  Centene Corp and  Aetna Inc   NYSE AET  entered in some counties that Anthem left after the insurance commissioner said he would favor these insurers for its Medicaid contract bids  But they are unlikely to find replacements for new dropouts in these final weeks  particularly if the Trump administration signals it won t fund  8 billion in subsidies for out of pocket medical costs       There is almost no chance they would step in to participate   said Kurt Wrobel  a fellow at the Society of Actuaries and chief financial officer of the Geisinger Health Plan in Pennsylvania           Some insurers say they will likely just raise rates and hope it works  Blue Cross Blue Shield of Michigan filed two sets of rates with the state department of insurance  one up to 32 percent higher if the fate of subsidies remains unclear   
     We don t have any plans to pull out   said Rick Notter  director of the individual business at BCBS Michigan   But it would certainly help to have more certainty around what the market holds  ",2017-07-28,Reuters,https://www.investing.com/news/politics-news/hundreds-of-counties-at-risk-for-no-obamacare-insurer-in-2018-511957,511957
147410,368926,CI,Multiline Insurance Stocks Outlook  Prospects Look Promising ,opinion,"The Zacks  industry comprises companies that provide single insurance coverage bundling automobile  homeowner  long term care  life and health insurance to individuals and businesses  The insured is covered for many things through a single contract by paying just one premium These companies cover commercial and personal properties  automobiles  marine  livestock  aviation  personal accident  life  including permanent and term insurance  supplemental accident and health insurance  workers  compensation  annuity products  private mortgage insurance  among others  They also provide risk management services Multiline insurers stand to gain from disseminating the risk among different coverage Here are the three major industry themes These insurers are one of the major beneficiaries of an improving rate environment  as higher rates allow them to invest the premiums at a higher rate and generate better investment income  After four rate hikes in 2018  the Federal Reserve intends to implement two hikes in the current year   Also  a strengthening economy backed by low unemployment level  improving wages and growing GDP should drive demand for coverages from these companies Multiline insurers  profits are vulnerable to catastrophes because of the presence of property coverage in their bundle  As a result  frequent natural disasters of significant magnitude occurring since 2017 have compelled these insurers to raise prices for most of their products to safeguard profitability  Nonetheless  pricing for workers compensation and international liability continue to remain weak Increasing adoption of technologies like artificial intelligence  robotic process automation  cognitive intelligence or blockchain and cloud computing should help insurers control costs  A solid capital level continues to support active merger and acquisitions Zacks Industry Rank Indicates Bright ProspectsThe group s   which is basically the average of the Zacks Rank of all the member stocks  indicates bright prospects in the near term  The Zacks Multiline Insurance industry  which is housed within the broader Zacks  sector  currently carries a Zacks Industry Rank  94  which places it at the top 37  of more than 250 Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperforms the bottom 50  by a factor of more than 2 to 1 The industry s positioning in the top 50  of the Zacks ranked industries is the result of positive earnings outlook for the constituent companies in aggregate  In about six months  time  the industry s EPS estimates for the current year have gone up nearly 43   Before we present a few multiline insurance stocks that you may want to consider for your portfolio  let s take a look at the industry s recent stock market performance and valuation picture Industry Lags S P 500 and SectorThe Multiline Insurance industry has underperformed the Zacks S P 500 composite and its own sector over the past year  The stocks in this industry have collectively declined 22 1  in the past year while the Finance sector declined 14 1   Meanwhile  the Zacks S P 500 composite has lost 6 7  One Year Price Performance
Current ValuationOn the basis of trailing 12 month price to book  P B  ratio  which is commonly used for valuing insurance stocks  the industry is currently trading at 1 50X compared with the S P 500 s 3 71X and the sector s 2 40X Over the past five years  the industry has traded as high as 1 98X  as low as 1 33X and at the median of 1 62X Price to Book  P B  Ratio  TTM 
Price to Book  P B  Ratio  TTM 

Bottom LineAdoption of technology  product development  prudent underwriting practices  competitive pricing and a compelling product portfolio should keep supporting business growth for multiline insurers  Also  a sturdy capital level should support effective capital deployment like investing in growth opportunities and returning capital to shareholders Stocks to ConsiderInvestors may consider buying the following stocks that carry a Zacks Rank  1  Strong Buy  or  2  Buy   You can see the complete list of today s Zacks  1 Rank stocks here Kemper Corp   KMPR   This provider of property and casualty  and life and health insurance to individuals and businesses in the United States is based in Chicago  IL  The Zacks Consensus Estimate for 2019 EPS has moved 1 5  north over the past 60 days  As a result  the stock currently carries a Zacks Rank  1 Price and Consensus  KMPR
MGIC Investment Corp   MTG   This Milwaukee  WI based provider of private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States company sports a Zacks Rank of 1  The company has a long term earnings growth rate of 5   It surpassed estimates in each of the trailing four quarters Price and Consensus  MTG
Aegon N V   AEG   Headquartered in Netherlands  this Zacks Rank  1 provider life insurance  pensions  and asset management services has seen its consensus estimate for 2019 move 5 2  north in the past 60 days  The Zacks Consensus Estimate for 2019 indicates an increase of nearly 63  year over year Price and Consensus  AEG
ageas SA NV  AGESY   Brussels  Belgium based ageas SA NV engages in insurance business in Europe and Asia  The Zacks Consensus Estimate for 2019 EPS has moved up by a couple of cents over the past 60 days  The stock too sports a Zacks Rank  1 Price and Consensus  AGESY
Radian Group Inc   RDN   This Philadelphia  PA based provider of provides mortgage and real estate products and services in the United States sports a Zacks Rank of 1  The Zacks Consensus Estimate for 2019 translate to a year over year increase of 3 2  and has a long term earnings growth rate of 5   It surpassed estimates in each of the trailing four quarters Price and Consensus  RDN
Cigna Corporation  NYSE CI   CI   This Bloomfield  CT based company is a health services organization providing insurance and related products and services in the United States and internationally  The consensus EPS estimate for this Zacks Rank  2 stock has moved 10 9  north over the past 60 days Price and Consensus  CI
MetLife  NYSE MET   Inc   MET   This insurer engages in engages in the insurance  annuities  employee benefits  and asset management businesses  The Zacks Consensus Estimate for 2019 EPS of this Schaumburg  IL based company has moved up by a cent over the past 60 days and carries a Zacks Rank  2 Price and Consensus  MET

Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-17,Zacks Investment Research,https://www.investing.com/analysis/multiline-insurance-stocks-outlook-prospects-look-promising-200376930,200376930
147411,368927,CI,Cigna  CI  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Cigna  CI  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on February 1  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This health insurer is expected to post quarterly earnings of  2 55 per share in its upcoming report  which represents a year over year change of  31 4  
Revenues are expected to be  11 34 billion  up 7 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1 75  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Cigna 
For Cigna  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 45  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Cigna will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Cigna would post earnings of  3 45 per share when it actually produced earnings of  3 84  delivering a surprise of  11 30  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Cigna appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-24,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-reports-next-week-wall-street-expects-earnings-growth-200379543,200379543
147412,368928,CI,Is A Beat Likely For Arthur J  Gallagher  AJG  Q4 Earnings ,opinion,Arthur J  Gallagher   Co    NYSE AJG   is slated to report fourth quarter 2018 results on Jan 31  after the market closes  In the last reported quarter  the company delivered a positive earnings surprise of 1 30  Why a Likely Positive Surprise Our proven model clearly shows that Arthur J  Gallagher has the right combination of the following two key ingredients to beat estimates this earnings season Earnings ESP  Arthur J  Gallagher has an  of  3 42   This is because the Most Accurate Estimate is pegged at 53 cents  higher than the Zacks Consensus Estimate of 51 cents  You can uncover the best stocks to buy or sell before they re reported with our  Arthur J  Gallagher   Co  Price and EPS Surprise    Zacks Rank  Arthur J  Gallagher has a Zacks Rank  3  Hold   which increases the predictive power of ESP as stocks with a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3 along with a positive Earnings ESP have significantly higher chances of an earnings beat Conversely  the Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Factors Driving the Better Than Expected EarningsArthur J  Gallagher has possibly displayed top line growth in the soon to be reported quarter  mainly driven by organic sales as well as strategic mergers and acquisitions  Also  a probable revenue improvement  primarily across the segments of Brokerage and Risk Management  is likely to contribute to this anticipated upside  The Zacks Consensus Estimate for revenues is pegged at  1 6 billion  representing a 0 6  rise from the prior year quarter The company expects stronger organic growth at its Brokerage segment in the period to be reported  aided by strong growth across all divisions  An expected increase in fees  commissions and supplemental plus contingent revenues has likely supported this uptrend  In fact  the Zacks Consensus Estimate for this segment s revenues stand at  1 billion  reflecting a 0 3  increase from the year ago quarter With respect to Risk Management segment  the company might have experienced organic growth and a better margin in the to be reported quarter  mainly boosted by a diversified product portfolio coupled with a few specialty mergers already in the company s pipeline  During the fourth quarter  organic growth is projected in the 5 7  range while margins are estimated to be between 17  than 18   The Zacks Consensus Estimate for the revenues of this segment is predicted at  210 million  indicating 6 6  growth from the year earlier period Riding on the strength of rising interest rates  investment results likely have improved in the soon to be reported quarter Also  we assume employee benefit consulting operations to have registered organic growth on new business opportunities However  the insurance broker is likely to incur a noticeable increase in expenses  primarily due to higher compensation and operating expenses The Zacks Consensus Estimate for fourth quarter earnings is pegged at 51 cents per share  depicting a noticeable decline of 37 8  from the comparable period last year Other Stocks to ConsiderSome stocks worth considering from the insurance industry with the perfect mix of elements to also surpass estimates this time around are as follows Cigna Corporation   NYSE CI   is set to report fourth quarter earnings on Feb 1 and has an Earnings ESP of  0 28   The company has a Zacks Rank  2  You can see  Willis Towers Watson Public Limited Company   NASDAQ WLTW   has an Earnings ESP of  0 63  and a Zacks Rank of 3  The company is slated to announce fourth quarter earnings on Feb 7 Radian Group Inc    NYSE RDN   has an Earnings ESP of  3 03  and a Zacks Rank of 1  The company is anticipated to release fourth quarter earnings on Feb 8 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-likely-for-arthur-j-gallagher-ajg-q4-earnings-200379977,200379977
147413,368929,CI,Here s Why You Should Hold Old Republic International Stock,opinion,"Old Republic International Corporation   NYSE ORI   is poised for long term growth on the back of solid segmental performances  improving housing market fundamentals and solid capital position  The company has a favorable  of B  This style score analyzes the growth prospects of a company Recently  the company reported its fourth quarter and full year 2018 results  Premiums in 2018 increased 5 3  year over year  Premiums have been benefiting from sustained economic growth  strong renewal retention ratios and new business growth   The company has been witnessing rate increase in its commercial auto  Premiums and fees continue surpassed the  2 billion mark for four consecutive years  The title group exceeded  200 million in pretax operating earnings for three straight years However  total expenses increased 3 4  to  1 4 billion  driven by a 19 8  rise in claims cost  Claim ratio increased 720 basis points year over year Shares of this Zacks Rank  3  Hold  insurer have lost 9 4  in a year compared with the  s 21 2  decrease 

Given improving real estate market fundamentals  increasing home sales should continue to support premiums and fees improvement  Housing price inflation should help the company witness increased revenues  The company noted that home prices have gone up in the last three years  driving premiums higher A sound financial position helps the company keep its balance sheet low levered by avoiding excess debt  Its debt to equity ratio of 18 5 is lower than the industry average of 48 5 Old Republic International has a strong capital management policy in place  The company has a track record of posting at least 25 straight years of annual dividend growth  Its dividend yield of 3 9  betters the industry average of 2 4  This insurance underwriter carries an impressive  of A  VGM Score helps identify stock with the most attractive value  best growth  and most promising momentum The Zacks Consensus Estimate for 2019 earnings is pegged at  2 74  indicating 5 4  year over year increase on 0 3  higher revenues  The company has outperformed earnings expectations in three consecutive quarters   Stocks to ConsiderSome other top ranked multiline insurers are Radian Group Inc    NYSE RDN    Cigna Corp    NYSE CI   and MGIC Investment Corp    NYSE MTG   Radian Group provides mortgage and real estate products and services in the United States  It came up with a 12 70  positive surprise in the last reported quarter  The stock sports a Zacks Rank  1  You can see  Cigna provides health services such as medical  dental  behavioral health  pharmacy  vision  supplemental benefits  among others  The company delivered 11 30  positive earnings surprise in the last reported quarter   The stock carries a Zacks Rank  2 MGIC Investment provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  The company delivered 13 51  positive earnings surprise in the last reported quarter  The stock carries a Zacks Rank  2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-old-republic-international-stock-200380246,200380246
147414,368930,CI,Cigna  CI  Misses Q4 Earnings Estimates,opinion,"Cigna  CI  came out with quarterly earnings of  2 46 per share  missing the Zacks Consensus Estimate of  2 53 per share  This compares to earnings of  1 94 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  2 77   A quarter ago  it was expected that this health insurer would post earnings of  3 45 per share when it actually produced earnings of  3 84  delivering a surprise of 11 30  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Cigna  which belongs to the Zacks Insurance   Multi line industry  posted revenues of  13 75 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 21 61   This compares to year ago revenues of  10 51 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cigna shares have added about 5 2  since the beginning of the year versus the S P 500 s gain of 7 9  
What s Next for Cigna 
While Cigna has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cigna was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  4 02 on  34 46 billion in revenues for the coming quarter and  17 18 on  140 40 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Insurance   Multi line is currently in the top 38  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-01,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-misses-q4-earnings-estimates-200382502,200382502
147415,368931,CI,Company News For Feb 4  2019,opinion,Cigna Corporation s   NYSE CI   shares dipped 2 9  after reporting fourth quarter 2018 earnings per share of  2 46  lower than the Zacks Consensus Estimate of  2 53Honeywell International Inc  s   NYSE HON   shares increased 0 8  after reporting fourth quarter 2018 earnings per share of  1 91  higher than the Zacks Consensus Estimate of  1 88Shares of Yum China Holdings  Inc    NYSE YUMC   rallied 8  after reporting fourth quarter 2018 earnings per share of  0 12  higher than the Zacks Consensus Estimate of  0 07Shares of Cypress Semiconductor Corporation   NASDAQ CY   rallied 6 6  after reporting fourth quarter 2018 earnings per share of  0 35  higher than the Zacks Consensus Estimate of  0 33,2019-02-03,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-feb-4-2019-200383258,200383258
147420,368936,CI,Top Ranked Value Stocks To Buy For February 5th,opinion,Here are four stocks with buy rank and strong value characteristics for investors to consider today  February 5th AVX Corporation  AVX   This electronic products manufacturer has a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 9 7  over the last 60 days AVX Corporation Price and Consensus   AVX has a price to earnings ratio  P E  of 11 26  compared with 15 30 for the industry  The company possesses a  of A AVX Corporation PE Ratio  TTM    Ardagh Group S A   ARD   This rigid packaging solutions manufacturer has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 1  over the last 60 days Ardagh Group S A  Price and Consensus   Ardagh has a price to earnings ratio  P E  of 7 09  compared with 10 90 for the industry  The company possesses a Value Score of A Ardagh Group S A  PE Ratio  TTM    China Unicom  Hong Kong  Limited  CHU   This telecommunications services provider has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 1 5  over the last 60 days China Unicom  Hong Kong  Ltd Price and Consensus   China Unicom has a price to earnings ratio  P E  of 16 74  compared with 61 50 for the industry  The company possesses a Value Score of A China Unicom  Hong Kong  Ltd PE Ratio  TTM    Cigna Corporation  NYSE CI   CI   This health services company has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 5 3  over the last 60 days Cigna Corporation Price and Consensus   Cigna has a price to earnings ratio  P E  of 11 27  compared with 17 40 for the industry  The company possesses a Value Score of B Cigna Corporation PE Ratio  TTM    See the Learn more about the  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-february-5th-200383894,200383894
147429,368945,CI,Anthem tries to keep Cigna in deal,news,Anthem  NYSE ANTM  is making another push to salvage its  48B merger with Cigna  NYSE CI  by asking a Delaware judge to extend an order blocking its would be partner from pulling out of the deal for 60 days A  1 85B break up fee is on the line  Judge Travis Laster said Anthem s case is a  long shot   but he ll consider it and issue a ruling as soon as possible Now read ,2017-05-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/anthem-tries-to-keep-cigna-in-deal-481488,481488
147430,368946,CI,Trump U S  antitrust nominee says will be independent of White House,news,"WASHINGTON  Reuters    Makan Delrahim  who was chosen by President Donald Trump to be the top U S  antitrust regulator  said on Wednesday that he would maintain independence from the White House in enforcing antitrust law 
The Senate must still vote to confirm Delrahim 
In a hearing before the Senate Judiciary Committee overshadowed by repercussions over Trump s firing of Federal Bureau of Investigation Director James Comey  Delrahim reiterated that he would recuse himself from a fight over whether health insurer Anthem may merge with rival Cigna  NYSE CI  
Delrahim had worked for Anthem as a lobbyist when he was with the law firm Brownstein Hyatt Farber Schreck  LLP 
Obama s Justice Department sued to stop the deal  and the case is currently under appeal 
Asked what he would do if the White House wanted to discuss a deal being considered by the division  Delrahim said antitrust enforcement was law enforcement 
 The independence of the decisions made in prosecuting and reviewing mergers as well as other conduct is a serious one that should be free from any political influence   he said   They will be free if I am fortunate enough to be confirmed  
Delrahim currently works in the White House as deputy assistant and deputy counsel to the president 
If confirmed as expected  Delrahim s antitrust division would review corporate mergers at a time when many investors and corporate executives are anticipating a more relaxed view of deal making 
Former President Barack Obama s administration faced a large number of megadeals in what one enforcer called a  merger tsunami  and blocked many of them 
Antitrust experts who have followed Delrahim s career expect him to follow in the footsteps of a former boss  Hewitt Pate  who was assistant attorney general for antitrust from 2003 to 2005  Delrahim was Pate s deputy  specializing in international antitrust 
Under Pate  the division was criticized for allowing too many deals  but it sued to stop US Airways from merging with United Airlines and blocked a deal to combine DirecTV and EchoStar  It tried but failed to stop  Oracle Corp   NYSE ORCL  from buying PeopleSoft 
If confirmed  Delrahim would oversee the Justice Department s assessment of AT T  NYSE T  s Inc plan to buy  Time Warner  Inc  NYSE TWX   the owner of HBO  Warner Brothers and news network CNN 
The department is reviewing major transactions in seeds and agricultural chemicals  like the mergers of  Dow Chemical   NYSE DOW  Co and Dupont  and of Bayer  DE BAYGN  and  Monsanto   NYSE MON   Those proposed deals  along with ChemChina s purchase of Syngenta  would consolidate six agricultural chemical companies into three ",2017-05-10,Reuters,https://www.investing.com/news/politics-news/trump-u.s.-antitrust-nominee-says-will-be-independent-of-white-house-482673,482673
147431,368947,CI,Delaware judge denies Anthem injunction  effectively ending Cigna merger,news,"WILMINGTON  Del   Reuters    A judge effectively killed off any practical chance of Anthem Inc  N ANTM  merging with  Cigna Corp   N CI  on Thursday as he declined to order Cigna not to terminate the deal  Judge Travis Laster of Delaware s Court of Chancery denied Anthem s request for a preliminary injunction but stayed implementation of his ruling until noon on Monday to give the insurer time to decide if it will pursue an appeal to the Delaware Supreme Court   I recognize that this ruling will permit Cigna to terminate the merger and effectively end Anthem s path to closing   he said in the hearing  The U S  Justice Department and 11 states sued last year to stop the  54 billion merger  which would have created the largest U S  health insurer  and won in both district court and an appeals court   Anthem had asked the U S  Supreme Court to hear the federal antitrust case and requested the preliminary injunction in order to hold the proposed deal together long enough for the high court to decide if it would take it  Neither company immediately responded to a request for comment  Barring a successful appeal at the Delaware Supreme Court  the two sides will likely continue to fight over a  1 85 billion break up fee and damages for failing to close the deal  Laster said that Anthem could seek  potentially massive damages  for Cigna failing to meet it obligation to help close the deal  At a hearing on Monday  Anthem presented evidence it said showed Cigna executives were plotting to get out of the deal by refusing to help with a plan to win antitrust approval  
Cigna has accused Anthem of breaching the merger agreement by pursuing a failed strategy to get regulatory approval ",2017-05-11,Reuters,https://www.investing.com/news/stock-market-news/delaware-judge-denies-anthem-injunction-request-in-fight-with-rival-cigna-483412,483412
147432,368948,CI,Cigna returns Anthem s salvo  seeks  1 85B break up plus  13B in damages,news,Cigna  NYSE CI  and Anthem  NYSE ANTM  are positioning themselves for one of the ugliest divorces in corporate history  Shortly after the latter announced that it would not pay the  1 85B break up fee and would seek  massive damages  allegedly incurred related to the failed merger  Cigna returned the favor by saying it will seek prompt payment of the  1 85B in addition to  over  13B  in purported damages to the company and its shareholders  If nothing else  the spat should be good theater Now read ,2017-05-12,Seeking Alpha,"https://www.investing.com/news/stock-market-news/cigna-returns-anthem's-salvo,-seeks-$1.85b-break-up-plus-$13b-in-damages-483856",483856
147433,368949,CI,Anthem battle behind it  Cigna gives stock to 40 000 workers,news,"By Caroline Humer NEW YORK  Reuters     Cigna Corp   N CI   which recently won court approval to break off its failed deal with Anthem Inc  N ANTM   on Thursday said it would give its more than 40 000 employees five Cigna shares each and expand its paid leave  as it embarks on its next phase of growth   It s meant to be a reinforcement of all of us as owners   Cigna Chief Executive Officer David Cordani said in an interview  Cigna shares were trading near a 52 week high at about  163 24 on Thursday  Cordani said that the benefit awards  which amount to  35 million to  40 million  come as the company moves to the next phase of its growth strategy  He said the company has grown its employee base by 10 percent over the last year  Cigna  which sells commercial health insurance in the U S  and overseas and provides U S  government paid plans  agreed to be bought by Anthem nearly two years ago  After the U S  Justice Department sued to stop that deal last summer  it disagreed with Anthem on pushing forward and has spent the past year in court battles  Cigna and Anthem are still in court over the  1 8 billion break up fee that Cigna says it is entitled to  Anthem is fighting the payout  Cigna said it plans to extend paid paternity and adoption leave to four weeks and offer up to four weeks of paid leave for employees caring for others including to support child bonding and ill family members  Cordani said Cigna also is starting a sabbatical program in which 12 employees a year can receive a paid one to three month fellowship and up to a  20 000 stipend to support a community work project  Cigna said that the post Anthem path forward involves growing its existing businesses  which include government paid plans such as Medicare Advantage and drug benefits for older people  and its primary business of managing benefits for corporations both in the United States and overseas   The company also has more than 350 000 members in individual health plans  Plans that comply with the terms set out by the Affordable Care Act  often called Obamacare  account for most of those  Cordani said the company is still deciding how it will proceed regarding selling Obamacare plans in 2018  Currently  it sells those plans in seven states   
Insurers are trying to design plans and price premiums for 2018  but generally say it is difficult because Republicans have vowed to repeal and replace the law but have not agreed on how to do so or how to manage the years of transition until new laws are passed ",2017-05-25,Reuters,"https://www.investing.com/news/stock-market-news/anthem-battle-behind-it,-cigna-gives-stock-to-40,000-workers-488570",488570
147434,368950,CI,Healthcare stocks can t fight the tide of selling,news,This morning s broad sell off has engulfed healthcare stocks  All industries sectors are down in early trading Selected tickers   IBB  1 2   XBI  1 4   PJP  1   IHE  0 4   XPH  0 9   IHI  0 8   XHE  1 2   XHS  0 2   GILD  0 6   AMGN  0 9   MRK  0 6   PFE  0 4   MDT  0 5   HCA  1 1   CI  0 6   UNH  0 3  Now read ,2017-06-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-stocks-can't-fight-the-tide-of-selling-495836,495836
147444,368960,CI,CNO Financial s Subsidiaries Get Ratings From A M  Best,opinion,Credit rating agency A M  Best recently asserted the Financial Strength Rating   FSR   of A   Excellent  and the Long Term Issuer Credit Ratings   Long Term ICR   of  a   of CNO Financial Group  Inc  s   NYSE CNO   life health units  Moreover  AM Best affirmed CNO Financial s Long Term ICR and the Long Term Issue Credit Ratings of  bbb    The outlook of these ratings remains stable Reasons Behind the RatingsThese ratings highlight the company s solid balance sheet  impressive operating performance  neutral business profile and enterprise risk management  Per the credit rating giant  the company closed an indemnity coinsurance deal with a top counterparty wherein CNO Financial reinsured majority of its long term care legacy business as part of its strategy  This consists of its pre 2003 issued comprehensive and nursing home long term care policies  LTC  policies The rating agency expects a reduction in morbidity and low tail risk due to the interest rate risk and policy holder behavioral pattern that the LTC policies are exposed to  The deal is expected to result in lower earnings volatility and related capital at risk Notably  CNO Financial has witnessed a consistent profitability ratio on the back of revenue growth  excellent investment returns and encouraging expense management initiatives  It is also aiming at maintaining pre transaction and post transaction risk adjusted capitalization levels across its regulated insurance entities and on a consolidated basis  The company s positive earnings trend and favorable premium growth across its core business lines have also supported the remarkable capital ratios  Risk based capital requirements are likely to decrease owing to the relatively capital intensive nature of the company s LTC business Although the company s leverage has slightly deteriorated  its financial leverage and interest coverage ratios remain in line with expectations  according to the credit rating agency noticed that The company s first year premium levels increased during last year  primarily on the back of solid indexed annuity sales growth  somewhat offset by lower premium trends in the Medicare supplement and LTC product lines Shares of this Zacks Rank  2  Buy  company have lost 36 8   wider than its  s decline of 22 1  Other Stocks to ConsiderA few other top ranked stocks from the multiline insurance sector are Cigna Corporation   NYSE CI    MetLife  Inc    NYSE MET   and Kemper Corporation   NYSE KMPR    You can see  Cigna is a health services organization  providing insurance and related products and services in the United States and around the globe  It carries a Zacks Rank of 2  In the trailing four reported quarters  the stock pulled off average positive surprise of 15 61  MetLife provides insurance  annuities  employee benefits and asset management businesses  The stock is a Zacks  2 Ranked player  It came up with average earnings surprise of 12 34  over the last four reported quarters Kemper is a diversified insurance holding company  offering property and casualty plus life and health insurance services in the United States  This Zacks Rank  1 player managed to deliver a whopping average trailing four quarter beat of 90 78  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/cno-financials-subsidiaries-get-ratings-from-am-best-200374398,200374398
147445,368961,CI,Cigna Sees Hammer Chart Pattern  Time To Buy ,opinion,Cigna Corporation   NYSE CI   has been struggling lately  but the selling pressure may be coming to an end soon  That is because CI recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 2 estimates have gone higher  compared to 1 lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if CI stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-10,Zacks Investment Research,https://www.investing.com/analysis/cigna-sees-hammer-chart-pattern-time-to-buy-200374302,200374302
147449,368965,CI,Genworth Financial  GNW  Hits Fresh High  Is There Still Room To Run ,opinion,"Have you been paying attention to shares of Genworth Financial  NYSE GNW   Shares have been on the move with the stock up 16 4  over the past month  The stock hit a new 52 week high of  5 in the previous session  Genworth Financial has gained 6 7  since the start of the year compared to the 4 5  move for the Zacks Finance sector and the 7 6  return for the Zacks Insurance   Life Insurance industry 
What s Driving the Outperformance 
The stock has a great record of positive earnings surprises  as it hasn t missed our earnings consensus estimate in any of the last four quarters  In its last earnings report on October 30  2018  Genworth Financial reported EPS of  0 29 versus consensus estimate of  0 23 while it missed the consensus revenue estimate by 0 68  
For the current fiscal year  Genworth Financial is expected to post earnings of  1 02 per share on  8 56 billion in revenues  Meanwhile  for the next fiscal year  the company is expected to earn  1 per share on  8 51 billion in revenues  This represents a year over year change of  13 56  and  0 58   respectively 
Valuation Metrics
Genworth Financial may be at a 52 week high right now  but what might the future hold for the stock  A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level 
On this front  we can look at the Zacks Style Scores  as these give investors a variety of ways to comb through stocks  beyond looking at the Zacks Rank of a security   These styles are represented by grades running from A to F in the categories of Value  Growth  and Momentum  while there is a combined VGM Score as well  The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style 
Genworth Financial has a Value Score of A  The stock s Growth and Momentum Scores are D and A  respectively  giving the company a VGM Score of B 
In terms of its value breakdown  the stock currently trades at 4 9X current fiscal year EPS estimates  On a trailing cash flow basis  the stock currently trades at 2 5X versus its peer group s average of 9 1X  This isn t enough to put the company in the top echelon of all stocks we cover from a value perspective 
Zacks Rank
We also need to look at the Zacks Rank for the stock  as this supersedes any trend on the style score front  Fortunately  Genworth Financial currently has a Zacks Rank of  2  Buy  thanks to favorable earnings estimate revisions from covering analysts 
Since we recommend that investors select stocks carrying Zacks Rank of 1  Strong Buy  or 2  Buy  and Style Scores of A or B  it looks as if Genworth Financial fits the bill  Thus  it seems as though Genworth Financial shares could have potential in the weeks and months to come 
How Does Genworth Financial Stack Up to the Competition 
Shares of Genworth Financial have been soaring  and the company still appears to be a decent choice  but what about the rest of the industry  Some of its industry peers are also solid potential picks  including FGL Holdings  FG   Athene Holding  ATH   and Cigna  NYSE CI   all of which currently have a Zacks Rank of at least  2 and a VGM Score of at least B  making them well rounded choices 
The Zacks Industry Rank is in the top 17  of all the industries we have in our universe  so it looks like there are some nice tailwinds for Genworth Financial  even beyond its own solid fundamental situation ",2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/genworth-financial-gnw-hits-fresh-high-is-there-still-room-to-run-200376116,200376116
147454,368970,CI,Justice Department antitrust nominee Makan Delrahim s hearing delayed,news,By Diane Bartz WASHINGTON  Reuters    The confirmation testimony expected on Wednesday for Makan Delrahim  who was nominated to head U S  Justice Department s Antitrust Division  has been delayed by missing paperwork  Senator Charles Grassley said in a hearing  Delrahim is a member of President Donald Trump s transition team   I m disappointed we couldn t go forward with Mr  Delrahim s hearing this morning  We are still waiting on one piece of paperwork  which we understood we d have by now  And I imagine that will be transmitted to us within another day or two  and we look forward to including him on our next hearing   Grassley told the Senate Judiciary Committee   Grassley  an Iowa Republican who chairs the committee  did not say which paperwork was missing  Senator Amy Klobuchar  a Democrat from Minnesota  called the missing document a  snag   Delrahim was expected to move to the Justice Department after finishing up in the White House counsel s office  where he worked to steer Supreme Court Justice Neil Gorsuch through the Senate confirmation process  The Senate must vote to confirm Delrahim  As the proposed chief of the Antitrust Division  Delrahim would review corporate mergers at a time when many investors and corporate executives are anticipating a more relaxed view of deal making  Former President Barack Obama s administration faced a large number of megadeals in what one enforcer called a  merger tsunami  and blocked many of them  Before going to work at the White House after Trump s inauguration in January  Delrahim was a lobbyist with the law firm Brownstein Hyatt Farber Schreck  LLP  One client in 2016 was health insurer Anthem Inc  which this year lost a court fight with the Justice Department over whether it would be allowed to merge with Cigna  NYSE CI   Anthem has appealed the loss ,2017-04-26,Reuters,https://www.investing.com/news/politics-news/justice-department-antitrust-nominee-makan-delrahim's-hearing-delayed-477646,477646
147455,368971,CI,Federal appeals court ruling all but ends Anthem Cigna merger,news,A U S  appeals court declines to allow Anthem  NYSE ANTM  to buy Cigna  NYSE CI   affirming a lower court s recent ruling that blocked the deal on antitrust grounds  Today s rejection of ANTM s argument that the trial court had failed to sufficiently weigh the company s claim that billions of dollars in cost savings would flow from the merger could mark the death blow to the acquisition plan  The litigation has played out amid acrimony between the two companies  which had been feuding even before the Justice Department filed its antitrust lawsuit last year  with ANTM and CI eventually accusing the other of violating the merger agreement Now read  Filing Season Finds  Week Of February 21 25,2017-04-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/federal-appeals-court-ruling-all-but-ends-anthem-cigna-merger-478689,478689
147456,368972,CI,S P 500 hits record on rebound in U S  job growth  energy shares,news,"By Lewis Krauskopf  Reuters    Major U S  stock indexes gained on Friday  with the S P 500 ending at a record high close  as energy stocks bounced back along with oil prices and U S  job growth rebounded  U S  nonfarm payrolls surged by 211 000 jobs last month after a paltry gain of 79 000 in March  and the unemployment rate dropped to 4 4 percent  near a 10 year low  Energy was the best performing sector  rising 1 6 percent  after falling sharply a day earlier  Oil prices rebounded following assurances by Saudi Arabia that Russia is ready to join OPEC in extending supply cuts   There has been and probably will continue to be a little bit of a fear that perhaps the economy isn t accelerating like people thought it would or want it to      said Chuck Carlson  chief executive officer at Horizon Investment Services in Hammond  Indiana   So any day where you get a little bit more confirmation that perhaps the economy is OK   and we got that today in the sense of an OK jobs report  oil is up  transports are doing better today   that that probably is something that helped the broader market   Carlson said  The Dow Jones Industrial Average rose 55 47 points  or 0 26 percent  to 21 006 94  the S P 500 gained 9 77 points  or 0 41 percent  to 2 399 29 and the Nasdaq Composite added 25 42 points  or 0 42 percent  to 6 100 76  All three indexes posted gains for a third straight week  After seven sessions of not moving more than 0 2 percent in either direction  the S P 500 eclipsed that range on Friday as stocks strengthened late in the day  The S P 500 has gained 12 1 percent since President Donald Trump s Nov  8 election  fueled by his plans for tax cuts  infrastructure spending and deregulation  But the rally had slowed as some investors questioned Trump s ability to enact his agenda  The Federal Reserve left interest rates unchanged at its policy meeting this week  The central bank downplayed weak first quarter economic growth while emphasizing the strong labor market  in a sign it was still on track for two more rate rises this year  Investors are pricing in a 75 percent chance of a hike in June  according to Thomson Reuters data  In corporate news   IBM   NYSE IBM  shares fell 2 5 percent after Warren Buffett said he sold about one third of Berkshire Hathaway  NYSE BRKa  Inc s stake in the company  Earnings season has come in generally above expectations  encouraging investors  First quarter profits at S P 500 companies are estimated to have increased 14 7 percent  the strongest since 2011  according to Thomson Reuters I B E S  Shares of health insurer Cigna  NYSE CI  and IT services provider Cognizant rose after their respective reports  Advancing issues outnumbered declining ones on the NYSE by a 2 66 to 1 ratio  on Nasdaq  a 1 39 to 1 ratio favored advancers  The S P 500 posted 55 new 52 week highs and no new lows  the Nasdaq Composite recorded 123 new highs and 67 new lows   
About 6 5 billion shares changed hands in U S  exchanges  just below the 6 6 billion daily average over the last 20 sessions ",2017-05-05,Reuters,https://www.investing.com/news/stock-market-news/futures-flat-ahead-of-jobs-report;-ibm-drops-480537,480537
147458,368974,CI,Anthem argues for 60 days to save merger with balky Cigna,news,"By Tom Hals and Diane Bartz WILMINGTON  Del  WASHINGTON  Reuters    Health insurer Anthem Inc  N ANTM  asked a Delaware judge on Monday to give it more time to try to win approval for a merger with rival  Cigna Corp   N CI   which is seeking to end the deal and collect a  1 85 billion break up fee  Anthem asked Vice Chancellor Travis Laster of Delaware s Court of Chancery to grant a 60 day preliminary injunction that would prevent Cigna from terminating the  54 billion deal that would create the largest U S  health insurer  Laster said after about five hours of arguments that he would rule as soon as possible  The U S  Justice Department and 11 states sued to stop the proposed transaction and won in both district court and an appeals court  Anthem wants the injunction while it pursues an appeal to the U S  Supreme Court  Anthem attorney Glenn Kurtz of White   Case told the Delaware court on Monday that he hoped the U S  Supreme Court would decide before July if it would take the case  Kurtz also said that Anthem would try to negotiate a solution with the Justice Department s Antitrust Division once the Trump administration s officials were in place   Laster expressed reservations about allowing the deal to be terminated but said it was  a long shot  for Anthem to succeed in winning merger approval  Kurtz presented documents that he said showed Cigna  including Chief Executive David Cordani  failed to help close the deal as required  Kurtz said Cigna refused to help craft a divestiture package to allay antitrust concerns and was unhelpful in the district court fight   If this case is not a breach of best efforts  then I m not sure that  best efforts  has any meaning at all   said Kurtz  who called Cigna s actions  unprecedented   Cigna s attorney argued that it was Anthem that had breached the merger agreement by pursuing a failing antitrust strategy   Anthem drove this transaction into a regulatory ditch and had Cigna tied up in the back seat   said William Savitt of Wachtell  Lipton  Rosen   Katz  Regardless of Laster s ruling on the injunction  litigation will continue over the  1 85 billion breakup fee  Kurtz said Anthem believes Cigna owes it for damages  The fight takes place as Republicans seek to repeal and replace the Affordable Care Act  often called Obamacare  which had brought big changes in the insurance business  
Many insurers have lost money on Obamacare  and some of Cigna s largest competitors  including  Aetna Inc   N AET   have largely left the market ",2017-05-08,Reuters,https://www.investing.com/news/stock-market-news/anthem-argues-for-60-days-to-save-merger-with-balky-cigna-481410,481410
147462,368978,CI,Why You Should Add Brown   Brown  BRO  To Your Portfolio,opinion,Brown   Brown Inc    NYSE BRO   is poised for long term growth on the back of its prudent growth initiatives  solid capital position and effective capital deployment  The Zacks Consensus Estimate for 2019 earnings is pegged at  1 35  indicating 9 8  year over year increase on 15 9  higher revenues A compelling product portfolio has been helping the company generate strong commission and fees  which  in turn  has been fueling revenue growth  Brown   Brown estimates revenues between  210 million and  220 million in 2019Apart from organic growth  Brown   Brown s impressive growth is also driven by inorganic means  Strategic acquisitions and mergers help it spread its operations  In over a span of a little more than two decades  the company has acquired more than 470 insurance intermediary operations  The recent acquisition of Hays Companies is expected to generate  210 million to  220 million and  47 million to  53 million of EBITDAC in 2019  Also  the addition of Hays will drive revenue growth of more than 10  and EBITDAC growth of more than 8  Brown   Brown will be implementing an annual incentive program for its middle market producers in the Retail division  This program is expected to fuel growth by focusing on customer retention and new business A sustained operational performance should continue to help maintain a solid capital position  Brown   Brown deploys capital effectively that in turn enhances its shareholders value  The company has raised its dividend for 25 years  Its dividend currently yields 1 2  Shares of this Zacks Rank  2  Buy  insurance broker have gained 7 9  in a year  outperforming the  s 5 9  increase  The Zacks S P 500 composite has however declined 6 8  in the same time frame Valuation looks attractive at current level as the price to book multiple of 2 62 is lower than the industry average of 4 66  Undervalued stocks with solid fundamentals are best investment bets The company s expected long term earnings growth is pegged at 10  Other Stocks to ConsiderInvestors interested in the insurance space can look at Cigna Corporation   NYSE CI    MGIC Investment Corporation   NYSE MTG   and MetLife  Inc    NYSE MET    Each of the stocks carries a Zacks Rank  2  You can see  Cigna provides health services  such as medical  dental  behavioral health  pharmacy  vision  supplemental benefits  among others  The company delivered 11 30  positive surprise in the last reported quarter MGIC Investment provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  The company delivered 33 33  positive surprise in the last reported quarter MetLife engages in the insurance  annuities  employee benefits  and asset management businesses  It came up with 10 40  positive surprise in the last reported quarter The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-01,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-add-brown--brown-bro-to-your-portfolio-200372292,200372292
147463,368979,CI,Why You Should Add Radian Group  RDN  To Your Portfolio,opinion,Radian Group Inc    NYSE RDN   is poised for long term growth on the back of declining delinquency  lower level of paid claims and an improving risk based capital ratio  The company has a favorable  of B  This style score analyzes the growth prospects of a company Being a mortgage insurer  the company was severely hit by the economic downturn  Nonetheless  it has gradually recovered due to high volume of quality and profitable business written after 2008  This has also created a foundation for solid future earnings Insurance in force should continue to grow driven by higher level of persistency and an increase in new mortgage insurance business  Radian has been focusing more on its core operations that have better growth prospects and ensure steady stream of earnings The company has also been pursuing strategic initiatives that should help it improve return on required capital  enhance financial flexibility and prudently manage the mortgage insurance business mix Radian has also been experiencing lower claims  payments over the last few years  Given strong credit characteristics of the new loans insured  we expect the momentum to last  Radian also remains focused on improving its mortgage insurance portfolio This provider of private mortgage insurance and related risk management products and services carries an impressive  of A  Back tested results show that stocks with a favorable Value Score of A or B coupled with a solid Zacks Rank  1  Strong Buy  and 2  Buy  offer the best investment opportunity Valuation looks attractive at current level as the price to book multiple of 1 04 is lower than the industry average of 1 2  The company has an impressive  of A  Value Score helps to find undervalued stocks Shares of this Zacks Rank  2 insurer have lost 21 7  in a year compared with the  s 22 2  decrease The Zacks Consensus Estimate for 2019 earnings is pegged at  2 74  indicating 2 9  year over year increase  The company s expected long term earnings growth is projected to be 5   The company has a solid track of outperforming earnings expectations in the last six quarters   Other Stocks to ConsiderInvestors interested in multiline insurers can look at Cigna Corporation   NYSE CI    MGIC Investment Corporation   NYSE MTG   and MetLife  Inc    NYSE MET    Each of the stocks carries a Zacks Rank  2  You can see  Cigna provides health services  such as medical  dental  behavioral health  pharmacy  vision  supplemental benefits  among others  The company delivered a 11 30  positive surprise in the last reported quarter MGIC Investment provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  The company delivered a 33 33  positive surprise in the last reported quarter MetLife engages in insurance  annuities  employee benefits  and asset management businesses  It came up with a 10 40  positive surprise in the last reported quarter The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-01,Zacks Investment Research,https://www.investing.com/analysis/why-you-should-add-radian-group-rdn-to-your-portfolio-200372267,200372267
147464,368980,CI,Cigna  CI  Stock Moves  0 85   What You Should Know,opinion,"In the latest trading session  Cigna  CI  closed at  185 57  marking a  0 85  move from the previous day  This change was narrower than the S P 500 s daily loss of 2 48   Meanwhile  the Dow lost 2 83   and the Nasdaq  a tech heavy index  lost 3 04  
Coming into today  shares of the health insurer had lost 14 08  in the past month  In that same time  the Finance sector lost 8 4   while the S P 500 lost 8 82  
CI will be looking to display strength as it nears its next earnings release  which is expected to be February 7  2019  The company is expected to report EPS of  2 51  up 29 38  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  11 35 billion  up 8  from the year ago period 
It is also important to note the recent changes to analyst estimates for CI  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 11 17  higher  CI is currently sporting a Zacks Rank of  3  Hold  
Investors should also note CI s current valuation metrics  including its Forward P E ratio of 10 1  For comparison  its industry has an average Forward P E of 10 62  which means CI is trading at a discount to the group 
We can also see that CI currently has a PEG ratio of 0 78  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  Insurance   Multi line stocks are  on average  holding a PEG ratio of 0 92 based on yesterday s closing prices 
The Insurance   Multi line industry is part of the Finance sector  This industry currently has a Zacks Industry Rank of 83  which puts it in the top 32  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-stock-moves-085-what-you-should-know-200372708,200372708
147468,368984,CI,Here s Why You Should Add CVS Health To Your Portfolio Now,opinion,CVS Health Corporation   NYSE CVS   has been gaining investors  confidence on consistently positive results  Over the past six months  the company s stock has underperformed its   The stock has gained 0 3   in comparison with the 2 8  rise of the industry  However  the company has outperformed the S P 500 s 8 2  decline This renowned pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care has a market cap of  66 81 billion  The company s five year projected growth rate is an attractive 11  With solid prospects  this Zacks Rank  2  Buy  stock is a great pick for investors at the moment What Working in Favor of the Stock Impressive Synergies From Aetna  NYSE AET  DealA momentous healthcare consolidation has commenced with CVS Health s recently completed acquisition of the U S  health insurance giant Aetna for a colossal  70 billion  Economists have termed this as one valuable deal that could change the face of American health care  On completion of the deal  CVS Health expects to earn  750 million from near term synergies with low to mid single digit accretion in the second year  Per the company  this merger has the potential to deliver a significant incremental value as it is likely to spur development of products and generate new growth opportunities as a uniquely integrated retailer  pharmacy benefits manager and a far sighted health planner PBM Business Gaining TractionWith regard to its 2019 PBM selling season  CVS Health has noted that it has completed more than 70  of its client renewals  roughly in line with the previous year  The retention rate is currently higher than the rates seen over the last few years However  the company noted that it sees fewer RFP opportunities in the market than the past few years  Despite this  current gross wins stand at an impressive level of  1 8 billion with net new business of approximately  200 million Retail on Growth TrackOver the last few quarters  the retail Long Term Care business registered positive revenue growth after several quarters of a drag  The year over year growth was 6 4  in the third quarter  The strong growth was primarily driven by strong comp script growth from continued adoption of Patient Care Programs  successful partnerships with PBMs and health plans across the industry and the company s preferred position in a number of Medicare Part D networks in 2018  The company has seen significant uptick in both Optum and Cigna  NYSE CI  clients for many CVS Pharmacy and MinuteClinic programs Other Key PicksOther top ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and Surmodics  Inc    NASDAQ SRDX   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Integer Holdings  with a Zacks Rank  1  has an earnings growth rate of 31 2  for the first quarter of 2019 Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2  Buy  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-cvs-health-to-your-portfolio-now-200372880,200372880
147469,368985,CI,Top Ranked Value Stocks To Buy For January 4th,opinion,Here are four stocks with buy rank and strong value characteristics for investors to consider today  January 4th Cardtronics PLC  CATM   This automated consumer financial services provider has a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 1  over the last 60 days Cardtronics PLC Price and Consensus   Cardtronics has a price to earnings ratio  P E  of 12 33  compared with 19 50 for the industry  The company possesses a  of A Cardtronics PLC PE Ratio  TTM    Colfax Corporation  CFX   This diversified industrial technology company has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 4 3  over the last 60 days Colfax Corporation Price and Consensus   Colfax has a price to earnings ratio  P E  of 7 86  compared with 16 60 for the industry  The company possesses a Value Score of A Colfax Corporation PE Ratio  TTM    Cigna Corporation  NYSE CI   CI   This health services provider has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 10 7  over the last 60 days Cigna Corporation Price and Consensus   Cigna has a price to earnings ratio  P E  of 10 10  compared with 15 50 for the industry  The company possesses a Value Score of B Cigna Corporation PE Ratio  TTM    AGNC Investment Corp   AGNC   This real estate investment trust has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 0 4  over the last 60 days AGNC Investment Corp  Price and Consensus   AGNC Investment has a price to earnings ratio  P E  of 7 23  compared with 10 90 for the industry  The company possesses a Value Score of B AGNC Investment Corp  PE Ratio  TTM    See the Learn more about the  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-january-4th-200372986,200372986
147470,368986,CI,Cigna  CI    Units Receive Rating Actions From A M  Best ,opinion,Credit rating agency AM Best assigned the Financial Strength Rating of A  Excellent  and the Long Term Issuer Credit Ratings of  a  to the main life health units  health maintenance organizations and New Zealand as well as Europe based insurance companies of Cigna Corporation   NYSE CI     This action followed the closure of Cigna s pending acquisition of Express Scripts Holding Company  NASDAQ ESRX   The outlook of the aforementioned ratings is stable Notably  the credit rating giant has also removed from under review and has affirmed the FSR of A   Excellent  along with the Long Term ICR of  a   of Medco Containment Life Insurance Company and Medco Containment Insurance Company of New York  The mentioned companies are arms of Express Scripts and the current parent company  Cigna Rationale Behind the RatingsMost of Cigna s operating entities are referred to as Cigna Life   Health Group  Their ratings reflect the company s robust balance sheet with abundant cash flow from operations  excellent operating performance  impressive business profile and enterprise risk management  ERM   Other reasons behind the ratings are its high financial leverage and goodwill of the parent company  Moreover  there is an execution risk related to the merger between Cigna and Express Scripts The ratings of Medco Containment Group reflect its solid balance sheet  strong underwriting leverage  liquidity  standard operating performance  ERM and its restricted business profile  However  the upside is partially offset by cash flow uncertainty Also  the ratings of Cigna Life Insurance Company of Europe and New Zealand represent a firm balance sheet  decent operational excellence  neutral business profile and an accurate ERM Price PerformanceShares of this Zacks Rank  2  Buy  company have lost 9 3  in a year s time  narrower than the  s decline of 22 4   The company has been suffering high debt level and escalating expenses  which weigh on its performance  However  solid fundamentals such as acquisitions  robust Global Health Care Segment  a strong balance sheet and an increasing membership help the stock bounce back going forward Other Stocks to ConsiderInvestors interested in the insurance multi line industry might also take a look at a few other top ranked stocks like MGIC Investment Corporation   NYSE MTG    CNO Financial Group  Inc    NYSE CNO   and MetLife  Inc    NYSE MET   MGIC Investment Corporation offers private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  The stock sports a Zacks Rank  1  Strong Buy   It came up with average four quarter positive surprise of 34 32   You can see CNO Financial develops  markets and administers health insurance  annuity  individual life insurance and other insurance products in the United States  It pulled off average four quarter earnings surprise of 11 7   The company has a Zacks Rank of 2 MetLife provides solutions to insurance  annuities  employee benefits and asset management businesses  It delivered average four quarter beat of 9 67   The company is a Zacks  2 Ranked stock 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci--units-receive-rating-actions-from-am-best-200373283,200373283
147475,368991,CI,Top Ranked Value Stocks To Buy For January 8th,opinion,"Here are four stocks with buy rank and strong value characteristics for investors to consider today  January 8th Foot Locker  NYSE FL   Inc   FL   This shoes and apparel retailer has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings advancing 0 9  over the last 60 days Foot Locker  Inc  Price and Consensus   Foot Locker has a price to earnings ratio  P E  of 12 51 compared with 14 60 for the industry  The company possesses a  of A 
Foot Locker  Inc  PE Ratio  TTM    Cigna Corporation  NYSE CI   CI   This health services provider has a Zacks Rank  2  and seen the Zacks Consensus Estimate for its current year earnings rising 0 7  over the last 60 days 
Cigna Corporation Price and Consensus   Cigna has a price to earnings ratio  P E  of 9 38  compared with 16 00 for the industry  The company possesses a Value Score of A 
Cigna Corporation PE Ratio  TTM    Colfax Corporation  CFX   This diversified industrial technology company has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 0 4  over the last 60 days 
Colfax Corporation Price and Consensus   Colfax has a price to earnings ratio  P E  of 8 23  compared with 16 90 for the industry  The company possesses a Value Score of A 
Colfax Corporation PE Ratio  TTM    MGIC Investment Corporation  MTG    This provider of private mortgage insurance and ancillary services has a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 0 5  over the last 60 days 
MGIC Investment Corporation Price and Consensus   MGIC Investment has a price to earnings ratio  P E  of 6 86  compared with 16 00 for the industry  The company possesses a Value Score of B 
MGIC Investment Corporation PE Ratio  TTM    See the 
Learn more about the  Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-january-8th-200373731,200373731
147480,368996,CI,Why The Earnings Surprise Streak Could Continue For Cigna  CI ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Cigna  CI   which belongs to the Zacks Insurance   Multi line industry 
When looking at the last two reports  this health insurer has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 14 06   on average  in the last two quarters 
For the most recent quarter  Cigna was expected to post earnings of  3 45 per share  but it reported  3 84 per share instead  representing a surprise of 11 30   For the previous quarter  the consensus estimate was  3 33 per share  while it actually produced  3 89 per share  a surprise of 16 82  
Price and EPS Surprise

Thanks in part to this history  there has been a favorable change in earnings estimates for Cigna lately  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the stock is positive  which is a great indicator of an earnings beat  particularly when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Cigna currently has an Earnings ESP of  0 48   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on February 1  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-cigna-ci-200373708,200373708
147482,368998,CI,Exclusive  Delrahim to head Justice Department antitrust unit   sources,news,By Diane Bartz and Svea Herbst Bayliss WASHINGTON BOSTON  Reuters    Makan Delrahim  a veteran lobbyist on President Donald Trump s transition team  is expected to be nominated to head the U S  Justice Department s Antitrust Division  two sources familiar with the vetting process told Reuters on Friday  Delrahim is expected to move to the Justice Department after finishing up in the White House counsel s office  where he is working to steer Supreme Court nominee Neil Gorsuch through the Senate confirmation process  The sources spoke on background because an announcement has not yet been made  As the proposed new chief of the Antitrust Division  he would be in charge of overseeing corporate mergers at a time when many investors and corporate executives hope for a more relaxed attitude toward deal making after years of tougher oversight by the Obama administration  The department is reviewing a number of major deals  including mergers of Dow and Dupont and Bayer  DE BAYGN  and  Monsanto   NYSE MON   Those proposed transactions  along with a third deal  ChemChina s purchase of Syngenta  would consolidate six agricultural chemical giants into three  The Justice Department is also assessing AT T s controversial plan to buy Time Warner  owner of HBO  Warner Brothers and the news network CNN  President Trump has not criticized the Time Warner deal since the November election but during his campaign he said it was an example of  too much concentration of power in the hands of too few   Delrahim must be confirmed by the Senate  Before coming to work at the White House following Trump s inauguration in January  Delrahim was a lobbyist with the law firm Brownstein Hyatt Farber Schreck  LLP  In 2016  he lobbied for the semiconductor company Qualcomm  NASDAQ QCOM   Comcast Corp  NASDAQ CMCSA  and Zuffa LLC  also known as the Ultimate Fighting Championship  among others  according to the Lobbying Disclosure Act Database  Another client in 2016 was health insurer Anthem Inc  which this year lost a court fight with the Justice Department over whether it would be allowed to merge with rival Cigna  NYSE CI   Anthem is appealing the loss  Delrahim  whose family emigrated from Iran when he was young  cemented his loyalty to Trump last summer when he wrote a piece in the New York Post urging Republicans to fall in line behind Trump  Only Trump would be able to win and ensure conservatives on the Supreme Court  the lawyer argued  adding  There s no glory in handing the Supreme Court to a Democratic president  But if we write off Trump  that s what will happen   Delrahim is a veteran of the Justice Department s Antitrust Division  where he was deputy assistant attorney general from 2003 to 2005  under then President George W  Bush  He specialized in international antitrust ,2017-03-17,Reuters,https://www.investing.com/news/politics-news/exclusive:-delrahim-to-head-justice-department-antitrust-division---sources-467110,467110
147483,368999,CI,Delrahim to be nominated to head U S  Justice Department s Antitrust Division,news,"WASHINGTON  Reuters    A member of President Donald Trump s transition team  Makan Delrahim  will be nominated to head the U S  Justice Department s Antitrust Division  the White House said on Monday 
Delrahim is expected to move to the Justice Department after finishing up in the White House counsel s office  where he has worked to steer Supreme Court nominee Neil Gorsuch through the Senate confirmation process 
The Senate must vote to confirm Delrahim once the nomination is formalized 
As the proposed chief of the Antitrust Division  Delrahim would review corporate mergers at a time when many investors and corporate executives are anticipating a more relaxed view of deal making after years of tough oversight by the administration of former President Barack Obama 
Antitrust experts who have followed Delrahim s career have said that when it comes to merger approvals he would follow in the footsteps of a former boss  Hewitt Pate  who was assistant attorney general of antitrust from 2003 to 2005  Delrahim was Pate s deputy  specializing in international antitrust 
Under Pate  the division was criticized for allowing too many deals  but it sued to stop US Airways from merging with United Airlines and blocked a deal to combine DirecTV and EchoStar  It tried but failed to stop  Oracle Corp   NYSE ORCL  from buying PeopleSoft 
 I know Makan Delrahim to be smart  energetic and expert in antitrust  He is certainly no pushover   said Seth Bloom  a former general counsel of the Senate antitrust subcommittee who knew Delrahim when both worked on Capitol Hill 
Reuters first exclusively reported on March 17 that Delrahim was expected to be nominated to head the Justice Department s Antitrust Division 
If confirmed  Delrahim would oversee the Justice Department s assessment of AT T  NYSE T  s Inc plan to buy  Time Warner  Inc  NYSE TWX   the owner of HBO  Warner Brothers and news network CNN 
The department is reviewing a number of major transactions in seeds and agricultural chemicals  like the mergers of  Dow Chemical   NYSE DOW  Co and Dupont  and of Bayer  DE BAYGN  and  Monsanto   NYSE MON   Those proposed deals  along with ChemChina s purchase of Syngenta  would consolidate six agricultural chemical companies into three Before going to work at the White House after Trump s inauguration in January  Delrahim was a lobbyist with the law firm Brownstein Hyatt Farber Schreck  LLP 
One client in 2016 was health insurer Anthem Inc  which this year lost a court fight with the Justice Department over whether it would be allowed to merge with Cigna  NYSE CI   Anthem has appealed the loss ",2017-03-27,Reuters,https://www.investing.com/news/politics-news/delrahim-named-to-head-u.s.-justice-department's-antitrust-division-469190,469190
147490,369006,CI,Why Horace Mann  HMN  Could Be Positioned For A Slump,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Horace Mann Educators Corporation   NYSE HMN    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  4  Sell  further confirms weakness in HMN A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen one estimate moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from  1 58 a share a month ago to its current level of 80 cents Also  for the current quarter  Horace Mann has seen one downward estimate revision versus no revisions in the opposite direction  dragging the consensus estimate down to a loss of 8 cents a share from earnings of 75 cents over the past 30 days   The stock also has seen some pretty dismal trading lately  as the share price has dropped 8 9  in the past month Horace Mann Educators Corporation Price and Consensus   So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Insurance   Multi line industry  you may instead consider a better ranked stock   Cigna Corporation   NYSE CI    The stock currently holds a Zacks Rank  2  Buy  and may be a better selection at this time  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-25,Zacks Investment Research,https://www.investing.com/analysis/why-horace-mann-hmn-could-be-positioned-for-a-slump-200370948,200370948
147494,369010,CI,Marsh   McLennan s  MMC  Unit Launches China Desk In Dubai,opinion,"Marsh   McLennan Companies  Inc  s   NYSE MMC   unit Marsh recently launched a China desk in Dubai to gain traction from the expanding commercial links between China  the Middle East and Africa  Marsh is the latest multinational arm to create a China desk in Dubai  which is the primary channel for regional business taking place in China s Belt and Road initiative Since setting up the desk  the company has been constantly making efforts to explore opportunities for growth  It has a few projects in Africa but not restricted to the region  There s also a Chinese investment involved in the Middle East  Marsh is mainly concentrating on China and Chinese contractors and principles Africa and the Middle East are important parts of Chinese President Xi Jinping s Belt and Road initiative  which is a  126 billion project to boost a network of infrastructure connecting China by land and sea to Southeast Asia  Central Asia  the Middle East  Europe and Africa Marsh is expected to receive an insurance broking license in Iraq next year where reconstruction of infrastructure is highly imperative after a four year war against the Islamic State  All these initiatives poise the company well for growth Marsh has been quite active when it comes to expanding and boosting its portfolio  Recently  it closed the buyout of Otis Magie Insurance Agency Inc  Last month  it also announced the unveiling of Bluestream  a cloud based digital broker platform targeting the affinity market  With this introduction  Marsh s affinity clients would be able to provide customers with insurance products and services through a new and streamlined method  It is also likely to start a new specialty business called Marsh JLT Specialty  subject to the completion of Jardine Lloyd Thompson Group s acquisition Shares of this Zacks Rank  3  Hold  company have lost 7 6  in a year s time  wider than its  s slip of 1 4  Stocks to ConsiderInvestors interested in the insurance industry might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average being 7 13   You can see   eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with average three quarter earnings surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  The stock sports a Zacks Rank  1 and pulled off average four quarter beat of 13 46  
 Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-25,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennans-mmc-unit-launches-china-desk-in-dubai-200370991,200370991
147495,369011,CI,MGIC Investment New Business Written Growth Momentum Sustains,opinion,MGIC Investment Corporation   NYSE MTG    which boasts being the largest private mortgage insurer in the United States  has been experiencing a sustained improvement in new business written for a considerable period of time  The company expects this momentum to continue on the back of a solid purchase market and a probable share gain from The Federal Housing Administration  FHA   In fact  the company estimates writing  50 billion in new insurance during 2018 Also  the Multi line insurer continues to witness favorable persistency while the credit trends consistently get better owing to legacy book  It is important to note here that higher level of new business written coupled with the anticipated increase in persistency will result in an improved insurance in force Interestingly  insurance in force is the main driver of the insurer s revenues and the metric has been impressive for the past several years  In the last three years  the top line has grown 4 2  and we expect this growth trend to sustain in the future as well Another important factor to consider is the growing private mortgage market share and the company is committed to increase the same with each passing year  The insurer s current market share is 18  and it projects to reach 19 20  in the industry it operates in  This will also help improve its insurance in force  leading to higher revenues Further  the company has been displaying a persistent decline in paid claims and going by this declining pattern of claim filings  we expect lower paid claims in the near term  This in turn  will enable the company to strengthen its balance sheet  boosting its financial profile in turn  Moreover  the insurer anticipates the number of loans in delinquent inventory along with claim rate applied to new delinquent notices to decrease in the future MGIC Investment has been bolstering its capital position ever since it entered into a reinsurance transaction in 2013 together with its own capital contribution  To that end  the company has been witnessing improved risk to capital as well as debt to capital ratios in the last few quarters Although shares of this Zacks Rank  2  Buy  Multi line insurer have lost 27 5  year to date  slightly wider than the  s decline of 23   we expect the aforementioned positives to turn the stock around in the near term The stock also carries a favorable  of B  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors  Back tested results have shown that stocks with a VGM Score of A or B when combined with a top Zacks Rank  1  Strong Buy  or 2 offer best investment opportunities Shares of MGIC Investment are trading at a price to book multiple of 1 06  lower than the industry average of 1 19  Price to book value ratio is the best multiple for valuing life insurers because of large variations in earnings results from one quarter to the next  This ratio essentially measures a life insurer s current market value  relative to what it would be worth if it chooses to shut down  Underpriced shares with solid fundamentals are profitable picks Other Stocks That Warrant a LookInvestors interested in other top ranked stocks from the same space can also consider Cigna Corporation   NYSE CI    Radian Group Inc    NYSE RDN   and MetLife  Inc    NYSE MET    each carrying a Zacks Rank of 2  You can see  Cigna operates as a health service company worldwide  Its products and services include an integrated suite of health services  such as medical  dental  behavioral health  pharmacy  vision  supplemental benefits and other related products including group life  accident and disability insurance  The company delivered positive surprises in all the trailing four reported quarters  the average being 13 46  Radian Group provides mortgage and real estate products and services in the United States  The company pulled off earnings surprises in all the previous four reported quarters  the average being 11 33  MetLife engages in insurance  annuities  employee benefits and asset management businesses  The company surpassed estimates in all the preceding four reported quarters  the average beat being 9 67  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-30,Zacks Investment Research,https://www.investing.com/analysis/mgic-investment-new-business-written-growth-momentum-sustains-200371917,200371917
147497,369013,CI,AIG s UK Unit Closes Buyout Of Ellipse  Boosts Portfolio,opinion,American International Group  Inc  s   NYSE AIG   UK arm  namely AIG Life Limited recently closed the acquisition of Ellipse from Munich Re  However  terms of the transaction have been kept under wraps Ellipse is a specialty provider of group life  critical illness and income protection in the United Kingdom  The acquirer believes that Ellipse s expertise in group protection and advanced technology will be in sync with its current business model in the United Kingdom With the closure of this transaction  AIG Life will now distribute group as well as individual protection insurance products to United Kingdom based customers via financial intermediaries  collaborations and employee benefits consultants  This buyout would help AIG Life to establish an even stronger presence in the United Kingdom market  The transaction is likely to strengthen AIG s position in Life   Retirement businesses Over the past few years  AIG has been on a buyout spree to boost its portfolio and penetrate into new markets  Recently  it acquired Validus Holdings  Ltd  and Glatfelter Insurance Group  which is likely to enhance its global General Insurance business  The company s CEO Brian Duperreault  appointed last year  has made a significant shift in its capital utilization and now expects to utilize capital for possible buyouts in the international markets  bolstering the company s personal and life lines segments plus investing in the domestic middle market as opposed to its hitherto usage of capital resource for share repurchases  This strategy should lead to long term growth via business expansion Shares of this Zacks Rank  5  Strong Sell  company have lost 33 8  in a year s time  compared with the  s decline of 22 2   The company s shares have been suffering over the past few years on account of declining revenues and weakness in the General Insurance segment  However  growth initiatives taken by the company should help the shares bounce back Stocks to ConsiderInvestors looking for some better ranked stocks in the same industry may consider options like Cigna Corporation   NYSE CI    MetLife  Inc    NYSE MET   and MGIC Investment Corporation   NYSE MTG    each carrying a Zacks Rank  2  Buy  Cigna offers insurance plus related products and services in the United States and internationally  It came up with average trailing four quarter positive surprise of 13 46   You can see MetLife offers services in the insurance  annuities  employee benefits and asset management businesses  The stock delivered average beat of nearly 9 67  in the last four reported quarters MGIC Investment Corporation provides private mortgage insurance and ancillary services in the United States  The company pulled off encouraging average earnings surprise of 34 32  over the preceding four reported quarters The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-01-01,Zacks Investment Research,https://www.investing.com/analysis/aigs-uk-unit-closes-buyout-of-ellipse-boosts-portfolio-200372255,200372255
147501,369017,CI,U S  Republicans wrestle with effort to gut Obamacare,news,"By Susan Cornwell WASHINGTON  Reuters    Republicans in Congress struggled on Thursday with their efforts to dismantle Obamacare  with conservatives urging haste while some lawmakers said the task had become more of a repair job than the repeal of the U S  healthcare law promised by President Donald Trump s administration  Two influential conservatives in the House of Representatives  worried that the process was getting bogged down  said the repeal measure that the Republican majority Congress passed last year should be taken up quickly  But in the Senate  Republican Lamar Alexander of Tennessee and chairman of the health committee counseled patience  He said changes to the law would be made in  chunks  and would be better labeled a  repair    It s more accurate to talk about repairing it     we re repairing the damage Obamacare has done   Alexander said outside the Senate   We re not repealing all of Obamacare  it s not technically possible to do that  now  in the procedures that we have in the Senate  and secondly  there are some parts of it we want to keep   he said  But Vice President Mike Pence  asked in a Fox News interview about talk of repairing Obamacare  pushed back  saying   We are absolutely committed to follow through on President Trump s directive to repeal and replace Obamacare and to have the Congress do it at the same time    Trump and congressional Republicans campaigned on a promise to dismantle the 2010 Affordable Care Act  former President Barack Obama s signature domestic legislation that Republicans consider federal government overreach   While Republicans voted last month to start the process of scrapping the law  they missed a target date of Jan  27 to begin drafting legislation to do so  At a congressional retreat last week  Republican leaders told lawmakers they hoped Congress would finish the repeal by March or April   Representative Mark Meadows  chairman of the conservative Freedom Caucus  and Representative Jim Jordan  the caucus  former chairman  urged the party leadership on Thursday to quickly enact a repeal measure   That s what the American people expect us to do   and they expect us to do it quickly   they said  Obama  a Democrat  vetoed the repeal passed by the Republican controlled Congress last year  INSURERS URGE CHANGES Three of the biggest national insurers have also stepped up pressure on the lawmakers to act   Aetna Inc   N AET   Anthem Inc  N ANTM  and  Cigna Corp   N CI  this week urged changes in Obamacare individual plan regulations in the next few weeks  in time for them to decide if they will sell the products in 2018  They want stricter oversight of eligibility and enrollment periods  as well as other changes  Without them  these insurers say they may pull out of the Obamacare exchanges next year  which would lead to less competition and higher premium rates  Rates for 2017 rose an average of 25 percent  Edmund Haislmaier  a Heritage Foundation senior research fellow who advised the Trump transition team to help craft the regulation change but has not seen the final version  said he expected it to address concerns of insurers  He said insurers were consulted   The incoming administration and the insurers have by in large the same agenda on a lot of this stuff   said Haislmaier  He said that pleasing the insurers could help Congress move more quickly on a plan to repeal and replace the law   The  administration  can reassure Republicans that we re taking steps so the market doesn t blow up when you move ahead with legislation  and I think that would actually maybe move the process along on the Hill   he said  Democrats were enjoying the Republican turmoil  They have long accused Republicans of rushing to gut the law without having a replacement plan ready  The law has enabled up to 20 million previously uninsured Americans to obtain health coverage  
 They  Republicans  haven t come up with the so called repairs   the Senate s No  2 Democrat  Dick Durbin of Illinois  said in a hallway   What a departure  for the Republicans   from  let s repeal it and walk away from it and America will be a better place   ",2017-02-03,Reuters,https://www.investing.com/news/world-news/u.s.-republicans-wrestle-with-effort-to-gut-obamacare-457560,457560
147502,369018,CI,Cigna CFO Thomas McCarthy to retire,news, Reuters     Cigna Corp   N CI  said Chief Financial Officer Thomas McCarthy will retire this summer  a week after the health insurer s  54 billion deal to be acquired by Anthem Inc  N ANTM  was blocked by the U S  Justice Department   Eric Palmer  who is currently chief financial officer of the company s global health  Cigna HealthSpring  employer based health care  group and supplemental insurance businesses  will succeed McCarthy  the company said on Thursday  The company said Palmer will immediately become its deputy chief financial officer   Cigna  which also reaffirmed its forecast for 2017 adjusted income from operations  promoted three other executives to its enterprise leadership team   Michael Triplet  Alan Muney and Christopher Hocevar will join the team immediately  the company said  Last week  Anthem won a temporary restraining order that blocked smaller rival Cigna from officially terminating their proposed merger  Cigna had notified Anthem that it had ended the deal and filed a lawsuit in Delaware  seeking legal sanction for its decision to end the deal and  13 billion in damages ,2017-02-23,Reuters,https://www.investing.com/news/stock-market-news/cigna-cfo-thomas-mccarthy-to-retire-461772,461772
147515,369031,CI,AIG Slips To 52 Week Low  Will The Stock Decline Further ,opinion,Shares of American International Group  Inc    NYSE AIG   tumbled to a 52 week low of  37 83 on Friday  However  the same recovered to some extent to close the trading session at  37 90  The shares might probably took a hit from the recent catastrophe loss estimates issued by the company  which might in turn weigh on its fourth quarter profitability Shares of this Zacks Rank  5  Strong Sell  company have lost 36 6  in a year s time  wider than its  s decline of 6 4  Factors Inducing the DowntrendThe company recently announced its catastrophe loss projection of  750  800 million for the fourth quarter of 2018  This loss will be incurred in AIG s General Insurance segment  which contributed a lion s share to the company s adjusted revenues for the first nine months of 2018  This weather related loss will likely weigh on the company s profitability  which suffered losses during 2016 and 2017 as well Moreover  the company s cat loss of  2 15 billion for the first nine months of 2018  though 37  narrower than the year ago period s figure  weighed on its underwriting profitability  We believe that high exposure to catastrophe events will be a headwind going forward as well Moreover  the company s revenues have been declining since 2013 due to competitive market conditions and a reduction in business due to numerous divestitures undertaken  This momentum persisted in the first nine months of 2018  mainly because of challenges in the property and casualty market and continued business dispositions will keep the top line under pressure in the coming quarters The company s earnings have substantially missed estimates over the last five reported quarters  which remains an uninviting proposition for investors Its return on equity stands at 3 44   significantly lower than the industry s average of 7 71   This reflects the company s inefficiency to use shareholder s funds Will the Stock Sink Further AIG witnessed its 2018 and 2019 earnings estimates move south by 1 5  and 1   respectively  over the past seven days  Its unattractive  of D also disappoints  The company currently has a  of F  Here V stands for Value  G for Growth and M for Momentum with the score being a weighted combination of all three factors  All these headwinds might pull the stock down going forward Stocks to ConsiderInvestors looking for some better ranked stocks in the same industry may consider options like Cigna Corporation   NYSE CI    MetLife  Inc    NYSE MET   and MGIC Investment Corporation   NYSE MTG   Cigna offers insurance plus related products and services in the United States and internationally  It sports a Zacks Rank  1  Strong Buy  and came up with average trailing four quarter positive surprise of 13 46   You can see  MetLife offers services in the insurance  annuities  employee benefits and asset management businesses  The stock carries a Zacks Rank  2  Buy  and delivered average beat of nearly 9 67  in the last four reported quarters MGIC Investment Corporation provides private mortgage insurance and ancillary services in the United States  The company pulled off encouraging average earnings surprise of 34 32  over the preceding four reported quarters  The stock has a Zacks Rank of 2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-09,Zacks Investment Research,https://www.investing.com/analysis/aig-slips-to-52-week-low-will-the-stock-decline-further-200366663,200366663
147517,369033,CI,MGIC Investment Reports Solid November Insurance In Force ,opinion,MGIC Investment Corp    NYSE MTG   recently announced its November 2018 operating business statistics  Insurance in force was  208 4 billion  up 7 7  year over year  Delinquency loans  loans that failed to pay back  at MGIC Investment declined on a year over year basis  Delinquent inventory decreased 29  year over year to 33 314 MGIC Investment has been severely hit by the financial crisis in 2008   Nonetheless  improving housing market fundamentals  such as household formations and home sales and the current capital status have been aiding the company s performance over the last several quarters Strengthening purchase mortgage market and the mortgage insurer s solid market share  measured by new insurance written  have been aiding improvement in new business written  Moreover  MGIC Investment expects to have 19 20  of market share in the industry in which it operates  This company is one of the six private mortgage insurers operating in the competitive industry and currently holds 18  market share Given the strong purchase market and potential share gain from Federal Housing Administration  FHA   the company expects to write  50 billion new insurance in 2018  Improvement in new business along with expected rise in persistency should lead to increased insurance in force for 2018  MGIC Investment is well poised to benefit from improving housing market fundamentals Also  decline in loss and claims will strengthen the company s balance sheet and hence improve its financial profile Shares of MGIC Investment have lost 24 8  in a year compared with the  s decline of 20 5  Improving housing market  solid insurance in force and fall in delinquency should help the stock rebound MGIC Investment has a Zacks Rank  2  Buy  Other Stocks to ConsiderInvestors interested in multiline industry can look at Cigna Corp   NYSE CI    MetLife  Inc    NYSE MET   and Radian Group  Inc    NYSE RDN   Cigna provides health care and related benefits  the majority of which are offered through workplace  The company came up with average four quarter beat of 13 46   The stock sports a Zacks Rank  1  Strong Buy   You can see MetLife engages in insurance  annuities  employee benefits  and asset management businesses  The company delivered average four quarter earnings surprise of 9 67   The stock carries a Zacks Rank  2 Radian Group provides mortgage and real estate products and services in the United States  The company pulled off an average four quarter positive surprise of 11 33   The stock carries a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-10,Zacks Investment Research,https://www.investing.com/analysis/mgic-investment-reports-solid-november-insurance-in-force-200367109,200367109
147518,369034,CI,Marsh   McLennan s Arm Acquires Otis Magie Insurance Agency,opinion,Marsh   McLennan Companies  Inc    NYSE MMC   recently announced that Marsh   McLennan Agency LLC   MMA   closed the buyout of Otis Magie Insurance Agency Inc  Notably  MMA is the middle market agency unit of Marsh  an arm of the parent company  Terms of the deal were  however  not disclosed by the companies Otis Magie offers business insurance  employee benefits and personal insurance products and services to customers residing in northern Minnesota  With this transaction  the acquired company s existing employees will continue to operate in their current locations under the brand of Otis Magie  a Marsh   McLennan Agency LLC company This unit of Marsh is dedicated to investing in and supporting the insurance and risk management needs of employers and individuals in northern Minnesota and Wisconsin  MMA is really hopeful of providing better experience to clients in these regions because of the addition of Otis Magie Insurance s skilled battery of staff to the teams This is yet another strategic initiative of Marsh   McLennan to boost its portfolio  A number of acquisitions made over the past many years  significant capital expenditures undertaken for growth  launch of products and services  enhancement of digital capabilities and branching out into new businesses will further drive the company s growth In recent months  the company completed several buyouts such as Pavilion Financial Corporation  Summit Strategies Group  Klein Agency and Insurance Associates  Houston based Wortham Insurance plus Eustis Insurance   Benefits  The company is also going to buy JLT Specialty  currently subject to certain closing conditions All these transactions further poise the company well for long term growth Shares of this Zacks Rank  3  Hold  company have inched up 1 4  in a year s time against its  s decline of 1  Stocks to ConsiderInvestors interested in the insurance industry might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average being 7 13   You can see  eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with average three quarter earnings surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  The stock sports a Zacks Rank  1  Strong Buy  and pulled off average four quarter beat of 13 46  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennans-arm-acquires-otismagie-insurance-agency-200367357,200367357
147519,369035,CI,Zacks com Featured Highlights Include  Allison Transmission  Cigna  Celanese And Stryker,opinion,For Immediate ReleaseChicago  IL   December 13  2018   Stocks in this week s article are  Allison Transmission Holdings  Inc    NYSE ALSN    Cigna Corp    NYSE CI    Celanese Corp    NYSE CE   and Stryker Corp    NYSE SYK   4 GARP Stocks for a Winning PortfolioInvestors on the lookout for stocks with the potential for maximum growth and value investing may consider the growth at a reasonable price or GARP strategy This popular strategy helps investors gain exposure to stocks with impressive growth prospects that are trading at a discount  GARP investing employs popular value metrics   price to earnings  P E  and price to book value  P B  ratio   to evaluate whether a stock is undervalued GARP Metrics   Mix of Growth   Value MetricsThe GARP strategy seeks to offer an ideal investment by utilizing the best features of both value and growth investing  Investors adopting the GARP approach will prefer to buy stocks that are priced below the market or any reasonable target determined by fundamental analysis  These stocks also have solid prospects in cash flow  revenues  earnings per share  EPS  and so on Growth MetricsBoth strong earnings growth history and impressive earnings prospects are the main concepts that GARP investors borrow from the growth investing strategy  However  instead of super normal growth rates  pursuing stocks with a more stable and reasonable growth rate is also a tactic of GARP investors  Hence  growth rates between 10  and 20  are considered ideal under the GARP strategy Another growth metric that is considered by both growth and GARP investors is return on equity  ROE   GARP investors look for strong and higher ROE compared to the industry average to identify superior stocks  Moreover  stocks with positive cash flow find precedence under the GARP plan Value MetricsGARP investing gives priority to one of the popular value metrics   price to earnings  P E  ratio  Though this investing style picks stocks with higher P E ratios compared to value investors  it avoids companies with extremely high P E ratios  Moreover  the price to book value  P B  ratio is also considered Using the GARP principle  we have run a screen to identify stocks that should offer solid returns in the near term For the rest of this Screen of the Week article please visit Zacks com at Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-allison-transmission-cigna-celanese-and-stryker-200367825,200367825
147520,369036,CI,Chart Of The Day  Molina Torpedoed by Obamacare Ruling  Here s The Trade,opinion,"The healthcare sector dropped 1 99  on Monday after a US District Court judge in Texas ruled that Obamacare was unconstitutional since Congress repealed the individual care mandate  Markets took it as a signal that healthcare providers could be in line to lose a considerable chunk of business 
However  many are skeptical of the decision  questioning its merit  BMO Capital s healthcare analyst Matt Borsch believes there will be an appeal on the ruling within a year  He considers the current brouhaha a buying opportunity 
Indeed it may be  Shares of healthcare insurer Cigna  NYSE CI  were down 3 3  and US hospital manager HCA Holdings  NYSE HCA  was down almost 3   Molina Healthcare  NYSE MOH  which works with state agencies to help manage Medicaid programs plunged as much as much as 16  intraday  but closed 8 9  lower 

While the 200 DMA supported Molina s freefall and bounced it back above the November 20 trough  the damage may have already been done  Yesterday s low created the second trough to complete a downtrend 
Even if there s an appeal on the ruling  and irrespective of whether it will happen in as little as 12 months  that s still a long time for investors to hold on to shares that were torpedoed by the ruling  especially when the broader market is already falling  For that reason we predict prices will keep falling  However  be cautious of the confluence of supports  the November 20   114 44 low  which is a mighty hammer due to its small real body and exceptionally long lower shadow  as well as the 200 DMA 
Trading Strategies
Conservative traders might want to wait for a close below the 200 DMA  then  wait for a rebound to retest the 200 DMA from below  with at least one long  red candle  following a green or small candle of either color 
Moderate traders may wait to wait for a close below the Nov  20   114 44 low or at least the Nov  19   118 21 close 
Aggressive traders may short after a close below the  110 41 hammer low  Then  they may take a contrarian  long position  hoping for a bounce 
Aggressive Short Trade Sample 

Entry   120
Stop loss   122
Risk   2
Target   112  above the 200 DMA
Reward   8
Risk Reward Ratio  1 4

Aggressive Long Trade Sample 

Entry   112  above the 200 DMA
Stop loss   110  below yesterday s low
Risk   2
Target   118
Reward   6
Risk Reward Ratio  1 3",2018-12-18,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/chart-of-the-day-200369011,200369011
147524,369040,CI,Cigna  CI  Gains As Market Dips  What You Should Know,opinion,"Cigna  CI  closed the most recent trading day at  193 30  moving  0 65  from the previous trading session  This move outpaced the S P 500 s daily loss of 1 54   Meanwhile  the Dow lost 1 49   and the Nasdaq  a tech heavy index  lost 2 17  
Heading into today  shares of the health insurer had lost 7 57  over the past month  outpacing the Finance sector s loss of 7 86  and lagging the S P 500 s loss of 6 77  in that time 
Investors will be hoping for strength from CI as it approaches its next earnings release  which is expected to be February 7  2019  On that day  CI is projected to report earnings of  2 52 per share  which would represent year over year growth of 29 9   Our most recent consensus estimate is calling for quarterly revenue of  11 35 billion  up 8 02  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  14 35 per share and revenue of  45 68 billion  which would represent changes of  37 19  and  10 4   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for CI  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  CI is holding a Zacks Rank of  1  Strong Buy  right now 
Valuation is also important  so investors should note that CI has a Forward P E ratio of 13 38 right now  For comparison  its industry has an average Forward P E of 11 83  which means CI is trading at a premium to the group 
It is also worth noting that CI currently has a PEG ratio of 1 08  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Insurance   Multi line industry currently had an average PEG ratio of 1 13 as of yesterday s close 
The Insurance   Multi line industry is part of the Finance sector  This group has a Zacks Industry Rank of 99  putting it in the top 39  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-gains-as-market-dips-what-you-should-know-200369645,200369645
147525,369041,CI,Cigna  Express Scripts Join Forces For Better Healthcare,opinion,Cigna Corporation   NYSE CI   completed the pending merger with Express Scripts Holding Company  NASDAQ ESRX    Express Scripts    effective Dec 20  2018  With this deal  the combined organization is likely to provide enriched and affordable care to their customers  Cigna aims to transform the healthcare system through this significant transaction This merger brings two complementary healthcare service companies together  both having leading cost trend abilities  which will provide customers with better healthcare and more options to choose from  This latest deal with Express Scripts can effectively drive the breadth of value based relationships for Cigna  The deal undoubtedly adds significantly to Cigna s fast growing collaborative care network Moreover  Cigna announced an additional investment of  200 million to its charitable foundation and communities  It is even launching Healthier Kids for Our Future  a program aimed at addressing the well being of children around the globe  In the next year  Cigna will solely focus on improving the health of children by eradicating hunger and enhancing nutrition Both the companies are currently working on a blueprint to provide special  personalized and value based care  which would allow them to prioritize the needs and requirements of customers  They have the intention to provide feasible  convenient and affordable solutions to customers  The joint effort by the companies would help in mending the gaps in care in the local communities Cigna expects the merger to deliver impressive sustained returns to shareholders  As discussed  the company estimates delivering adjusted income from operations per share of  20  21 in 2021 Shares of the companies stopped trading on Dec 20  2018  The combined unit has started trading from today under the ticker symbol  CI  Shares of this Zacks Rank  2  Buy  company have lost 12 1  in a year s time  narrower than the  s decline of 24 9    Other Stock to ConsiderInvestors interested in the insurance multi line industry might take a look at a few other stocks like MGIC Investment Corporation   NYSE MTG    Old Republic International Corporation   NYSE ORI   and MetLife  Inc    NYSE MET    each carrying a Zacks Rank  2  You can see  MGIC Investment Corporation offers private mortgage insurance and ancillary services to lenders  and government sponsored entities in the United States  It came up with a positive four quarter surprise of 34 32  Old Republic engages in the insurance underwriting and related services business  primarily in the United States and Canada  The company managed to deliver a trailing four quarter positive surprise of 15 66  MetLife provides solutions to insurance  annuities  employee benefits  and asset management businesses  It came up with a four quarter surprise of 9 67  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/cigna-express-scripts-join-forces-for-better-healthcare-200370207,200370207
147527,369043,CI,U S  insurer lobby group seeks delay in 2018 Obamacare deadline,news,"By Caroline Humer NEW YORK  Reuters    The largest lobbying group for health insurers has asked U S  lawmakers weighing the fate of Obamacare to push back the due date for 2018 individual insurance submissions to regulators in hopes of obtaining greater clarity on the program s future later on   Republican leaders including President elect Donald Trump and U S  Senate Majority Leader Mitch McConnell have said they are keen to repeal President Barack Obama s signature health insurance program  the Affordable Care Act  which provides coverage to millions of Americans  The process of repealing and replacing Obamacare could take two to three years  however  according to some senators  How much of the law will change and when is still unclear  Trump has said some aspects of the program are good  such as allowing young adults to stay insured with their parents until age 26   The trade association America s Health Insurance Plans  or AHIP  has been speaking with senators for the past few weeks  spokeswoman Kristine Grow said on Tuesday  She provided a list of issues under discussion  which touch on the individual exchanges  Medicare and Medicaid  Insurers backed the idea of high risk pools  saying they can mitigate the risk of adverse selection and deliver effective coverage  Both Trump and his choice to head the U S  Department of Health and Human Services  Tom Price  advocate for use of the pools to insure the very sick  Two of AHIP s largest members are Anthem Inc and  Cigna Corp   NYSE CI   both of which plan to sell Obamacare plans in 2017   Insurers also asked for funding through Jan  1  2019  for cost sharing programs and making the 2016 reinsurance payments to insurers who qualify for them as planned  And they asked for elimination of two health insurance taxes  which they said would help slow premium growth  They suggested extending the deadline to file health exchange plans by a few months until the summer of 2017  when there will be less uncertainty and more insurers are likely to submit bids  Insurers are asking senators for limited changes to the Medicaid program during the transition period  and to ensure a transition period for states that have expanded Medicaid  the program for the poor jointly funded by the federal government and states  Republicans are considering changing its funding to block grants  which could cut the total amount  
On Medicare  the insurers are seeking changes as soon as February  when the government will propose target rates for 2018 Medicare Advantage plans ",2016-12-06,Reuters,https://www.investing.com/news/politics-news/u.s.-insurer-lobby-group-seeks-delay-in-2018-obamacare-deadline-446061,446061
147528,369044,CI,CVS starts selling Impax s cheaper EpiPen rival,news," Reuters    Drugstore chain CVS Health Corp  N CVS  has started selling a generic version of Impax Laboratories Inc s  O IPXL  emergency allergy injection  a device similar to Mylan NV s  O MYL  controversial EpiPen  Mylan  which has been lambasted by consumers and lawmakers for raising EpiPen prices six fold in less than a decade  said last month it would start selling a generic version of EpiPen for  300 per two pack  a more than 50 percent discount  CVS s move comes after health insurer  Cigna Corp   N CI  revised its coverage list to include the generic version of Epipen instead of the branded version   These formulary changes were anticipated and are why we anticipate successful generic utilization   Mylan spokeswoman Julie Knell said in an email  Impax s branded Adrenaclick has not caught on with patients and doctors and is not considered by regulators to be an exact copy of EpiPen  The authorized Adrenaclick generic is available at all CVS Pharmacy locations at  109 99 for a two pack for both insured and cash paying patients without insurance  CVS said on Thursday  The two pack device  which is assembled by hand by manufacturers  has a list price of more than  400  
Mylan s branded EpiPen doublet has a list price of  649 99  and the authorized generic costs  339 99  CVS added ",2017-01-12,Reuters,https://www.investing.com/news/stock-market-news/cvs-starts-selling-impax's-cheaper-epipen-rival-452851,452851
147529,369045,CI,Anthem extends Cigna deal closing date ahead of court ruling,news,"NEW YORK  Reuters    Anthem Inc  N ANTM  on Thursday said it extended the deadline for its acquisition of  Cigna Corp   N CI  by three months as it awaits a federal court ruling on the U S  government s lawsuit to block the deal  Anthem  which operates Blue Cross Blue Shield health insurance plans in 14 states  is trying to buy smaller rival Cigna  The government sued seven months ago to stop the deal  saying it was anti competitive   Judge Amy Berman Jackson of the U S  District Court for the District of Columbia has not yet issued an opinion on the case  The trial began late last year  and Cigna said it ended on Jan  4  Anthem said in a regulatory filing that as permitted by its merger agreement with Cigna  it would extend the deadline for completion of the deal from Jan  31 to April 30  regardless of the outcome of the court proceedings  
Cigna said in a statement that it had received notice of Anthem s extension and that it would evaluate its options after the court ruling ",2017-01-19,Reuters,https://www.investing.com/news/stock-market-news/anthem-extends-cigna-deal-closing-date-ahead-of-court-ruling-454299,454299
147530,369046,CI,Judge to block mega merger of Anthem and Cigna  NY Post,news," Reuters    A federal judge is expected to block a proposed deal between health insurer Anthem Inc  N ANTM  and  Cigna Corp   N CI  as soon as Thursday  the New York Post reported  citing sources  Anthem  which operates Blue Cross Blue Shield health insurance plans in 14 U S  states  is trying to buy smaller rival Cigna  The government sued seven months ago to stop the deal  saying it was anti competitive  Judge Amy Berman Jackson of the U S  District Court for the District of Columbia has not yet issued an opinion on the case  The trial began late last year  and Cigna said it ended on Jan  4  Anthem is preparing for an appeal of any ruling that doesn t go its way and insiders expect Jackson to rule against the deal  the Post reported     Anthem said earlier on Thursday it extended the deadline for its acquisition of Cigna by three months  
Anthem and Cigna could not be immediately reached for comment ",2017-01-19,Reuters,https://www.investing.com/news/stock-market-news/judge-to-block-mega-merger-of-anthem-and-cigna:-ny-post-454367,454367
147553,369069,CI,7 Solid Reasons Why Cigna Is A Must Add To Your Portfolio,opinion,Estimates for Cigna Corporation   NYSE CI   have been revised upward over the past 30 days  reflecting analysts  optimism on the stock  The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings move 3 2  and 5 3  north  respectively  over the same time frame Shares of this Zacks Rank  1  Strong Buy  company have gained 4 5  against its  s decline of 14 5  The company also carries an impressive  of B  Our research shows that stocks with a solid Value Style Score of A or B when combined with a favorable Zacks Rank  1  Strong Buy  or 2  Buy  offer the best opportunities in the value investment space The mid term election remains positive for the Health Maintenance Organization  HMO  industry and in turn  would benefit all the players including Cigna  The repeal of the Affordable Care Act  ACA  is not likely to happen anytime soon and the overall scenario bodes well for the HMOs as membership growth in Medicare and Medicaid should drive their top line Now  let s focus on some important factors that make the company an investor favorite Robust Third Quarter Results  Cigna reported third quarter 2018 earnings per share of  3 84  beating the Zacks Consensus Estimate by 11 3   The metric also surged by an impressive 36  year over year  driven by solid segmental performances across Global Health Care  Global Supplemental Benefits plus Group Disability and Life businesses  Moreover  it generated revenues of  11 44 billion  surpassing the Zacks Consensus Estimate by 2   The top line also improved 9  year over year  led by robust business growth in Global Healthcare and Global Supplemental Benefits segments Stellar Earnings Surprise History  The company boasts an encouraging earnings surprise history  having outpaced the Zacks Consensus Estimate in each of the trailing four reported quarters  the average beat being 13 46   Further  this upside speaks volumes for the company s operational excellence Strong Performance of Global Health Care Segment  This segment contributes a lion s share to the company s total revenue base  The segment witnessed a CAGR of 6  for revenues from 2014 to 2017  The metric rose 11  in the first nine months of 2018  driven by Commercial customer growth and expansion of specialty relationships as well as premium increases  consistent with the underlying cost trends  The company is expected to see commendable revenue growth going forward  which in turn  should boost its top line Raised Guidance  Following sturdy results in the first nine months of 2018  Cigna lifted its earnings outlook  It now expects consolidated adjusted income from operations for 2018 in the range of around  3 49  3 54 billion or  14 20  14 40 per share  reflecting an increase of 50 60 cents per share over the previous expectation and representing per share growth of 36 38  over 2017 level  Total revenues are expected to grow approximately 8 5  compared with the earlier projection of approximately 8   This upbeat view should instill investors  confidence in the stock Increasing Membership  The company has witnessed higher membership for the past many years  For 2018  Cigna forecasts global medical customers  growth in the band of 400 000 500 000  We believe that the company s solid fundamentals along with its diversified product portfolio would attract more members going forward Firm Capital Position  Cigna s cash flow from operations has been increasing for the past four years and the trend continued into the first nine months of 2018  This momentum was constantly sustained by its disciplined capital management strategy consisting of prudent mergers  acquisitions and other investments  The company is generating high margins and is capital efficient  leading to organic growth and significant free cash flow Growth Projections  The Zacks Consensus Estimate for current year earnings per share is pegged at  14 31  representing a year over year increase of 36 81  on 10 4  higher revenues of  45 68 billion For 2019  the Zacks Consensus Estimate for earnings per share stands at  16 55 on  48 56 billion revenues  translating into a respective 15 64  and 6 29  year over year rise Further  the company s estimated long term  five years  EPS growth rate of 12 4   which is greater than the industry s earnings growth rate of 8 1   promises rewards for investors Other Stocks to ConsiderInvestors interested in the insurance multiline industry might also take a look at a few other top ranked stocks like MGIC Investment Corporation   NYSE MTG    Old Republic International Corporation   NYSE ORI   and MetLife  Inc    NYSE MET    each carrying a Zacks Rank  2  Buy   You can see MGIC Investment Corporation offers private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  It came up with average four quarter positive surprise of 34 32  Old Republic engages in the insurance underwriting and related services business  primarily in the United States and Canada  The company managed to pull off average trailing four quarter earnings surprise of 15 66  MetLife provides solutions to insurance  annuities  employee benefits and asset management businesses  It delivered average four quarter beat of 9 67  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/7-solid-reasons-why-cigna-is-a-must-add-to-your-portfolio-200362007,200362007
147554,369070,CI,American International s  AIG  New Subsidiaries Get Ratings,opinion,Credit rating giant Moody s Investors Service  Moody s  recently allocated definitive A2 insurance financial strength  IFS  ratings to American International Group  Inc  s   NYSE AIG   arms  namely  UK based American International Group UK Limited  AIG UK  and Luxembourg based AIG Europe S A   AESA  The above two recently formed indirect units of the parent company will continue with AIG s property   casualty  P C  business in the UK and other European countries  respectively  replacing the UK based AIG Europe Limited  AIEGL   The rating outlook of these subsidiaries is stable The rating action was undertaken by Moody s following the October 2018 approval of AIGEL s plan by the High Court of England   Wales to move its business into AIG UK and AESA in preparation for Brexit  AIGEL will transfer the current UK business to AIG UK and its existing other European business affairs to AESA while both AIG UK and AESA will commence writing AIG s P C business in respective regions  effective Dec 1  2018 The IFS ratings on the units replace the provisional ratings assigned by Moody s in May 2018  The agency will withdraw its current IFS rating for AIGEL once it is merged with AESA Ratings RepresentationThe AIG UK and AESA ratings signify a solid market position in the UK commercial lines  diversified product offerings in Europe  investment strategy and the support provided by affiliates  The ratings reflecting explicit and implicit backing from affiliates include reinsurance ceded to AIG s flagship P C business activities in the United States and the required capital available from AIG parent   However  such positives are somewhat offset by the group s weak operating results over the recent years  primarily due to adverse loss development along with catastrophe loss  and its moderate capitalization on a statutory basis For recovering from its profit challenges in its European and global P C operations  AIG has appointed many new P C business leaders and is even shifting its resources toward comparatively profitable segments  The company has also taken strict actions to restrict policy limits  buy more reinsurance to check volatility and decrease costs  The credit rating entity projects to take a year or more for the parent company to stabilize its P C results in Europe and worldwide Factors Leading to Stable OutlookThe stable rating outlook of the subsidiaries mirror the parent company s intent to improve its P C results by lowering volatility from reserves and catastrophes and also working on improving its combined ratio by containing it below 100  Factors That Drive Future RatingsThe rating upgrade can be seen for AIG UK and AESA provided that there is betterment in underwriting results and profitability  benign development of loss reserves  progress in the AIG PC US ratings and also if gross underwriting leverage is less than 3 5x Factors that can downgrade the ratings of new units are persistently poor underwriting performances  adverse loss development  losses inducing the capital to decline by more than 10  in a particular year or deterioration of the AIG PC US ratings Shares of this Zacks Rank  2  Buy  company have lost 27 5  in a year s time  wider than its  s decline of 14  Other Stocks to ConsiderInvestors looking for some other top ranked stocks in the same industry may also consider options like Cigna Corporation   NYSE CI    MetLife  Inc    NYSE MET   and MGIC Investment Corporation   NYSE MTG   Cigna offers insurance and related products and services in the United States and internationally  It sports a Zacks Rank  1  Strong Buy  and came up with trailing four quarter surprise of 13 46   You can see  MetLife offers services in the insurance  annuities  employee benefits and asset management businesses  The stock carries a Zacks Rank of 2 and delivered average beat of nearly 9 67  in the last four reported quarters MGIC Investment Corporation provides private mortgage insurance and ancillary services in the United States  The company came up with an encouraging earnings surprise of 34 32  over the preceding four reported quarters  It is a Zacks  2 Ranked stock 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/american-internationals-aig-new-subsidiaries-get-ratings-200364045,200364045
147555,369071,CI,Cigna  CI  Gains But Lags Market  What You Should Know,opinion,"Cigna  CI  closed the most recent trading day at  224 84  moving  0 65  from the previous trading session  The stock lagged the S P 500 s daily gain of 1 09   Elsewhere  the Dow gained 1 13   while the tech heavy Nasdaq added 1 51  
Heading into today  shares of the health insurer had gained 3 28  over the past month  outpacing the Finance sector s gain of 2 32  and the S P 500 s gain of 1 92  in that time 
Investors will be hoping for strength from CI as it approaches its next earnings release  which is expected to be February 7  2019  The company is expected to report EPS of  2 52  up 29 9  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  11 35 billion  up 8 02  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  14 35 per share and revenue of  45 68 billion  These totals would mark changes of  37 19  and  10 4   respectively  from last year 
It is also important to note the recent changes to analyst estimates for CI  Recent revisions tend to reflect the latest near term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 3 51  higher  CI currently has a Zacks Rank of  1  Strong Buy  
In terms of valuation  CI is currently trading at a Forward P E ratio of 15 56  This represents a premium compared to its industry s average Forward P E of 12 19 
Also  we should mention that CI has a PEG ratio of 1 26  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  Insurance   Multi line stocks are  on average  holding a PEG ratio of 1 2 based on yesterday s closing prices 
The Insurance   Multi line industry is part of the Finance sector  This group has a Zacks Industry Rank of 97  putting it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-gains-but-lags-market-what-you-should-know-200364612,200364612
147556,369072,CI,6 Solid Reasons To Invest In MetLife For Portfolio Growth,opinion,Estimates for MetLife  Inc    NYSE MET   have been revised upward over the past 30 days  reflecting analysts  optimism on the stock  The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings move 1 3  and 0 4  north  respectively  over the same time frame The company also has an impressive  of A and a Zacks Rank  2  Buy   Our research shows that stocks with a solid Value Style Score of A or B when combined with a top Zacks Rank  1  Strong Buy  or 2 offer the best opportunities in the value investment space Now  let s focus on some important factors that make the company an investor favorite Revenue Growth  The company s revenues are up by 11  year over year in the first nine months of 2018  mainly on the back of sales growth in Asia and EMEA  rise in operating premiums  fees and other revenues in its Group Benefits segment and an increase in net investment income owing to rising interest rates  Last year  the metric increased 3   Given the company s core fundamentals and its strong performing segments  the bottom line is expected to improve going forward Business Streamlining  MetLife has been constantly putting in efforts over the past few years to restructure its business for focusing on its core businesses  which have potential  A very significant step taken in this direction was the company s recently completed separation of its U S  Retail business named BrightHouse Financial  This business required MetLife to hold a huge capital buffer at its disposal  The move in turn  freed MetLife from a capital intensive business  It also saved the company from exposure to interest rate and equity market volatility related to the exited business Moreover  the company  closed its UK Wealth Management business  which was suffering low interest rates  The company also sold MetLife Afore  S A  de C V   its pension fund management business in Mexico  Though these divested businesses will dent top line growth to some extent in the form of fees and premium lost  over the long term  such strategic steps will transform MetLife into a company with less instability and more free cash flow  which should lead to higher return on equity Strong Capital Management  The company boasts a strong risk based capital position  sufficient liquidity and a low debt ratio  It is also managing its capital efficiently  evident from its return on Equity  ROE  of 9 76   higher than the industry s average of 7 7   It has been buying back shares  which is aiding its bottom line  Recently  the company announced an additional  2 billion of share repurchases  bringing its current authorized buyback capacity to almost  2 5 billion  Over the three year period from 2016 through 2018  MetLife will return close to  12 billion to its shareholders through share repurchases and common dividends  During the same timeframe  its share count will be down by more than 10  Positive Earnings Surprise History  The company s surprise history shows that its earnings beat estimates in the trailing four reported quarters  the average positive surprise being 9 67  Growth Projections  The Zacks Consensus Estimate for current year earnings per share is pegged at  5 35  representing a year over year increase of 18 89  on 2 9  higher revenues of  68 96 billion Long term earnings growth rate is pegged at 12 6   higher than the industry s average of 8 1   which remains a positive for the company Undervalued  Its valuation looks attractive at the current level  The company has a forward 12 month P B ratio of 0 86  significantly lower than the industry average of 2 29 Shares of the  company have lost 15 5  versus its  s growth of 0 7   This provides an attractive entry point to own the stock  Other Stocks to ConsiderInvestors interested in the insurance multiline industry might also take a look at a few other top ranked stocks like Cigna Corporation   NYSE CI    MGIC Investment Corporation   NYSE MTG   and Old Republic International Corporation   NYSE ORI   Cigna provides insurance and related products and services in the United States and internationally  The company sports a Zacks Rank  1  Strong Buy  and delivered average four quarter beat of 13 46   You can see MGIC Investment Corporation offers private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  It came up with average four quarter positive surprise of 34 32   The company carries a Zacks Rank of 2 Old Republic engages in the insurance underwriting and related services business  primarily in the United States and Canada  The company managed to pull off average trailing four quarter earnings surprise of 15 66  and is a Zacks  2 Ranked player Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/6-solid-reasons-to-invest-in-metlife-for-portfolio-growth-200364842,200364842
147557,369073,CI,Marsh   McLennan s  MMC  Unit Closes Pavilion Acquisition,opinion,Marsh   McLennan Companies  Inc  s   NYSE MMC   subsidiary Mercer announced completing the pending buyouts of the investment consulting  alternatives consulting and wealth management operations of Pavilion Financial Corporation  Pavilion  effective Nov 30  2018  However  terms of the deal were not disclosed With this deal  Mercer is expecting to provide wider and deeper global research and specialist resources to its consultants and clients  The acquired company s expertise in the healthcare  insurance and endowment plus foundation segments along with Mercer s intellectual capital would definitely help clients with enriched  personalized and comprehensive solutions  The Pavilion will represent Mercer s U S  not for profit and insurance offerings  Mercer will offer its new suite of alternative investments through an online platform Marsh   McLennan has been consistently putting in efforts to expand its footprint via acquisitions and penetration into new areas  The company has made numerous purchases within its different operating units that have enabled it to enter new geographical regions  extend within the existing ones and foray into new businesses In recent months  the company acquired Klein Agency and Insurance Associates with which  it will be able to grow in the greater Washington DC region and enhance its construction capabilities  It also completed a buyout in Scotland  adding to its revenue base  The company recently bought Houston based Wortham Insurance along with Eustis Insurance   Benefits  a leading independent insurance agency in Louisiana Mercer has also closed the purchase of Summit Strategies Group on Nov 15  2018  Moreover  the unit is going to buy JLT Specialty  subject to certain closing conditions  All these transactions further poise the company well for growth Shares of this Zacks Rank  3  Hold  company have gained 2 1  in a year s time against its  s decline of 3 3  Stocks to ConsiderInvestors interested in the insurance sector might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average being 7 13   You can see eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with average three quarter positive surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  The stock sports a Zacks Rank  1  Strong Buy  and pulled off average four quarter earnings surprise of 13 46  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennans-mmc-unit-closes-pavilion-acquisition-200365280,200365280
147563,369079,CI,U S  presidential contest takes center stage for investors,news,"By Noel Randewich SAN FRANCISCO  Reuters    Who becomes the next U S  president will be a primary focus for Wall Street next week and beyond  starting on Monday with the first debate between candidates Hillary Clinton and Donald Trump  While the White House race has so far had little discernible effect on the market  that may soon change as polls show a tightening race  Clinton s once comfortable lead in opinion polls has evaporated  and with just over six weeks until Election Day  some investors see a toss up contest creating volatility in certain sectors  including health insurers  drugmakers and industrials  Also  many on Wall Street worry about the uncertainty of what Trump would do as president  as well as his sometimes contradictory proposals at odds with mainstream Republicans  such as his protectionist stance on international trade  Some investors believe U S  equities are likely to edge higher next week after the Federal Reserve on Wednesday left interest rates unchanged  The S P 500 has gained 6 percent in 2016 and is about 1 percent short of its record high set in August    We re probably looking at a modestly positive week pushing the high end of the S P 500  unless something comes out of the debate that spells real success for Trump   said Phil Blancato  chief executive of Ladenburg Thalmann Asset Management in New York   The market seems to favoring the  known  of Hilary rather than the  unknown  of Trump    In a recent report   Wells Fargo   NYSE WFC  said a Clinton presidency with a divided U S  Congress would have a  neutral  impact on financial markets  A Trump victory and a divided Congress would have a  slightly negative  market impact  Wells Fargo said  So far  the election has been too close to call and too far away to trade specific stocks  some investors said   Still  many view a Clinton presidency as broadly negative for pharmaceutical companies because of criticisms she has made about high drug prices  Clinton frequently said during the primary that she would fight pharmaceutical companies  part of an attempt to counter criticism that she was too closely tied to the insurance industry  Trump s disapproval of free trade agreements suggests that industrial companies and other major exporters might suffer should he become president  said David Schiegoleit  managing director at the Private Client Reserve at U S  Bank  With Trump vowing to repeal the Affordable Care Act and Clinton promising to build on it  health insurance stocks could swing if the debate produces a clear winner  Convergex market strategist Nicholas Colas wrote in a note on Friday  
Health insurers have been big winners since President Barack Obama signed his healthcare overhaul in 2010  UnitedHealth Group  N UNH  has jumped 325 percent  Aetna  N AET  is 234 percent higher and Cigna  N CI  has risen 257 percent  During the same time  the S P 500 rose 85 percent ",2016-09-23,Reuters,https://www.investing.com/news/stock-market-news/u.s.-presidential-contest-takes-center-stage-for-investors-428201,428201
147564,369080,CI,Trump  U S  Congress will agree on some issues  long term questions loom,news,"By Susan Cornwell and Richard Cowan WASHINGTON  Reuters    President elect Donald Trump will enjoy Republican majorities in both chambers of Congress when he takes office in January and an early Capitol Hill honeymoon is likely on several issues  but a long term romance may be more challenging  Under normal circumstances  a president whose party controls both the Senate and House of Representatives can count on getting things done fairly quickly and Trump likely will not be an exception  but he will start with unusual handicaps  Many Republicans in Congress only backed Trump after he became the nominee  Some never fell in line  He offended and attacked some while running  including House of Representatives Speaker Paul Ryan  who did not campaign with him  On top of that  the New York real estate businessman and former reality television celebrity who will head the world s most powerful government and largest economy  has no governing experience   Donald Trump will lead a unified Republican government   Ryan told a news conference in his home state  Wisconsin  on Wednesday  promising to  work hand in hand  with him  Ryan said his relationship with Trump  is fine  and he has already spoken to the president elect twice  and to his running mate  Indiana Governor Mike Pence  a former House member  Trump and the Republican leadership in Congress agree on at least one major policy  They want to repeal Democratic President Barack Obama s landmark healthcare law  known as Obamacare  enacted in 2010  Ryan said Congress would move quickly to deal with the law  Trump also spoke extensively about scrapping trade deals and building a wall along the 1 989 mile  3 200 km  U S   Mexico border  but some Republicans are skeptical about both of those campaign pledges  INFRASTRUCTURE EARLY ON In his victory speech  Trump promised to invest in infrastructure  a proposal popular with lawmakers from both parties  possibly funded by ending a law that lets corporations hold profits offshore without paying U S  taxes on them  Plans by House Financial Services Committee Chairman Jeb Hensarling  a Texas Republican  to rewrite banking law to ease regulations  and to limit powers of the Consumer Financial Protection Bureau  are likely to have smoother sailing   My hope is that President elect Trump will focus on issues that unite us   Maine Republican Senator Susan Collins  an outspoken Trump critic  said in a statement  Trump appealed to voters as a Washington outsider  at times leading his rallies in chants of  Drain the swamp   about the capital city  But outside experts said the party leaders share enough of an agenda with Trump that they will move together as a group  Ryan credited Trump with turning his home state of Wisconsin to the Republican Party for the first time in decades  Trump is  going to pursue every deal that can get done and there is a large possibility that Congress is going to work to go along  but also to get passed what they want   said Lara Brown  interim director of the Graduate School of Political Management at George Washington University  Republicans kept control of both the House of Representatives and Senate  although Democrats cut slightly into their majorities  With a few races undecided  Republicans had secured 51 seats to Democrats 47 in the Senate  That number could rise to 48  New Hampshire Governor Maggie Hassan  a Democrat  claimed victory in New Hampshire on Wednesday morning over incumbent Republican Senator Kelly Ayotte  although Ayotte said the race was too close to call  COMMON GROUND ON OBAMACARE  TAXES  Repealing Obamacare would shake the U S  healthcare and insurance industries  which have broadly called for measured reforms  although not for its full scale elimination  America s Health Insurance Plans  or AHIP  a trade association that represents insurers such as Anthem Inc and  Cigna Corp   NYSE CI  in Washington  said late on Tuesday that it would work with any new administration on the issue  Trump has called Obamacare a  disaster  and vowed to repeal and replace it  House Republicans have already voted more than 50 times to repeal all or part of the law  Senate Democrats were certain to fight an Obamacare rollback  but could be outmaneuvered by Republicans at the procedural level with Trump s cooperation   It would be a tragedy  and I certainly won t in any way cooperate or work with an effort to take health insurance away   Senator Angus King  a Maine independent who caucuses with Democrats  told CNN   Trump and congressional Republicans will find common ground on taxes  Trump generally sees eye to eye with Republicans in Congress in calling for major tax cuts  including those for the wealthy  although details of their plans are not an exact match  Trump has called for cutting the U S  corporate income tax rate to 15 percent from the current level of 35 percent  Ryan s tax plan proposes going to 20 percent  Trump and Ryan both back reducing the current number of tax brackets to three from seven  Trump supports lowering the top individual income tax rate to 25 percent from 39 6 percent  while Ryan wants it to go to 33 percent   Congressional Republicans likely would welcome a move by Trump to rescind some of Obama s executive actions on immigration  labor rights  the environment and global warming  Virginia Republican Representative Dave Brat said one thing he expected Trump to do early as president would be  taking a pen to all of Obama s executive overreach      That s a quick  easy fix to get the regulatory burden down   
Trump has also said he wants to do some things as president  such as ban Muslims from the country and allow torture in the fight against terrorism  that some experts say are legally questionable ",2016-11-09,Reuters,"https://www.investing.com/news/politics-news/trump,-congress-will-be-in-sync-on-some-issues,-but-long-term-questions-loom-439037",439037
147576,369092,CI,New Strong Buy Stocks For November 2nd,opinion,"Here are 5 stocks added to the Zacks Rank  1  Strong Buy  List for Friday 
Aerojet Rocketdyne Holdings  Inc   AJRD   This company that develops  manufactures  and sells aerospace and defense products and systems has witnessed the Zacks Consensus Estimate for its current year earnings increasing 42 3  over the last 60 days Aerojet Rocketdyne Holdings  Inc  Price and Consensus
    CACI International Inc  CACI   This provider of information solutions and services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 6  over the last 60 days CACI International  Inc  Price and Consensus
    Signet Jewelers Limited  SIG   This company that engages in the retail sale of diamond jewelry  watches  and other products has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1 2  over the last 60 days Signet Jewelers Limited Price and Consensus
    WellCare Health Plans  Inc   WCG   This company that provides managed care services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 7  over the last 60 days WellCare Health Plans  Inc  Price and Consensus
    Cigna Corporation  NYSE CI   CI   This health services organization has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 6  over the last 60 days Cigna Corporation Price and Consensus
    You can see  Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/new-strong-buy-stocks-for-november-2nd-200354160,200354160
147578,369094,CI,Here s Why Momentum Investors Will Love Cigna  CI ,opinion,"Momentum investing is all about the idea of following a stock s recent trend  which can be in either direction  In the  long  context  investors will essentially be  buying high  but hoping to sell even higher   And for investors following this methodology  taking advantage of trends in a stock s price is key  once a stock establishes a course  it is more than likely to continue moving in that direction  The goal is that once a stock heads down a fixed path  it will lead to timely and profitable trades 
While many investors like to look for momentum in stocks  this can be very tough to define  There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance  The Zacks Momentum Style Score  part of the Zacks Style Scores  helps address this issue for us 
Below  we take a look at Cigna  CI   which currently has a Momentum Style Score of A  We also discuss some of the main drivers of the Momentum Style Score  like price change and earnings estimate revisions 
It s also important to note that Style Scores work as a complement to the Zacks Rank  our stock rating system that has an impressive track record of outperformance  Cigna currently has a Zacks Rank of  1  Strong Buy   Our research shows that stocks rated Zacks Rank  1  Strong Buy  and  2  Buy  and Style Scores of A or B outperform the market over the following one month period 
You can see the current list of Zacks  1 Rank Stocks here    
Set to Beat the Market 
Let s discuss some of the components of the Momentum Style Score for CI that show why this health insurer shows promise as a solid momentum pick 
Looking at a stock s short term price activity is a great way to gauge if it has momentum  since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment  It is also useful to compare a security to its industry  as this can help investors pinpoint the top companies in a particular area 
For CI  shares are up 2 12  over the past week while the Zacks Insurance   Multi line industry is up 1 14  over the same time period  Shares are looking quite well from a longer time frame too  as the monthly price change of 6 62  compares favorably with the industry s 0 45  performance as well 
While any stock can see a spike in price  it takes a real winner to consistently outperform the market  Over the past quarter  shares of Cigna have risen 15 72   and are up 10 02  in the last year  On the other hand  the S P 500 has only moved  3 26  and 7 61   respectively 
Investors should also pay attention to CI s average 20 day trading volume  Volume is a useful item in many ways  and the 20 day average establishes a good price to volume baseline  a rising stock with above average volume is generally a bullish sign  whereas a declining stock on above average volume is typically bearish  CI is currently averaging 2 413 399 shares for the last 20 days 
Earnings Outlook
The Zacks Momentum Style Score also takes into account trends in estimate revisions  in addition to price changes  Please note that estimate revision trends remain at the core of Zacks Rank as well  A nice path here can help show promise  and we have recently been seeing that with CI 
Over the past two months  9 earnings estimates moved higher compared to none lower for the full year  These revisions helped boost CI s consensus estimate  increasing from  13 87 to  14 23 in the past 60 days  Looking at the next fiscal year  8 estimates have moved upwards while there have been no downward revisions in the same time period 
Bottom Line
Taking into account all of these elements  it should come as no surprise that CI is a  1  Strong Buy  stock with a Momentum Score of A  If you ve been searching for a fresh pick that s set to rise in the near term  make sure to keep Cigna on your short list ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-momentum-investors-will-love-cigna-ci-200358803,200358803
147580,369096,CI,Marsh   McLennan  MMC  To Launch Specialty Business ,opinion,Marsh   McLennan Companies  Inc  s   NYSE MMC   unit Marsh recently announced the launch of a new specialty business within Marsh called Marsh JLT Specialty  This will be a combination of the specialty teams of Marsh and Jardine Lloyd Thompson Group plc  JLT   The new segment would be effective upon the closure of Jardine Lloyd Thompson Group s buyout  The deal  subject to closing conditions  is expected to be completed during the spring of 2019  Marsh   McLennan would fund this transaction through cash in hand as well as proceeds from debt financing With this new specialty  the combined firm will be able to cater to clients  who require specialized products as well as services  Dominic Burke  the current CEO of JLT Group  will also become the Chairman of Marsh JLT Specialty  While Lucy Clarke  CEO of JLT Specialty  will become the President of this Specialty Currently operating across 40 countries  JLT provides risk and insurance broking advice to energy  mining  healthcare  construction  marine and aerospace sectors as well as in financial lines  political risk and trade credit  The to be acquired company s impressive profile boasting constant organic growth and geographic diversification will surely be able to fortify Marsh   McLennan s portfolio  The acquirer expects to create a convincing value proposition to clients and shareholders with this consolidation The purchase is further likely to strengthen the company s initiative to emerge as a distinguished global firm in areas of risk  people and strategies  Annual cost synergies of around  250 million are expected to be realized from this transaction over the next three years  This apart  the deal is estimated to be immediately accretive to the acquiring company s adjusted cash EPS and also produce a double digit internal rate of return The company s efforts to expand in higher growth and higher margin sectors have been strongly evident from its string of earlier acquisitions as well In August 2018  the company announced that it will acquire the investment consulting  alternatives consulting and wealth management operations of Pavilion Financial Corporation to complement its current investment consulting  alternatives and wealth management offerings  Moreover  the parent company s unit Mercer has also signed an agreement to purchase Summit Strategies Group for brace its growth profile and enhancing the service portfolio Shares of this Zacks Rank  3  Hold  company have gained 4   underperforming its  s growth of 8 3  Stocks to ConsiderInvestors interested in the insurance sector might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average beat being 7 13   You can see  eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with an average three quarter positive surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  It is a Zacks  1 Ranked stock and pulled off an average four quarter beat of 13 46  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-13,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennan-mmc-to-launch-specialty-business-200359200,200359200
147581,369097,CI,Marsh   McLennan s Arm Sets Up Digital Broker Platform,opinion,Marsh   McLennan Companies  Inc  s   NYSE MMC   unit Marsh recently announced the launch of Bluestream  a cloud based digital broker platform targeting the affinity market  With this introduction  Marsh s affinity clients would be able to provide customers with insurance products and services through a new and streamlined method The new digital platform seamlessly integrates the current digital channels with the user experience of clients  Moreover  the same will be open to and connect with the global insurance marketplace with the help of application program interfaces  APIs   Clients would enjoy freedom to choose and scale the insurance program that matches requirements of customers  contractors or employees in every area and also maintain a consistent global experience  It is a configurable and secure platform where clients can pick one or more insurance providers to quote  bind and issue policies Moreover  clients would be provided with state of the art reporting and analytics on insurance programs and get an easy access to evolving technology services like blockchain and machine learning through AI  Artificial Intelligence   Currently  Marsh is accepting beta clients for this latest technology and is also looking forward to scaling the same to a wider client base next year The platform is more useful for global clients in digitally progressive sectors and digital native organizations Marsh   McLennan s subsidiary is constantly making concerted efforts to enrich its customers  experience  This is one of their initiatives wherein a cutting edge technology is adopted to offer customers a better experience and help expand their businesses as well The unit has also announced its plan to launch Marsh JLT Specialty  subject to the closing of the Jardine Lloyd Thompson Group plc acquisition Shares of this Zacks Rank  3  Hold  company have rallied 6   underperforming its  s growth of 9 2  Stocks to ConsiderInvestors interested in the insurance sector might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average beat being 7 13   You can see  eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with the average three quarter positive surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  The stock sports a Zacks Rank  1  Strong Buy  and pulled off the average four quarter earnings surprise of 13 46  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-15,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennans-arm-sets-up-digital-broker-platform-200360056,200360056
147582,369098,CI,Marsh   McLennan Unit Buyout To Offer Better Client Services,opinion,Marsh   McLennan Companies  Inc  s   NYSE MMC   unit Mercer recently announced the completion of its purchase of Summit Strategies Group  Summit  on Nov 15  2018  However  terms of the transaction are unknown With the consolidation of Summit s enriched client service experience and Mercer s top notch investment capabilities  customers would be highly benefited from this deal  They would continue working with their current consulting team and also access Mercer s resources Apart from its contract to acquire Summit  the unit announced owning certain operations of Pavilion Financial Corporation on Aug 13  2018  The latter buyout is expected to close in the fourth quarter of 2018 Strategic acquisitions have always been one of the core growth strategies at Marsh and McLennan  In the past  the parent company made numerous purchases to boost its portfolio  enter new geographies  expand within the existing businesses and foray into new ones  In recent months  the company bought Klein Agency and Insurance Associates  which helped fortifying its footprint in greater Washington DC region and enhance its construction capabilities  The company also completed a buyout in Scotland  adding to its revenue base  Of late  it acquired Houston based Wortham Insurance along with Eustis Insurance   Benefits  a leading independent insurance agency in Louisiana  Integration of Jardine Lloyd Thompson Group is also due and with its culmination  the company s subsidiary Marsh would launch a specialty business Shares of this Zacks Rank  3  Hold  company have gained 4 4  in a year s time  underperforming its  s growth of 8 2  Stocks to ConsiderInvestors interested in the insurance sector might consider a few better ranked stocks like Willis Towers Watson Public Limited Company   NASDAQ WLTW    eHealth  Inc    NASDAQ EHTH   and Cigna Corporation   NYSE CI   Willis Towers works as an advisory  broking and solutions company worldwide  The company carries a Zacks Rank  2  Buy  and managed to deliver positive results in the trailing four reported quarters  the average beat being 7 13   You can see  eHealth offers private online health insurance exchange services in the United States and China  It holds a Zacks Rank of 2 and came up with average three quarter positive surprise of 7 29  Cigna provides insurance and related products and services in the United States and internationally  The stock sports a Zacks Rank  1  Strong Buy  and pulled off average four quarter earnings surprise of 13 46  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/marsh--mclennan-unit-buyout-to-offer-better-client-services-200361436,200361436
147598,369114,CI,Want To Tap Merger Mania  Play Top Ranked Health Care ETFs,opinion,"When it comes to merger  the Healthcare sector steals the show  The U S  healthcare supply chain is consolidating fast  with  ranging from insurers  pharmacies to drug distributors  The last four years were pretty solid for global healthcare mergers 
According to an analysis by Kaufman Hall   were merged through the third quarter of 2017  against 102 overall in 2016  Among these  eight transactions comprised hospitals with  1 billion or more in revenues  double the big ticket mergers in 2016 
Hospitals and health systems announced 561 transactions consisting about 1 260 hospitals   according to the American Hospital Association  Health insurers are also striving to cut deals in this field 
Some noted deals planned in  include UnitedHealth Group Inc  s   NYSE UNH    the biggest U S  health insurer   4 9 billion deal to acquire DaVita Medical Group and CVS Health Corp  s   NYSE CVS   acquisition plans for Aetna Inc    NYSE AET    one of the top U S  health insurers   for about  67 5 billion in cash and stock  CVS s acquisition of Aetna is expected to close in 2H 2018  Cigna  NYSE CI  also  acquisition of Express Scripts 
What Promotes HealthCare Industry Merger  
A surge in interest has been noticed for vertical mergers  This would help companies to  by consolidating supply chains and enjoy scale advantage  per State Street  read    
Investors should note that the healthcare sector s debt to equity levels are 30  lower than the broader S P 500  The sector is estimated to see return on equity more than double to 27 2  by the end of 2019 against the 19 72  expected growth in the broad market  The factors made the sector more attractive to companies that are eyeing inorganic expansion 
Other Tailwinds 
So  investors can definitely play the merger mania in this field  Apart from this  there are some specific factors that can favor the sector in the near term 
President Trump s announcement of the drug plans in May  which were in the best interest of pharma companies  may benefit the space  The drug plans will likely put pressure on U S  trading partners  forcing them to pay more for medicines 
Also  on May 30  the President signed the  Right To Try  bill into law  This law will help patients suffering from terminal diseases  and use drugs that are not yet approved by the FDA  Needless to say  the law brought good news for biotech companies  read    
Healthcare ETFs in Focus
Given the above fundamentals  investors can tap a few top ranked healthcare ETFs 
Health Care Select Sector SPDR ETF  NYSE XLV     Up 2 6  in the last one month
iShares US Healthcare ETF    Up 2 9 
Vanguard Health Care ETF   AX VHT     Up 3 3 
Invesco S P 500 Equal Weighted Health Care ETF   Up 3 3 
JHancock Multifactor Health Care ETF   Up 3 4 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-06-27,Zacks Investment Research,https://www.investing.com/analysis/want-to-tap-merger-mania-play-topranked-health-care-etfs-200328137,200328137
147600,369116,CI,5 Trade Ideas For Monday  Cboe  Cigna  General Mills  Norfolk Southern   Rapid7,opinion,"Cboe  Ticker   CBOE
Cboe   CBOE  started moving lower in January with the market  Fast move at first and then an bounce followed by a steady 5 month decline  That made a bottom in August  It has been rising since then and is now near the point of making a higher high  The RSI is rising and bullish with a MACD that is rising and positive  Look for that higher high to participate   
Cigna  Ticker   CI
Cigna   CI  gapped down below its 200 day SMA in March and then had a slow 5 month consolidation  It started back higher in July and gathered pace as August started  As it crossed the 200 day SMA it stalled and it has consolidated ever since  The RSI is rising in the bullish zone with the MACD flattening and positive after a pullback  Look for a push over resistance to participate   
General Mills  Ticker   GIS
General Mills   GIS  started lower with the market in January and continued with a couple of gaps to a low in May  Since then it has drifted slightly higher  but has yet to fill the first gap  The RSI is now bullish and rising with the MACD crossing up and positive as the price consolidated under resistance  Look for a push over it to participate higher   
Norfolk Southern  Ticker   NSC
Norfolk Southern   NSC  started higher off of a low in April  It paused through May and June and then made a second leg higher  That met resistance in mid August and it has consolidated since  Friday saw a strong push higher to resistance  The RSI is rising in the bullish zone and the MACD is turning back up  Look for a push over resistance to participate higher   
Rapid7  Ticker   RPD
Rapid7   RPD  was a Top 10 idea a month ago  and went on to a failed break out  Since then it broke out again and held  continuing higher to the present consolidation  It has a RSI that is rising and bullish with the MACD turning back up  Look for a new high to participate   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which after closing the books on summer vacations with the short week  saw some profit taking in the equity markets  but they all remained with strong long term charts 
Elsewhere look for Gold to possibly pause in its downtrend while Crude Oil slowly drifts higher long term  The US Dollar Index is marking time sideways while US Treasuries are biased to continue lower  The Shanghai Composite and Emerging Markets did nothing to change their downside trends 
Volatility has crept higher and set up to slowly continue  keeping pressure on equity markets  The equity index ETF s SPY  IWM and QQQ  all reacted with moves lower on the week  The QQQ was the hardest hit and then the small caps with the SPY down less than 1   Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-09-10,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-cboe-cigna-general-mills-norfolk-southern--rapid7-200343008,200343008
147601,369117,CI,Why Cigna  CI  Might Surprise This Earnings Season,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Cigna Corporation   NYSE CI   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Cigna is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for CI in this report In fact  the Most Accurate Estimate for the current quarter is currently at  3 46 per share for CI  compared to a broader Zacks Consensus Estimate of  3 45 per share  This suggests that analysts have very recently bumped up their estimates for CI  giving the stock a Zacks Earnings ESP of  0 37  heading into earnings season Cigna Corporation Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that CI has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Cigna  and that a beat might be in the cards for the upcoming report 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/why-cigna-ci-might-surprise-this-earnings-season-200352325,200352325
147602,369118,CI,Cigna  CI  Q3 Earnings   Revenues Beat  Guidance Up,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings per share of  3 84 in third quarter 2018  beating the Zacks Consensus Estimate by 11 3   The same was up 36  year over year  Strong performance across the company s Global Health Care  Global Supplemental Benefits and Group Disability and Life businesses aided earnings Cigna posted revenues of  11 44 billion  surpassing the Zacks Consensus Estimate by 2   Revenues grew 9  year over year led by strong business growth in Cigna s Global Healthcare and Global Supplemental Benefits segments Premiums were up 11  year over year to  9 billion  while fees increased 8 5  to  1 35 billion The company s medical enrollment grew by 34 000 lives to 16 27 million customers driven by growth in Select  Individual and Middle Market segments Cigna Corporation Price  Consensus and EPS Surprise   Strong Segment PerformanceGlobal Health Care  Operating revenues of  9 11 billion were up 11 5  year over year driven by Commercial customer growth and expansion of specialty relationships  as well as premium increases consistent with the underlying cost trends Adjusted operating earnings were  804 million  up 40  year over year was due to medical and specialty business growth  strong medical cost performance  a lower tax rate and favorable prior year reserve development Global Supplemental Benefits  Operating revenues of  1 09 billion were up 11  year over year  reflecting continued business growth in the company s targeted markets Adjusted operating income decreased 14 7  year over year to  93 million  reflecting business growth and gains from expense management  which was more than offset by unfavorable claims experience Global Disability and Life  Operating revenues of  1 12 billion were up 2  year over year from solid disability performance and favorable life results Adjusted operating income increased 37  year over year to  100 million 2018 Guidance RaisedFor 2018  the company expects to earn in the range of  14 20 and  14 40 on a per share basis   up 50 to 60 cents from the previous outlook range  Total revenue growth is expected to grow in the range of approximately 8 5  compared with the previous growth range of 8  and medical customers are projected to grow by 0 4 million to 0 5 million lives   unchanged from the previous forecast  During the quarter  the U S  Department of Justice has cleared Cigna s  52 billion acquisition of Express Scripts  NASDAQ ESRX   The deal is expected to close by the end of the year 2018 Zacks Rank and Other ReleasesCigna carries a Zacks Rank  3  Hold  
You can see  Among the other health insurers that have reported third quarter earnings so far  the bottom line of Anthem  Inc    NYSE ANTM    Centene Corporation   NYSE CNC   and UnitedHealth Group Incorporated   NYSE UNH   beat the respective Zacks Consensus Estimate 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q3-earnings--revenues-beat-guidance-up-200353024,200353024
147603,369119,CI,Cigna  CI  Q3 Earnings And Revenues Top Estimates,opinion,"Cigna  CI  came out with quarterly earnings of  3 84 per share  beating the Zacks Consensus Estimate of  3 45 per share  This compares to earnings of  2 83 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 11 30   A quarter ago  it was expected that this health insurer would post earnings of  3 33 per share when it actually produced earnings of  3 89  delivering a surprise of 16 82  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Cigna  which belongs to the Zacks Insurance   Multi line industry  posted revenues of  11 45 billion for the quarter ended September 2018  surpassing the Zacks Consensus Estimate by 2 02   This compares to year ago revenues of  10 27 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Cigna shares have added about 5 3  since the beginning of the year versus the S P 500 s gain of 1 4  
What s Next for Cigna 
While Cigna has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Cigna was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 40 on  11 31 billion in revenues for the coming quarter and  13 87 on  45 38 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Insurance   Multi line is currently in the bottom 41  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-q3-earnings-and-revenues-top-estimates-200353072,200353072
147608,369124,CI,Is Cigna  CI  Stock Outpacing Its Finance Peers This Year ,opinion,"Investors focused on the Finance space have likely heard of Cigna  CI   but is the stock performing well in comparison to the rest of its sector peers  A quick glance at the company s year to date performance in comparison to the rest of the Finance sector should help us answer this question 
Cigna is a member of our Finance group  which includes 853 different companies and currently sits at  9 in the Zacks Sector Rank  The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  CI is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past three months  the Zacks Consensus Estimate for CI s full year earnings has moved 2 33  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Our latest available data shows that CI has returned about 6 49  since the start of the calendar year  In comparison  Finance companies have returned an average of  5 81   This means that Cigna is performing better than its sector in terms of year to date returns 
To break things down more  CI belongs to the Insurance   Multi line industry  a group that includes 26 individual companies and currently sits at  98 in the Zacks Industry Rank  Stocks in this group have lost about 11 86  so far this year  so CI is performing better this group in terms of year to date returns 
Going forward  investors interested in Finance stocks should continue to pay close attention to CI as it looks to continue its solid performance ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/is-cigna-ci-stock-outpacing-its-finance-peers-this-year-200353958,200353958
147616,369132,CI,Anthem  Cigna merger squabbles could delay antitrust approval  WSJ,news,"WASHINGTON  Reuters    Quarrels have broken out behind the scenes of Anthem Inc s  N ANTM  proposed acquisition of  Cigna Corp   N CI   as the health insurers seek regulatory approval for their landmark deal  the Wall Street Journal reported on Sunday  The newspaper said the squabbles could delay or derail antitrust approvals  though the deal does not appear to be in danger of imminent collapse  Sources familiar with the matter confirmed the citations in the Journal story   An Anthem spokeswoman declined to comment on the Journal report  Cigna officials were not immediately available to comment   In a series of letters between top officials including their chief executives  the Journal said Anthem and Cigna accuse each other of violating the July merger agreement and fumbling submissions to regulators  A key point of contention is Anthem s lawsuit against Express Scripts Holding Co  O ESRX   a middleman for prescription drugs  according to the newspaper  The suit accuses Express Scripts of overcharging Anthem for drugs  Cigna Chairman Isaiah Harris Jr   in an April 9 letter to Anthem s board  said the suit could hurt the prospects for regulatory approval and the combined company s value  the Journal said  Anthem responded to Cigna s board that it had alerted Cigna to the possibility of a lawsuit early in their merger talks  and that getting better prices from Express Scripts could only be beneficial  the newspaper reported  Disclosure statements from the two companies earlier this month hinted that they had different views about when the deal would close   In a filing with the Securities and Exchange Commission Cigna said that the deal may close in 2017  rather than in 2016 due to the complexity of the regulatory process  
Anthem  meanwhile  said it had not changed its expectations on timing ",2016-05-22,Reuters,"https://www.investing.com/news/stock-market-news/anthem,-cigna-merger-squabbles-could-delay-antitrust-approval:-wsj-403652",403652
147624,369140,CI,Why Is Cigna  CI  Down 2  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Cigna Corporation   NYSE CI    Shares have lost about 2  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is CI due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Cigna Q1 Earnings Top on Higher Enrollment  2018 View UpCigna came up with adjusted earnings per share of  4 11 in first quarter 2018  beating the Zacks Consensus Estimate of  3 37  Also  earnings grew 48  year over year  Better than expected earnings were primarily driven by revenue growth Cigna posted revenues of  11 4 billion  which surpassed the Zacks Consensus Estimate of  11 billion   Revenues grew 9  year over year  led by strong business growth in Cigna s Commercial Healthcare and GlobalSupplemental Benefits segments Premiums were up 10 4  year over year to  9 billion  while fees increased 8 4  to  1 35 billion The company s medical enrollment grew by 327 000 lives to 16 2 million customers driven by growth in Select  Individual and Middle Market segments Total benefits and expenses of  10 16 billion increased 6  year over year  led by higher global health care medical cost and operating expenses Global Health Care  Operating revenues of  9 09 billion were up 9 7  year over year  led by continued strong performance of the company s Commercial Employer business in its targeted markets Adjusted operating earnings were  871 million  up 42 8  year over year due to strong medical cost performance  a lower tax rate and favorable prior year reserve development Global Supplemental Benefits  Operating revenues of  1 10 billion were up 21  year over year  reflecting continued business growth and favorable foreign currency effect Adjusted operating income increased 51 4  year over year to  112 million  reflecting business growth and gains from expense management Global Disability and Life  Operating revenues of  1 12 billion were down 0 4  year over year as premium growth from disability and other was offset by lower premium in Life business Adjusted operating income declined 1 5  year over year to  67 million  due to an increase in life insurance claims Financial PositionCigna s cash and marketable investments were of  2 77 billion as of Mar 31  2018  down from  2 97 billion as of Dec 31  2017 Long term debt was  5 2 billion as of Mar 31  2018  almost unchanged from the Dec 31  2017 level 2018 Guidance RaisedFor 2018  the company expects to earn in the range of  12 85 to  13 25  up from the previous outlook range of  12 40 to  12 90  on a per share basis  Total revenue growth  kept unchanged  is expected to grow in the range of 7  to 8  and medical customers are projected to grow by 0 4 million to 0 5 million lives  from the previous estimate of 0 3 million to 0 5 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been five revisions higher for the current quarter compared to three lower Cigna Corporation Price and Consensus    VGM Scores
At this time  CI has a strong Growth Score of A and a grade with the same score on the momentum front  The stock was also allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is equally suitable for value  growth and momentum investors 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  It comes with little surprise CI has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-cigna-ci-down-2-since-its-last-earnings-report-200321792,200321792
147625,369141,CI,Anthem Boosts Integrated Care With Aspire Health Buyout,opinion,Anthem  Inc    NYSE ANTM   has completed the acquisition of Aspire Health  a non hospice  community based palliative care provider  The deal is aimed at providing unique and innovative medical care to the community outside hospitals The company anticipates the buyout to be neutral to current year earnings but accretive to the bottom line in 2019 Aspire Health provides services under contracts with above 20 health plans to patients across 25 U S  states  The company identifies patients suffering serious illnesses and helps them fight fatigue  shortness of breath  nausea  appetite loss and depression through supreme medical care Anthem already owns Blue Cross and Blue Shield plans in 14 states and purchasing Aspire Health would enable it to enhance its medical care business  providing better services along with other clinical care assets  namely CareMore Health and AIM Specialty Health  Through this transaction  Anthem plans to introduce advanced illness programs to deliver optimum patient satisfaction via home based care  reducing medical costs in the process Palliative care is fast gaining ground as the U S  healthcare system shifts to value based care from a volume based one  The consolidation should aid Anthem to dispense treatment affordable costs to patients with complex medical conditions  Thus this move might effectively lower overall medical costs  boosting margin expansion in the process The Aspire Health deal is projected to be a kind of vertical integration for Anthem and will craft it into a more wholesome and integrated healthcare service provider Vertical tie ups are anyways in vogue in the healthcare industry with two mega deals comprising Express Scripts Holding Company  NASDAQ ESRX  by Cigna Corp    NYSE CI   and Aetna Inc    NYSE AET   by CVS Health Corp    NYSE CVS   being already underway  Both these transactions are the combination of a health insurer with a pharmacy benefit manager Year to date  the stock has gained 8 5  compared with the  s rally of 13 8   Anthem carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-06-18,Zacks Investment Research,https://www.investing.com/analysis/anthem-boosts-integrated-care-with-aspire-health-buyout-200326166,200326166
147631,369147,CI,Health insurer Cigna reports better than expected third quarter profit,news," Reuters    Health insurer  Cigna Corp   N CI  reported a better than expected quarterly profit  helped by strong performance in its government and commercial businesses 
Revenue at Cigna s unit that sells commercial and government plans rose 8 percent to  6 62 billion  Membership in government plans  in particular  increased 8 5 percent 
Cigna manages insurance plans for large companies and sells health plans to individuals on government exchanges created under the U S  Affordable Care Act  It also manages government Medicare and Medicaid plans 
Net income attributable to the company s shareholders rose to  547 million  or  2 10 per share  in the third quarter ended Sept  30  from  534 million  or  2 01 per share  a year earlier 
On an adjusted basis  Cigna earned  2 28 per share  well above the average analyst estimate of  2 20 according to Thomson Reuters I B E S 

Revenue rose 7 2 percent to  9 39 billion  missing the average analyst estimate of  9 52 billion ",2015-11-06,Reuters,https://www.investing.com/news/stock-market-news/health-insurer-cigna-reports-better-than-expected-third-quarter-profit-370051,370051
147636,369152,CI,Anthem targets  3 billion in drug cost savings with Express Scripts,news,"By Susan Kelly and Caroline Humer  Reuters    Anthem Inc could save  3 billion annually on drug costs from a re pricing provision in its current contract with pharmacy benefits manager Express Scripts Holding Co  the health insurer s chief executive officer said Tuesday  Anthem said it is working to renegotiate the contract this year to avoid overpaying for pharmaceuticals based on current market conditions  It first announced that it was going to rework the contract about two years ago  but it has not previously disclosed an estimate on the cost savings from the move   Anthem s 10 year contract with Express Scripts runs through 2019 but includes the re pricing clause that became effective Jan  1  Joseph Swedish  chief executive of the insurer  said in remarks at the J P  Morgan Healthcare Conference in San Francisco    This represents a substantial adjustment to drive lower care costs for our customers and improve our competitive position in the marketplace   Swedish said  Express Scripts spokesman Brian Henry said the company is in full compliance with the terms of its agreement with Anthem  The contract calls for negotiations regarding a pricing review  but Anthem is not entitled to  3 billion  Henry said in an email to Reuters  Anthem conducted a market analysis to identify the potential savings  which would come primarily from lower generic drug pricing  Swedish said   We have seen a substantial improvement in market pricing in just the last 12 months   he said   Swedish said in an interview with Reuters at the San Francisco conference this week that the company is still undecided about when and if it will sign a new contract with Express Scripts that would go into effect when the current one expires  Negotiations have picked up pace  he said  and he is hopeful about making a decision in 2016 about how to proceed  Express Scripts values its relationship with Anthem and remains committed to productive discussions regarding its relationship with the insurer  Express Scripts spokesman Henry said  
Anthem  which manages Blue Cross Blue Shield plans in 14 states  is the country s second largest health insurer  It could become the nation s largest if its proposal to buy  Cigna Corp   N CI  is approved by antitrust regulators ",2016-01-13,Reuters,https://www.investing.com/news/stock-market-news/anthem-targets-$3-billion-in-drug-cost-savings-with-express-scripts-379829,379829
147646,369162,CI,Cigna Q1 Earnings Top On Higher Enrollment  2018 View Up,opinion,Cigna Corp    NYSE CI   came up with adjusted earnings per share of  4 11 in first quarter 2018  beating the Zacks Consensus Estimate of  3 37  Also  earnings grew 48  year over year  Better than expected earnings were primarily driven by revenue growth Cigna posted revenues of  11 4 billion  which surpassed the Zacks Consensus Estimate of  11 billion   Revenues grew 9  year over year  led by strong business growth in Cigna s Commercial Healthcare and Global Supplemental Benefits segments Premiums were up 10 4  year over year to  9 billion  while fees increased 8 4  to  1 35 billion The company s medical enrollment grew by 327 000 lives to 16 2 million customers driven by growth in Select  Individual and Middle Market segments Total benefits and expenses of  10 16 billion increased 6  year over year  led by higher global health care medical cost and operating expenses Strong Segment PerformanceGlobal Health Care  Operating revenues of  9 09 billion were up 9 7  year over year led by continued strong performance of the company s Commercial Employer business in its targeted markets Adjusted operating earnings were  871 million  up 42 8  year over year due to strong medical cost performance  a lower tax rate and favorable prior year reserve development Global Supplemental Benefits  Operating revenues of  1 10 billion were up 21  year over year  reflecting continued business growth and favorable foreign currency effect Adjusted operating income increased 51 4  year over year to  112 million  reflecting business growth and gains from expense management Global Disability and Life  Operating revenues of  1 12 billion were down 0 4  year over year as premium growth from disability and other was offset by lower premium in Life business Adjusted operating income declined 1 5  year over year to  67 million  due to an increase in life insurance claims Financial PositionCigna s cash and marketable investments were of  2 77 billion as of Mar 31  2018  down from  2 97 billion as of Dec 31  2017 Long term debt was  5 2 billion as of Mar 31  2018  almost unchanged from the Dec 31  2017 level 2018 Guidance RaisedFor 2018  the company expects to earn in the range of  12 85 and  13 25  up from the previous outlook range of  12 40 and  12 90  on a per share basis  Total revenue growth  kept unchanged  is expected to grow in the range of 7  to 8  and medical customers are projected to grow by 0 4 million to 0 5 million lives  from the previous estimate of 0 3 million to 0 5 million Our TakeCigna s results reflect its strong market positioning in a competitive market  The company is on track to buy Express Scripts  which should raise its rank in the health insurance industry and equip it better to face stiff competition  Synergies from the acquisition should buoy the company s long term growth potential  Its robust Global Supplemental business  growing Government business and increasing membership  and strong capital position are the other positives  A strong outlook for 2018 reflects its business strength Zacks Rank and Other ReleasesCigna carries a Zacks Rank  3  Hold  You can see  Other health insurers UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Aetna Inc    NYSE AET   beat estimates in the first quarter by 4 11   12  and 7 4   respectively 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/cigna-q1-earnings-top-on-higher-enrollment-2018-view-up-200312307,200312307
147647,369163,CI,Health Insurance Industry Outlook   May 2018,opinion,"Strong operating performance of health insurers for the past many years continued in the first quarter of 2018  Higher medical enrollment  surging revenues  medical cost management and an increasing share of revenues from complementary services helped results  Most of the major players raised their earnings guidance for 2018  reflecting solid operating environment down the road  
Moreover  a strong U S  economy has held the health insurance industry in good stead  A record low unemployment rate and gradual wage increase bode well for the space  High employment and wage growth fuel demand for health insurance and various other health related services provided by these insurers  
The overall bullishness reinforces our sentiment that the growth cadence for the sector should continue  Despite being tied by a strict regulatory regime and a fast changing industry backdrop  insurers have time and again emerged as winners  
To put it into perspective  revenues and earnings of almost all dominant health insurers have shown a secular rise since 2010  when a sweeping and historical health care reform was put into effect by ex president Obama Ever since the enactment of the healthcare reform act  numerous changes have gone into effect  which have altered the traditional operating model of the health insurers  The ensuing changes were taken sportingly by health insurers  which then adapted themselves to the changed industry dynamics  
A shift in business mix from commercial to government  the way care is delivered from fee for service to value for care  greater emphasis on medical cost management  growing consumerism and technical innovations have been the game changers  
Rapid evolution is  however  continuing in the industry  Given the need of the hour  players in the industry are taking concerted efforts to transform themselves into comprehensive health care providers from their earlier role of being traditional payers  The same is being effectuated by a cross sector collaboration wherein health insurers are foraying into another realm of the health care sector such as pharmacy benefit management  ambulatory care and physician services  
Some of the deals that are underway in this vein are the merger of CVS Health Corp  NYSE CVS    CVS  with Aetna Inc  NYSE AET    AET  and Cigna Corp   CI  take over od Express Script Holding Co   ESRX  as well as the UnitedHealth Group Inc   UNH  acquisition of DaVita Inc   DVA   
All said  the industry has remained an outperformer having generated returns higher than the S P 500 index in each year since 2012  In the past five years  the health insurance industry has returned a whopping 257  compared with the S P 500 index s gain of 91   
Is Further Upside Potential Left  
While the industry has outperformed the broader market  valuations remain at the same level as that of the industry The Zacks HMO industry is currently trading at a forward 12 month price to earnings ratio of 16 95 which is near 17 for the S P 500 index as a whole  Over the last five years  the industry has traded in a range of 10 6 to 20 1  with a median of 15 3  
We therefore go a bit further and look at the PEG ratio which bakes in the growth rate of the industry  The industry s PEG ratio is 1 3  which compares favorably with the industry s PEG ratio of 1 8  This shows that the industry is undervalued and has room for upside  
Zacks Industry Rank 
Within the Zacks Industry classification  health insurers are broadly grouped in the Medical sector  one of the 16 Zacks sectors   
We rank 256 industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  
We club our industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank   Over the last 10 years  using a one week rebalance  the top half beat the bottom half by a factor of more than 2 to 1   To learn more visit     
Stocks Worth Adding 
Though past performance does not guarantee future returns  strong industry fundamentals keep our confidence undeterred  Therefore investing in stocks from the health insurance industry is a good investment decision The following stocks with solid fundamental and a favorable Zacks Rank make them perfect picks 
WellCare Health Plans  Inc   WCG   This Zacks Rank  1  Strong Buy  stock has seen the Zacks Consensus Estimate for current year earnings being revised 3 3  upward over the last 30 days  
Anthem  Inc   ANTM   This Zacks Rank  2  Buy   stock has seen the Zacks Consensus Estimate for current year earnings being revised 1 7  upward over the last 30 days 
Triple S Management Corp   GTS   This Zacks Rank  2 stock has seen the Zacks Consensus Estimate for current year earnings being revised21 7  upward over the last 30 days 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-05-17,Zacks Investment Research,https://www.investing.com/analysis/health-insurance-industry-outlook--may-2018-200317156,200317156
147649,369165,CI,Anthem To Buy Aspire Health For Better Healthcare Service,opinion,Anthem  Inc    NYSE ANTM   has announced that it will acquire Aspire Health  a non hospice  community based palliative care provider  The agreement is aimed at providing unique and innovative medical care in the community outside hospitals  Financial terms of the transaction have not yet been disclosed  The acquisition  pending standard closing conditions and customary approvals  is expected to wrap up in the third quarter of 2018 The company anticipates the buyout to be neutral to 2018 s earnings but accretive to 2019 s bottom line Buyout BenefitsFounded in 2013  Aspire provides services under contracts with above 20 health plans to patients across 25 states  The company identifies patients suffering serious illnesses and helps them fight fatigue  shortness of breath  nausea  appetite loss and depression through supreme medical care Anthem already owns Blue Cross and Blue Shield plans in 14 states and purchasing Aspire would help it enhance its medical care business and provide better services along with its other clinical care assets such as CareMore Health and AIM  Through this transaction  Anthem plans to introduce advanced illness programs to provide optimum patient satisfaction through home based care and reduce medical costs in the process Other recent acquisitions made by this Zacks Rank  2  Buy  HMO are America s 1st Choice  Health Sun  which expanded the company s reach in the highly coveted Medicare market The health insurance industry is witnessing increased consolidation with a host of changes like rise in health care cost  shift to value based care  heightened regulations  need for managing steep health care costs and augmented consumerism  In the same vein  two major integrations underway are Express Scripts Holding Company  NASDAQ ESRX  by Cigna Corp    NYSE CI   and that of Aetna Inc    NYSE AET   by CVS Health Corp    NYSE CVS   Share Price PerformanceIn the past year  the stock has rallied 27 86   underperforming the  s growth of 31 6   Nonetheless  effective capital deployment plan  growing membership strength and accretion from acquisitions are likely to help the shares bounce back Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-05-23,Zacks Investment Research,https://www.investing.com/analysis/anthem-to-buy-aspire-health-for-better-healthcare-service-200319176,200319176
147650,369166,CI,Cigna CEO says has begun talks with regulators about Anthem deal,news,"NEW YORK  Reuters     Cigna Corp   N CI  CEO David Cordani said on Thursday that the company has begun conversations with regulators  including state regulators and antitrust regulators  about its  47 billion agreement to be purchased by Anthem Inc   N ANTM   Speaking on CNBC  Cordani said that the company expects a 12 to 18 month regulatory review process  Antitrust experts have said that regulators are likely to ask the companies to sell some assets in regional areas where the two companies have high market share  
Concerns about antitrust review have led to some skepticism of the deal  Anthem s cash and stock offer is worth  183 40 but its shares closed on Wednesday at  145 41  about 26 percent below that level ",2015-07-30,Reuters,https://www.investing.com/news/stock-market-news/cigna-ceo-says-has-begun-talks-with-regulators-about-anthem-deal-353671,353671
147674,369190,CI,Healthy Q1 Earnings At UnitedHealth  ETFs To Watch,opinion,"The largest U S  health insurer UnitedHealth Group   NYSE UNH   reported robust first quarter 2018 results  The company breezed past the Zacks Consensus Estimate on both the top and the bottom lines as well as raised its full year outlook  sending its shares rallying  UNH gained 3 6  on Apr 17  after reporting earnings 
Earnings per share came in at  3 04  well above the Zacks Consensus Estimate of  2 92 and 28 3  higher than the year ago earnings  Revenues rose 13 3  year over year to  55 2 billion  edging past the Zacks Consensus Estimate of  54 9 billion 
For 2018  the company raised its outlook  UnitedHealth now projects adjusted earnings per share in the range of  11 70  11 95 compared with the previous forecast of  11 65  11 95  This suggests a solid outlook for the company s growth 
Further  the stock currently has a Zacks Rank  3  Hold  and a solid industry Rank in the   It has a VGM  Value  Growth  Momentum  score of B  underscoring its potential to outperform in the weeks ahead   
Given the strong fundamentals  investors should tap the opportunity with ETFs having the largest allocation to this health insurer giant  For them  we have presented four ETFs that could see potential upside in the days ahead  see  here  
iShares U S  Healthcare Providers ETF 
This ETF follows the Dow Jones U S  Select Healthcare Providers Index with exposure to companies that provide health insurance  diagnostics and specialized treatment  In total  the fund holds 46 securities in its basket and UNH occupies the top position with 14 2  share  The fund has amassed  488 0 million in its asset base  It charges 44 bps in annual fees and has a Zacks ETF Rank  1  Strong Buy with a Medium risk outlook  read    
Health Care Select Sector SPDR Fund 
The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  15 4 billion in its asset base  Expense ratio comes in at 0 13   In total  the fund holds 61 securities in its basket with UNH taking the second spot at 7 1  of the assets  Pharma accounts for 33  share from a sector look while healthcare equipment   supplies  and health care providers   services make up for a double digit exposure each  It has a Zacks ETF Rank  3 with a Medium risk outlook  read    
iShares U S  Healthcare ETF 
This fund offers exposure to 119 securities by tracking the Dow Jones U S  Health Care Index  Here again  UnitedHealth is the second firm accounting for 6 7  of total assets  In terms of industrial exposure  pharma takes the top spot at 31 9   followed by biotech  20 5    and healthcare equipment  20    The product has amassed nearly  2 billion in its asset base while charges 44 bps in annual fees  It has a Zacks ETF Rank  3 with a Medium risk outlook 
SPDR Dow Jones Industrial Average ETF   V DIA  
This fund follows the Dow Jones Industrial Average  providing exposure to 30 blue chip U S  stocks  UNH occupies the third position in the basket with 6 45  share  The ETF is well spread out across a number of sectors with industrials  information technology  financials  consumer discretionary and health care taking the top five spots with a double digit exposure each  DIA is one of the largest and most popular ETFs in the space with AUM of  21 4 billion  It charges 17 bps in annual fees from investors and has a Zacks ETF Rank  1  Strong Buy  
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-04-18,Zacks Investment Research,https://www.investing.com/analysis/healthy-q1-earnings-at-unitedhealth-etfs-to-watch-200306684,200306684
147675,369191,CI,Will Higher Premiums Drive XL Group s  XL  Q1 Earnings ,opinion,XL Group Ltd   NYSE XL   is slated to report first quarter 2018 results on May 2 after the market closes  In fourth quarter 2017  the company delivered a negative earnings surprise of 8 16  Let s see  how things are shaping up for this announcement Factors to be Considered This QuarterThe P C insurer is likely to witness premium growth in the to be reported quarter  fueled by higher premiums at both its Insurance and Reinsurance segments  Strong international exposure  expanded capabilities and diversified product offerings will likely fuel premiums  The consensus mark is pegged at  2 7 billion  translating into a 6 5  improvement from the year ago quarter XL Group is projected to report higher net investment income in the quarter to be reported  driven by improved interest rates as well as better than expected reinvestment rates and portfolio management activities Improved net investment income and premiums are expected to have supported the company s top line  In fact  the Zacks Consensus Estimate for the metric is pegged at  2 9 billion  representing a rise of 4 8  on a year over year basis The company is likely to have witnessed an increase in operating expenses this yet to be reported quarter  mainly due to higher net loss and loss expenses incurred as well as claims and policy benefits  This in turn might restrict the operating margin expansion as well  But the company assumes that a rise in expenses will be a fraction of business growth  thereby continuing to drive the operating expense leverage   As a property and casualty  P C  insurer  XL Group is highly exposed to unpredictable weather related events that result in substantial catastrophe loss  Therefore  the company might report cat loss in the soon to be reported quarter  which is anticipated to impact the insurer s results  Nonetheless  the corporate tax cut  which lowered the tax rate to 21  from 35   is expected to aid the companies  bottom line and drive margin expansion  The Zacks Consensus Estimate for earnings in the to be reported quarter is pegged at 95 cents per share  reflecting an increase of a whopping 90  from the prior year period XL Group Ltd  Price and EPS Surprise     What the Quantitative Model Says Our proven model does not conclusively show that XL Group is likely to beat on earnings this earning season  This is because a stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  XL Group has an Earnings ESP of  5 80   You can uncover the best stocks to buy or sell before they are reported with our    Zacks Rank  XL Group carries a Zacks Rank  4  Sell   which lowers the predictive power of ESP  We caution against the Sell rated stocks  4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions  Stocks to ConsiderSome stocks worth considering from the insurance industry with the right combination of elements to surpass estimates this time around are as follows American Financial Group  Inc    NYSE AFG   is set to report first quarter earnings on May 2  The stock has an Earnings ESP of  4 46  and a Zacks Rank  2  You can see      Cigna Corporation   NYSE CI   has an Earnings ESP of  0 62  and is a Zacks  3 Ranked player  The company is slated to release first quarter earnings on May 3 National General Holdings Corp    NASDAQ NGHC   has an Earnings ESP of  5 59  and is a Zacks  1 Ranked player  The company is slated to release first quarter earnings on May 7 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/will-higher-premiums-drive-xl-groups-xl-q1-earnings-200311093,200311093
147691,369207,CI,Profit From Record Q1 M A With These ETFs,opinion,Merger and acquisition activities across the globe picked up rapidly in the first quarter thanks to U S  tax reform and faster economic growth in Europe Per the preliminary Thomson Reuters data  global mergers and acquisitions had their strongest start ever totaling  in the first quarter of 2018  This is up 67  over the past year and marks the fourth quarter that has surpassed  1 trillion over the past three years  United States M A volumes climbed 67  while Europe volumes doubled  Meanwhile  Asia saw an 11  increase  However  the number of deals dropped 10  year over year to 10 338 According to a report by research firm Mergermarket  M A activity across the world has hit a 17 year high record in the first quarter with 3 774 deals globally  totaling   This was the strongest start to the year since 2001 and represents an 18  year over year increase in value The healthcare space has so far been at the forefront as Amazon s move into the pharmaceutical sphere has spurred the major pharmacy retailers to consolidate  With regard to this  U S  health insurer Cigna   NYSE CI   will acquire the largest pharmacy benefit manager Express Scripts Holding   NASDAQ ESRX   for  67 billion  The deal is expected to close by the end of this year  In another deal  the drug chain and a pharmacy giant CVS Health Corp   NYSE CVS   is also in a process of acquiring the nation s third largest health insurer Aetna   NYSE AET   for  69 billion  The deal is expected to close in the second half of the year  read    Another large agreement is German utility EON SE s  38 5 billion deal to acquire RWE AG s renewable energy business Innogy SE The boom in M A is likely to continue given an accelerating economy  still low interest rates  and tax reform  which allows companies to bring offshore cash back home  Potential cost savings through mergers are further fueling the urge to merge in the current ultra competitive environment How to Tap Investors could easily take advantage of this surge in deals by employing the merger arbitrage strategy in their portfolio  This strategy looks to tap the price differential  or spread  between the stock price of the target company after the public announcement of its proposed acquisition and the price offered by the acquirer to pay for the stock of the target company  This is especially true given that investors should go long on the target or the acquired company and short on the acquiring company  When the deal is completed  shares of the target company will increase to the full deal price  in some cases slightly below the deal price   giving investors a nice profit Below  we have highlighted three merger ETFs to ride out the surge from the increasing M A deals  Any of these could make compelling options for investors seeking to implement this low correlation strategy to their portfolio  IQ Merger Arbitrage ETF  This fund offers capital appreciation by investing in global companies for which there has been a public announcement of a takeover by an acquirer while at the same time provides short exposure to global equities as a partial equity market hedge  This is done by tracking the IQ Merger Arbitrage Index  The fund has 44 holdings in its basket with the largest allocation to Blue Buffalo Pet Products   NASDAQ BUFF   and Rockwell Collins   NYSE COL   on the long side  These two firms combined to make up for 17 5  share  The product has amassed  503 7 million in its asset base and trades in average volume of around 119 000 shares a day  It charges 77 bps in annual fees  The ETF has lost about 2 3  year to date  see     ProShares Merger ETF  This product provides exposure to a global merger arbitrage strategy  which seeks to capture the spread between the price at which the stock of a company  a target  trades after a proposed acquisition of such target is announced and the value  cash plus stock  that the acquiring company has proposed to pay for the stock of the target  a spread   This can be easily done by the S P Merger Arbitrage Index  The fund holds a well diversified portfolio of 33 stocks  Technology  industrials  healthcare and financials are the top three sectors  The ETF has been able to manage assets worth  4 4 million while it sees light volume of just 1 000 shares a day  Bottom Line While investors could capitalize on merger arbitrage by trading in a particular target company stock  the ETFs provide diversified exposure in the basket form with lower risk  Further  these could be excellent choices for investors in the rocky market due to their low correlation with the overall market  read     This is because companies in merger and acquisition deals generally move independently  ignoring all other issues that influence the movement of other stocks  As a result  investors could definitely focus on these products for relatively higher returns in any type of market Want key ETF info delivered straight to your inbox  Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/profit-from-record-q1-ma-with-these-etfs-200304473,200304473
147698,369214,CI,Express Scripts  ESRX  Soars  Stock Adds 8 6  In Session,opinion,Express Scripts Holding Company   NASDAQ ESRX   was a big mover last session  as the company saw its shares rise nearly 9  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  72 89 to  78 64 in the past one month time frame The stock gained after Cigna  NYSE CI  agreed to buy the company  including its debt  for  67 billion The company has seen two positive estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks  suggesting that more solid trading could be ahead for Express Scripts  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road Express Scripts currently has a Zacks Rank  2  Buy  while its  is negative   Express Scripts Holding Company Price   Another stock worth considering in the Medical Services industry is Healthways  Inc    NASDAQ TVTY   which carries a Zacks Rank  1  Strong Buy  You can see  Is ESRX going up  Or down  Predict to see what others think   or Don t Even Think About Buying Bitcoin Until You Read This The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/express-scripts-esrx-soars-stock-adds-86-in-session-200296900,200296900
147707,369223,CI,Cigna To Buy Express Scripts  Healthcare ETFs In Focus,opinion,Waves of mergers and acquisitions have been heating up the healthcare space this year that could change the landscape of healthcare business  This is especially true given that health insurers are trying to consolidate with pharmacy benefits managers to streamline and cut costs in the drug supply chain The latest catalyst is the health insurer Cigna   NYSE CI    which has planned to acquire the largest pharmacy benefit manager Express Scripts Holding   NASDAQ ESRX   for  67 billion  including  15 billion in debt  The moves comes three months after a drug chain and a pharmacy giant CVS Health Corp   NYSE CVS   agreed to buy the nation s third largest health insurer Aetna   NYSE AET    for  207 per share or  69 billion  read    Inside The DealUnder the terms of the deal  Cigna will pay  48 75 in cash and 0 2434 shares of stock of the newly combined company  Upon closure  Cigna shareholders will own approximately 64  of the combined company The merged company would create a one stop shop for customers  healthcare needs  ranging from sale of drugs to insurance cover  It would benefit consumers by bringing together the medical care and pharmacy benefits at one roof to improve treatments and lower costs The combined company could pose a bigger threat to UnitedHealth Group Inc    NYSE UNH    the largest U S  health insurer having its own pharmacy benefits unit  and CVS after it completes its merger with Aetna  The move is also to stave off threats from Amazon com Inc    NASDAQ AMZN    which is making huge expansion in the world of pharmacy business  The e commerce giant recently announced a joint venture with JPMorgan Chase   NYSE JPM   and Warren Buffett s Berkshire Hathaway  in order to curb medical costs for their employees The transaction would result in total cost synergies of  650 million and double digit accretion to earnings in the first year after it closes  As a result  Cigna expects the deal to increase earnings per share from  18 to  20  21 in 2021  The deal is expected to close by Dec 31  2018 and is subject to approval from shareholders of both companies and anti trust regulatory approvals  see    ETF ImpactThe announced merger has put the spotlight on a few healthcare ETFs that could be the best ways for investors to tap the opportunity arising from the CI ESRX deal iShares U S  Healthcare Providers ETF This ETF follows the Dow Jones U S  Select Healthcare Providers Index with exposure to companies that provide health insurance  diagnostics and specialized treatment  In total  the fund holds 44 securities in its basket with Cigna and ESRX occupying the fourth and fifth position  accounting for over 5  share each  The fund has amassed  493 7 million in its asset base while volume is light at about 24 000 shares per day on average  It charges 44 bps in annual fees and has a Zacks ETF Rank  1  Strong Buy  with a Medium risk outlook  read    SPDR S P Health Care Services  NYSE XHS  ETF The fund uses an equal weight methodology to each security by tracking the S P Health Care Services Select Industry Index  Holding 49 stocks in its basket  CI and ESRX account for 2  share each  The fund has accumulated  91 5 million in its asset base and trades in a paltry volume of around 6 000 shares a day  Expense ratio comes in at 0 35   The ETF has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  read    First Trust Health Care AlphaDEX Fund  FXH This fund follows an AlphaDEX methodology and ranks stocks in the space on various growth and value factors  eliminating the bottom ranked 25  of the stocks  This approach results in a basket of 73 stocks with ESRX and CI taking 2 4  and 1 4  share  respectively  Health care providers   services is the top sector with 38 4  allocation  followed by healthcare equipment  23 5    and biotech  18 9    This fund has AUM of  974 5 million in its asset base and trades in volume of around 85 000 shares  Expense ratio comes in at 0 62  annually  The fund has a Zacks ETF Rank  2  Buy  with a Medium risk outlook Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  15 8 billion in its asset base and trades in heavy volume of around 8 1 million shares  Expense ratio comes in at 0 13  annually  In total  the fund holds 61 securities in its basket with CI and ESRX accounting for over 1  of the assets  Pharma takes the largest share at 31 7  from a sector look while healthcare providers and services  biotech  and healthcare equipment and supplies make up for a double digit exposure each  It has a Zacks ETF Rank  3  Hold  with a Medium risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/cigna-to-buy-express-scripts-healthcare-etfs-in-focus-200296997,200296997
147708,369224,CI,Cigna On Raters  Radar After Express Scripts Bid  Stock Down ,opinion,"Following Cigna Corp  s   NYSE CI   announcement to buy the pharmacy benefit manager Express Scripts Holding Co    NASDAQ ESRX    rating agencies A M Best and Moody s has sprung into action Under the terms of the deal  Cigna will pay  48 75 in cash and 0 2434 shares of stock of the newly combined company  Upon closure  Express Scripts  shareholders will own approximately 36  of the combined company A M  Best has placed under review with negative implications the Financial Strength Rating  FSR  of A  Excellent  and the Long Term Issuer Credit Ratings  Long Term ICR  of  a  of the key life health subsidiaries  health maintenance organizations  New Zealand and European insurance companies of Cigna The FSR of A  and Long Term ICRs of  a   of Cigna Supplemental Benefit Companies  as well as the Cigna HealthSpring companies have also received the same treatment A M  Best has placed under review with negative implications the Long Term ICR of  bbb  and the Long  and Short Term Issue Credit Ratings  Long Term IR  Short Term IR  of Cigna The move sent the shares down  declining 1 75  to close at  164 39 in last trading session Since the announcement of the deal  the stock has lost 13  against the  s growth of 2 1  The rating agency s concerns stem from Cigna s higher leverage ratio due to the use of  22 5 billion of new debt to finance the Express Scripts transaction  The funding will expectedly cause the leverage ratio to go up to 49   while its goodwill plus intangibles to equity ratio will likely exceed 125   Though the company s capacity to service its debt  as measured by interest coverage ratio  will fall under 10x  the level is still considered as strong The deal  being one of the biggest in Cigna s history  might pose significant execution risks   There is also a fear of customer losses from Express Scripts  which might dent the combined entity s growth to some extent Last week  another rating agency  Moody s Investors Service placed Cigna s debt ratings on review for downgrade  senior at Baa1  as well as the A1 insurance financial strength ratings of some of its operating subsidiaries Despite initial skepticism from the rating agencies  we believe that Cigna will be able to secure back its favorable rating after it utilizes the synergies from the acquisition to pay back debt The transaction is expected to result in total cost synergies of  650 million and double digit accretion to earnings in the first year after its closure  As a result  Cigna expects the deal to increase earnings per share from  18 to  20  21 in 2021 
Cigna carries a Zacks Rank  2  Buy   Other stocks worth considering in the same space are Centene Corp    NYSE CNC   and UnitedHealth Group Inc    NYSE UNH    While Centene sports a Zacks Rank  1  Strong Buy   UnitedHealth holds the same rank as Cigna  You can see  Centene beat earnings estimates in each of the four reported quarters with an average positive surprise of 9 8  UnitedHealth surpassed earnings estimates in each of the trailing four quarters with an average positive surprise of 4 8  Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-03-13,Zacks Investment Research,https://www.investing.com/analysis/cigna-on-raters-radar-after-express-scripts-bid-stock-down-200298071,200298071
147710,369226,CI,Experts warn 2015 could be  Year of the Healthcare Hack ,news,"By Caroline Humer and Jim Finkle NEW YORK BOSTON  Reuters    Security experts are warning healthcare and insurance companies that 2015 will be the  Year of the Healthcare Hack   as cybercriminals are increasingly attracted to troves of personal information held by U S  insurers and hospitals that command high prices on the underground market      Anthem Inc  the No  2 U S  health insurer  last week disclosed a massive breach of its database containing nearly 80 million records  prompting investigations by state and federal authorities  That hack followed a breach last year at hospital operator Community Health Systems  which compromised some 4 5 million records       People feel that this will be the year of medical industry breaches   said Dave Kennedy  chief executive of TrustedSEC LLC      In the past decade  cybercriminals focused their efforts on attacking banks and retailers to steal financial data including online banking credentials and payment card numbers  But as those companies boost security  using stolen credit card numbers has become more difficult   Their prices on criminal exchanges have also dropped  prompting hackers to turn to the less secure medical sector  just as the amount of digital healthcare data is growing dramatically  Kennedy said  Stolen healthcare data can be used to fraudulently obtain medical services and prescriptions as well as to commit identity theft and other financial crimes  according to security experts  Criminals can also use stolen data to build more convincing profiles of users  boosting the success of scams   All of these factors are making healthcare information more attractive to criminals   said Rob Sadowski  marketing director at RSA  the security division o  NYSE E  NYSE EMC MC f EMC Corp  MONETIZING STOLEN DATA  RSA Executive Chairman Art Coviello recently wrote in a letter to customers that he expected well organized cybercriminals to turn their attention to stealing personal information from healthcare providers   A name  address  social and a medical identity     That s incredibly easy to monetize fairly quickly   said Bob Gregg  CEO of ID Experts  which sells identity protection software and services  Identities can sell for  20 apiece  or more  he said      Insurers  medical equipment makers and other companies say they have been preparing for breaches after seeing the waves of attacks on other industries     NYSE   NYSE CI CI     Cigna Corp has looked to financial and defense companies for best practices  including hiring hackers to break into its systems  said Chief Executive David Cordani  Attempts to break into corporate systems to probe for information are a constant  he said in an interview   St Jude Medical Inc CEO Daniel Starks said the company increased investment in cybersecurity significantly over the last few years  to protect both patient data and the medical devices it manufactures   You may see from time to time law enforcement briefings on nation based  intellectual property  issues  espionage   he said   Those are things that we take very seriously and have been briefed on and that we work to guard against        The FBI is investigating the Anthem breach alongside security experts from FireEye Inc   The insure  NYSE UNH rs UnitedHealth Gr  NYSE AE  NYSE AET T oup Inc and Aetna Inc have warned investors about the risks of cyber crime in their annual reports since 2011   UnitedHealth has said the costs to eliminate or address the threats could be significant and that remediation may not be successful  resulting in lost customers      In response to the Anthem attack  UnitedHealth spokesman Tyler Mason said in an emailed statement   We are in close contact with our peers in     the industry cybersecurity organization  and are monitoring our systems and the situation closely   Aetna has cited the automated attempts to gain access to public facing networks  denial of service attacks that seek to disrupt websites  attempted virus infections  phishing and efforts to infect websites with malicious content   
Aetna spokeswoman Cynthia Michener said in a statement   We closely follow the technical details of every breach that s reported to look for opportunities to continually improve our own IT security program and the health sector s information protection practices broadly  ",2015-02-11,Reuters,https://www.investing.com/news/technology-news/experts-warn-2015-could-be-'year-of-the-healthcare-hack'-327662,327662
147712,369228,CI,Wall Street rises on Greece optimism  Nasdaq ends at record,news,"By Ryan Vlastelica NEW YORK  Reuters    U S  stocks ended higher on Monday  with the Nasdaq closing at a record as hopes grew that a deal would be reached to prevent Greece from defaulting on loans  Equities have been largely driven by the situation in Greece of late  with investors concerned that if the country defaults on its loans  it may have to leave the euro or the European Union  potentially shaking the region s economic foundations  Athens presented new reform proposals which were cautiously welcomed by euro zone finance on Monday  though the Eurogroup said the proposals required detailed study and that it would take several days to determine whether they can lead to an agreement  Greece needs fresh funds to avoid defaulting on a  1 8 billion debt repayment to the International Monetary Fund on June 30   This takes one anxiety off the table  even if it doesn t yet resolve the primary issues that made investors anxious in the first place   said Bruce McCain  chief investment strategist at Key Private Bank in Cleveland  Ohio   Sentiment was also lifted by merger and acquisition activity  The S P energy index  rose 1 percent as the top performing sector of the day after  Energy Transfer  Equity LP  N ETE  confirmed it had made a  48 billion unsolicited bid for Williams Companies Inc  N WMB   hours after Williams rejected the offer as significantly too low  Shares of Williams surged 26 percent to  60 90 and were the biggest percentage gainer on the S P 500 by far  Separately   Cigna Corp   N CI  rose 4 8 percent to  162 65 after the health insurer rebuffed Anthem s  N ANTM   47 billion merger proposal on Sunday  Anthem rose 3 6 percent to  171 04  Homebuilders rose as existing home sales grew more than expected in May  surging to their highest in five  and a half years  The PHLX Housing index  HGX  rose 0 9 percent while  Lennar  Corp  N LEN  added 1 7 percent to  49 49   Martha Stewart Living Omnimedia   N MSO  slumped 12 5 percent to  6 11 on heavy volume after  Sequential  Brands  O SQBG  agreed to buy the company in a deal that values it at about  353 million  or  6 15 a share  Martha Stewart shares had risen about 37 percent over two days after news of the deal emerged  The Dow Jones industrial average  DJI  rose 104 53 points  or 0 58 percent  to 18 120 48  the S P 500  SPX  gained 13 points  or 0 62 percent  to 2 122 99 and the Nasdaq Composite  IXIC  added 36 97 points  or 0 72 percent  to 5 153 97  With the day s gains  the Nasdaq ended at a record while the S P closed 0 3 percent away from its own record close  Currently  the S P trades at 17 3 times earnings  according to Thomson Reuters data  above its long term average   Valuations are somewhat high  but there aren t many alternatives that look attractive   said McCain   Stocks will probably get a lot higher before there s any serious risk of a pullback on valuation   Advancing issues outnumbered declining ones on the NYSE by 1 830 to 1 238  for a 1 48 to 1 ratio on the upside  on the Nasdaq  1 819 issues rose and 988 fell for a 1 84 to 1 ratio favoring advancers  The benchmark S P 500 index was posting 51 new 52 week highs and 1 new lows  the Nasdaq Composite was recording 207 new highs and 26 new lows  
About 5 31 billion shares traded on all U S  platforms  according to BATS exchange data  compared with the month to date average of 6 17 billion ",2015-06-22,Reuters,https://www.investing.com/news/stock-market-news/u.s.-futures-rise-on-optimism-over-greek-deal-347593,347593
147722,369238,CI,Cigna Q4 Earnings Top On Higher Enrollment  2018 View Issued,opinion,"Cigna Corp    NYSE CI   came up with adjusted earnings per share of  1 94 for the fourth quarter  beating the Zacks Consensus Estimate of  1 87  Earnings also grew 3 7  year over year Better than expected earnings were primarily driven by strong contribution from its Global Supplemental Benefits segment Other DetailsCigna posted revenues of  10 53 billion  which surpassed the Zacks Consensus Estimate of  10 29 billion  Revenues grew 5 9  year over year Premiums were up 7  year over year to  8 2 billion  while fees increased 5  to  1 19 billion Total benefits and expenses of  9 78 billion increased 5  year over year  led by higher global health care medical cost The company s medical enrollment grew to 15 91 million from 15 19 million in the year ago quarter  driven by growth in its Commercial Mrket segment Cigna Corporation Price  Consensus and EPS Surprise   Strong Segment PerformanceGlobal Health Care  Operating revenues of  8 3 billion were up 6  year over year on a 6 8  year over year increase in premiums and fees to  7 3 billion  The improvement was driven by customer growth in the Commercial Market segment  However  the upside was partially offset by reductions in Government customers Adjusted operating earnings were  397 million  down 2  year over year due to higher medical costs Global Supplemental Benefits  Operating revenues of  1 02 billion were up 17  year over year on a 17 2  increase in premiums and fees  reflecting continued business growth Adjusted operating income increased 28 5  year over year to  81 million  reflecting business growth and favorable claims experience  particularly in South Korea Global Disability and Life  Operating revenues of  1 1 billion were down 1  year over year due to a 1 4  decrease in premiums and fees Adjusted operating income declined 11 6  year over year to  61 million Financial PositionCigna s cash and marketable investments were of  1 2 billion as of Dec 31  2017  down from  2 8 billion as of Dec 31  2016 Long term debt was  5 2 billion as of Dec 31  2017  reflecting a 9 3  increase year over year 2018 GuidanceThe company expects to earn in the range of  12 40 and  12 90  on a per share basis  Total revenue growth is projected in the range of 7  to 8  and medical customers are projected to grow by 0 3 million to 0 5 million lives The consolidated adjusted tax rate should fall in the range of 22 5  to 23 5  Zacks Rank and Other Releases
Cigna carries a Zacks Rank  1  Strong Buy   You can see  Other health insurers UnitedHealth Group Inc    NYSE UNH    Anthem Inc    NYSE ANTM   and Aetna Inc    NYSE AET   beat estimates in the fourth quarter by 3 6   3 2  and 5 93   respectively Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-01-31,Zacks Investment Research,https://www.investing.com/analysis/cigna-q4-earnings-top-on-higher-enrollment-2018-view-issued-200285878,200285878
147725,369241,CI,3 Stable Low Beta Stocks To Buy During Volatile Markets,opinion,"Markets began to rebound on Monday after their worst week in nearly two years  The Dow Jones Industrial Average and the S P 500 both climbed over 1 30   Still  analysts are divided over whether the recent sell off is over just yet 
Concern that the Fed will raise interest rates faster than initially expected on the back of the first jobs report of 2018 is one possible reason for the pullback  A simple market correction  amid what has been a historic run  is another possibility 
Whatever the case may be  no one is sure if the worst is over right now  With that said  investors should consider looking for stocks that have proven to be less volatile compared to the market as a whole 
One tool we can turn to here is a stock s beta rating  which is a representation of how a security responds to rapid swings in the market  Historically  stocks and securities with betas below 1 0 are less volatile than the market 
Let s look at three low beta stocks to consider now 
1        Cigna Corporation   NYSE CI  
Cigna is an American health and life insurance giant that is currently a Zacks Rank  2  Buy  and rocks an overall  B  VGM grade  The stock s earnings estimates have been trending upward on strong revision agreement for the current quarter  current fiscal year  and the following fiscal year 
Investors should also be happy to note that Cigna has matched or topped earnings estimates all but once over the last three years  The company s bottom line is projected to expand at a healthy annualized rate of 12 90  over the next three to five years  And during these recent uncertain times  Cigna s beta of 0 45 theoretically presents less volatility compared to the market average 
2        Burlington Stores  Inc    NYSE BURL  
This off price department store sells far more than coats  and its name is iconic throughout the industry  Burlington is currently a Zacks Rank  2  Buy  and sports an  A  grade for Growth and an overall  B  VGM score  Burlington s beta of 0 48  which is calculated using data over a five year period  means that the company is less volatile compared to the market as a whole  in theory 
Burlington has also been on a hot streak when it comes to topping or meeting earnings expectations  The company has achieved this feat every quarter since the start of 2014  with an average surprise of over 15  in the trailing four periods  Looking down the road  investors should note that Burlington is projected to expand its EPS figure at an annualized rate of 18 65  over the next three to five years 
3        Anthem  Inc    NYSE ANTM  
Analysts have shown strong agreement when it comes to upping earnings estimates for this Indianapolis  Indiana health insurance and HMO powerhouse over the last 60 days  This has helped Anthem earn its current Zacks Rank  2  Buy  rating  The company also boasts an  A  grade for Momentum and has topped quarterly earnings expectations by an average of 9 60  over the last four quarters 
Anthem also currently rocks a beta of 0 83  which should help show investors that the HMO provider is a relatively stable investment compared to the average stock on the market  The company also looks poised to steadily grow its bottom line over the next three to five years  helping further demonstrate its solid overall fundamentals 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/3-stable-lowbeta-stocks-to-buy-during-volatile-markets-200289702,200289702
147727,369243,CI,Cigna  Express Script Deal To Continue Healthcare Reshuffle,opinion,Cigna Corp    NYSE CI   has announced that it will buy Express Scripts Holding Co     NASDAQ ESRX   a pharmacy benefits provider and other medical servcies The deal  valued  67 billion  will be financed by a mix of cash and debt  It will be one of the biggest deals for Cigna  What s in the Offing for Cigna The deal is expected to be mutually beneficial  given that it would lead to a solid combination of Cigna s strong position and expertise in the health benefits space with Express Scripts  leading position in the pharmacy benefits market  PBM  This combined entity would create a mammoth healthcare set up with wide ranging operations from sale of drugs to insurance cover The deal will add to Cigna s scale and size and equip it to negotiate with drug manufacturers and pharmacies better  This would lower the cost of acquiring prescription drugs  enabling the company to share the savings in with its consumers by way of more customer friendly insurance plans like enhanced frills or lower premium  thus ultimately leading to market share gains  Odds of the deals getting a clearance from regulators seem high  as it will be a vertical integration  Last year  Cigna s merger with Anthem Inc    NYSE ANTM   was blocked by regulators last year  on concerns that the combination would stifle competition in the healthcare industry since both companies had overlapping businesses  In a year s time shares of the company have gained 28  compared with the  s growth of 8 2  Growing Trend of Health Insures Catching up with PBMWith this deal  Cigna will be catching up with the growing bandwagon of health insurers tying up with pharmacy benefits mangers  The acquisition of Aetna Inc    NYSE AET    one of the nation s leading health insurers  by pharmacy benefit major CVS Health Corp  NYSE CVS   is already underway  Another deal in the same vein was the takeover of Catamaran by health insurer leader UnitedHealth Group Inc  NYSE UNH    in 2015   Pharmacy benefit managers work primarily for insurers and employers and seek to negotiate drug prices with pharmaceutical companies and drugstores to reduce the pocket pinch for consumers  This in turn lowers the medical cost for insurers Moreover  insurers seek an attractive business opportunity in the PBM market  which largely benefits from an aging population  which depends largely on drugs and pharmacy benefit plans  Per a report by Technavio  nearly 14 4  of the U S  population is aged 65 years and above  which buoys optimism Many analysts believe that rising expenditure on prescription drugs and growing demand for specialty drugs have also been strengthening the PBM market  The Centers for Medicare and Medicaid Services report published by Advisory Board predicts the continuation of this trend  Per the report  prescription drug spending is projected to grow roughly 7  between 2018 and 2019 Consolidation in HealthcareMost economists believe this coming together of two different industries in the healthcare sector will add a new dimension and might help in checking soaring costs Moreover  necessitated by the need of the players to gain in scale and size to weather the changes taking place within the industry  mergers and acquisitions  both horizontal and vertical  are common  No matter whether a company wishes to grow horizontally  expand in the existing business  or vertically  expand into new business   the most sought after way is to acquire the best fit   Cigna carries a Zacks Rank  2  Buy   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/cigna-express-script-deal-to-continue-healthcare-reshuffle-200296609,200296609
147728,369244,CI,Cigna Eyes ESRX  Cycles Suggest It Will Fall,opinion,"Cigna  NYSE CI  dropped 10  and Express Scripts  NASDAQ ESRX  jumped 11  on Thursday morning 
The price action was driven by Cigna s planned purchase ESRX for  67 billion in cash and stock  Cigna will also assume  15 billion in ESRX debt  If executed  Cigna shareholders will own 64  of the combined firm  which will lead to expanded offerings and consolidated costs 
Before the deal  our analysis was that ESRX faced considerable risk  Looking at its market cycles  our outlook projected down to  70 for the near term  The cycles are designated by the black semicircles at the bottom of the chart  
Our analysis of Cigna also suggested substantial risk  as the declining phase of its current cycle completes  Our target is for a continued drop to  170 in the near term ",2018-03-08,Steve Miller,https://www.investing.com/analysis/cigna-indulges-on-esrx-cycles-suggest-it-will-continue-to-fall-200296714,200296714
147729,369245,CI,Here s How I m Playing Cigna,opinion,"Shares of Cigna Corporation  NYSE CI  tanked on Thursday on its intent to buy Express Scripts  NASDAQ ESRX   Investors are taking the buyout as a sharp negative for shares  which likely means they think that big money believes the offer price is too rich 
Point Of Entry
Whatever the case  the stock fell more than 11   which may give investors waiting for an entry an opportunity to buy at a discount  There is a pivot to  170  which is where I m looking to pick up some calls ",2018-03-08,Gareth Soloway,https://www.investing.com/analysis/heres-how-im-playing-cigna-200296717,200296717
147737,369253,CI,INTERVIEW DexCom aims steady  09 growth  eyes Europe expansion,news,"  Aims to post sequential quarterly revenue growth
   Sees growing demand for CGM products
   Says reimbursement not a barrier to CGM adoption
   Expects to expand in Europe
 By Anand Basu
 BANGALORE  July 2   Medical device maker DexCom Inc aims to
post higher sequential revenue through each quarter of 2009 and
expects to expand its presence in Europe 
  We continue to see demand for continuous glucose
monitoring  CGM  growing despite the economy and are quite
pleased with that growth opportunity   Chief Executive Terrance
Gregg said in an interview 
 The CGM systems  which DexCom markets under the Seven and
Seven Plus brands  check for dangerous spikes or dips in blood
sugar levels via a wire like sensor inserted under the skin of
diabetic patients  mainly Type 1 diabetics 
  Such products are not yet covered broadly by insurance
companies and depend heavily on reimbursement for higher
adoption rates due to the cost associated with both the device
and the sensors that need frequent replacement 
  However  the company said it does not see the
reimbursement environment threatening the adoption of its CGM
systems as more insurers  like Aetna Inc and Cigna Corp  are
now amending their policies to cover more patients 
  Two of the largest payers have actually amended their
coverage decisions to be more comprehensive and allow more
patients to receive coverage in reimbursement for the product
over the last six to nine months   Gregg said 
 However  patients may still have to go through a long
documentation process to have their claims reimbursed by the
insurers  DexCom Chief Administrative Officer Steven Pacelli
said 
 READY FOR EXPANSION
 DexCom also plans to expand its presence outside the United
States especially in Europe  its CEO said 
  We are currently in a couple of countries with the Seven
system and as we receive CE mark on the Seven Plus system  our
goal is to expand to a number of countries later this year  
Gregg said 
 In November  the company received the CE mark for its Seven
system  CE mark is required to sell any product in the European
Union 
 Gregg said there were seven countries in Western Europe
with reimbursement facility and the necessary infrastructure
for the distribution of CGM products  but refused to comment on
the revenue expectations from international operations 
  Reporting by Anand Basu  Editing by Aradhana Aravindan ",2009-07-02,Reuters,"https://www.investing.com/news/equities-news/interview-dexcom-aims-steady-'09-growth,-eyes-europe-expansion-68612",68612
147738,369254,CI,US STOCKS Futures off ahead of data  GM up after net doubles,news,"  Initial jobless claims on tap
   Retailers begin posting monthly sales
   Futures off  Dow 63 pts  S P 9 pts  Nasdaq 14 5 pts
   For up to the minute market news see  STXNEWS US 
   Adds quote  updates prices 
 By Chuck Mikolajczak
 NEW YORK  Aug 4  Reuters    Wall Street equity futures fell
on Thursday  indicating the market may resume its downturn
after snapping a seven day losing streak ahead of a report on
the labor market that will give clues on the economy s health 
 Data on first time jobless claims data for the week ended
July 30 is due at 8 30 a m  EDT  1230 GMT   Economists forecast
405 000 new filings  compared with 398 000 in prior week 
 The S P 500 index rose on Wednesday after seven straight
losing sessions  but worries about the economy kept investors
jittery and trading volatile 
  After the recent jolt the market took  it is difficult to
regain firm footing   said Andre Bakhos  director of market
analytics at Lek Securities in New York 
  With the market being near flat on the year  investors are
looking for the next theme to bring us back positive  And with
a headline sensitive market  there is nothing tangible to latch
on to  
 S P 500 futures  fell 9 points and were below fair
value  a formula that evaluates pricing by taking into account
interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  lost 63
points  and Nasdaq 100 futures  advanced 14 5 points 
 Retailers will be in focus as chain stores report July
sales  The chains  led by warehouse clubs and high end stores 
are expected to report higher sales due to deep discounts and
the warmest July weather in decades   ID nN1E7721K0 
 In one early report  warehouse club operator Costco
Wholesale Corp  posted a higher than expected 10
percent rise in same store sales  helped by higher gasoline
prices and strengthening foreign currencies   ID nL3E7J41MV 
 General Motors Co  advanced 3 2 percent to  28 05 in
premarket trading after its quarterly profit nearly doubled as
the top U S  automaker boosted global sales and raised prices
on its vehicles   ID nN1E77305C 
 Kraft Foods Inc  jumped 9 1 percent to  37 41 in
premarket trading after it said it plans to split itself into
two listed companies  global snacks and North American
groceries  It also posted quarterly results  ID nL3E7J42PN 
 Cigna Corp  posted higher than expected
second quarter profit early Thursday on strength in its main
U S  healthcare plans and its international business  The
insurer raised its full year forecast   ID nN1E77301F 
 American International Group Inc  is due to report
results later Thursday 
 European shares fell 0 8 percent and touched a fresh
11 month low on Thursday on a weakening outlook for the global
economy  with miners the hardest hit as the price of copper and
other base metals fell   MKTS GLOB 
 The European Central Bank is expected to keep rates on hold
this month after raising them to 1 5 percent in July  The Bank
of England is also likely to keep rates unchanged 
 Japan s government sold one trillion yen   12 5 billion 
after days of official warnings that the yen had risen so much
it threatened to derail Japan s recovery   ID nL3E7J41YW 
 The move buoyed shares of big Japanese exporters  driving
the Nikkei average  up 0 2 percent on a day when the
rest of the region fell around 1 4 percent   ID nL6E7J40I3 
   Reporting by Chuck Mikolajczak  editing by Jeffrey Benkoe ",2011-08-04,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-futures-off-ahead-of-data,-gm-up-after-net-doubles-221098",221098
147739,369255,CI,S P500 index posts worst fall since April  indexes down for July,news,"By Caroline Valetkevitch  NEW YORK  Reuters    The U S  S P500 stock index posted its worst daily fall since April and its first monthly drop since January on Thursday  as economic data sparked concern the Federal Reserve could raise interest rates sooner than some have expected   Data showing that U S  labor costs recorded their biggest gain in more than 5 1 2 years in the second quarter this year came a day after the Fed upgraded its assessment of the U S  economy while reiterating it was in no hurry to raise rates   Problems in overseas economies added to the bearish tone  with Argentina defaulting on its debt for the second time in 12 years    If we start to see wages moving higher that s got a be a signal that we are getting closer to the Fed s mandates   said Quincy Krosby  market strategist at Prudential Financial in Newark  New Jersey   The Fed has kept overnight rates near zero since December 2008  but at its meeting on Wednesday it took note of both faster economic growth and a decline in the unemployment rate  while expressing concern about remaining slack in the labor market   On Thursday  all 10 S P500 index stock sectors fell more than 1 0 percent  with energy  down 2 4 percent leading the decline  Exxon Mobil Corp s  N XOM  second quarter earnings beat expectations but oil production dropped  and its shares fell 4 2 percent to  98 94   The CBOE Volatility index   often referred to as Wall Street s fear gauge  jumped 27 2 percent to close at 16 95  its highest level since April 11   The Dow Jones industrial average  fell 317 06 points or 1 88 percent  to 16 563 3  while the S P 500  lost 39 4 points or 2 0 percent  to 1 930 67 and the Nasdaq Composite  dropped 93 13 points or 2 09 percent  to 4 369 77   Trading volume was much heavier than average  About 8 billion shares changed hands on U S  exchanges  well above the 5 6 billion average for the month to date  according to data from BATS Global Markets   The stock price falls pushed the Dow into negative territory for the year  It is now down 0 1 percent since Dec  31  while the S P500 and Nasdaq are still higher for the year to date   The S P500 and Nasdaq both marked their biggest daily percentage drops since April 10  For the Dow  the percentage drop was the biggest since Feb  3   In a signal of possible further weakness ahead  the S P500 index closed below its 50 day moving average for the first time since April 15   For the month  the Dow was down 1 6 percent  the S P 500 was down 1 5 percent  and the Nasdaq was down 0 9 percent   ARGENTINA DEFAULT  Investors on Wednesday had hoped for a midnight deal in Argentina s debt talks with so called holdout creditors  but the plan fell through  Even a short default will raise companies  borrowing costs  add to pressure on the peso  drain the country s dwindling foreign reserves and fuel what is already one of the world s highest inflation rates   In Russia  news agencies reported that Russia banned soy imports from Ukraine and may restrict Greek fruit and U S  poultry in what could be responses to new Western sanctions over Ukraine   In after hours trade  shares of LinkedIn  N LNKD  jumped 8 9 percent to  196 70 when the corporate networking site reported a 47 percent increase in quarterly revenue and forecast better than expected adjusted profit and revenue in the current quarter   
During the regular session  Kraft Foods Group  O KRFT  shares fell 6 4 percent to  53 59  The stock was the biggest percentage decliner on the Nasdaq after Kraft late on Wednesday reported a scant rise in quarterly revenue     Additional reporting by Rodrigo Campos  Editing by Leslie Adler ",2014-07-31,Reuters,"https://www.investing.com/news/stock-market-news/stock-futures-fall-after-argentina-default,-data-awaited-299604",299604
147740,369256,CI,Wall Street ends down on heightened Russia concerns,news,"By Akane Otani  NEW YORK  Reuters    Stocks ended lower on Thursday  continuing a recent streak of weakness as Russia s surprisingly harsh retaliatory measures in response to Western sanctions raised concerns about global growth   In addition to Moscow s ban on imports of many Western foods  following sanctions imposed for Russia s support of rebels in eastern Ukraine  investors worried that the conflict between Russian and Ukraine is escalating  with the downing of a Ukrainian fighter jet   The declines briefly dragged the Dow below its 200 day moving average in afternoon trading  The S P 500 is now nearly 4 percent below the record closing high it set last month  While the full extent of the sanctions are still unknown  escalating tensions in Russia could continue to spur selling in stocks  analysts said    Before this point  U S  investors have always thought of geopolitical concerns as being largely no more than a 24 hour event  Now  the growing concern is that the outlook for global growth is pointing down   said Andrew Wilkinson  chief market analyst at Interactive Brokers Group in Greenwich  Connecticut    To that extent  investors seem more prone to selling  and asking questions later rather than buying the dip as they had become accustomed to doing in the past    All but one of the S P 500 s industry sectors ended down on the day  backtracking from brief gains in the morning  Consumer staples shares   the bright spot of trading on Wednesday  slipped 0 8 percent on Thursday  while utilities  shares posted the sole sector gains   Health insurer stocks were poor performers  dipping after Goldman Sachs downgraded Aetna  N AET  to  neutral  and cut earnings estimates on a number of its peers  Aetna  N AET  shares slid 4 0 percent to  75 22  UnitedHealth Group  N UNH  shares lost 2 7 percent to  79 26 and Cigna shares  N CI  fell 3 0 percent to  88 75   The Dow Jones industrial average  DJI   fell 75 07 points  or 0 46 percent  to 16 368 27  the S P 500  SPX   ended down 10 67 points  or 0 56 percent  to 1 909 57  and the Nasdaq Composite  IXIC   lost 20 09 points  or 0 46 percent  to 4 334 97   Twenty First Century Fox  O FOXA  surged 5 1 percent to  33 97 after the company s quarterly profit beat Wall Street s expectations   Jobless claims reports lent optimism to the market in the morning as the four week claims average fell to its lowest level since February 2006  suggesting labor market conditions are continuing to improve   
About 5 5 billion shares traded on all U S  platforms  according to BATS exchange data  compared with the five day average of 6 9 billion     Editing by Leslie Adler ",2014-08-07,Reuters,"https://www.investing.com/news/stock-market-news/futures-climb-ahead-of-data,-russian-sanctions-in-focus-301841",301841
147741,369257,CI,Cigna fourth quarter profit rises 29 percent due to higher premium revenue ,news," Reuters    Health insurer Cigna Corp  N CI  reported a 29 percent rise in fourth quarter profit  driven by increased premium revenue and effective medical cost management  The company s net income attributable to shareholders rose to  467 million  or  1 77 per share  in the quarter ended Dec  31  from  361 million  or  1 29 per share  a year earlier  Net income attributable to shareholders included a special charge of  40 million  or  0 15 per share  related to organizational costs in the fourth quarter of 2013  Total revenue rose to  8 93 billion from  8 15 billion  
Cigna manages insurance plans for large corporations and sells health plans on government exchanges created under the U S  Affordable Care Act  often called Obamacare  The company also offers dental and other benefits ",2015-02-05,Reuters,https://www.investing.com/news/stock-market-news/cigna-fourth-quarter-profit-rises-29-percent-due-to-higher-premium-revenue-326682,326682
147759,369275,CI,Anthem  ANTM  Tops Q4 Earnings   Revenues  Issues  18 View,opinion,Anthem Inc  s   NYSE ANTM   fourth quarter 2017 adjusted net income per share of  1 29 surpassed the Zacks Consensus Estimate of  1 25 by 3 2   The bottom line  however declined 27  year over year For 2017  the company s adjusted net income came at  12 04 per share  up 9 5  from the last year Operating revenues of  22 4 billion surpassed the Zacks Consensus Estimate by 1 3   The top line also grew 4 5  year over year due to premium rate increases as well as higher enrollment in the Medicaid  Medicare  and Local Group insured and self funded businesses  The upside was partially offset by the impact of the one year waiver of the health insurance tax in 2017 For 2017  operating revenues came at  89 billion  up 5 8  year over year Quarterly Operational UpdateMedical enrollment increased 0 8  year over year to 40 2 million members  The rise was primarily driven by commercial   specialty business  Enrollment growth in Government business also contributed to the appreciation  This upside was partially offset by a decline in membership in the National Account and Individual businesses Total expenses increased nearly 7 1  to  22 6 billion in the reported quarter  mainly due to a 6 3  rise in benefitexpenses and 4  increase in selling  general and administrative SG A  expenses  both on a year over year basis Anthem s benefit expense ratio of 88 6  deteriorated 140 basis points  bps  from the prior year quarter  This was largely due to the one year waiver of the health insurance tax in 2017  However  the deterioration was partially offset by improved medical cost performance in the Individual and Local Group businesses SG A expense ratio of 15 1  improved 10 bps from the year ago quarter  This was due to one year waiver of the health insurance tax in 2017 and the impact of fixed cost leverage on operating revenue growth  However  the decline was partially offset by increased spend to support growth initiatives during the quarter Segment UpdateCommercial   Specialty BusinessOperating revenues were  10 1 billion in the fourth quarter  up 4 9  year over year Operating gain totaled  71 2 million  down 62 4  year over year due to increased spend to support growth initiatives and the impact of the one year waiver of the health insurance tax in 2017  The decrease was partially offset by improved medical cost performance in the Local Group and Individual businesses Operating margin was 0 7   down 130 bps year over year Government BusinessOperating revenues were  12 3 billion in the fourth quarter  up 4  from the prior year quarter Operating gain was  360 8 million  down 31 9  year over year  The downside reflected increased spend to support growth initiatives during the quarter and the impact of the one year waiver of the health insurance tax in 2017  However  the deterioration was partially offset by improved medical cost performance in the Medicaid business Operating margin was 2 9   declining 160 bps year over year Other  Operating revenues were  13 6 million in the fourth quarter  up 84  from the prior year quarter The segment reported an operating loss of  51 million  narrower than an operating loss of  66 1 million in the prior year quarter  The improvement was primarily driven by lower expenses related to the terminated Cigna  NYSE CI  acquisition Operating margin was 1 7   down 130 bps year over year Anthem  Inc  Price  Consensus and EPS Surprise   Financial UpdateAs of Dec 31  2017  Anthem had cash and cash equivalents of  3 6 billion  down 11  from year end 2016 As of Dec 31  2017  its long term debt increased 21  to  17 4 billion from year end 2016 As of Dec 31  2017  shareholder equity was  26 5 billion  up 5 5  from year end 2016 Operating cash outflow was  1 3 billion in the fourth quarter  This brings full year 2017 operating cash flow to  4 2 billion  or 1 1 times net income  This also reflects 28  year over year growth over 2016 During the fourth quarter  Anthem recorded a one time  non cash deferred tax benefit from corporate tax reform of  1 1 billion  This reduces total income tax expenses in 2017 to  121 million Share Repurchase and Dividend UpdateDuring the quarter  Anthem repurchased 1 8 million shares of its common stock for  362 million During 2017  it repurchased 10 5 million shares of its common stock for  2 billion As of Dec 31  2017  it had approximately  7 2 billion of share repurchase authorization remaining During the fourth quarter  Anthem paid a quarterly dividend of 70 cents per share On Jan 30  2017  the board declared dividend of 75 cents per share for the first quarter of 2018  This reflects a hike of 7 1   The dividend will be paid on Mar 23 to shareholders of record on Mar 9 Guidance for 2018Anthem expects adjusted net income to be greater than  15 00 per share Medical membership is now expected in the range of 40 40 2 million Operating revenues are projected in the range of  90 5  91 5 billion Benefit expense ratio is expected to be around 84 5   with adjustment of 30 bps SG A ratio is expected to be around 15 5   with adjustment of 30 bpsAnthem expects operating cash flow to be more than  4 billion Zacks Rank and Performance of Other PeersAnthem sports a Zacks Rank  1  Strong Buy   You can see  Among other players in the Medical sector that have reported their fourth quarter earnings so far  AbbVie Inc    NYSE ABBV    UnitedHealth Group Incorporated   NYSE UNH   and Abbott Laboratories   NYSE ABT   have surpassed their respective Zacks Consensus Estimate The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/anthem-antm-tops-q4-earnings--revenues-issues-18-view-200285469,200285469
147760,369276,CI,Key Predictions For Q4 Earnings Reports Of CI  MMC  XL  VR,opinion,"The fourth quarter earnings season is in full swing with 133 members of the elite S P 500 index having already reported financial numbers so far   Per the latest   performances of these index members indicate that total earnings have increased 12 3  on 8 8  higher revenues  The beat ratio is impressive with 81 2  companies surpassing bottom line expectations and 78 9   outperforming on the top line front The  sector  one of the 16 Zacks sectors  has delivered a strong performance till now Per Earnings Preview  earnings are expected to grow 8 4  on 2 4  higher revenues Integral to the Finance sector  the insurance industry is likely to witness better results this yet to be reported quarter compared with the third  Underwriting profitability continued to be hurt in the fourth quarter by the wildfires in California  This downside added to the woes with the catastrophe modeling firm AIR Worldwide estimating losses at approximately  10 5 billion However  such a massive loss led insures to brave the price hike that remained flat due to a not so active catastrophe environment  This in turn has helped improving the premiums and driving the top line as well Also  prudent underwriting practices aided insurers to weather the cat event Net investment income  an important component of an insurer s top line  is anticipated to have increased on the back of an improving rate environment  Though the same witnesses progress at a slower pace  the impact of rate increase is clearly visible in the insurer s investment results  The Fed delivered its promise of three hikes in 2017  the last one made in December Diverse product offerings  a wide geographic footprint and strong client retention likely have enhanced insurers  performance in the quarter to be reported With 400 companies  121 S P 500 members  set to announce earnings this week  let s find out where the following insurers stand before their quarterly releases on Feb 1 Cigna Corp s   NYSE CI   fourth quarter performance should reflect growth in total enrollment and specialty relationships  continued effective medical cost management and operating expense discipline  and strong capital management The Zacks Consensus Estimate of a loss of 26 cents per share for the yet to be reported quarter reflects a 108 9  year over year slump  Cigna sports a bullish Zacks Rank  1  Strong Buy   which increases the predictive power of ESP  However  combined with an of  0 11  leaves surprise prediction inconclusive as the company needs a positive ESP to be confident about an earnings surprise  Read more   Cigna Corporation Price and EPS Surprise
   You can uncover the best stocks to buy or sell before they re reported with our  Marsh   McLennan Companies  Inc    NYSE MMC   is projected to benefit from increased revenues at its both operating segments namely Risk and Insurance Services and Consulting A combination of organic and inorganic growth measures is likely to boost revenues  The Zacks Consensus Estimate for net operating revenues is pegged at  3 6 billion  representing 6 5  year over year growth The Zacks Consensus Estimate is pegged at 95 cents for the soon to be reported quarter  up 6 7  year over year   Marsh   McLennan has an Earnings ESP of  0 18  and a favorable Zacks Rank  3  Such a right combination of the two key ingredients makes us confident of an earnings beat   Read more   Marsh   McLennan Companies  Inc  Price and EPS Surprise
   You can see  Earnings of XL Group plc   NYSE XL   will likely be weighed on by cat loss stemming from California wildfires as well as a rise in operating expenses  Nonetheless  improving premiums at both its Insurance and Reinsurance segments is projected to limit this downside The Zacks Consensus Estimate is pegged at 49 cents for the yet to be reported quarter  up 4 3  year over year   XL Group has a bearish Zacks Rank  5  Strong Sell  and further combined with an Earnings ESP of 0 00  makes surprise prediction difficult this time around   Read more   
XL Group Ltd  Price and EPS Surprise
   The Zacks Consensus Estimate for Validus Holdings  Ltd    NYSE VR   is pegged at 87 cents  up 8 7  year over year  Though the company is a Zacks  3 Ranked player  its Earnings ESP of 0 00  makes surprise prediction difficult 
Validus Holdings  Ltd  Price and EPS Surprise
   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-01-30,Zacks Investment Research,https://www.investing.com/analysis/key-predictions-for-q4-earnings-reports-of-ci-mmc-xl-vr-200285433,200285433
147786,369302,CI,5 Trade Ideas For Monday  BSX  CI  GDOT  HPQ  MMM,opinion,"Boston Scientific  NYSE BSX 
Boston Scientific   BSX  started higher after the November 2016 election  taking several steps to get to the top in October 2017  It then corrected in two steps to the current base consolidation  The price action Friday took it back to the top of consolidation with the Bollinger Bands  squeezed in  This often precedes a big move  A push over the top of consolidation would confirm a double bottom reversal  The RSI is moving up through the mid line toward the bullish zone with the MACD rising  Look for a push over resistance to participate higher   
Cigna  NYSE CI 
Cigna   CI  moved steadily higher all year long until the current consolidation  At the end of last week it was at the top of that consolidation with the Bollinger Bands squeezed  It had retouched the 50 day SMA and has a RSI moving higher in the bullish zone with the MACD about to cross up  Look for a push to a new high to participate   
Green Dot Corporation  NYSE GDOT 
Green Dot   GDOT  started higher at the beginning of 2017  lifting off of and continuing to the peak in early November  It has left a few small gaps along the way and a couple of consolidations  each time with the 50 day SMA holding as support  The price broke above the latest consolidation Friday and up off of that 50 day SMA  The RSI is rising in the bullish zone and the MACD is about to cross up  Look for continuation to participate higher   
HP Inc  NYSE HPQ 

HP   HPQ  moved out of a consolidation in September  racing to a top in October  After a small pullback it sprinted to a higher high and dropped again  It has been consolidating against resistance since  The Bollinger Bands have squeezed and are now starting to open to allow a move  The RSI is rising and bullish with the MACD moving higher as well  Look for a push over resistance to participate   
3M Company  NYSE MMM 
3M   MMM  started higher out of consolidation in February  up off of its 100 day SMA  It stalled in June and digested the move before a second leg higher in October  That move topped out at the beginning of December and was followed by a bull flag  Friday saw the price break the bull flag to the upside  The RSI is running higher in the bullish zone with the MACD about to cross up  Look for continuation to participate higher   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  This week s list contains the first five below to get you started early  These were selected and should be viewed in the context of the broad  picture reviewed Friday which with the first week of the New Year under our belts sees the equity markets looking spectacular  and maybe they have run a bit too far too fast 
Elsewhere look for Gold to continue in its uptrend while Crude Oil may pause in its move higher  The US Dollar Index is weak but may be finding support while US Treasuries are biased lower in consolidation  The Shanghai Composite and Emerging Markets have both broken to the upside in a strong manner out of consolidation 
Volatility looks to remain very low keeping the bias higher for the equity index ETF s SPDR S P 500  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts agree on the longer timeframe  with the SPY and QQQ very strong and the IWM just starting to break out  On the shorter timeframe the SPY and QQq are overbought and may need a pause  perhaps giving rise to rotation in to the IWM  Use this information as you prepare for the coming week and trad em well 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2018-01-08,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-boston-scientific-cigna-green-dot-hp--3m-200278208,200278208
147787,369303,CI,Here s Why You Should Hold Onto Willis Towers Watson Stock ,opinion,Willis Towers Watson Public Limited Company   NASDAQ WLTW   remains well poised for growth  banking on incremental revenue rise  cost synergies  investing in new growth avenues and a solid capital position  This Zacks Rank  3  Hold  insurance broker bears immense potential owing to a few good growth drivers Growth Projections  The Zacks Consensus Estimate for earnings per share is pegged at  9 80 for 2018 on  8 38 billion revenues  The consensus mark reflects a year over year increase of 16 9  for the bottom line and a 3 3  rise for the top line The expected long term earnings growth rate for the stock is 10 2  Positive Earnings Surprise History  Willis Towers Watson has surpassed the Zacks Consensus Estimate in two of the last four quarters with an average beat of 6 32  The company is expected to report fourth quarter results in the first week of February   Our proven model shows that Willis Towers Watson is likely to beat estimates this quarter based on the ideal combination of two strong ingredients  a Zacks Rank of 3  which increases the predictive power of ESP and an  of  0 63   which makes us confident of a likely positive earnings surprise Price Performance  Shares of Willis Towers Watson have rallied 20  in a year  outperforming the  s 18  increase Underpriced  Looking at the company s price to book ratio   the best multiple for valuing insurers because of large variations in their earnings results from one quarter to the next   shares are underpriced at the current level  The company has a trailing 12 month P B ratio of 1 99  significantly higher than the industry average of 4 35   Growth Drivers in PlaceOrganic growth in commissions and fees  which form the major component of Willis Towers  revenues  continues to post positive numbers on the back of organic growth across segments and a rich contribution from acquisitions  The company projects constant currency revenue growth to hover around 3  in 2017 The momentum in exchange business remains strong  Willis Towers Watson noted that in active exchanges  it has six large clients with about 0 15 million total lives  already committed to the 2018 enrollment period and one large client  committed to the 2019 enrollment period Its inorganic story remains impressive as strategic acquisitions diversify the product portfolio  generates synergies and expand international presence  The company has been progressing well and also anticipates achieving  125 million  in relation to cost synergies  by 2018 Willis Towers Watson expects adjusted earnings per share between  8 36 and  8 51 in 2017  Constant currency revenue growth is estimated at 2 3  range while EBITDA margin in the band of 23 24  A strong financial position aids the company to return value to shareholders through dividend hikes as well as pursue growth initiatives  While the company has increased its dividend at a five year CAGR  2011 2016  of 15 3   it has  671 million remaining under its share repurchase authorization  The company targets dividend payout ratio of about 25  Stocks to ConsiderSome better ranked stocks from the finance sector are Brown   Brown  Inc    NYSE BRO    Marsh   McLennan Companies  Inc    NYSE MMC   and Cigna Corp    NYSE CI   Brown   Brown markets and sells insurance products and services primarily in the United States as well as in England  Bermuda and the Cayman Islands  The company came up with an average four quarter beat of 4 31   The stock sports a Zacks Rank  1  Strong Buy   You can see   Marsh   McLennan provides advice and solutions in the areas of risk  strategy and people worldwide  The company delivered an average four quarter beat of 4 08   The stock boasts a Zacks Rank of 1 Cigna Corp provides insurance  investment management and other financial products and services in the United States and internationally  The company pulled off an average four quarter positive surprise of 0 16   The stock carries a Zacks Rank  2  Buy  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-onto-willis-towers-watson-stock-200278720,200278720
147816,369332,CI,Is Cigna Corporation  CI  A Good Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Cigna Corporation   NYSE CI   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Cigna Corporation has a trailing twelve months PE ratio of 19 6  as you can see in the chart below This level actually compares favorably with the market at large  as the PE for the S P 500 stands at about 21 5  If we focus on the long term PE trend  Cigna Corporation s current PE level puts it above its midpoint over the past five years  with the number having risen slightly over the past few months However  the stock s PE compares unfavorably with the industry s trailing twelve months PE ratio  which stands at 14 3  This indicates that the stock is relatively overvalued right now  compared to its peers We should also point out that Cigna Corporation has a forward PE ratio  price relative to this year s earnings  of 19 7  which is marginally higher than the current level  So on the ground of the forward earnings estimates  we might say that the company s share price is likely to appreciate in the near future P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Cigna Corporation has a P S ratio of about 1 3  This is lower than the S P 500 average  which comes in at 3 4 right now  However  as we can see in the chart below  this is in line with the highs for this stock in particular over the past few years  which suggests that the company s stock price has already appreciated to some degree  relative to its sales Broad Value OutlookIn aggregate  Cigna Corporation currently has a Zacks Value Style Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Cigna Corporation a solid choice for value investors What About the Stock Overall Though Cigna Corporation might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of A and a Momentum score of D  This gives CI a Zacks VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen zero estimates go higher in the past sixty days compared to nine lower  while the full year estimate has seen ten upward and no downward revisions in the same time period As a result  the current quarter consensus estimate has fallen by 7  in the past two months  while the full year estimate has increased 3   You can see the consensus estimate trend and recent price action for the stock in the chart below Cigna Corporation Price and Consensus    Despite this somewhat mixed trend  the stock has a Zacks Rank  2  Buy  on the back of its strong value metrics and this is why we are expecting above average performance from the company in the near term   Bottom LineCigna Corporation is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a robust industry rank  among the Top 38   and a solid Zacks Rank instills investor confidence However  it is hard to get too excited about this company overall as over the past two years  the industry has underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-25,Zacks Investment Research,https://www.investing.com/analysis/is-cigna-corporation-ci-a-good-stock-for-value-investors-200275847,200275847
147817,369333,CI,Top Ranked Growth Stocks To Buy For December 28th,opinion,Here are three stocks with buy ranks and strong growth characteristics for investors to consider today  December 28th Boise Cascade Company  BCC   This manufacturer of wood products  which carries a Zacks Rank  1  Strong Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 19 6  over the last 60 days Boise Cascade  L L C  Price and Consensus   Boise Cascade has a PEG ratio 1 15  compared with 4 09 for the industry  The company possesses a  of A Boise Cascade  L L C  PEG Ratio  TTM    Cigna Corporation  NYSE CI   CI   This health services organization  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings rising 3  over the last 60 days Cigna Corporation Price and Consensus   Cigna has a PEG ratio 1 55  compared with 2 80 for the industry  The company possesses a Growth Score of A Cigna Corporation PEG Ratio  TTM    Owens Corning  OC   This producer of glass fiber reinforcements  which carries a Zacks Rank  2  Buy   has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0 2  over the last 60 days Owens Corning Inc Price and Consensus   Owens Corning has a PEG ratio 1 39  compared with 1 93 for the industry  The company possesses a Growth Score of A Owens Corning Inc PEG Ratio  TTM    See the  Learn more about the  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-12-27,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-growth-stocks-to-buy-for-december-28th-200276452,200276452
147837,369353,CI,Anthem s  ANTM  Notes Receive Rating Action From A M Best,opinion,Anthem Inc    NYSE ANTM   recently received rating action on its senior unsecured notes from A M Best  The rating giant has assigned Long Term Issue Credit Ratings of  bbb   to Anthem s  900 million 2 5  notes due 2020   750 million 2 95  notes due 2022   850 million 3 35  notes due 2024   1 6 billion 3 65  notes due 2027 and  1 4 billion 4 375  notes due 2047  The outlook for these Credit Ratings has remained stable The rating giant believes that Anthem will use the proceeds from this offering for the tender offer announced on Nov 14  2017  to pay its debt obligations that includes a debt maturity in January 2018  The proceeds will also be used to finance the upcoming acquisitions of HealthSun and America s 1st Choice to be completed in the fourth quarter of 2017 and the first quarter of 2018  respectively According to A M  Best  these notes issuances are likely to increase Anthem s financial leverage to 45  or below compared with the present level of 38   The rating giant expects the level to moderate with time  However  the issue regarding the terminated merger between Anthem and Cigna Corp   NYSE CI   that involved a break up fee of  1 85 billion is still not resolved  The leverage estimates do not include the possibility of the payment of this break up fee In a year s time  its shares have gained 57 7   outperforming the  s rally of 40 5 Anthem has been continuously delivering solid operating earnings on the back of revenue growth  Sufficient generation of cash flows has provided it with strong liquidity as well  Its profitability has been mainly driven by its Commercial business  partially offset by a lower margin in its government business and challenges faced in Individual business Moreover  the upcoming acquisitions of HealthSun and America s 1st Choice are likely to add nearly 170 000 Medicare Advantage members to Anthem s existing Simply Healthcare Medicare Advantage and Amerigroup Managed Medicaid membership  Also  the addition of HealthSun s primary care and specialty centers  along with their vast network of medical centers and care delivery capabilities are likely to boost Anthem s enrollment in Florida Zacks Rank   Stocks to ConsiderAnthem presently carries Zacks Rank  3  Hold  You can see   Some better ranked stocks in the industry are Centene Corp   NYSE CNC   and The Joint Corp   NASDAQ JYNT    Both the stocks carry a Zacks Rank  2  Buy  Centene is a well diversified  multi national healthcare company that also delivered positive surprises in each of the last four quarters with an average beat of 10 6    Shares of Centene have gained 65 7  in a year s time  outperforming the industry Joint Corp develops  owns  operates  franchises  supports and manages chiropractic clinics in the United States  The company has delivered positive surprises in three of the last four quarters with an average beat of 5 5   Shares of the company have rallied 135  in a year s time  outperforming the industry Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-11-15,Zacks Investment Research,https://www.investing.com/analysis/anthems-antm-notes-receive-rating-action-from-am-best-200265798,200265798
147838,369354,CI,Pick 4 Solid Insurance Stocks From The Bull Market In 2017,opinion,Looking back  the year 2017 was full of both pleasant and unpleasant surprises  While an improving employment scenario and rising interest rates came as a breather to the insurance industry  the severe damages caused by devastating catastrophe events hampered the insurers  overall performance to a great degree  The insurance industry has been wading through these challenges this year and there have been a few outperformers  which have sparked an interest among investors and raised optimism among them Based on the above scenario  picking the prospective winning stocks and making a prudent investment decision for the best returns may seem an uphill task  We will discuss below about the various scenarios  which have influenced the insurance industry to a large extent Catastrophe Loss Loomed LargeAlthough the first half of 2017 was mainly affected by a hail driven weather related catastrophe loss  the second half proved even costlier for the insurance industry as well as the market as a whole  With the occurrence of hurricanes Harvey  Irma and Maria  the relevant industry suffered an apparent dent in the underwriting results  thus hurting its overall performance Even though the mounting losses badly impacted the overall performance of the insurers  there were a few good stocks  which weathered such losses and emerged winners Interest Rate Hike   A Long Awaited Boon to InsurersThe gradual rise in interest rates has benefited the insurance industry to a great extent  The Federal Reserve delivered in its promise to increase the rates thrice in 2017 by announcing the third and the final interest rate hike at the Federal Open Market Committee s meeting on Wednesday  Dec 13  2017  Notably  the interest rate now ranges between 1 25  and 1 50   which in turn has boosted the insurance industry s prospects and helped the companies strengthen their market position Even with the slow paced rising rate environment  life insurers   who have been suffering from spread compression on products like fixed annuities and universal life due to persistently low rates   have heaved a sigh of relief  Thus  given the high dependence on investment income  life insurers will gain more from a progressing rate environment  While non life insurers have already begun to display an improving investment income  instilling confidence in investors A progressing rate environment will also lessen the pressure on the insurers  investment income  thus boosting their earnings  This in turn will accelerate the insurance companies  overall growth in the future    Other Factors Resulting in Favorable PerformanceA few other factors have also impacted the industry performance so far  To that end  low inflation is expected to remain at 1 6   falling shy of the 2  target  which is considered good for the economy This apart  a reviving housing market has enhanced insurable exposures and premiums written  Additionally  an improving employment scenario and a positive consumer sentiment buoy optimism Outperformers in 2017Despite adversities raising concerns for insurers this year  positives like rising interest rate environment and an improving economy have helped the following stocks perform well and yield profits through an underlying strength and business modification We have zeroed in on four stocks having outperformed so far despite all odds based on price performance  positive estimate revisions  strong surprise history in the last three quarters and a favorable Zacks Rank Chicago  IL based CNA Financial Corporation   NYSE CNA   offers commercial property and casualty insurance products  primarily in the United States  The stock has seen the Zacks Consensus Estimate for current year earnings being revised 3 4  upward to  3 07 and moved 7 9  up to  3 42 for 2018 over the last 60 days  This is reflected through the company s Zacks Rank  1  Strong Buy   You can see   With respect to surprise history  the company delivered positive surprises in the last three quarters with an average beat of 53 2  Shares of CNA Financial have gained 27 5  year to date  outperforming the  s increase of 17 4  and the S P 500 index s gain of 19 3  West Des Moines  IA based American Equity Investment Life Holding Company   NYSE AEL   develops and sells fixed index and fixed rate annuity products in the United States  The stock has seen the Zacks Consensus Estimate for current year earnings being revised 13 2  upward to  3 00 and moved 4 1  up to  2 77 for 2018 over the last 60 days  This is reflected through the company s Zacks Rank of 1  With respect to surprise history  the company came up with positive surprises in the last three quarters with an average beat of 28 8    Shares of American Equity Investment have surged 38 5  year to date  outperforming the  s rally of 23 1  and the S P 500 index s gain of 19 3  Milwaukee  WI based MGIC Investment Corporation   NYSE MTG   provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States  The Zacks Consensus Estimate for current year earnings moved up 9  to  1 21 and 6 1  to  1 21 for 2018 over the last 60 days  This is reflected through the company s bullish Zacks Rank which is as same as the above two  With respect to its earnings track record  the company pulled off positive surprises in the trailing three quarters with an average beat of 27 1     Shares of MGIC Investment have soared 48 6  year to date  outperforming the  s increase of 9 8  and the S P 500 index s gain of 19 3   Bloomfield  CT based Cigna Corporation   NYSE CI   provides insurance and related products and services in the United States and internationally  The Zacks Consensus Estimate for current year earnings has been raised nearly 3  to  10 34 and 0 9  to  11 53 for 2018 over the last 60 days  This stock carries a Zacks Rank  3  Hold   With respect to its earnings history  the company delivered beat estimates in the trailing three quarters with an average positive surprise of 16 9    Shares of Cigna have gained 55 9  year to date  outperforming the industry s rise of 9 8  and the S P 500 index s gain of 19 3  Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/pick-4-solid-insurance-stocks-from-the-bull-market-in-2017-200273218,200273218
147839,369355,CI,Cigna  CI  Buys Brighter To Enhance Technology Investment,opinion,Cigna Corp    NYSE CI   has acquired Brighter Inc   a healthcare software company The deal is an extension of the agreement existent between the two companies for the past couple of years now  Brighter will develop Cigna s mobile and desktop platforms and create new end to end experiences  This is primarily aimed at providing a comprehensive support to its customers to better manage their health and providing high quality care at minimum costs Cigna remains quite active in pushing the boundaries with technological innovations  Recently it updated its MyCigna app and the Cigna com website  terming the same as One Guide personalized health benefits and wellness program Notably  a growing emphasis on the use of information technology to simplify  automate and increase efficiency in operations and data management has prompted healthcare providers and payers to step up their digital transformation game Insurers have taken great strides in the recent years to make tech investments  More and more players are partnering with tech companies to solve customer  operational and business model issues Such a deal was very much anticipated with management giving out cues at its recent investor conference that growth will be accelerated via capital deployment in multiple avenues   For instance  strategic mergers and acquisition and the recent deal uniquely fits the bill here The company is aggressively trying to expand inorganically across all verticals  Recently  it bought Zurich Insurance Middle East  which will lend it a stronger foothold in the Gulf countries of UAE  Lebanon  Kuwait and Oman  This contract has raised optimism among the company s investors about its endeavors to diversify operations outside the U S  markets that are faced with stiff competition and stringent regulations So far this year  the stock has soared a whopping 53   significantly outperforming the  s growth of 14  Cigna carries a Zacks Rank  3  Hold    You can see   Investors interested in the same space can consider some better ranked stocks like Triple S Management Corporation   NYSE GTS    Wellcare Health Plans Inc   NYSE WCG   and Magellan Health  Inc    NASDAQ MGLN    each sporting a Zacks Rank  1 Triple S Management delivered positive surprises in two of the last four quarters with an average beat of 74  Wellcare Health came up with positive surprises in each of the last four quarters with an average beat of 64 3  Magellan Health pulled off positive surprises in three of the last four quarters with an average beat of 0 9  Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-buys-brighter-to-enhance-technology-investment-200273719,200273719
147868,369384,CI,5 Trade Ideas For Monday  APA  CI  LOW  NKTR  OLN,opinion,"5 Trade ideas excerpted from the detailed analysis and plan for premium subscribers 
Apache  NYSE APA   Ticker   APA

Apache   APA  ran to the downside hard in early August  It found a bottom at the end of the month and bounced  That bounce found resistance at a lower high and the 100 day SMA and held for 2 weeks  Last week it fell back again but to a higher low  The RSI is leveling at the edge of the bullish zone and the MACD is falling  Look for a push above Friday s close to participate higher   
Cigna  NYSE CI 

Cigna   CI  has had a smooth and steady trend higher out of consolidation in April  Last week ended with the price bouncing off of rising trend support  The RSI is at the mid line while the MACD is falling  but positive  Look for continued motion higher to participate   
Lowe s Companies Inc  NYSE LOW 

Lowe s   LOW  started to pullback from a high in May  After a few bounces  it found a bottom in July around 72  It retested that bottom in August and then confirmed a Double Bottom reversal in early September  It has continued higher from there  The RSI is bullish and rising with the MACD avoiding a cross down  Look for a push over resistance to participate higher   
Nektar Therapeutics  NASDAQ NKTR 

Nektar Therapeutics   NKTR  rose up off of support in August  stalling as it touched the March high  It pulled back from there two weeks ago to find support at a higher low last week  The RSI is holding and turning back up at the mid line while the MACD is falling  Look for a higher close to participate in an upside reversal   
Olin Corporation  NYSE OLN 
Olin   OLN  rose from an August 2026 low finding resistance in March  It consolidated in a rounding bottom from there  starting to rise out of it in August  It made a high 3 weeks ago and consolidated before a shallow pullback last week  Friday s candle suggests a reversal to the upside  The RSI has reset from an overbought condition and the MACD is crossed down  Look for continuation higher to participate   
Up Next  Bonus Idea
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad  picture reviewed Friday which heading into October Options Expiration sees the equity markets are all at record highs and looking strong 
Elsewhere look for Gold to continue higher in the short term while Crude Oil also slowly grinds its way up  The US Dollar Index may be pausing in the longer downtrend while US Treasuries are strong and rising short term  The Shanghai Composite and Emerging Markets both look to continue to move higher in slow fashion 
Volatility looks to remain at very low levels keeping the bias higher for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts agree completely on the longer timeframe  And all 3 look good on the shorter timeframe with the QQQ benefiting from short term consolidation in the IWM  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2017-10-16,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-apache-cigna-lowes-nektar-therapeutics--olin-200218868,200218868
147869,369385,CI,Anthem s  ANTM  Q3 Earnings Beat Estimates  Improve Y Y,opinion,Anthem Inc  s   NYSE ANTM   third quarter 2017 adjusted net income per share of  2 65 surpassed the Zacks Consensus Estimate of  2 41 by 10   The bottom line also jumped 8 2  year over year Operating revenues of  22 1 billion missed the Zacks Consensus Estimate by 0 1   The top line  however  grew 4 6  year over year due to premium rate increases as well as higher enrollment in the Medicaid  Medicare  and Local Group insured and self funded businesses Operational UpdateMedical enrollment increased 0 9  year over year to 40 3 million members  The rise was primarily recorded by commercial   specialty business as well as fully insured and self funded Local Group businesses  Medicare and Medicaid enrollment also contributed to the appreciation  This upside was partially offset by a decline in membership in the National Account and Individual businesses Total expenses increased nearly 5 1  to  21 3 billion in the reported quarter  mainly due to a 7  rise in benefitexpenses and 3  increase in selling expenses  both on a year over year basis Anthem s benefit expense ratio of 87  deteriorated 150 basis points  bps  from the prior year quarter  This was largely due to the one year waiver of the health insurance tax in 2017  However  the impact of a retroactive revenue adjustment in the Medicaid business and improved medical cost performance in the Individual and Large Group businesses were offsets The Selling  General   Administrative  SG A  expense ratio of 13 6  increased 120 bps from the year ago quarter  This was due to one year waiver of the health insurance tax in 2017 and the impact of fixed cost leverage on operating revenue growth  However  the rise was partially offset by increased spend to support growth initiatives during the quarter Segment UpdateCommercial   Specialty BusinessOperating revenues were  10 billion in the third quarter  up 4 1  year over year Operating gain totaled  534 6 million  down 16 2  year over year due to increased spend to support growth initiatives during the quarter and the impact of the one year waiver of the health insurance tax in 2017  The decrease was partially offset by improved medical cost performance in the Local Group and Individual businesses Operating margin was 5 3   down 130 bps year over year Government BusinessOperating revenues were  12 billion in the third quarter  up 5  from the prior year quarter Operating gain was  457 5 million  down 4 5  year over year  The downside reflected increased spend to support growth initiatives during the quarter and the impact of the one year waiver of the health insurance tax in 2017  However  the deterioration was partially offset by the timing impact of a retroactive revenue adjustment in the Medicaid business Operating margin was 3 8   declining 40 bps year over year Other  Operating revenues were  7 3 million in the third quarter  up 21 7  from the prior year quarter The segment reported an operating loss of  10 1 million  narrower than an operating loss of  38 5 million in the prior year quarter  The improvement was primarily driven by lower expenses related to the terminated Cigna  NYSE CI  acquisition Operating margin was 4 4   down 70 bps year over year Anthem  Inc  Price  Consensus and EPS Surprise   Financial UpdateAs of Sep 30  2017  Anthem had cash and cash equivalents of  6 1 billion  up 49 6  from year end 2016 As of Sep 30  2017  its long term debt declined 4  to  13 8 billion from year end 2016 As of Sep 30  2017  shareholder equity was  25 9 billion  up 3 3  from year end 2016 Operating cash flow was  5 5 billion for the first nine months of 2017  reflecting year over year growth of 83  Share Repurchase and Dividend UpdateDuring the quarter  Anthem repurchased 5 9 million shares of its common stock for  1 1 billion During the first nine months of 2017  it repurchased 8 8 million shares of its common stock for  1 6 billion As of Sep 30  2017  it had approximately  2 5 billion of share repurchase authorization remaining During the third quarter  Anthem paid a quarterly dividend of 70 cents per share  representing a distribution of cash totaling  181 4 million On Oct 24  2017  the Audit Committee declared third quarter dividend of 70 cents per share  payable on Dec 21  2017 to shareholders of record at the close of business on Dec 5  2017 Guidance for 2017Anthem expects adjusted net income in the range of  11 90 to  12 00 per share while in the previous quarter the company expected the same to be more than  11 70 The company has lowered its guidance for medical enrollment  Medical membership is now expected in the range of 40 40 2 million compared with the previous expectation of 40 2 40 4 million Fully insured membership and self funded membership are likely to be in the band of 15 1 15 2 million and 24 9 25 million  as against the previously guided range of 15 2 15 3 million and 25 25 1 million  respectively Operating revenues are projected in the range of  88 5  89 5 billion  unchanged from the previous guidance Benefit expense ratio is expected to be around 86 8  against the earlier projection of 87   with adjustment of 30 bps SG A ratio is expected to be around 13 8  compared with the earlier projection of 13 6   with adjustment of 30 bpsAnthem expects operating cash flow to be more than  4 billion compared with the previous projection of more than  3 5 billion Zacks Rank and Performance of Other PeersAnthem presently carries a Zacks Rank  3  Hold   You can see  Among other players in the Medical sector that have reported their third quarter earnings so far  Abbott Laboratories    NYSE ABT       Johnson   Johnson   NYSE JNJ   and UnitedHealth Group Incorporated   NYSE UNH   beat their respective Zacks Consensus Estimate Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/anthems-antm-q3-earnings-beat-estimates-improve-yy-200220945,200220945
147885,369401,CI,Collegium Pharmaceutical  COLL  Looks Good  Stock Adds 6  In Session,opinion,Collegium Pharmaceutical  Inc    NASDAQ COLL   was a big mover last session  as the company saw its shares rise 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  9 44 to  10 98 in the past one month time frame The move came after the company signed a value based contract with Cigna Corporation  NYSE CI  regarding its Xtampza ER The company has seen one positive estimate revision in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months  suggesting that more solid trading could be ahead for Collegium Pharmaceutical  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road Collegium Pharmaceutical currently has a Zacks Rank  3  Hold  while its  is negative   Collegium Pharmaceutical  Inc  Price   A better ranked stock in the Medical   Drugs industry is Corbus Pharmaceuticals Holdings  Inc    NASDAQ CRBP    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is COLL going up  Or down  Predict to see what others think   or 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-10-06,Zacks Investment Research,https://www.investing.com/analysis/collegium-pharmaceutical-coll-looks-good-stock-adds-6-in-session-200217473,200217473
147886,369402,CI,4 HMOS For Gains Amid Constant Regulatory Chaos ,opinion,"Healthcare  particularly Obamacare  had been at the receiving end of President Trump  even before he assumed office  The Republicans  repeal and replace efforts have  however  failed  with the American Health Care Act  AHCA  not getting enough support in the House  thanks to a solid opposition from both conservative and moderate lawmakers 
Failure of Last Ditch Efforts
The most recent effort  in the form of the Graham Cassidy bill  also failed to get any success  due to numerous suggestions having been not well received by the industry participants  Among the most unpopular of them were putting an end to individual and employer mandate  giving a block grant to Medicaid  loosening provisions with regard to pre existing conditions  elimination of Obamacare subsidies that lower premiums  deductibles and co pays  plus ending cost sharing subsidies by 2020 
Also  CBO  Congressional Budget Office  analysis of the proposal fund that millions of Americans would lose health coverage due to  1 trillion in cuts to Medicaid through 2026  and that the bill would have resulted in loss of health insurance coverage  has destabilized insurance markets and decreased access to affordable coverage and care for commoners 
A Short Lived Relief 
Though the failure of final attempts to undo Obamacare brought a sigh of relief to the industry  it should only be temporary  given the recent comments made by Chairman of the Republican Study Committee  Mark Walker  who stressed efforts to continue with the fight to remove Obamacare 
How to Play the Sector 
Amid this conundrum  investors primarily want to invest in stocks with a robust business model to protect and shield from market swings  Many good players from the space have remodeled their business mix  diversified into new product classes  new territories and added new functionalities to provide them with an armor against market vagaries 
Insurers  share price performance and steadily growing business profits stand as a testament to their ability to successfully sail through these high tides  created by these ill fated reform proposals ever since   
Though the repeal and replace efforts have been creating noise causing investors to shy away from the sector  it would be unwise to turn a blind eye to some stocks in this space  which offer solid businesses to serve up handsome returns over time 
These stocks sporting a favorable Zacks Rank are indicative of witnessing positive estimate revisions over time  which generally translate into rapid price appreciation 
They also pride over a positive earnings surprise history and have outperformed the  s increase of 44  in the past year  Additionally  they sport a Value Style Score of A or B  Back tested results show that stocks with a Value Score of A or B  when combined with a Zacks Rank  1  Strong Buy  or 2  Buy   effectively outperform other stocks 
Some of our preferred choices are 
Anthem Inc    NYSE ANTM   carries a Zacks Rank  2  It sports a Value score of A The stock beat estimates in three of the last four quarters  with an average positive surprise of 8 6   Also the stock has seen the Zacks Consensus Estimate for 2017 and 2018 being revised  0 7  and 0 3  upward  respectively  over the last 90 days  The company returned 55  in a year  You can see  
The company is poised for long term growth  given low exposure to the troubled health insurance exchanges and relatively small share of revenue from Medicaid  which might see change in funding  Also  a strong balance sheet offers the potential for accretive deals 
UnitedHealth Group Inc    NYSE UNH   carries a carries the same bullish Zacks Rank of 2  It sports a Value score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 4 6   Also  the Zacks Consensus Estimate for 2017 and 2018 has been inched up 0 7  and 0 4   respectively  in the last 90 days  The company returned 45  in the past year UnitedHealth is the leader in the health insurance space with massive diversified operations  The company s focus on growing health services business named Optum as well as expansion of international operations are particularly impressive  It is also broadening reach in the Medicare business  claiming a huge demand  thanks to the growing baby boomer population 
Centene Corp    NYSE CNC   is also a Zacks Rank  2 company  It sports a Value score of A  The stock beat estimates in three of the last four quarters  with an average positive surprise of 7 7   Also  the Zacks Consensus Estimate for 2017 and 2018 has been raised 3 4  and 1 3   respectively  over the last 90 days  The company returned 55  in a year s time Centene has a relatively larger portion of revenues coming from Medicaid business  which might notice a change in funding and affect this business line for the insurer  The company s growth of its Medicare business as well as flourishing international markets should fetch long term growth   
Cigna Corp    NYSE CI   carries a Zacks Rank  2  It sports a Value score of B  The stock beat estimates in each of the last four quarters with an average positive surprise of 10   Also  the Zacks Consensus Estimate for 2017 and 2018 has been nudged up 2 8  and 1 3   respectively  in the last 90 days  The company returned 50  over a year 

The insurer is poised for long term growth on the back of a robust Global Supplemental business  growing Government business and an increasing membership  Its strong capital position will also allow investments in business portfolio  In addition  strategic mergers and acquisitions  plus share repurchases will pave way for the company s future growth 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/4-hmos-for-gains-amid-constant-regulatory-chaos-200217828,200217828
147888,369404,CI,Why The Earnings Streak Will Continue For Cigna  CI  ,opinion,Looking for a stock that might be in a good position to beat earnings at its next report  Consider Cigna Corporation   NYSE CI    a firm in the Insurance   Multi line industry  which could be a great candidate for another beat This company has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  In fact  in these reports  CI has beaten estimates by at least 10  in both cases  suggesting it has a nice short term history of crushing expectations Earnings in FocusTwo quarters ago  CI expected to post earnings of  2 44 per share  while it actually produced earnings of  2 77 per share  a beat of 13 5   Meanwhile  for the most recent quarter  the company looked to deliver earnings of  2 48 per share  when it actually saw earnings of  2 91 per share instead  representing a 17 3  positive surprise Cigna Corporation Price and EPS Surprise   Thanks in part to this history  recent estimates have been moving higher for Cigna  In fact  the  for CI is positive  which is a great sign of a coming beat After all  the Zacks Earnings ESP compares the most accurate estimate to the broad consensus  looking to find stocks that have seen big revisions as of late  suggesting that analysts have recently become more bullish on the company s earnings prospects  This is the case for CI  as the firm currently has a Zacks Earnings ESP of  3 72   so another beat could be around the corner This is particularly true when you consider that CI has a great Zacks Rank  2  Buy  which can be a harbinger of outperformance and a signal for a strong earnings profile  You can see  When you add this solid Zacks Rank to a positive Earnings ESP   of the time  so it seems pretty likely that CI could see another beat at its next report  especially if recent trends are any guide Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-streak-will-continue-for-cigna-ci-200218008,200218008
147910,369426,CI,Cigna Hits 52 Week High On Strong Q2 Results  Upbeat View,opinion,"On Aug 16  the stock of Cigna Corp    NYSE CI   hit a 52 week high of  180 42  The rise in the stock is believed to have been driven by better than expected second quarter results and a subsequent guidance raise Cigna s second quarter earnings and revenues beat estimates by 17 3  and 2 9   respectively  The earnings beat reflected strong contribution from each of the company s business segments 
Cigna pulled up its 2017 earnings guidance after strong results  It expects adjusted income from operations between  2 50 billion and  2 58 billion  previous estimate was  2 41 billion to  2 53 billion   or  9 75 to  10 05 per share   9 25  9 75  
It  however  maintained the guidance for revenue growth rate at 3  to 4   and the global medical customer growth range of 0 5 million to 0 6 million In one year  the stock has rallied 35 6   outperforming the  s gain of 30  and significantly higher than the return of 12 4  from the S P 500 index 

Investors also favorably viewed Cigna s recent purchase of Zurich Insurance Middle East  which will strengthen its foothold in the Gulf countries of UAE  Lebanon  Kuwait and Oman  The deal will bolster its already strong international business  the premium at which has witnessed a 12  CAGR to  1 9 billion in 2016 from  0 9 billion in 2009   
This deal has made the company s investors quite optimism about its efforts to diversify operations outside U S  markets that are faced with stiff competition and stringent regulations 
Shares also received a boost from the lifting of MA sanctions  last month  by CMS  The company was restricted to sell MA plans since Jan 2016  after it was found guilty of violating regulations relating to these 
Now  with the sanctions lifted  Cigna will be able to participate in an open enrollment period for 2018 plans  which will start from Nov 1  2017  The development will add to the company s organic growth by increasing MA membership 
Shares of the company have performed strongly despite the failed merger of Cigna with Anthem Inc  Cigna s investors have the confidence in its ability to grow as a stand alone entity 
Recently  the company projected 2021 earnings per share  EPS  of  16  and an EPS annual growth guidance of 10 13   The 2021 EPS guidance took into consideration substantial balance sheet strength of  7 billion to  14 billion deployable cash 
Cigna carries a Zacks Rank  3  Hold   Some better ranked players in the space are Aetna Inc    NYSE AET    Anthem  Inc    NYSE ANTM   and WellCare Health Pans Inc    NYSE WCG    Each of these stocks carries a Zacks Rank  2  Buy   You can see  
Aetna  one of the largest health benefits companies  beat estimates in each of the last four quarters with an average positive surprise of 19  
Anthem is a health care company  which provides medical products  through its subsidiaries  It surpassed estimates in three of the last four quarters with an average positive surprise of 8 6  
WellCare Health Plans  provides managed care services targeted exclusively at government sponsored healthcare programs  It beat estimates in each of the last four quarters with an average positive surprise of 47 4  
One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/cigna-hits-52week-high-on-strong-q2-results-upbeat-view-200207986,200207986
147911,369427,CI,UnitedHealth Group Latest Acquisition Gives Competitive Advantage,opinion,"After UnitedHealth Group s subsidiary Optum recently purchased the Advisory Board for   we took a harder look at one of the nation s largest insurers and started to piece together their plan to become the complete healthcare package 
Who is UnitedHealth Group 
UnitedHealth Group  NYSE UNH  has a market cap of  184 billion according to Yahoo  NASDAQ AABA  Finance and operates two large subsidiaries  United Healthcare   Optum 
United Healthcare  which at its core is one of the nation s largest healthcare insurers  along with an international presence  You ll see the name United Healthcare along with other of the large insurers like Wellpoint  WLP   Aetna  NYSE AET   Cigna Corporation  NYSE CI  and others  They provide health benefit plans for individuals  national employees  public sector employees  military personnel and more 
Optum at its core is a healthcare data analytics firm  They provide   Optum Insight  health information  technology  services and consulting   Optum Health  population health management and healthcare delivery  and OptumRx  pharmacy care services   However they have a number of subsidiaries under them including OptumBank  Optum 360  Optum 360 Coding  Optu Care  OptumLabs  OptumRx  I ll focus on OptumCare in a bit 
Now why did Optum buy the Advisory Board for  1 3 billion 
The Advisory Board has partnerships with 4 400 healthcare organizations and provides data  research and consulting to these facilities  Optum want s to leverage those relationships and control more big data  UnitedHealth can now utilize the AB s clients to incrementally bolster its provider network and expand its user base of its Optum Insight software which analyzes the big data of Optum s and the AB s network  Here is a video on  to lower cost on multiple fronts 
Now Optum will control one of the largest healthcare consulting firms  Advisory Board  and has access to all of their data  In a time where big healthcare data is worth big money 
The biggest challenge with the acquisition will likely be to Advisory Board clients who entrust their data to the Advisory Board and may rely on its research in their pricing negotiations with big insurers like UnitedHealthcare  Yet Optum maintains that they re separated from UnitedHealthcare  at times advising hospitals and insurers that complete directly with UnitedHealthcare 
So at this point  UnitedHealth Group owns a large insurer network  and a large amount of analytical data to create predictive models to lower costs and provide competitive advantages 
Other Significant Acquisitions
In the last couple years  Optum s subsidiary OptumCare has been making other additional large acquisitions into the care provider realm  Meaning they are purchasing the facilities that people are actually getting their healthcare services from 
Some of these acquisitions are 
MedExpress   Owned by Optum has 141 urgent care centers around the country and growing  This acquisition happened in 2015 and since then these facilities have continuously popped up over 11 states at a time where outpatient procedures and checkups have been popularized by lower cost and convenient locations within local neighborhoods  To give you an idea the Urgent Care Market across the county has increased 14  to 9 300 centers since 2008 
New West Physicians   Owned by Optum  in 2017 New West Physicians  one of metro Denver s largest physician practices with 120 health care providers was acquired  These type of physician practices have been common acquisitions across multiple states including ProHealth Physicians of Connecticut in 2016  and a number of other states 
Surgical Care Affiliates   Owned by Optum in 2017  Surgical Care Affiliates operates 190 ambulatory surgery centers and surgical hospitals  most as joint ventures with physicians and health systems  Now those over 1 million patients that Surgical Care Affiliates serves per year  will in some way be touched by UnitedHealth Group 
Now at this point  UnitedHealth Group owns are large insurer network  a large amount of analytical data and the actual facilities where people get healthcare treatment 
Conflict of Interest 
Currently UnitedHealth Group has gotten away with these acquisitions that some have started to question  Traditionally patients have wanted to get the best healthcare possible from their doctor and insurers want to save costs every way they can  So what happens when the insurer now owns the doctor  insurance and the big data needed to influence the entire process 
Future of UnitedHealth Group
If current acquisitions are an indicator of future planning  I can see the UnitedHealth Group lowering their operating costs in a number of ways since they would own the entire patient process  They would own the facilities that patients go to get healthcare  the insurer who pays those healthcare facilities and the big data needed to inform future decisions  There is huge cost saving measures here that will provide a direct competitive advantage over their competitors in every sector 
Disclosure Andrew of Wallet Squirrel doesn t own any positions of UNH in his   but as a dividend investor  he may purchase UNH at a 1 53  dividend in the future ",2017-09-03,Modest Money,https://www.investing.com/analysis/unitedhealth-group-unh-latest-acquisition-gives-competitive-advantage-200211173,200211173
147912,369428,CI,Health Care Stocks In Focus As Repeal   Replace Gains Steam ,opinion,"Once again efforts are being made to repeal and replace Obamacare via the Graham Cassidy bill This bill is another attempt to undo Obamacare  after repeal and replace efforts by Trump hit the rocks due to insufficient votes The ChangesA number of proposals included in the plan would alter Obamacare  Among  the most unpopular of these are putting an end to individual and employer mandate  giving a block grant to Medicaid  elimination of  Obamacare subsidies that lower premiums  deductibles and co pays  and ending of cost sharing subsidies by 2020 Strict provisions relating to pre existing conditions are also likely to be loosened  While insurers will have to provide coverage for pre existing conditions  something that Obamacare also required   they will have the ability to charge more to sicker patients 
Concerns of Industry ParticipantsIn a letter addressed to the leaders McConnell and Schumer  America s Health Insurance Plans   AHIP   expressed its concerns that the bill  if passed  might have on the health care industry  The group is of the opinion that the proposal fails to stabilize the individual insurance market  which provides subsidized plans to low income people  It will also cause people with pre existing conditions to fall out of the insurance net and disrupt the Medicaid market  This would make health insurance less affordable and unattractive  ultimately causing more people to forego insurance  thereby leading to an increase in the uninsured rate Bernard Tyson  chairman and CEO of the sprawling Kaiser Permanente nonprofit health system  also holds a similar view on the proposal Overall  the various participants of the health care sector remain unsupportive of the bill and are lobbying against it Impact on Health Care CompaniesThe companies having high exposure to exchange business and Medicaid such as Centene Corp    NYSE CNC   and Molina Health Care   NYSE MOH   are likely to suffer the maximum earnings decline Hospital companies in general are expected to suffer from the likely increase in uninsured patients which will lead to a rise in uncompensated care and consequently increase their bad debt  Volumes will also be expected to remain under pressure as people shy away from medical help due to high deductibles and out of pocket costs Nevertheless  companies having more diversified operations such as UnitedHealth Group Inc    NYSE UNH    Aetna Inc    NYSE AET   and Cigna  NYSE CI  are relatively better positioned to sail through The concern was reflected in the decline of 0 8  in the Health Care Select Sector SPDR ETF  NYSE XLV  on Sep 19  just after the proposal was made The health care sector has been in the limelight since Donald Trump took charge  Thenumerous proposals of repeal and replace   from time to time  has sent shock waves across the industry  The sector however  has been able to shrug off all concerns and perform strongly as evident by a gain of 18 8  year to date compared with the 11  returns by the S P 500   Going ForwardSep 30  is the deadline for the bill to pass the Senate with a simple majority vote  50 rather than 60   under the rules of reconciliation  The bill is fast gaining support  this time also likely from a key Republican governor  Doug Ducey of Arizona  This could lug along the support of Senator John McCain  who voted against the last repeal bill 
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/health-care-stocks-in-focus-as-repeal--replace-gains-steam-200214646,200214646
147935,369451,CI,Berkshire Hathaway  BRK B  Q2 Earnings  What s In Store ,opinion,Berkshire Hathaway Inc   NYSE BRKa   is expected to report second quarter 2017 results on Aug 4 after the market closes  Last quarter  the company delivered a negative earnings surprise of 15 79   Let s see how things are shaping up for this announcement Factors to be Considered this QuarterBerkshire Hathaway is likely to report higher catastrophe losses in the soon to be reported quarter  which in turn will render volatility to the company s earnings  The company has also likely witnessed weaker underwriting results in the second quarter The property and casualty  P C  insurer has also likely experienced a decline in operating earnings across Insurance Operations and Finance   Financial products segments Further  the company s most non insurance subsidiary  BNSF  has likely incurred higher capital expenditure in the second quarter However  the company s Railroad  Utilities and Energy units have likely witnessed a rise in operating revenues  In addition  the segment has possibly displayed improved net earnings in the yet to be reported quarter  driven by increased earnings from the railroad as well as energy businesses With respect to the surprise trend  the company delivered positive surprises in two of the last four quarters  but with an average miss of 3 12  Berkshire Hathaway Inc  Price and EPS Surprise    Earnings WhispersOur proven model does not conclusively show that Berkshire Hathaway is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Berkshire Hathaway has an Earnings ESP of 0 00   which makes surprise prediction difficult  This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 85  You can uncover the best stocks to buy or sell before they are reported with our  Zacks Rank  Berkshire Hathaway carries a Zacks Rank  4  Sell   We caution against all Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome companies worth considering from the insurance industry with the right combination of elements to come up with an earnings beat this quarter are as follows Cigna Corporation   NYSE CI   is set to report second quarter earnings on Aug 4 with an Earnings ESP of  1 61  and a Zacks Rank  2  You can see  Manulife Financial Corporation   NYSE MFC   has an Earnings ESP of  7 32  and a Zacks Rank  2  The company is set to report second quarter earnings on Aug 9 Sun Life Financial Inc    TO SLF   has an Earnings ESP of  2 70  and a Zacks Rank  1  The company is slated to report second quarter earnings on Aug 9 More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ,2017-08-02,Zacks Investment Research,https://www.investing.com/analysis/berkshire-hathaway-brkb-q2-earnings-whats-in-store-200205115,200205115
147936,369452,CI,3 Reasons Why Cigna Corporation  CI  Is Poised To Beat Earnings,opinion,"Cigna Corporation   NYSE CI   is an investor owned employee benefits organization with subsidiaries who are major providers of health care products and services  group life  accident insurance  retirement products  and investment management  More importantly  the company will release its quarterly earnings report before the market opens on August 4 
Cigna currently sports a Zacks Rank  2  Buy  and has defeated its earnings projections in twelve of its past thirteen operational quarters  including an impressive beat last quarter of 13 52   Furthermore  Cigna operates in the Insurance   Multi line industry  which currently sits in the top 44  of the Zacks Industry Rank 
Cigna Corporation features a strong Zacks Rank  an impressive quarterly earnings performance  as well as an Earnings ESP of 1 61    All of these factors should allow investors to possess optimism as we approach its quarterly earnings release 
Here are 3 additional reasons to be bullish on Cigna Corporation as we near its report date 1        Strong Style Scores
The company currently holds a  B  Value grade on our Style Scores System  which means that we view Cigna as undervalued in comparison with the market  For example  Cigna possesses a cash price ratio of  31 00 and price cash flow ratio of  8 44  both of which defeat the industry averages of  4 89 and  7 44  respectively  Furthermore  the company boasts an impressive cash flow per share of  10 57  in comparison with the industry average of  2 90 
Additionally  Cigna Corporation holds an  A  grade for Growth  which means that the company holds intriguing future growth prospects  For instance  Cigna Corporation holds a projected EPS growth of 20 61  and RoE of 15 15   both of which compare favorably to the industry averages of 7 94  and 7 50   respectively 2        Increasing Membership
Cigna has continued growing its membership over the past couple of years  The company finished 2016 with 15 2 million global medical customers  with the addition of approximately 200 000 customers  Furthermore  Membership continued to increase throughout the first quarter of 2017 with an increase of 537 000 customers 
Membership is projected to continue rising moving forward  given its diversified product portfolio  a wide agent network  and superior service  For 2017  Cigna expects global medical customers to grow from 500 000 to 600 000 lives over year end 2016  reflecting the strong growth experienced by the company across its various market segments 3        Growing Customers Among Key Divisions
Cigna Corporation is projected to witness increases in customers throughout numerous divisions of the company  For example  customers within the pharmacy division are expected to increase to 8 909  which would constitute year over year growth of 7 31   Also  customers in the dental division are projected to increase to 14 880  which would represent strong year over year growth of 6 28  
These consensus estimates are from our exclusive non financial metrics estimate file  These estimates are updated daily and are based on the independent research of expert stock analysts  
Cigna Corporation is expected to report sales of  9 98 billion  which would be an increase from last year s figure of  9 89 billion  Also  the company is projected to report earnings of  2 48 per share  which would constitute impressive year over year growth of 25 25  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without 
Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future   Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-cigna-corporation-ci-is-poised-to-beat-earnings-200205175,200205175
147947,369463,CI,Brown   Brown  BRO  Q2 Earnings Beat  Revenues Improve Y Y,opinion,Brown   Brown  Inc    NYSE BRO   reported second quarter 2017 earnings of 49 cents per share that beat the Zacks Consensus Estimate by 4 3   However  earnings remained flat year over year   The quarter witnessed improved revenues  partially offset by a rise in expenses  Nonetheless  the company saw an increase in its commissions and fees Including change in estimated acquisition earn out payables of 3 cents per share  net income came in at 46 cents per share  down 2 1  from the year ago quarter Behind the HeadlinesTotal revenue amounted to  466 3 million  beating the Zacks Consensus Estimate of  465 million by approximately 0 3   Also  the top line improved 4 4  year over year riding on higher commissions and fees  Organic revenue growth was 1 6  in the reported quarter Commissions and fees rose 4 3  year over year to  464 7 million Investment income fell 20  year over year to  0 4 million Total expenses increased 6 2  to  358 3 million  owing to a rise in employee compensation and benefits  other operating expenses  depreciation  interest as well as change in estimated acquisition earn out payables Net income before interest  income taxes  depreciation  amortization and change in estimated acquisition earn out payables  EBITDAC  margin decreased 120 basis points to 32 3  Brown   Brown  Inc  Price  Consensus and EPS Surprise    Financial UpdateBrown   Brown exited the second quarter with cash and cash equivalents of  600 3 million  up 16 4  from the 2016 end level Long term debt of  965 4 million as of Jun 30  2017 was down 5 2  from  1 0184 billion at the end of 2016 Dividend UpdateIn the second quarter  this Zacks Rank  4  Sell  company s board of directors announced a quarterly dividend of 14 cents per share On Jul 13  2017  the company s board approved a quarterly cash dividend of 13 5 cents per share  The dividend will be paid on Aug 16 to shareholders on record as of Aug 9  2017 Stocks to ConsiderSome better ranked stocks from the insurance industry are Everest Re Group  Ltd    NYSE RE    Reinsurance Group of America  Incorporated   NYSE RGA   and Cigna Corporation   NYSE CI    Each stock holds a Zacks Rank  2  Buy   You can see  Everest Re Group offers reinsurance and insurance products  The company is set to release first quarter results on Jul 24 Reinsurance Group is primarily engaged in life reinsurance and international life and disability insurance on a direct and reinsurance basis  The company is set to release second quarter results on Jul 27 Cigna provides insurance plus related products and services in the United States and internationally  The company is slated to release second quarter results on Aug 4 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/brown---brown-(bro)-q2-earnings-beat,-revenues-improve-y-y-200201801",200201801
147967,369483,CI,Why Is It Right To Retain Manulife Financial  MFC  Stock Now,opinion,Shares of Manulife Financial Corporation   NYSE MFC   have soared 48 13  in the last one year  outperforming the Zacks categorized  industry s gain of 44 82   We expect the stock to retain this momentum  courtesy a few good positives This Zacks Rank  3  Hold  life insurer remains focused on developing its business in Asia  displaying a solid operational performance  Notably  the Asia business now contributes to one third of the company s earnings  Additionally  the division has been witnessing expansion in core earnings over the past few years  driven by an improved in force business and a continued rise in new business volumes in Asia  Manulife Financial expects to maintain its hold over the Asian markets to drive its long term growth Manulife Financial s inorganic growth remains impressive with strategic acquisitions  These have not only added capabilities to its compelling portfolio but also expanded its geographic reach Further  the company continues to diversify its wealth and asset management business around the world  Notably  at the end of first quarter 2017  the company achieved over  1 trillion in global assets under management and administration  Interestingly  this achievement was a milestone for the company as the whopping  1 trillion mark was never crossed earlier  Also  the company has been witnessing positive net flows over the last 29 quarters   Manulife expects to carry on with this positive trend in the near term However  core earnings at the Canadian division have been displaying a declining graph over a considerable period of time  The company anticipates the division s core earnings to remain volatile in the near term due to decreasing group benefit sales This apart  the ongoing volatile global equity markets and low bond yields have been largely affecting the company s capital position which might lead the stock to underperform Nonetheless  valuation is attractive at present as the stock is currently trading at a price to book multiple of 1 26  a massive 44 7  discount to the industry average of 2 28  in the last one year  Besides  the company has a trailing 12 month return on equity  ROE  of 10 6   widely higher than the industry s 7 1  average  Its expected long term earnings growth is decently pegged at 10 20    Furthermore  Manulife Financial carries a  of B  Here V stands for Value  G for Growth and M for Momentum and the score is a weighted combination of these three factors   Stocks to Consider  Some better ranked stocks from the insurance industry are Reinsurance Group of America  Incorporated   NYSE RGA    Cigna Corporation   NYSE CI   and FBL Financial Group  Inc    NYSE FFG    Each stock carries a Zacks Rank  2  Buy   You can see  Reinsurance Group deals in reinsurance business  The company has delivered positive surprises in three of the last four quarters with an average beat of 5 08  Cigna provides insurance plus related products and services in the United States and internationally  The company has delivered positive surprises in three of the last four quarters with an average beat of 1 35  FBL Financial sells individual life insurance and annuity products  The company has delivered positive surprises in two of the last four quarters with an average beat of 1 98  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-10,Zacks Investment Research,https://www.investing.com/analysis/why-is-it-right-to-retain-manulife-financial-(mfc)-stock-now-200200052,200200052
148006,369522,CI,BioDelivery Inks New Contract With CVS Caremark  Shares Up,opinion,BioDelivery Sciences International  Inc  s   NASDAQ BDSI   shares increased more than 5  after the company announced an agreement with CVS Caremark  a subsidiary of CVS Health Corporation   NYSE CVS    The agreement will extend access to BioDelivery s pain management product Belbuca and opioid dependence product Bunavail through 2020 The company has also separately announced that Belbuca prescription sales had reached its highest point of 1 657 prescriptions this month  Per the Symphony Health data  this publicized figure has exceeded the previous peak from Dec 2016  The new managed care contract with CVS Caremark may expand the recent gains in prescriptions for Belbuca BioDelivery is presently exploring commercial options for for both Belbuca and Bunavail s longer term growth within and outside the U S  The company is working on securing new or improved positioning on other managed care contracts either on an exclusive or preferred status  The new managed care contract with CVS Caremark holds potential as it represents a significant portion of the covered lives in the U S We remind investors that Belbuca was launched in Feb 2016 in the U S  by Endo Pharmaceuticals   NASDAQ ENDP    However in Jan 2017  BioDelivery reacquired worldwide rights to Belbuca from Endo  This was followed by a strategic decision announced by Endo in Dec 2016 to discontinue the commercial efforts for the U S  branded pain business  As a result  the company started recording product revenues for Belbuca against royalties being recorded previously BioDelivery s shares have significantly outperformed the Zacks classified  industry so far this year  Shares of the company rallied 57 1   while the industry registered an increase of 10 5  Apart from the CVS Caremark deal  BioDelivery is also pursuing additional managed care wins for Belbuca and is in contracting discussions with Cigna  NYSE CI   ProCareRx  EnvisionRx  Envolve  Health Partners and Kaiser BioDelivery also continues to work on improving Bunavail s performance  In the first quarter of 2017  Bunavail recorded 52 4  year over year surge in sales to  3 2 million  The improved prescription potential in new managed care contracts should boost sales and profitability of Bunavail further BioDelivery Sciences International  Inc  Price   Zacks Rank   Key PicksBioDelivery currently carries a Zacks Rank  3  Hold   A better ranked stock in healthcare sector is Regeneron Pharmaceuticals  Inc    NASDAQ REGN    which sports a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10 over the last 60 days  The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  Looking for Ideas with Even Greater Upside  Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-06-21,Zacks Investment Research,"https://www.investing.com/analysis/biodelivery-inks-new-contract-with-cvs-caremark,-shares-up-200196953",200196953
148064,369580,CI,When Will Stocks Perk Up ,opinion,"It s too bad the S P NASDAQ s seven day winning streak had to run right into the long Memorial Day weekend  The extra day off led to a groggy start this week  which saw the major indices lose ground but still stay atop psychological milestones that were recaptured just last week  The S P was off by 0 12  to 2412 9  its fourth straight session above 2400  The Dow declined 0 24  to 21029 5 and the NASDAQ slipped 0 11  to 6203 2 Stocks may have started the week in a haze with very low volume  in fact  one of the editors below said it s   as  dead as I have ever seen it in my career    but they should have a chance to perk up as this short week progresses  We re scheduled to receive the turn of the month economic reports in the days ahead  including ADP Employment and ISM Manufacturing on Thursday  and of course the Government Employment Situation report on Friday Data has been pretty good of late  as seen just this morning with solid readings for Personal Income   Outlays and Consumer Confidence  Stocks may be able to wake up if this trend continues  as long as Washington doesn t ruin things With the markets closed on Monday  the portfolios had to do some catch up  Black Box Trader s weekly realignment usually starts off the week  but it was postponed until today  There were six swaps this time  Zacks Confidential is also coming a day later  Meanwhile  Short List is right on time with three swaps  including a double digit winner Today s Portfolio Highlights Zacks Short List  The portfolio swapped out three positions in this week s adjustment  and one of them was a double digit winner for the service  The short covered names are   Bitauto Holding Limited  BITA   13 9  
  Atheanahealth Inc   ATHN  and
  Ctrip com Intl  CTRP The new buys that replaced these names are   Amazon com  NASDAQ AMZN 
  Apache Corp  NYSE APA  and
  Occidental Petroleum  NYSE OXY Learn more about this emotion free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide  Zacks Confidential  One of the best trends to follow are those that have been avoided for a long time and have a broad macro tailwind  In this week s Zacks Confidential  Brian Bolan explains why the truckers fit this definition to a T  Ironically  the space went soft despite dropping oil prices  but Steve is giving Brian the opportunity to explain why that s about to change  Read his article and get a trio of recommendations by clicking  Truckers Hauling in Big Gains Black Box Trader  Half of the six stocks that were sold from the portfolio this week were positive  Those sells included   UnitedHealth Group  NYSE UNH   6 5  
  Ultra Clean Holdings  UCTT   6 2  
  Toll Brothers  TOL   2 8  
  The Carlyle Group  NASDAQ CG 
  Platform Specialty  PAH  and
  Huntsman Corp  HUN The six new stocks that were bought today to replace these names are   Best Buy  BBY 
  Burlington Stores  BURL 
  Cigna Corp  NYSE CI 
  KB Home  KBH 
  PVH Corp  NYSE PVH  and
  Restoration Hardware  RH Read the Black Box Trader s Guide to learn more about this computer driven service designed to take the emotion out of investing Zacks Counterstrike   The low volume and tight ranges we saw from last week  continued over the long weekend to bring about a very boring day  While investors might appreciate a nice break from the volatility  traders are painfully trying to wait out the boredom  As we head into the summer  it seems like this historically low volatility will remain   It really doesn t get more boring than this  The market is dead as I have ever seen it in my career  If you subscribe to the other newsletters and are frustrated at the lack of picks  please be patient  The last thing you want to do is overtrade in this environment and my personal trading lately is proof of that   My watch list has some tempting stocks  but not many setups  So the game now is patience  we must wait before we act  Hopefully later in the week the market will get moving     Jeremy MullinHave a Good Evening 
Jim Giaquinto
Recommendations from Zacks  Private Portfolios   Believe it or not  this article is not available on the Zacks com website  The commentary is a partial overview of the daily activity from Zacks  private recommendation services  If you would like to follow our Buy and Sell signals in real time  we ve made a special arrangement for readers of this website  Starting today you can see all the recommendations from all of Zacks  portfolios absolutely free for 7 days  Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises  which we ve predicted with an astonishing 80   accuracy  ",2017-05-30,Zacks Investment Research,https://www.investing.com/analysis/when-will-stocks-perk-up-200192243,200192243
148095,369611,CI,FBL Financial  FFG  And Units  Ratings Upgraded By A M  Best,opinion,FBL Financial Group  Inc    NYSE FFG   and its units recently received rating action from credit rating giant A M  Best  The rating agency upgraded the Long Term ICR to  bbb   from  bbb  of FBL Financial  The rating outlook is revised to stable from positive At the same time  the rating agency upgraded the Long Term Issuer Credit Rating  Long Term ICR  to  a   from  a  and reiterated Financial Strength Rating  FSR  of A  Excellent  of Farm Bureau Life Insurance Company   FBL    a unit of FBL Financial Group  The rating giant revised the affiliate s Long Term ICR outlook to stable from positive  with the FSR outlook remaining stable The rating upgrade came on the back of its solid risk adjusted capitalization  strong operational performance  positive earnings trends and a capitalization profile of a very high quality However  continued spread contraction with a high percentage of annuity and universal life liabilities at guaranteed minimum crediting rates can partially offset the positives  This apart  absence of surrender charge protection in annuity liabilities and FBL s highly concentrated business profile in the Midwest and Western geographic regions might lead to a rating downgrade Rating affirmations or upgrades from credit rating agencies play an important role in retaining investor confidence as well as in maintaining credit worthiness of a stock  On the other hand  rating downgrades not only damage business but also increase the cost of future debt issuances  We believe that such ratings will help FBL Financial to retain investor confidence and write more businesses going forward   Zacks Rank and Share Price MovementFBL Financial currently carries a Zacks Rank  3  Hold   Shares of FBL Financial lost 6 24  since the release of first quarter 2017 earnings results  underperforming the  industry s decline of 1 45   However  we expect bottom line growth on the back of higher net investment income and improved revenues as well as growing book of profitable business and robust capital position should help the stock to turn around in the near term Stocks to ConsiderSome better ranked stocks from the same space include Cigna Corporation   NYSE CI    James River Group Holdings  Ltd    NASDAQ JRVR   and Old Republic International Corporation   NYSE ORI    Each of these stocks holds a Zacks Rank  2  Buy   You can see   Cigna Corp   which operates as a health services organization  offers insurance and related products and services in the United States and internationally  The company delivered positive surprises in three of the last four quarters with an average beat of 1 35   James River Group provides specialty insurance and reinsurance services in the United States  The company delivered positive surprises in all of the last four quarters with an average beat of 9 47    Old Republic International engages in the insurance underwriting and related services business primarily in the United States and Canada  The company delivered positive surprises in two of the last four quarters with an average beat of 11 37  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-05-14,Zacks Investment Research,https://www.investing.com/analysis/fbl-financial-(ffg)-and-units'-ratings-upgraded-by-a.m.-best-200189231,200189231
148096,369612,CI,CNO Financial Hikes Dividend  Announces Share Buyback Plan,opinion,The board of directors of CNO Financial Group   NYSE CNO   recently announced a dividend hike along with a share repurchase program  Year to date  the stock has gained approximately 11  compared with the 1  increase by the Zacks classified  industry     In a bid to return more value to shareholders  the board of directors of CNO Financial approved a 13  hike in its quarterly dividend  Previously  the company raised its dividend by nearly 14  in May 5  2016  In fact  the insurer s operating strength enables it to increase dividend each year  The company has grown its dividend at a five year CAGR  2012 2017  of 7 9  The company will now reward investors with a dividend of 9 cents per share as against 8 cents paid on Feb 27  2017  Shareholders on record as of Jun 9  2017  will have the meatier dividend in their pockets on Jun 23  2017  Based on the closing share price of  21 08 as of May 12  the increased payout translates to a dividend yield of 1 71  This apart  CNO Financial s board approved an additional  300 million to repurchase the company s outstanding common stock   As of Mar 31  2017  the company bought back  43 0 million of common stock and was left with approximately  210 million of authorization remaining  Dividend hikes and share buybacks not only testify to the operational and financial strength of a company  but also make a stock attractive for yield seeking investors  CNO Financial s strong capital management policy is largely supported by its solid cash flow generation  which in turn  is driven by consistently strong operational performance  Zacks Rank and Stocks to ConsiderCNO Financial has a Zacks Rank  3  Hold  Some better ranked multi line insurers are Cigna Corporation   NYSE CI    James River Group Holdings  Ltd    NASDAQ JRVR   and Old Republic International Corporation   NYSE ORI    All of the stocks carry a Zacks Rank  2  Buy   You can see  Cigna s earnings beat estimates in three of the last four quarters with an average earnings surprise of 1 35  Another multi line insurer  James River Group  delivered positive earnings surprise in the last four quarters with an average positive surprise of 9 47  Old Republic International surpassed expectations in two of the last four quarters with an average beat of 11 37  5 Trades Could Profit   Big League   from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-05-14,Zacks Investment Research,"https://www.investing.com/analysis/cno-financial-hikes-dividend,-announces-share-buyback-plan-200189230",200189230
148097,369613,CI,Horace Mann Educators   Its Units Get Rated By A M  Best,opinion,Horace Mann Educators Corporation   NYSE HMN   and its units recently received rating action from credit rating giant  A M  Best  The rating agency affirmed the Long Term Issuer Credit Ratings  Long Term ICR  of  bbb  of the Multi line insurer and the Long Term Issue Credit Rating of  bbb  on the company s 4 5  senior unsecured notes worth  250 million  These notes are set to mature in 2025 Also  the rating giant affirmed the Financial Strength Ratings  FSR  of A  Excellent  and the Long Term ICR of  a  of the property casualty units of Horace Mann Insurance Group   Horace Mann   as well as Horace Mann Life Insurance Company   Horace Mann Life    Notably  the outlook of the aforementioned ratings remained stable Solid overall capitalization  sustained operational performance and continued industry expertise in writing personal lines products are reflected by Horace Mann s ratings affirmation However  Horace Mann s property book of business is exposed to catastrophe and non catastrophe weather losses  which has resulted in underwriting deficit and lower pre tax operating earnings in 2016  This may partially offset the aforementioned positive rating affirmation Interestingly  Horace Mann Educators  financial flexibility  owing to its access to capital markets  along with decent financial leverage and robust fixed charge coverage  are represented from the company s ratings affirmation This apart  Horace Mann Life s ratings affirmation indicates its strategic position within the parent organization   Horace Mann Educators   as well as the benefits obtained from the same  Moreover  the ratings represent Horace Mann Life s sustained growth in the 403 b  tax qualified annuity market  overall strong operational performance  robust life insurance sales  and favorable persistency in the ordinary life segment  In addition  the ratings reflect positive risk adjusted capitalization as well as efficient asset liability management and cash flow analysis However  Horace Mann Life s significant block of annuity business  high exposure to interest sensitive liabilities and consistent spread contraction owing to a still low interest rate environment  as well as higher investment risk  can partially offset the ratings affirmed to this affiliate Rating affirmations or upgrades from credit rating agencies play an important role in retaining investor confidence as well as in maintaining credit worthiness of a stock  On the other hand  rating downgrades not only damage business but also increase the cost of future debt issuances  We believe that such ratings will help Horace Mann Educators to retain investor confidence and write more businesses going forward Zacks Rank and Share Price MovementHorace Mann Educators currently carries a Zacks Rank  4  Sell   Shares of Horace Mann Educators lost 3 95  since the release of first quarter 2017 earnings results  underperforming the  industry s increase of 1 81   However  we expect top line growth  higher net investment income as well as solid operational performance across Retirement and Life businesses to help the stock to turn around in the near term Stocks to ConsiderSome better ranked stocks from the same space include Cigna Corporation   NYSE CI    James River Group Holdings  Ltd    NASDAQ JRVR   and Old Republic International Corporation   NYSE ORI    Each of these stocks holds a Zacks Rank  2  Buy   You can see   Cigna Corp   which operates as a health services organization  offers insurance and related products and services in the United States and internationally  The company delivered positive surprises in three of the last four quarters with an average beat of 1 35  James River Group provides specialty insurance and reinsurance services in the United States  The company delivered positive surprises in all of the last four quarters with an average beat of 9 47    Old Republic International engages in the insurance underwriting and related services business  primarily in the United States and Canada  The company delivered positive surprises in two of the last four quarters with an average beat of 11 37  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-16,Zacks Investment Research,https://www.investing.com/analysis/horace-mann-educators---its-units-get-rated-by-a.m.-best-200189746,200189746
148098,369614,CI,China Life Revenue Growth Solid  Rising Costs Raise Concerns,opinion,China Life Insurance Company Ltd    NYSE LFC   shares have gained 24  outperforming the Zacks categorized  industry s gain of only 14   The price appreciation has likely been driven by the company s robust market position and organic growth initiatives that continued to solidify shareholders  confidence on the stock  We expect the stock to retain its momentum owing to a number of positives The company recently reported strong first quarter results  primarily driven by 17  year over year growth in earnings China Life has been witnessing consistent growth in revenues backed by a solid increase in premiums over the past few years  In the first quarter of 2017  net premiums earned grew 22  year over year to RMB 240 2 billion  US  36 billion   Also  net revenue from the insurance businesses reached RMB 246 2 billion  US  37 billion   up 22 1   year  on  year The company s regular product upgrades enable it to remain competitive in the international life insurance market  Following the launch of the upgraded Rui Xin insurance in 2013 and micro insurance program in 2015  the company promoted C ROSS in 2016  C ROSS is a risk management guidance that is expected to help the company maintain a robust risk control system  mitigate key risks  and ensure smooth business operations However  the company s earnings have been adversely impacted by the slowdown in the Chinese economy over the last few years  Despite the brake in economic slowdown in 2017  there is no immediate development opportunity or scope for growth in the near future In addition  the stock seems to be overvalued  Its Price to Earnings Growth  PEG  ratio of 2 68 is above the industry level of 1 08  The Price to Book  P B  ratio of 1 96 is also higher than the industry average of 1 10Moreover  rising expenses raise concerns  Continuing the previous trend  operating expenses increased 23 4  year over year to RMB 263 9 billion  US  39 6 billion  in the first quarter of 2017 The company s operating cash flows have been pretty volatile  Operating cash flow declined in 2011  2012 and 2013 owing to higher liquidity requirements  Although  it improved in 2014  the year 2015 witnessed cash outflow  In 2016  the company received an inflow of cash from operating activities amounting US  12 8 billion  The same  however  continued in the first quarter of 2017 with a cash inflow of US 16 1 billion  The volatile trend of cash flow raises concerns about the company s operating efficiency as it might weaken its balance sheet and financial position Zacks Rank and Stocks to ConsiderChina Life has a Zacks Rank  2  Buy   You can see Some better ranked insurers are Cigna Corporation   NYSE CI    James River Group Holdings  Ltd    NASDAQ JRVR   and Old Republic International Corporation   NYSE ORI    All of the stocks carry a Zacks Rank  2  Buy  Cigna s earnings beat estimates in three of the last four quarters with an average earnings surprise of 1 35  Another insurer  James River Group  delivered positive earnings surprise in the last four quarters with an average positive surprise of 9 47  Old Republic International surpassed expectations in two of the last four quarters with an average beat of 11 37  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-16,Zacks Investment Research,"https://www.investing.com/analysis/china-life-revenue-growth-solid,-rising-costs-raise-concerns-200189745",200189745
148099,369615,CI,Will CNO Financial Thrive Under New CEO  Gary Bhojwani ,opinion,CNO Financial Group  Inc    NYSE CNO   named Gary Bhojwani  who is currently the company s President  as its new Chief Executive Officer  CEO   effective Jan 1  2018 Bhojwani will succeed Edward J  Bonach  63  who will step down from his position as CEO of CNO Financial effective Dec 31  2017 Bhojwani doesn t have a long association with CNO Financial since he joined the company last year  Nevertheless  he is an industry veteran and has a vast working experience  including his association with Allianz  DE ALVG  for a span of eight years The company announced a number of executive leadership changes  in March  Mike Heard was appointed President of Washington National  Joel Schwartz was appointed President of Colonial Penn  and Gerardo Monroy was appointed Chief Marketing Officer  These moves were all internal promotions and demonstrate the company s efforts to develop and retain strong talent  This step was executed as part of a broader plan to accelerate the company s strategic growth  further strengthening the enterprise  and positioning the organization for continued success Shares of CNO Financial have been steadily rising on a year to date basis  generating a return of 12 01  compared with the Zacks Inurance Multi Line industry s gain of 2 21  However  CNO Financial did not see much top line growth since 2011  the year in which Bonach took over as the CEO of CNO Financial  Revenue for 2011 was  4 125 billion and declined to  3 985 billion in 2016  The  bottom line during the same time frame  however  showed considerable growth  up from 75 cents in 2011 to  1 34 in 2016 Along with instituting other required changes  we believe Bhojwani will work upon the set priorities for 2017 which includes  initiatives  to drive increased growth  productivity and retention of agent force  extension of customer reach within the middle income market  and increase timely delivery of product and service offerings by promptly responding to customer needs We look forward to seeing whether the new CEO keeps the growth momentum alive for CNO Financial Earlier during the week another insurer from the same space  American International Group Inc    NYSE AIG   appointed Brian Duperreault as its new CEO  after the company failed to perform well under  the outgoing CEO Peter Hancock CNO Financial carries a Zacks Rank  3  Hold   Some better ranked multi line insurers are Cigna Corporation   NYSE CI    and Old Republic International Corporation   NYSE ORI    These stocks carry a Zacks Rank  2  Buy   You can see Cigna s earnings beat estimates in three of the last four quarters with an average earnings surprise of 1 35  Old Republic International surpassed expectations in two of the last four quarters with an average beat of 11 37  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-17,Zacks Investment Research,"https://www.investing.com/analysis/will-cno-financial-thrive-under-new-ceo,-gary-bhojwani-200189804",200189804
148100,369616,CI,PRA Group  PRAA  Divests Govt  Business  Earnings Suffer,opinion,On May 18  2017  we issued an updated research report on PRA Group  Inc    NASDAQ PRAA   During the first quarter  the company s operating earnings of  0 38 per share in the year ago quarter not only missed the Zacks Consensus Estimate by 13 6  but also deteriorated 55 3  from the year ago quarter  The bottom line deterioration can be mainly attributed to a substantial decline in revenues The company s divesture of government business affected both of its revenues and margins  In the first quarter  the company witnessed a year over year decline of39 3  and 6  in fee income and receivable income  respectively  primarily due to the divesture Given the aforesaid factors  the PRA Group stock seems to have fallen out of favor with investors  Shares of the company have lost 5 6  compared with the  industry s 19  decline  year to date The company s operating expenses have increased at a five year CAGR  2009 2015  of 23 5   Although the company witnessed a year over year decline in operating expenses by 3 2  in 2016 and 0 6  in the first quarter of 2017  its compensation and employee service related expenses as well as legal collections costs continue to increase  PRA Group requires to enhance its cost management in order to improve earnings Another major concern for the company is its rising debt level that has led to a continuous increase in interest expenses  In 2016  interest expenses increased 35  year over year to followed by a 6 5  increase in the first quarter of 2017  The rise in debt financing continues to drain a significant portion of its operating cash flow to service debt payments The stock has also been overvalued than its peers in some respects  PRA Group is currently trading at 1 77X price to book value multiple  This is expensive when compared with the Zacks categorized Financial Miscellaneous Services industry s multiple of 1 65X  Moreover  the Price to Cash Flow  PCF  ratio for the stock is 26 55  which compares unfavorably with the industry average of 2 98  suggesting a significant level of overvalued trading Despite the headwinds  the company s substantial investment in receivables raises of optimism about improved receivable income The company also expects its fee income to increase on the back of its planned acquisitions and other strategic initiatives  In May 2017  the company has reached a settlement with the Internal Revenue Service  PRA Group will now utilize a new tax methodology to recognize net finance receivable  NFR  revenues  effective tax year 2017  The PRA Group will not be required to pay any interest or penalties related to the prior period  Zacks Rank   Stocks to ConsiderPRA Group has aZacks Rank  3  Hold   Some better ranked insurers are Cigna Corporation   NYSE CI    James River Group Holdings  Ltd    NASDAQ JRVR   and Old Republic International Corporation   NYSE ORI    All of the stocks carry Zacks Rank  2  Buy   You can see Cigna s earnings beat estimates in three of the last four quarters with an average earnings surprise of 1 35  Another insurer  James River Group  delivered positive earnings surprises in all of the last four quarters with an average beat of 9 47  Old Republic International s earnings  although surpassed expectation in only two of the last four quarters  it reported an average beat of 11 37  Will You Make a Fortune on the Shift to Electric Cars                                                                       Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-17,Zacks Investment Research,"https://www.investing.com/analysis/pra-group-(praa)-divests-govt.-business,-earnings-suffer-200190032",200190032
148136,369652,CI,Anthem s  ANTM  Q1 Earnings And Revenues Beat Estimates,opinion,Anthem  Inc    NYSE ANTM   is one of the premier healthcare service providers when it comes to providing medical and specialty products Already sporting one of the top position in the health insurance industry  the company is set to become a titan with the pending acquisition of another player Cigna Corp  NYSE CI   Anthem is projected to become one of the top three health insurers  Also  the company is expected to witness significant earnings accretion from the deal The company has been working towards enhancing healthcare through the provision of reliable and superior quality services  The aforementioned deal is expected to help it in this regard However  adverse effect of the Health Insurance Provider  HIP  fee  increased financial leverage  higher medical costs in the Senior  Local Group and State Sponsored businesses  lower favorable prior year reserve development and the impact of minimum medical loss ratio requirements are a drag Anthem has a decent history when it comes to earnings as the company has beaten estimates in three of the last four quarters  making for an average beat of 8 3  Currently  Anthem holds a Zacks Rank  2  Buy   but that could definitely change following its earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings   Anthem beats on earnings  Our consensus called for EPS of  3 85  and the company reported EPS of  4 68 Revenue  Operating revenues also surpassed our estimate  Our consensus called for revenues of  21 27 billion  and the company reported revenues of  22 3 billion Anthem  Inc  Price and EPS Surprise   Key Stats to Note  Medical enrollment grew 2 6  to 40 6 million However  first quarter benefit expense ratio deteriorated 190 basis points year over year to 83 7  The selling  general and administrative expense ratio was 15 3   improving 150 basis points year over year Operating cash flow for the first quarter was  2 7 billion  or 2 7 times net income For 2017  the company expects adjusted net income to be greater than  11 60 per share  medical membership is expected to be in the range of 40 2 million   40 4 million  operating revenue to be roughly between  88    89 billion Check back later for our full write up on this ANTM earnings report later Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public   Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-04-26,Zacks Investment Research,https://www.investing.com/analysis/anthem's-(antm)-q1-earnings-and-revenues-beat-estimates-200185271,200185271
148137,369653,CI,Cigna  C  Q1 Earnings  Is Disappointment In The Cards ,opinion,"Cigna Corp    NYSE CI   is scheduled to report first quarter 2017 results on May 5  before the opening bell 
Last quarter  Cigna beat the Zacks Consensus Estimate by 7 47   Let s see how things are shaping up for this announcement Q1 Flash Back
Cigna s upcoming results are expected to demonstrate its continued strong operating performance from the Commercial Healthcare business and Global Supplemental Benefits business  as well as improving results in its Group Disability and Life segment In its Government business  we expect revenues to decline due to CMS enrollment sanctions Within its Global Health Care segment  we expect the quarter to show membership increases from strong retention and customer growth in each of its employer segments   national accounts  middle market  select and international  Its U S  Individual customer base is also expected to grow  During the quarter  the company rejected Anthem Inc  s   NYSE ANTM    48 billion acquisition offer Cigna Corporation Price and EPS Surprise   Earnings Whispers
Our proven model does not conclusively show that Cigna is likely to beat on earnings this quarter  That is because a stock needs to have both a positive   and a Zacks Rank of  1  2 or 3 for this to happen  That is not the case here as you will see below Zacks ESP  Cigna has an Earning ESP of  0 41   This is because the Most Accurate estimate stands at a  2 43 per share  which is below the Zacks Consensus Estimate of  2 44   You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Though Cigna carries a Zacks Rank  2  Buy   its Earnings ESP of  0 41  makes surprise prediction difficult Stocks That Warrant a LookHere are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter   Wingstop Inc    NASDAQ WING   will report first quarter 2017 earnings results on May 4  The company has an Earnings ESP of  6 67  and a Zacks Rank  1  Strong Buy   You can see  eGain Corporation   NASDAQ EGAN   has an Earnings ESP of  50  and a Zacks Rank  2  The company is expected to report first quarter earnings results on May 4 
Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-02,Zacks Investment Research,https://www.investing.com/analysis/cigna-(c)-q1-earnings:-is-disappointment-in-the-cards-200186787,200186787
148138,369654,CI,Insurance Stocks To Watch For Earnings On May 5  BRK B  CI,opinion,"The Q1 earnings season has picked up pace with 78 2  members of the elite S P 500 Index reporting solid quarterly numbers so far  According to the latest   the performance of 358 index members that have already reported their financial numbers this quarter indicate that total earnings have increased 12 9  on 7 9  higher revenues  The beat ratio is impressive with 74 3  companies surpassing bottom line expectations and 65 9  outperforming on the top line front The Finance sector  one of the 16 Zacks sectors  has delivered a strong performance so far  Financial performance of 862  companies from this sector that have revealed their quarterly results shows 9 6  earnings growth on 6 3  increase in revenues  both on a year over year basis  The beat ratio of 70 4  for the bottom line is below the S P 500 but the beat ratio of 66 7  for the top line is higher than that of the S P 500   Insurers  particularly the property and casualty companies  are likely to witness improvement in underwriting results owing to a benign catastrophe environment  However  impact of storms in Midwest and the South that occurred during Feb 28 and Mar 22  as well as cyclone Debbie in Australia weighed on underwriting results Nonetheless  the improving interest rate  albeit at a slower pace  should cushion investment results that suffered due to the prolonged period of low rates  Owing to a stabilizing economy  improving employment and inflation reaching 2   the Fed raised interest rates in Dec 2016 and in Mar 2017   Investment income  which is a major component of insurers  top line  is improving  Also  a stronger economy means more disposable income and better consumer sentiment  This  in turn  is likely to have supported more policy writings  driving premiums higher Higher rates should offer some respite to life insurers that suffered spread compression on products like fixed annuities and universal life due to persistently low rates  Investment yield is also likely to have improved  Annuity sales too should have benefited from higher rates Prudent underwriting practices should also have supported investors  However  we do not expect pricings to have been strong  Nonetheless  core business growth  geographic expansion  strategic acquisitions and effective capital deployment via share repurchase should prove beneficial for insurers Per our earnings outlook  results from the remaining 142 index members should also be impressive  Earnings are estimated to grow 11 9  on 6 2  higher revenues  with Finance  Technology  Industrial Products  Basic Materials  and Business Services on track to achieve double digit earnings growth Let s find out how these two insurers might perform when they release their quarterly numbers on May 5 Berkshire Hathaway Inc   is primarily an insurer but also operates railroad systems in North America  In addition  it generates  transmits  and distributes electricity as well as operates natural gas distribution and storage facilities  The company s Zacks Rank  4  Sell  and an of 0 00  complicates surprise prediction  Both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at  1 71  You can uncover the best stocks to buy or sell before they re reported with our  Please note that the Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement Improved performance across Manufacturing  Service   Retailing as well as Finance   Financial Products businesses  Burlington Northern SantaFe Corp  and insurance operations should drive results  However  higher expenses due to railroad operations are likely to weigh on margin expansion   Read more     With respect to the surprise trend  Berkshire Hathaway surpassed expectations in two of the last four quarters Berkshire Hathaway Inc   NYSE BRKa  Price and EPS Surprise
    Cigna Corp    NYSE CI    through its subsidiaries  provides health care and related benefits  In the last reported quarter  Cigna beat the Zacks Consensus Estimate by 7 47   The company has a Zacks Rank  2  Buy   However  its Earnings ESP of  0 41  complicates surprise prediction  The Most Accurate Estimate stands at  2 43 while the Zacks Consensus Estimate stands at  2 44 According to our proven model a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2 or at least 3  Hold  for an earnings beat We expect the company s Commercial Healthcare business  Global Supplemental Benefits business  and Group Disability   Life segment to post improved results  However  revenues from the Government business are likely to decline due to CMS enrollment sanctions   Read more   With respect to the surprise trend  Cigna surpassed expectations in three of the last four quarters but with an average negative surprise of 0 30 Cigna Corporation Price and EPS Surprise
    Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-03,Zacks Investment Research,"https://www.investing.com/analysis/insurance-stocks-to-watch-for-earnings-on-may-5:-brk.b,-ci-200187083",200187083
148139,369655,CI,Company News For May 08  2017,opinion,     Shares of Activision Blizzard  Inc    NASDAQ ATVI   advanced 1 4  after the company reported first quarter 2017 adjusted earnings of  0 27  beating the Zacks Consensus Estimate of  0 16     CIGNA Corporation s   NYSE CI   shares gained 2 1  after the company reported first quarter 2017 earnings of  2 77 per share  beating the Zacks Consensus Estimate of  2 44     Shares of Cognizant Technology Solutions   NASDAQ CTSH   advanced 4 1  after the company reported first quarter 2017 revenues of  3 546 billion  beating the Zacks Consensus Estimate of  3 522 billion     Shake Shack Inc s   NYSE SHAK   shares surged 9 2  after the company reported first quarter 2017 earnings of  0 1 per share  surpassing the Zacks Consensus Estimate of  0 08 per share,2017-05-07,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-may-08,-2017-200187807",200187807
148163,369679,CI,Cigna Hurt By CMS Control  Blocked Deal  Yet On Growth Path,opinion,"Cigna Corp    NYSE CI   has been in troubled waters with the restriction imposed by the Centers for Medicare and Medicaid Services  CMS  on the sale of Medicare Advantage Prescription Drug and Medicare Part D Plans  The company is yet to correct the reasons that led to this restriction in Jan 2016  The sanctions point directly to failure to comply with coverage determinations  appeals and grievances  and Part D administration  which CMS characterized as  systemic  and  longstanding  and unchanged even several years after warning Cigna was disbarred from selling Medicare Advantage policies or Part D drug plans to new clients in the open enrollment season that started in Oct 2016  Also  in 2016  the company incurred  100 million in costs associated with its CMS audit response as well as loss ratio pressure in its Medicaid business  Cigna had earlier disclosed that these sanctions will likely cause net membership attrition of 50 000 lives in 2017  This will also cause revenue decline from its Seniors business Cigna is also mired in friction with Anthem Inc    NYSE ANTM    over their blocked merger  Both companies were involved in a blame game for wrongdoing in relation with the merger  Anthem has filed a countersuit against Cigna seeking a temporary restraining order to prevent it from terminating the merger agreement  This move by Anthem is in retaliation to the suit filed by Cigna against Anthem  seeking a breakup fee of  1 85 billion and other charges amounting to  13 billion on account of premiums that Cigna shareholders did not realize as a result of the failed merger process Anthem also charged Cigna for its indifference toward the merger and efforts at sabotaging the deal  We now believe the fight has reached a stage where the focus is on the breakup fee and damages rather than the sealing of the deal  The deal would have helped Cigna to catapult to the number one rank in terms of membership in the U S  health insurance industry  surpassing UnitedHealth Group Inc    NYSE UNH    which currently holds the top position Despite these troubles  Cigna has managed to carry on well as reflected by its share price which has gained 14 2  year to date  significantly outperforming the Zacks categorized  industry s decline of 0 3  

Cigna helped investors to stay calm by disclosing its 2017 growth outlook just after the termination of the merger  The company projected that adjusted income from operations will grow in the range of 12 18  aided by its significant capital available for deployment  Moreover  the company announced that its board of directors has expanded its share repurchase authority to an aggregate of  3 7 billion  The amount of buyback will  however  be capped at  250 million per quarter until there is more clarity with respect to the litigation with Anthem 
On the organic front  the company is expected to strengthen its business position in Global Supplemental Benefits  The segment grew at a CAGR of 17  for revenues and 24  for earnings over the last six years  2011 2016   For 2017  the company expects adjusted income from operations in the range of  295  315 million  which translates into a year over year growth rate of nearly 4   calculated at the mid point  
The company s membership has been growing  It is expected to add 300 000 to 500 000 total medical customers in the Global Health Care segment in 2017 
Cigna carries a Zacks Rank  3  Hold   A better ranked player is Radian Group Inc    NYSE RDN   with a Zacks Rank  2  Buy   Radian Group beat estimates in three of the last four quarters  with an average positive surprise of 6 5   You can see  
Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-11,Zacks Investment Research,"https://www.investing.com/analysis/cigna-hurt-by-cms-control,-blocked-deal,-yet-on-growth-path-200182335",200182335
148164,369680,CI,Why Is Anthem  ANTM  Up 5 3  Since The Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Anthem  Inc    NYSE ANTM    Shares have added about 5 3  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers 
Anthem Beats Q4 Earnings and Revenue EstimatesAnthem s fourth quarter 2016 adjusted net income per share of  1 76 surpassed the Zacks Consensus Estimate of  1 59 by 10 7   The bottom line also surged 54 4  year over year  Adjusted net income was  11 00 per share for full year 2016  up 8 3  year over year Operating revenues of  21 5 billion beat the Zacks Consensus Estimate of  20 9 billion  It also grew 7 3  year over year due to a 7 4  increase in premium revenues and 31  rise in net investment income  For 2016  the metric amounted  84 2 billion  up 7 4  year over year Medical enrollment was approximately 39 9 million as of Dec 31  2016  reflecting a 3 4  year over year increase Total expense increased nearly 6 3  year over year to  21 billion in the reported quarter  mainly due to a 7 7  rise in benefit expenses from the prior year quarter Anthem s benefit expense ratio was 87 2  in the reported quarter  up 20 basis points  bps  year over year  The deterioration was mainly due to higher medical cost experience in the Medicaid business The SG A expense ratio was 15 2  in the fourth quarter  down 110 bps from the prior year quarter  The improvement was primarily driven by lower administrative costs due to expense efficiency initiatives as well as higher operating revenues Segment ResultsCommercial   Specialty BusinessIn the fourth quarter  operating revenues totaled at  9 6 billion  This reflects year over year growth of 2 4   Operating gain soared 239 1  year over year to  189 2 million  Operating margin improved 140 bps to 2  The outstanding performance was driven by lower administrative costs due to expense efficiency initiatives undertaken by Anthem  the timing of lower medical cost experience in the Local Group business and self funded membership growth Government BusinessAt the end of the fourth quarter  operating revenues totaled  11 8 billion  up 11 6  year over year  Operating gain increased 26 8  year over year to  530 million  Operating margin improved 60 bps to 4 5  The upside reflected the impact of lower administrative costs due to expense efficiency initiatives taken by the company  the retroactive change in the minimum MLR calculation under California s Medicaid expansion program and lower medical cost experience in the Medicare business OtherAnthem incurred an operating loss of  66 1 million in this segment in the fourth quarter  This is substantially wider than an operating loss of  33 8 million in the prior year quarter  Expenses related to the Cigna  NYSE CI  acquisition primarily resulted in the wider loss Financial UpdateAs of Dec 31 2016  Anthem had cash and cash equivalents of  4 billion  up 93  from year end 2015 As of Dec 31  2016  long term debt of Anthem decreased 6 3  to  14 3 billion from  15 3 billion in year end 2015 As of Dec 31  2016  shareholder equity was  25 billion  up 8 6  from year end 2015 Operating cash flow was  275 million in the fourth quarter and approximately  3 2 billion in 2016 Share Repurchase and Dividend UpdateAnthem did not repurchase any shares during the fourth quarter due to the pending acquisition of Cigna  As of Dec 31  2016  the company had nearly  4 2 billion of board approved share repurchase authorization remaining In the reported quarter  Anthem paid a quarterly dividend of 65 cents per share  This amounts to a total cash distribution of  171 3 million Guidance for 2017Anthem expects adjusted net income to be greater than  11 50 Medical membership is expected in the range of 40 1  40 3 million  Expected range for fFully insured membership and self funded membership are 15 1 15 2 million and 25 25 1 million  respectively Operating revenues are projected in the range of 86 5  87 5 billion Benefit expense ratio and SG A ratio are expected to be around 87  and 13 3   respectively  with adjustment of 30 bps Anthem expects operating cash flow in excess of  3 5 billion 
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed an upward trend in fresh estimates  There have been two upward revisions for the current quarter Anthem  Inc  Price and Consensus
    VGM Scores
At this time  Anthem s stock has an average Growth Score of  C   though it is lagging a bit on the momentum front with a  D   However  the stock was allocated a grade of  A  on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of  B   If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for value investors than growth investors 
Outlook
The stock has a Zacks Rank  2  Buy   We are expecting an above average return from the stock in the next few months ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/why-is-anthem-(antm)-up-5.3-since-the-last-earnings-report-200183098,200183098
148198,369714,CI,Anthem  ANTM  Misses On Q3 Earnings  Revises Guidance,opinion,Anthem  Inc    NYSE ANTM   is one of the premier healthcare service providers when it comes to providing medical and specialty products Already sporting one of the top position in the health insurance industry  the company is set to become a titan with the pending acquisition of another player Cigna Corp  NYSE CI   Anthem is projected to become one of the top three health insurers  Also  the company is expected to witness significant earnings accretion from the deal The company has been working towards enhancing healthcare through the provision of reliable and superior quality services  The aforementioned deal is expected to help it in this regard However  adverse effect of the Health Insurance Provider  HIP  fee  increased financial leverage  higher medical costs in the Senior  Local Group and State Sponsored businesses  lower favorable prior year reserve development and the impact of minimum medical loss ratio requirements are a drag Anthem has a decent history when it comes to earnings as the company has beaten estimates in three of the last four quarters  making for an average miss of 0 64  Currently  Anthem holds a Zacks Rank  4  Sell   but that could definitely change following its earnings report which was just released  You can see  We have highlighted some of the key stats from this just revealed announcement below Earnings   Anthem misses on earnings  Our consensus called for EPS of  2 49  and the company reported EPS of  2 45 ANTHEM INC Price and EPS Surprise   Revenue  Operating revenues surpassed our estimate  Our consensus called for revenues of  20 7 billion  and the company reported revenues of  21 1 billion Key Stats to Note  Medical enrollment continues to impress us with a year over year increase of about 3 1  However  benefit expense ratio deteriorated 190 basis points year over year to 85 5   The selling  general and administrative expense ratio was 14 8   improving 80 basis points year over year Operating cash flow was  964 million  or 1 6 times net income The company expects net income to be nearly  9 28 per share  adjusted net income to be approximately  10 80 per share  medical membership is expected to be in the range of 39 65 million   39 85 million  operating revenue to be roughly  83 5 billion in 2016 Check back later for our full write up on this ANTM earnings report later Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-02,Zacks Investment Research,"https://www.investing.com/analysis/anthem-(antm)-misses-on-q3-earnings,-revises-guidance-200162189",200162189
148199,369715,CI,Cigna  CI  Beats Q3 Earnings Estimate  Updates Guidance,opinion,Cigna Corp    NYSE CI   is a national health benefits company with a comprehensive portfolio of businesses which includes Employee Healthcare  Disability and Life Its organizational efficiency plans as well as expansion of Seniors and Medicare business position it well for long run The company has a large international presence  which provides diversification benefits Cigna is due to be acquired by Anthem Inc  The merger  however  is wrapped in uncertainty with the DoJ opposing to the merger on grounds that the deal would curb competition in the market With respect to earnings surprise  though Cigna surpassed estimates in three of the past four quarters and delivered a negative surprise in only one  its average earnings miss is 1 34  Currently  Cigna has a Zacks Rank  3  Hold   but that could definitely change following Cigna earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below  You can see Earnings   Cigna surpassed the earnings estimate  Our consensus called for earning per share of  1 91  and the company reported earnings of  1 94 per share  Earnings per share was  however  down 15  year over year Revenue  Operating revenues of  9 81 billion surpassed the Zacks Consensus Estimate of  9 79 billion  Revenues also grew 5  year over year CIGNA CORP Price and EPS Surprise   Key Stats to Note Premiums of  7 6 billion increased 3 5  year over year  while mail order pharmacy revenues increased 18 5 Total Medical Customers totaled 15 2 million as on Sep 30  2016 Cigna updated its 2016 earnings guidance  It expects earning per share in the range of  7 80 to  8 05  It expects mid single digit growth in revenue  The company expects global medical customer growth in low single digits percentage range Check back later for our full write up on this CI earnings report later Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand    ,2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/cigna-(ci)-beats-q3-earnings-estimate,-updates-guidance-200162494",200162494
148200,369716,CI,3M  Mass Madness In The Making,opinion,"3M Company  NYSE MMM  is a diversified technology giant  founded in 1902  It is a component of the DJIA  the S P 500 and S P 100  Its steady earnings and dividend records makes it one of the most beloved blue chip stocks in the U S   which people think can be bought at any price  because they always seem to go up  We do not think so  No trend lasts forever so the price you pay always matters 
For instance  3M stock fell nearly 60  during the 2007 2009 market crash   from  97 to  40 87 a share  Fortunately  3M proved it is a great company and is currently trading above  178 a share   a recovery of over 430  from the March 2009 low  Does this mean investors should go ahead and buy near all time highs  The Elliott Wave Principle applied to the monthly log chart below might help us find the answer 

It makes the entire uptrend since the year 1970 visible  47 years of price data allow us to see that 3M s bull market has been developing as one large five wave   travelling from as low as  4 47 to as high as  182 27 in split adjusted prices  Wave II is a sideways  between a double zig zag in wave  w  and a  in wave  y   The sub waves of wave III are also clearly visible  Wave IV  obeying the guideline of alternation  is a sharp and swift decline  This leads us to wave V  which is still in progress  but seems to be in its final stages 
According to the Wave Principle  every impulse is followed by a correction of three waves in the opposite direction  This means that once wave  5  of V is over  3M stock should reverse to the downside for a major three wave decline  which could be expected to take prices down to the support area of wave IV  In terms of price  this translates into a selloff all the way back down to the 2009 lows near  40 a share  And before you say that this is impossible  we would like to remind you that the same pattern caused Cigna Corporation  NYSE CI  to crash from above  56 to  8 a share between June 2007 and November 2008 
Mark Twain once said that  history doesn t repeat itself  but it does rhyme   If we use history as a guide here  3M Company stock could be expected to enter a major bear market soon  which could ultimately cost it nearly 80  of its market value  In our opinion  2017 is going to be a bad year for 3M investors ",2017-01-02,EWM Interactive,https://www.investing.com/analysis/3m--mass-madness-in-the-making-200171231,200171231
148223,369739,CI,Multiline Insurance Q3 Earnings On Nov 3  CI  KMPR  FFG,opinion,The Q3 earnings season is in full swing  with 66 4  of the S P 500 Index members having reported their quarterly results so far  According to the latest   the performance of the 332 index members  accounting for 74 1  of the index s total market capitalization  that have already reported their financial numbers indicate that total earnings have improved 1 9  on 1 3  higher revenues  on a year over year basis  The beat ratio is also strong with 72 9  companies surpassing bottom line expectations and 55 4  outperforming on the top line The Finance sector  one of the 16 Zacks sectors  started the Q3 earnings season on a strong note  In fact  the financial performance of 86 7  companies from this sector that have already reported their quarterly results indicates 10 9  earnings growth due to a 6  increase in revenues  on a year over year basisThe Finance sector is highly diversified and includes several industries like insurance  banks and securities exchanges to name a few Amid a benign catastrophe environment in Q3  underwriting results improved  Lesser cat events favored capital gains and reserve release  but put pressure on pricing  The better payroll and employment scenarios should also benefit insurers  Insurers are poised to outperform in the quarter on the back of their core business  geographic expansion and strategic acquisitions Companies that are skewed toward providing health benefits may gain from the expansion of the Affordable Care Act  while improvement in the housing market should benefit mortgage insurers However  a soft interest rate environment continued to weigh on investment results  Nonetheless  spread compression on products like fixed annuities and universal life should improve Let s take a look at how these three multiline insurers might fare when they report their Q3 numbers on Nov 3 Cigna Corp    NYSE CI    a health services organization  provides insurance and related products and services in the United States and internationally  It operates through three segments  Global Health Care  Global Supplemental Benefits  and Group Disability and Life  Last quarter  the company posted a negative earnings surprise of 17 15   Cigna carries a Zacks Rank  3  Hold   It has an  of  2 09  as the Most Accurate estimate stands at  1 87  while the Zacks Consensus Estimate is pegged at  1 91  Please check our  that enables you to find stocks that are expected to come out with earnings surprises Cigna s U S  individual business is likely to have experienced softness similar to the rest of the industry  Third quarter results are expected to demonstrate continued strength in the operating performance of the Global Health Care and Global Supplemental benefits  business  We expect the company to continue posting favorable results on solid revenue growth in the government business  disciplined expense management and effective medical cost management  Favorable medical utilization along with medical cost management is expected to contribute to the bottom line  Moreover  its strong balance sheet  which enables share buyback  should support the upcoming results   Read more   Though the company surpassed estimates in three of the past four quarters and delivered a negative surprise in only one  its average earnings miss is 1 34   CIGNA CORP Price and EPS Surprise   Kemper Corporation   NYSE KMPR    a diversified insurance holding company  provides property and casualty  and life and health insurance to individuals and businesses in the United States  Last quarter  the company posted a negative earnings surprise of 17 15   Kemper has an Earnings ESP of 0 00  as the Most Accurate estimate of 52 cents per share is in line with the Zacks Consensus Estimate  It carries a Zacks Rank  3  You can see  The company missed estimates in two of the past four quarters  resulting in an average earnings miss of 1 42  KEMPER CORP Price and EPS Surprise   FBL Financial Group  Inc    NYSE FFG   through its subsidiaries  sells annuity and individual life insurance products  The Annuity segment sells various traditional annuity products that primarily consist of fixed rate and indexed annuities  and supplementary contracts  The Life Insurance segment offers whole life  term life  and universal life policies  Last quarter  the company posted a negative earnings surprise of 0 97   FBL Financial carries a Zacks Rank  3  It has an Earnings ESP of 0 00  as the Most Accurate estimate of  1 03 per share is in line with the Zacks Consensus Estimate With respect to surprise trend  the company beat estimates in two of the last four quarters  with an average positive earnings surprise of 2 87  FBL FINL GRP A Price and EPS Surprise   Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/multiline-insurance-q3-earnings-on-nov-3:-ci,-kmpr,-ffg-200162287",200162287
148226,369742,CI,Anthem  ANTM  Q3 Earnings Miss  Revenues Beat Estimates,opinion,Anthem Inc  s   NYSE ANTM   third quarter 2016 adjusted of  2 45 per share missed the Zacks Consensus Estimate of  2 49 by 1 6   The bottom line also declined 10 3  year over year Operating revenues of  21 1 billion surpassed the Zacks Consensus Estimate of  20 7 billion  It also increased 6 8  year over year  led by a 6 9  growth in premiums revenue and 24 8  growth in net investment income Medical enrollment that grew by 3 1  over the prior year quarter on the back of solid growth in n Medicaid business Total expense increased nearly 8  year over year to  20 3 billion in the reported quarter due to 9 4  rise in benefit expenses  5  increase in interest expenses and 2 4  rise in general and administrative expenses  all on year over year basis Anthem s benefit expense ratio was 85 5  in the reported quarter  up 190 basis points  bps  year over year Segment ResultsCommercial   Specialty BusinessAt the end of the third quarter  operating gain increased 3  year over year to  637 7 million  Lower administrative costs due to expense efficiency initiatives and the timing of lower medical cost experience in the Local Group business drove the upside  However  higher medical cost experience in the Individual business and the reduction in fully insured membership of the Local Group business were partial offsets Government BusinessAt the end of the third quarter  operating gain was  478 9 million  down 23 6  year over year  Higher medical cost experience resulted in the downside  Nevertheless  it was partially offset by lower administrative costs resulting from expense efficiency initiatives by Anthem OtherAnthem s operating loss of  38 5 million in this segment was 60  wider from the operating loss of  23 9 million in the prior year quarter  The wider loss primarily stemmed from acquisition related expenses for Cigna  NYSE CI  ANTHEM INC Price  Consensus and EPS Surprise    Financial UpdateAs of Sep 30  2016  Anthem had cash and cash equivalents of  2 5 billion  up 19  from  year end 2015 Long term debt of Anthem decreased 7 2  to  14 2 billion as of Sep 30  2016 from  15 3 billion in  year end 2015  As of Sep 30  2016  shareholder equity was  24 7 billion  up 7 4  from the end of 2015 Operating cash flow was  964 million  The reported figure was 1 6 times the net income in the reported quarter Share Repurchase and Dividend UpdateAnthem did not repurchase any shares during the third quarter of 2016 due to the pending acquisition of Cigna  As of Sep 30  2016  the company had nearly  4 2 billion of share repurchase authorization left In the reported quarter  Anthem paid a quarterly dividend of 65 cents per share Guidance for 2016Anthem affirmed  adjusted net income of about  10 80 per share   However net income is now expected to be nearly  9 28 per share  lower that  9 34 projected earlier Anthem raised its guidance for medical membership to the range of 39 65 39 85 million  from the earlier range of 39 6 39 8 million   The projection for fully insured membership is increased to the range of 15 15 1 million from the range of 39 6 39 8 million  along with the anticipation for self funded membership that made higher to the range of 24 65 24 75 million from the range of 24 6 24 7 million Operating revenues are projected around  83 5 billion against the range of  82 5  83 5 billion guided previously Benefit expense ratio and SG A ratio are expected to be around 84 9  and 14 5  respectively with adjustment of 30 basis points plus or minus similar to the previous projection Anthem continues to expect operating cash flow in excess of  3 billion in 2016 Zacks Rank and Performance of Other InsurersAnthem presently carries Zacks Rank  4  Sell   Among the other firms in the medical sector that have reported their third quarter earnings so far  the bottom line at Aetna Inc    NYSE AET    Molina Healthcare Inc   NYSE MOH   and UnitedHealth Group Inc    NYSE UNH   beat their respective Zacks Consensus Estimate You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/anthem-(antm)-q3-earnings-miss,-revenues-beat-estimates-200162367",200162367
148235,369751,CI,Is Anthem  ANTM  Stock Likely To See Further Downside ,opinion,"Anthem Inc    NYSE ANTM   is going through a tough phase with niggling concerns like uncertainty over the Cigna deal  weakness in public exchange business and low interest rates among others  These factors have led to investors  pessimism over the stock which has seen its value  fall 10 2  year to date 
Last year  the stock gained 12 4  on optimism surrounding the announcement of the Cigna deal and growing business opportunity from the public exchange business  But 2016 did not turn out as anticipated for the company Anthem s proposed acquisition of Cigna Corp    NYSE CI   has drawn flak from regulators  The Department of Justice  DoJ  has sued to block the merger with Cigna on concerns that it could stifle competition in the industry  The merged Anthem and Cigna would mean more power in the hands of the surviving company  Anthem  which will gain in size and scale  Though Anthem will challenge the lawsuit filed by the DoJ   it will tie them up in months of litigation  dragging out deal that was announced about a year ago  If the merger with Cigna falls apart  Anthem will have to pay a breakup fee of  1 85 billion The company is also witnessing losses on its public exchange business like UnitedHealth Group Inc    NYSE UNH   and Aetna Inc    NYSE AET    For 2016  the company expects a membership decline of approximately 300 000 in its individual business  It also expects to see a  mid single digit  margin loss for 2016 in this business instead of its prior expectation of a slight profitability The persistent low interest rate environment has also taken a toll on Anthem s investment income  For 2015  net investment income declined 6 5  year over year to  677 6 million  For 2016  the company projects investment income of approximately  650 million which translates into a year over year decline of 4  from the 2015 level  ANTHEM INC Price and Consensus
    The company also expects medical loss ratio in the range of 84 9  plus or minus 30 basis points for the year  reflecting higher than previously expected claims rates in its Individual ACA compliant plans  Also  the company expects the Medicaid business to remain at elevated levels throughout the year  This includes worse than expected results in the newly implemented Iowa market The share repurchase suspension in the wake of Cigna deal has affected the bottom line We believe the Anthem stock  carrying a Zacks Rank  4  Sell   will continue to slide till its headwinds subside and its road ahead becomes clear  Short term investors can shift their focus from Anthem at least for the time being and bet their bucks on other lucrative counters  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-26,Zacks Investment Research,https://www.investing.com/analysis/is-anthem-(antm)-stock-likely-to-see-further-downside-200155824,200155824
148252,369768,CI,Zacks Industry Outlook Highlights  Health Insurance Innovations  Allied World Assurance  Argo Group International  Cigna And MetLife,opinion,"For Immediate Release

	Chicago  IL   August 25  2016   Today  Zacks Equity Research discusses Insurance  Part 1  including  Health Insurance Innovations  Inc      Allied World Assurance Company Holdings  AG     Argo Group International Holdings  Ltd      Cigna Corp  NYSE CI        and MetLife  NYSE MET   Inc     

	Industry  Insurance  Part 1

	Link  

	The long awaited benefits of a rising rate environment that the insurance industry were highly hopeful of after the Federal Reserve s first rate hike  in Dec 2015  in almost a decade  are unlikely to be felt any time soon  as any further liftoff is probably off the table for the rest of 2016  Though domestic economic factors   including growth  labor market conditions and consumer price inflation   are favorable for the Fed s next rate hike move  it will perhaps wait to see stability on the global front 

	If concerns over global economic growth weren t enough  the Brexit storm gave the already dovish Fed more reasons for staying away from the next rate hike 

	The insurance industry is one of the very few to thrive in a rising interest rate environment as its investment strategies are liability driven  But a prolonged low rate environment could not stop the industry from drawing investors  attention  as evident from the SPDR S P Insurance ETF s 124  gain in the past five years versus 94  gain of the S P 500  What made this possible 

	Many insurers have changed their asset allocation strategies in an effort to minimize the impact of the prolonged low rate environment on their business  Moving beyond their traditional holdings  they are investing in racier asset classes for increased returns 

	In fact  this has now reduced their ability to reap the benefits of rising rates  Of course  pricing changes based on rising rates will let them earn more  but their revenue model is now stable enough to counter a low rate environment 

	A rising rate environment will surely brace insurers  businesss sooner or later  But the business dynamics of insurers are not that simple  and the relationship of profit with the interest rate is not direct either 

	In particular  Property   Casualty  P C  insurance  which is not very sensitive to the interest rate environment  holds a significant amount of bonds  which would fall in value with interest rates rising steadily  which is very unlikely  though   This will lead to capital volatility in the industry 

	However  a rising rate environment would keep alleviating the pressure on P C insurers  investment income  and thus their earnings  Moreover  a higher rate environment would make the pricing environment more competitive  further supporting carriers to grow 

	Life insurers  however  depend heavily on investment income  so they will benefit more from a rising rate environment  There will be relief from operating pressures resulting from tight credit spreads that the low rate environment has exerted for so long  However  the benefit is expected to be modest as life insurers have significantly reduced their interest sensitive product lines in this low rate era 

	No matter how the changing interest rate environment impacts insurers  normal catastrophe losses   11 billion insured losses in the in the first half of 2016 versus  8 billion a year ago  and continued influx of capital are expected to keep most lines of P C insurance favorable for buyers  Yet  evolving threats such as cyber attacks and a persistently soft market pose challenges for carriers 

	On the other hand  containment of underwriting expenses and a modest increase in premiums are shoring up the prospects of life insurers  But the prolonged low rate environment has been intensifying their struggle to generate adequate returns to meet their commitment to policyholders 

	With glaring dissimilarity in business dynamics  it makes better sense to look at the prospects of these two key segments of the U S  insurance space separately  read our subsequent posts for a detailed insight  

Overall Insurance Market at a Glance

	While continued economic uncertainty across the globe is not leaving the U S  totally unscathed  domestic economic progress makes the backdrop stronger for the country s insurers  Insurers might not see significant improvement in their rate sensitive business in the near term  but growing demand for coverage with improving labor market conditions and evolving insurable risks  such as cyber threat  endemic disease  etc   should keep them afloat  In fact  increasing demand from economically recuperating American households should eventually place insurers in a favorable pricing cycle  too 

	Moreover  a strong liquidity profile by virtue of continued capital inflow into the industry  ample capacity  conservative product design and evolving coverage will not only limit any downside but will also keep the growth trend alive  Also  the ongoing reserve development should continue to support insurers  financials 

	Further  recovery in underwriting and a lower combined ratio for P C insurers are expected to continue if the trend of modest catastrophe losses prevails  Then again  lower catastrophe losses indicate lower premium rates 

	Moreover  heightened competition might curb insurers  profitability in the quarters ahead  But the rapid influx of alternative capital will keep prices down and expedite M A activities 

Will Regulation Hinder Insurers  Growth Prospects 

	Apparently  a safe and sleepy business nature keeps U S  insurers out of federal regulations  which could have marred business expansion  But the industry is yet to be strongly braced by the advantages of operating under state run regulations  Instead  decentralized regulation and consumer protection make the industry susceptible to insolvency 

	Now  the changing nature of business    more like banks in terms of liabilities    perhaps calls for federal oversight  Though the necessity for a regulatory revamp has been strongly felt after banks witnessed success  this would deliver another blow to the insurance industry 

	A provision of the 2010 Dodd Frank Act requires setting minimum capital and leverage standards on insurance companies  but these have yet to be implemented by U S  lawmakers  who are considering distinct business fundamentals different from banks  But the industry  which is increasingly contributing to GDP  has scant chance of being relieved of Federal Reserve control for very long 

Zacks Industry Rank

	Within the Zacks Industry classification  insurers are broadly grouped in the Finance sector  one of the 16 Zacks sectors  and are further sub divided into five industries at the expanded  aka  X   level  P C  Multiline  Accident   Health  Life and Brokers  The level of sensitivity and exposure to different stages of the economic cycle vary for each industry 

	We rank 265 X industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry 

	We put our X industries into two groups  the top half  industries with the best average Zacks Rank  and the bottom half  the industries with the worst average Zacks Rank   Over the last 10 years  using a one week rebalance  the top half beat the bottom half by a factor of more than 2 to 1   To learn more visit   

	The Zacks Industry Rank is  60 for Life   180 for Accident   Health   218 for P C   224 for both Brokers and Multiline 

Earnings Trends

	All S P 500 companies in the broader Finance sector  of which the Insurance industry is a medium level  or M level  component  have reported second quarter 2016 results  The earnings beat ratio  percentage of companies coming up with positive surprises  is 66 7   while the revenue beat ratio is 54 4  

	The sector has witnessed an earnings decline of 5 2  year over year compared with a 6 9  decline in the prior quarter  Revenues have declined 0 2  compared with an increase of 2 1  in the prior quarter 

	For the third quarter  the sector is expected to witness year over year earnings growth of 4 9  and revenue growth of 2 3  

	For a detailed look at the earnings trend for this sector and others  please read the latest  report 

Bottom Line

	Looking at the broader trends  the growth prospects of the industry appears bright even if the low rate environment continues  The emergence of new issues might not significantly dampen insurers  business either  Particularly  learning from past experience  insurers are resorting to expense saving measures to tread water 

	It may not be very difficult for insurers to overcome short term resistance  While the inability to increase premium rates will keep on curbing profitability  there are enough drivers for margin expansion in the medium term  Also  in the absence of federal regulation  insurers can take on new challenges with the ample capital that they now have 

How to Play the Insurance Industry

	As you can see  though the interest rate environment may not significantly benefit insurers any time soon  there are plenty of reasons to be optimistic about the industry s prospects  So it would be prudent to pick a few insurance stocks that might outperform the markets in the near term 

	We highly recommend stocks with a Zacks Rank  1  Strong Buy  such as Health Insurance Innovations  Inc      Allied World Assurance Company Holdings  AG    and Argo Group International Holdings  Ltd      

	However  we suggest staying away from or getting rid of Zacks Rank  5  Strong Sell  stocks such as Cigna Corp     and MetLife  Inc      

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-24,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-health-insurance-innovations,-allied-world-assurance,-argo-group-international,-cigna-and-metlife-200150031",200150031
148253,369769,CI,Cigna Extends Partnership With Hollard Insurance In Africa,opinion,"Cigna Corporation s   NYSE CI   global expatriate business segment  Cigna Global Health Benefits  recently extended its partnership with Hollard Insurance Group  an insurer based in Africa The alliance is expected to address the requirement of a fully compliant health insurance product for residents of sub Saharan Africa  This new health insurance product to be offered has been named Hollard Cigna Health  This custom made product will also cater to the legal needs of staff members who are mobile across regions and nations  expatriates and even key local nationals operating in different regions This partnership combines Cigna s global exposure and substantial expertise in Health solution with Hollard s dominance in the African markets owing to its brand recognition and local market knowledge  Hence  the partnership can make use of its ISO certified procedures to establish an all in one solution for multinational corporations that intend to build a presence in sub Saharan Africa as well as companies already operating in the region African markets are segregated by unique demands  expectations and legislations  Therefore  Hollard Insurance is well positioned as a local insurance player to have extensive insight on the varied and distinctive markets of sub Saharan Africa  This should prove to be highly beneficial for Cigna in its efforts to penetrate into the concerned African markets and profit by delivering premium quality yet affordable health care to its clients  customers and partners in the area  In addition  this strategic alliance is likely to expand Cigna s global footprint with more customized and compliant regional health insurance solutions This expansion into African market reflects the company s long term strategy of accelerating international operations  Notably  the insurer has been expanding its base to new markets  owing to the significant regulatory pressure in the domestic market in the face of the Healthcare reform  To this end  Cigna has been diversifying its operations in China  India  Turkey and the other Middle Eastern countries to fuel future growth Moreover  we believe that the company s distinctive presence in the emerging markets will bolster its earnings and expand margins  Its international business offers faster growth  high double digits  and higher margins  high single digits to low double digits  than its commercial book  Given the aggressiveness with which Cigna is forging ahead with its  Go Global  strategy  we expect the contribution of its international business to be largely accretive to total earnings  going forward Companies like Aetna Inc    NYSE AET   and UnitedHealth Group Inc    NYSE UNH   who deal with medical product and services  are also growing their international businesses With the optimism over the recent partnership with Hollard Insurance  the Zacks Rank  5  Strong Sell  multi line insurer might witness favorable estimate revisions and in turn a rank upgrade CIGNA CORP Price
    Stock to ConsiderA better ranked multi line Insurers is CNO Financial Group Inc   NYSE CNO    It carries a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-07,Zacks Investment Research,https://www.investing.com/analysis/cigna-extends-partnership-with-hollard-insurance-in-africa-200152472,200152472
148284,369800,CI,Cigna  CI  Narrows 2016 Guidance After Q2 Earnings Miss ,opinion,"Cigna Corp    NYSE CI   reported second quarter 2016 operating net earnings of  1 98 per share that significantly missed the Zacks Consensus Estimate of  2 39  Also  earnings declined 22 3  year over year  The earnings decline stemmed from poor performance by the company s Global Disability and Life segment which sustained an operating loss due to poor life claims experience and the impact of modifications to the disability claims management process implemented in the previous quarter However  revenues of  9 89 billion surpassed the Zacks Consensus Estimate of  9 78 billion  Revenues also grew 4 5  year over year  Higher contribution from its segments  namely Global Health Care  Global Supplemental Benefits and Group Disability and Life  drove the upside Cigna s global medical customers were 15 1 million  up 2 5  from 14 8 million members in the year ago quarter  The improvement was driven by organic growth in the Middle Market  Medicare Advantage and Select segments Premiums of  7 7 billion increased 3  year over year  All the segments of the company registered premium growth Quarterly Review by Segment Premiums and fees from the Global Health Care segment increased 3 1  year over year to  6 9 billion  Customer growth  specialty contributions and rate actions in the company s Commercial employer group drove the upside  However  the increase was partially offset by a lesser number of Medicare Part D and Individual customers  Operating earnings were  486 million  down 8  year over year due to strong contributions from Commercial employer  Government and specialty businesses  The company expects adjusted income from operations in the range of  1 9 billion to  1 93 billion for the segment  Premiums and fees from Cigna s Global Supplemental Benefits climbed 6 8  year over year to  800 million on the back of strong new sales in the company s target markets  Operating income increased 7 8  year over year to  83 million  The company expects adjusted income from operations in the range of  255 million to  275 million for the segment The Global Disability and Life segment s premiums and fees also increased 3  year over year to  1 0 billion  primarily driven by consistent strong persistency and new sales  However  the segment posted operating loss of  12 million against operating profit of  106 million in the year ago quarter  The loss was an impact of modifications to the company s disability claims management process implemented in the first quarter and a poor life claims experience  For 2016  adjusted income from operations is expected in the range of  40 million to  80 million for the segment 2016 GuidanceFor 2016  Cigna expects earnings per share of  7 75  8 10  down from the earlier guidance of  8 95  9 35 per share  The company projects mid single digit percentage growth in revenues  while the number of global medical customers are projected to increase in low single digits 
CIGNA CORP Price  Consensus and EPS Surprise   Zacks Rank   Performance of Other Multi Line Insurers Currently  Cigna carries a Zacks Rank  3  Hold   Among the other multi line insurers that have reported their second quarter earnings results so far  the bottom line at Anthem Inc    NYSE ANTM    Centene Corp    NYSE CNC   and UnitedHealth Group Inc    NYSE UNH   beat their Zack Consensus Estimate 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-07-28,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci)-narrows-2016-guidance-after-q2-earnings-miss-200145066,200145066
148286,369802,CI,Cigna  CI  Misses Q2 Earnings Estimate  Guides For 2016,opinion,Cigna Corp    NYSE CI   is a national health benefits company with a comprehensive portfolio of businesses which includes Employee Healthcare  Disability and Life Its organizational efficiency plans as well as expansion of Seniors and Medicare business positions it well for long run Cigna has a large international presence  which provides diversification benefits Cigna was due to be acquired by Anthem Inc  The merger  would have helped Cigna  currently holding fourth rank  to leapfrog to the number one rank  in terms of membership in the U S  health insurance industry  But the deal has been sued by the regulators and now remains on tenterhooks Cigna does have a decent history when it comes to earnings as the stock has beaten estimates in each of the last four reported quarters making for an average surprise of 5 93  Currently  Cigna has a Zacks Rank  3  Hold   but that could definitely change following Cigna earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings   Cigna missed the earnings estimate  Our consensus called for earning per share of  2 39  and the company reported earnings of  1 98 per share  Earnings per share was down 22 3  year over year Revenue  Revenues of  9 89 billion surpassed the Zacks Consensus Estimate of  9 78 billion  Revenues also grew 4 5  year over year Key Stats to Note Premiums of  7 6 billion increased 3  year over year  All the segments of the company   Global Health Care  Global Supplemental Benefits and Group Disability and Life   registered premium growth Total Medical Customers totaled 15 1 million as on Jun 30  2016 Cigna gave its 2016 earnings guidance  It expects earning per share is expected in the range of  7 75 to  8 10  It expects mid single digit growth in revenue  Cigna expects global medical customer growth in low single digits percentage range CIGNA CORP Price and EPS Surprise   Check back later for our full write up on this CI earnings report later Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-29,Zacks Investment Research,"https://www.investing.com/analysis/cigna-(ci)-misses-q2-earnings-estimate,-guides-for-2016-200144934",200144934
148287,369803,CI,MetLife  MET  Q2 Earnings And Revenues Miss  Decline Y Y,opinion,MetLife  Inc  s   NYSE MET   second quarter 2016 earnings of 83 cents per share missed the Zacks Consensus Estimate of  1 36 by 39   Earnings also plunged 47  year over year During the second quarter  MetLife generated revenues of  16 95 billion  The top line lagged the Zacks Consensus Estimate of  17 07 billion by 0 4  and also declined 2 4  year over year MetLife s premiums  fees and other revenues slipped 1  year over year  Operating premiums  fees   other revenues also dipped 1  During the reported quarter  MetLife s total operating expenses increased 4 5  year over year to  15 7 billion Segment DetailsAmericasOperating earnings in this segment declined 42   or 41  on constant currency basis  year over year to  835 million due to reserve adjustments resulting from modeling improvements in the reserving process and the annual variable annuity actuarial assumption review In the reported quarter  operating return on allocated equity was 8 6   operating return on allocated tangible equity was 9 6  and operating premiums  fees   other revenues grew 1   or 3  on a constant currency basis  to  9 3 billion AsiaOperating earnings were down 39   or 41  on constant currency basis  year over year to  259 million  This was primarily due to unfavorable tax related adjustments in Japan  reinsurance receivables adjustment in Australia and lower fixed annuity surrenders In the reported quarter  operating return on allocated equity was 9 4   while operating return on allocated tangible equity was 16 2    Operating premiums  fees   other revenues in Asia declined 8   or 13  on a constant currency basis  to  2 1 billion Total sales for the region decreased 3  on a constant currency basis due to the impact of management actions to enhance value in targeted markets EMEAOperating earnings from EMEA increased 28   or 36  on constant currency basis  year over year to  64 million In the reported quarter  operating return on allocated equity was 7 9   while operating return on allocated tangible equity was 13 8   Operating premiums  fees   other revenues were down 4   or 1  on a constant currency basis  to  633 million Moreover  total sales jumped 10  on a constant currency basis  Growth in employee benefits in the Middle East as well as accident and health products across the region drove the upside Also  Corporate   Other operating loss was  234 million  substantially wider than the loss of  153 million in the year ago quarter Investment   Financial UpdateIn the reported quarter  net investment income slipped 6  year over year to  4 9 billion  Variable investment income was  285 million  down 33 2  from  427 million in the prior year quarter  mainly due to lower alternative investment income Zacks RankCurrently  MetLife carries a Zacks Rank  4  Sell  METLIFE INC Price  Consensus and EPS Surprise   Performance of Other Multi Line InsurersAmong other multi line insurers that have reported their second quarter results so far  the bottom line at CNO Financial Group Inc    NYSE CNO   and American International Group Inc    NYSE AIG   beat the respective Zack Consensus Estimate  while Cigna Corp  s   NYSE CI   earnings missed the same  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/metlife-(met)-q2-earnings-and-revenues-miss;-decline-y-y-200146185,200146185
148325,369841,CI,Stocks Rally To Start Week,opinion,"U S  stocks rallied on the heels of broad based advances in Asia and Europe  with global risk aversion pulling back amid eased U K  Brexit concerns following new polls over the weekend ahead of Thursday s vote  Financials and technology issues saw solid gains  while a jump in crude oil prices powered the energy sector  Treasuries  gold and the U S  dollar were lower  while the domestic economic front was quiet today 
The Dow Jones Industrial Average  DJIA  rallied 130 points  0 7   to 17 805  the S P 500 Index jumped 12 points  0 6   to 2 083  and the Nasdaq Composite finished 37 points  0 8   higher at 4 837  In moderately heavy volume  892 million shares were traded on the NYSE and 1 8 billion shares changed hands on the Nasdaq  WTI crude oil increased  1 40 to  49 96 per barrel and wholesale gasoline added  0 07 to  1 58 per gallon  while the Bloomberg gold spot price decreased  8 98 to  1 289 67 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was 0 6  lower at 93 67 
Dow member Wal Mart Stores Inc   NYSE WMT  71  announced a strategic alliance with JD com  NASDAQ JD  22   China s largest e commerce company by revenue  The companies said the agreement includes a wide range of business initiatives  covering both online and offline retail  Shares of both companies traded higher 
Cigna Corp   NYSE CI  128  and Anthem Inc   NYSE ANTM  133  are in focus following a report from the Wall Street Journal suggesting their  44 billion merger agreement is raising antitrust concerns among U S  regulators  per people familiar with the matter  None of the entities has commented on the report  while the companies have more meetings this week with top Justice Department officials  CI closed lower  while ANTM gained modest ground 
Economic calendar dormant today 
Treasuries were lower  while the U S  economic calendar was void of any major releases today  The yield on the 2 year note rose 4 basis points  bps  to 0 73   while the yields on the 10 year note and the 30 year bond gained 6 bps to 1 67  and 2 48   respectively  Bond yields rebounded somewhat from their recent fall as the Fed suggested that it is still in a  wait and see  mode  remaining data dependent in the wake of May s severely disappointing labor report  while growth concerns and uncertainty regarding a U K  exit from the European Union  EU   known as a Brexit  have also applied pressure 
Recent pressure on global bond yields has amplified the uneasy sentiment  with rates in Germany  Japan and the U K  hitting record lows  while the U S  10 year Treasury yield touched to a four year low 
This week s economic front will start slow but pick up steam tomorrow as Federal Reserve Chairwoman Janet Yellen will begin her two day semiannual monetary policy report to Congress  Yellen s testimony will be accompanied by some key reads later this week on housing in the form of existing and new home sales reports  as well as manufacturing  with preliminary releases of durable goods orders and Markit s Manufacturing PMI Index  Other notable domestic reports due out this week include  the Leading Index and the final June University of Michigan Consumer Sentiment Index 
However  the focus of the global markets will likely be the looming June 23 U K  Brexit vote and no matter the outcome  the issue of a Brexit may not be put to rest entirely as EU member parliaments must also agree to the changes being proposed  Nevertheless  the British understand the key role trade has always played in their economy  The British may resent bailed out banks and bureaucrats in Brussels  but we believe economic considerations will favor the U K  remaining within the EU 
Europe and Asia gain ground as Brexit fears recede 
European equities moved broadly higher  with global sentiment being soothed by eased concerns about a U K  Brexit on the heels of new polls over the weekend suggesting the  remain  camp gained ground ahead of Thursday s vote  Financials rallied to lead the advance and higher crude oil prices lifted the energy sector  while the British pound surged versus the U S  dollar  The euro rose versus the U S  dollar and bond yields in the region were mixed  In economic news  eurozone construction output declined in April 
Stocks in Asia finished broadly higher with global risk aversion waning as recent polls are easing concerns about a U K  Brexit ahead of Thursday s vote  The yen gave back some of its recent rally to boost Japanese equities  despite a report showing the nation s exports fell more than expected in May  Chinese stocks battled back from some early weakness to finish higher  aided by an upbeat read on the country s May property prices  Australian securities advanced  led by strong gains in the heavy weight oil and gas  basic materials and financial sectors  while South Korean listings also rose  Indian stocks moved higher  with the announcement that Reserve Bank of India s Governor Rajan will step down at the end of his term in September being overshadowed by the eased Brexit concerns and the announcement that India s government relaxed foreign direct investment rules 
Tomorrow  the international economic docket will be light  offering CPI from Hong Kong  the Zew Economic Sentiment Survey from Germany and public sector net borrowing from the U K ",2016-06-21,Marvin Clark,https://www.investing.com/analysis/stocks-rally-to-start-week-200137130,200137130
148326,369842,CI,AEGON Announces Plan To Repurchase 29 3 Million Shares,opinion,AEGON N V    NYSE AEG   announced that its board of directors has approved a 29 3 million share buyback plan to offset the dilutive effect of the 2015 final stock dividend  The company will pay future stock dividends with these repurchased shares  In addition  these shares will be held as treasury shares The buyback plan became effective on Jul 4  2016 and the company anticipates the repurchase to be completed on or before Aug 12  2016  The company  via third party  will buy back the shares at a maximum of the daily volume weighted average price In May  the company completed the buyback of 42 million shares  The company spent  226 2 million   200 million  and  225 6 million   200 million  in two tranches In January  the company presented its financial targets for 2018 at the Analyst   Investor Conference in London  The company intends to increase capital returns to shareholders  which will be underscored by the previously announced buyback of  451 8 million   400 million   Moreover  the capital return will includes the 9  increase in the dividend declared in 2015 With an efficient capital deployment strategy and stable financial position  the multi line insurer remains well poised to engage in more activities that in turn will boost shareholders return Further  AEGON has sufficient liquidity owing to solid operational performance that should support more such buyback activities in the future   Hence  the company s capital deployment through share buybacks  as well as dividend payment looks impressive  This in turn  makes the stock an attractive pick for yield seeking investors AEGON N V Price   Investors interested in the insurance industry can consider stocks like MGIC Investment Corp    NYSE MTG    Cigna Corp    NYSE CI   and James River Group Holdings  Ltd    NASDAQ JRVR   ,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/aegon-announces-plan-to-repurchase-29.3-million-shares-200140326,200140326
148365,369881,CI,Cigna  CI   Can The Stock Surprise This Earnings Season ,opinion,Cigna Corp    NYSE CI   is scheduled to report first quarter 2016 results on May 6  In the last quarter  this company delivered a 5 06  positive earnings surprise  Let s see how things are shaping up for this announcement Factors Influencing this Past QuarterCigna is likely to benefit from its strong membership driven by organic growth in the Middle Market  International  Select and Medicare segments  Exposure to the Medicare Advantage market is expected to add to the upside Evolving Global Supplemental Benefits should also support Cigna s results as the insurer has a strong market position and strategic investments in the same However  restrictions to market or sell Medicare Advantage policies or Part D drug plans to new clients may weigh on its top line  Adverse effect of forex and higher expenses are expected to taper the bottom line With respect to the surprise trend  Cigna surpassed expectations in each of the last four quarters  with an average beat of 5 69  The company s share price has been fluctuating over the last few days  We wait to see how the stock reacts to the quarter s results Earnings WhispersOur proven model does not conclusively show that Cigna will beat the Zacks Consensus Estimate in the first quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy  or at least 2  Buy  or 3  Hold  for this to happen  But this is not the case here as elaborated below Zacks ESP  Cigna has an Earnings ESP of  0 46   This is because the Most Accurate estimate stands at  2 18 while the Zacks Consensus Estimate is pegged lower at  2 17 Zacks Rank  Cigna has a Zacks Rank  4  Sell   The Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement Stocks to ConsiderHere are some companies that you may want to consider as these have the right combination of elements to post an earnings beat this quarter   Physicians Realty Trust   NYSE DOC   has an Earnings ESP of  4 35  and a Zacks Rank  3  The company is scheduled to report first quarter earnings results on May 5 Fidus Investment Corporation   NASDAQ FDUS   has an Earnings ESP of  2 44  and a Zacks Rank  1  The company is scheduled to report first quarter earnings results on May 5 Garrison Capital Inc   NASDAQ GARS   has an Earnings ESP of  6 25  and a Zacks Rank  3  The company is scheduled to report first quarter earnings results on May 9 ,2016-05-03,Zacks Investment Research,https://www.investing.com/analysis/cigna-(ci):-can-the-stock-surprise-this-earnings-season-200127979,200127979
148366,369882,CI,Major Insurers  Q1 Earnings Slated Tomorrow  BRK B  CI  WLTW,opinion,The first quarter earnings season is wrapping up with results from 75  of the S P 500 members already on board as per our  report  These 374 index members reported total earnings decline of 7 5  on 1 9  lower revenues  However  the beat ratio is 71 4  for the bottom line and 56 4  for the top line About 87 5  of the companies in the Finance sector have already reported their results  Total earnings have declined 7 6  though revenues managed a 0 5  improvement  The beat ratio also compares unfavorably with the S P 500 index The insurance industry is part of the broader finance sector  In the first quarter  insurers had to digest catastrophe losses stemming from the hail storm in north Texas in March  This is weighing on their underwriting results and the bottom line  However  these are unlikely to drain out insurers  capital  Also  a diversified portfolio and geographic expansion may safeguard their performance Nonetheless  a still soft interest rate environment will keep investment results under pressure  However  the slight rate rise by the Fed was a silver lining for life insurers which suffered spread compression on products like fixed annuities and universal life due to sustained low rates   With earnings releases coming in thick and fast  the end of the week will have earnings results from nearly 88  of the index members  Let s find out what s in store for three major insurance companies that will report on May 6 Berkshire Hathaway  NYSE BRKa  Inc   is a conglomerate  which has nearly 90 subsidiaries in insurance  rail roads  utilities  manufacturing services  retail and home building  The company has the investment icon Warren Buffet at the helm  Last quarter  the company delivered an 8 0  positive surprise  Berkshire Hathaway has an  of 0 00  and a Zacks Rank  3  Hold   The Zacks Consensus Estimate for the quarter is pegged at  1 75 Berkshire Hathaway is expected to perform well on the strength of its insurance  financials and manufacturing segments  Strategic acquisitions should continue to support results  However  Berkshire Hathaway s insurance business remains exposed to catastrophe and high expenses incurred on rail road operations  which can taper margins   Read more   With respect to the surprise trend  Berkshire Hathaway surpassed expectations in only one of the last four quarters  with an average negative surprise of 3 42  Cigna Corp    NYSE CI   along with its subsidiaries provides health care and related benefits  the majority of which are offered through workplace  The company delivered a 5 06  positive surprise in the last quarter  For the first quarter of 2016  Cigna has an Earnings ESP of  0 46   It currently carries a Zacks Rank  4  Sell  Cigna is likely to benefit from its strong membership  Exposure to the Medicare Advantage market is expected to add to the upside  Evolving Global Supplemental Benefits should also support Cigna s results  However  restrictions to market or sell Medicare Advantage policies or Part D drug plans to new clients may weigh on its top line  Adverse effect of forex and higher expenses are expected to taper the bottom line  The Zacks Consensus Estimate for the quarter is pegged at  2 17   Read more   With respect to the surprise trend  Cigna surpassed expectations in each of the last four quarters  with an average beat of 5 69  Willis Towers Watson plc    NASDAQ WLTW   is a leading global advisory  broking and solutions company  The company caters to large companies and mid market and small businesses across the world  Last quarter  Willis Towers delivered a 22 7  negative surprise  Willis Towers has an Earnings ESP of  4 29  and a Zacks Rank  4  The Zacks Consensus Estimate for the quarter is pegged at  2 80 This is the first quarter in which the company will report its earnings after the merger of Willis Group and Towers Watson  The combination of two heavy weights is likely to boost operational results in the to be reported quarter  Strategic acquisitions are also expected to add to the top line  However  adverse forex effects  soft interest rates and higher expense may hurt the bottom line   Read   With respect to the surprise trend  Willis Towers surpassed expectations in only one of the last four quarters  with an average  negative surprise of 11 03  Keep an eye on our full earnings articles to see how these S P 500 members finally fared ,2016-05-04,Zacks Investment Research,"https://www.investing.com/analysis/major-insurers'-q1-earnings-slated-tomorrow:-brk.b,-ci,-wltw-200128232",200128232
148367,369883,CI,Key Morning Earnings For May 6  CI  CST  MSG  USM,opinion,"As   more and more companies are posting their earnings results  On Friday  four big names in the health insurance  retail  entertainment  and wireless industries reported their quarterly earnings before the bell  Let s take a look 
Cigna Corp    NYSE CI  
The healthcare insurance company reported Q1 operating earnings of  2 32 per share  comfortably beating the Zacks Consensus Estimate of  2 17 by 6 9  and rising 18 4  year over year  Revenues of  9 9 billion topped our consensus estimate of  9 6 billion and increased 5 6  year over year  Higher contribution from its segments  namely Global Health Care  Global Supplemental Benefits  and Group Disability and Life  drove the upside  For 2016  Cigna forecasts income from operations in the high single digit range  with earnings per share of  8 95  9 35  The company also expects mid single digit growth in revenues 
CST Brands  Inc    NYSE CST  
The San Antonio  Texas based gas station convenience store retailer reported adjusted earnings per share of  0 27  excluding special items   beating the Zacks Consensus Estimate of  0 24  Revenues of  2 03 billion in the quarter  also topping our consensus estimate of  2 02 billion  Store operations delivered a strong performance with U S  Merchandise and Services Gross Profit growth of 25  year over year  thanks to 20  sales growth and a 160 basis point improvement in gross margin 
Madison Square  NYSE SQ  Garden Co    NYSE MSG  
A company involved in the sports  entertainment  and media industries  Madison Square Garden reported a Q3 loss of  60 8 million  Adjusted earnings per share came in at a loss of   0 77  missing the Zacks Consensus Estimate of a loss of   0 49 per share  Revenues of  336 3 million beat our consensus estimate of  325 5 million but decreased 25 26  year over year  The company noted that the results for the third quarter reflect the allocation of corporate general and administrative costs based on accounting requirements for the preparation of carve out financial statements 
U S  Cellular Co    NYSE USM  
One of the largest wireless companies in the U S   U S  Cellular reported disappointing Q1 results  Earnings per share of  0 10 fell way behind the Zacks Consensus Estimate of  0 23 per share  Revenues of  958 million also missed our consensus estimate of  972 2 million  The company reiterated its full year 2016 guidance  with total operating revenues expected to be in the range of  3 9 billion  4 1 billion and adjusted EBITDA in the range of  725 million  850 million ",2016-05-05,Zacks Investment Research,"https://www.investing.com/analysis/key-morning-earnings-for-may-6:-ci,-cst,-msg,-usm-200128530",200128530
148368,369884,CI,Stocks Manage Gains Despite Jobs Report Miss,opinion,"U S  stocks managed to move above the flatline in afternoon action and close the regular trading session with decent gains  displaying some resiliency in the face of a disappointing monthly labor report which showed job growth missed forecasts and the unemployment rate failed to decline  Treasuries were lower and the U S  dollar was nearly unchanged  while gold and crude oil prices advanced 
The Dow Jones Industrial Average  DJIA  advanced 80 points  0 5   to 17 741  the S P 500 Index gained 7 points  0 3   to 2 057  and the Nasdaq Composite added 19 points  0 4   to 4 736  In moderately heavy volume  955 million shares were traded on the NYSE and 1 8 billion shares changed hands on the Nasdaq  WTI crude oil ticked  0 34 higher to  44 66 per barrel  wholesale gasoline increased  0 01 to  1 60 per gallon  and the Bloomberg gold spot price gained  11 01 to  1 288 75 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was flat at 93 85  Markets were lower for the week  as the DJIA declined 0 2   the S P 500 Index lost 0 4  and the Nasdaq Composite decreased 0 8  
Activision Blizzard Inc   NASDAQ ATVI  38  reported 1Q earnings per share  EPS  ex items of  0 23  above the  0 12 FactSet estimate  as revenues rose 29 2  year over year  y y  to  908 million  north of the projected  814 million  The video game publisher issued 2Q guidance that topped expectations  while it raised its full year outlook  Shares traded nicely higher 
Cigna Corp   NYSE CI  131  posted 1Q earnings of  2 32 per share  above the  2 16 estimate  as revenues rose 6 0  y y to  9 9 billion  below the projected  10 0 billion  CI raised its full year EPS outlook and reaffirmed its revenue guidance  Separately  the company said in light of the complexity of the regulatory process and the dynamic environment  it is possible that regulatory approval of its merger with Anthem Inc   NYSE ANTM  137  may not be obtained in 2016  Shares closed lower 
Herbalife Ltd   NYSE HLF  64  achieved 1Q EPS ex items of  1 36  well above the  1 09 expectation  with revenues rising 1 0  y y to  1 1 billion  roughly in line with forecasts  HLF raised its full year profit outlook  Separately  the company said it is in late stage talks regarding the investigation into its marketing practices with the Federal Trade Commission  FTC   estimating that if a settlement is reached  the likely cost would be  200 million  HLF rallied 
Endo International PLC   NASDAQ ENDP  16  fell over 35  after the pharmaceutical company slashed its full year guidance  despite topping the Street s 1Q EPS and revenue projections  The company cited increasing competitive and pricing pressures across both its generics and branded businesses  as well as delays on regulatory actions related to certain products 
April labor report misses job growth expectations
Nonfarm payrolls rose by 160 000 jobs month over month  m m  in April  compared to the Bloomberg forecast of a 200 000 increase  The initial rise of 215 000 seen in March was revised to a gain of 208 000 jobs  The total downward revision to job gains in March and February was 19 000  Excluding government hiring and firing  private sector payrolls increased by 171 000  versus the forecasted gain of 195 000  after expanding by a downwardly revised 184 000 in March  from the 195 000 rise that was initially reported  Job gains occurred in professional and business services  health care  and financial activities  while job losses continued in mining 
The unemployment rate remained at 5 0   compared to expectations of a dip to 4 9   while average hourly earnings grew by 0 3  m m  matching projections  and March s 0 3  rise was adjusted to a 0 2  increase  Finally  average weekly hours rose to 34 5 from March s unrevised 34 4 hours level  in line with expectations 
The job growth  which was the lowest in seven months  likely exacerbated recently flared up global growth concerns and could be preserving worries about a potential U S  recession  However  over the past 12 months  employment growth has averaged 232 000 per month  That data still suggests although we re unlikely to exit from a muddle through state  the risk of recession is objectively low 
Also  an upbeat aspect of the report was the rise in wages  which now have increased 2 5  over the past 12 months  an acceleration from the 2 3  pace in the prior month  Wage growth helps underpin consumer spending  which is the main driver of the U S  economy and could help the housing market another key economic driver improve further 
Consumer credit  released in the final hour of trading  showed consumer borrowing expanded by  29 7 billion during March  well above the  16 0 billion forecast of economists polled by Bloomberg  while February s figure was adjusted down to an increase of  14 2 billion from the originally reported  17 2 billion  Non revolving debt  which includes student loans and loans for vehicles and mobile homes  rose  18 6 billion  while revolving debt  which includes credit cards  increased by  11 1 billion 
Treasuries were lower  with the yields on the 2 year note and the 30 year bond increasing 2 basis points  bps  to 0 73  and 2 63   respectively  and the yield on the 10 year note ticking 3 bps higher to 1 78  
Europe mixed  Asia mostly lower
European equities finished mixed  posting a solid weekly loss  Traders digested the softer than expected U S  April employment report that appeared to dampen Fed rate hike expectations  likely helping crude oil prices overcome early pressure to boost the energy sector  and supporting an upside reversal in basic materials stocks  Basic materials issues showed some resiliency and the euro gained modest ground on the U S  dollar  while bond yields in the region mostly moved lower 
Stocks in Asia finished mostly to the downside amid cautious trading ahead of today s key employment report in the U S  Japanese stocks declined  returning to action following a three day holiday break with the yen showing some late day strength to weigh on the markets  Chinese stocks fell with the recent pullback in commodity prices pressuring the resource sector  Also  this week s reports on manufacturing and services sector activity  which showed growth slowed  continued to foster uneasiness regarding the health of the world s second largest economy 
Indian equities dipped ahead of the U S  jobs report  while Australian securities rose after overcoming early pressure as the Reserve Bank of Australia lowered its inflation outlook  sending the Australian dollar lower  The forecast comes as inflation was cited as a reason for the central bank to unexpectedly cut its benchmark interest rate this week  Markets in South Korea remained closed for a holiday 
Stocks pullback on soured global sentiment
U S  stocks posted a back to back weekly loss as global growth sentiment was challenged by U S  and Chinese manufacturing reports clinging to expansion territory  and U K  manufacturing output unexpectedly contracting  while the Reserve Bank of Australia surprisingly announced a rate cut  Also  volatility in the Japanese yen persisted and banking results in Europe did little to soothe heightened concerns about the health of the sector  Reports showing solid expansion in the all important U S  services sector and a surprising upwardly revised eurozone manufacturing growth were largely overshadowed  Crude oil prices pulled back to weigh on the energy sector and basic materials stocks saw pressure  while Treasury yields moved lower and the U S  dollar gained some ground  Earnings season  which is now in the home stretch  continued to paint a mixed picture  with about 76  of the 437 companies that have reported in the S P 500 topping profit forecasts  while only about 54  have bested sales projections  per data compiled by Bloomberg 
Currency moves have been a hot topic during 1Q earnings season with a lot of companies citing the strong dollar over the past year as a drag on profits  Others in Europe and Japan have acknowledged concerns over weaker exports stemming from the sharp year to date rise in their currencies  These drags may begin to fade if currency moves become less pronounced  and may help to lift earnings out of the slump they have been in for the past year or so  The return of earnings growth is a key factor in getting global stocks to move materially higher 
Health of the consumer set to take center stage
Next week s domestic economic calendar is poised to be headlined by data pointing to the health of the key U S  consumer  with the releases of April retail sales and the preliminary University of Michigan Consumer Sentiment Index for May  Data on retail sales and consumer confidence suggest a still cautious shopper  but we think these reports underestimate what is actually occurring  as some services and experience type items aren t included in those numbers  The trend may also be shifting as consumers appear to have slowed paying down their debt balances  potentially a positive development for spending  but still seem reluctant to increase their borrowing 
Other key U S  reports next week include  the NFIB Small Business Optimism Index  wholesale and business inventories  the JOLTS Job Openings report  the Import Price Index  and the Producer Price Index 
International reports slated for next week include  Australia consumer confidence  China trade balance  Consumer Price Index  CPI  and PPI  foreign direct investment  new yuan loans  and aggregate financing  India trade balance  CPI and industrial production  Japan trade balance  Eurozone investor confidence  industrial production  new car registrations and 1Q GDP  as well as German factory orders  trade balance and CPI  U K  trade balance  industrial and manufacturing production and the Bank of England monetary policy decision 
Schwab Center for Financial Research   SCFR   is a division of Charles Schwab  NYSE SCHW    Co   Inc  The information contained herein is obtained from third party sources and believed to be reliable  but its accuracy or completeness is not guaranteed  This report is for informational purposes only and is not a solicitation  or a recommendation that any particular investor should purchase or sell any particular security  The investment information mentioned here may not be suitable for everyone  Each investor needs to review an investment strategy for his or her own particular situation before making any investment decision  All expressions of opinions are subject to change without notice in reaction to shifting market conditions ",2016-05-08,Marvin Clark,https://www.investing.com/analysis/stocks-manage-gains-despite-jobs-report-miss-200128565,200128565
148392,369908,CI,5 Safe Stocks In A Dangerous Market,opinion,"Back in the peak bull days of 2013  it seemed like you could buy just about anything and its price would increase  It s safe to say those days are gone as the market has rediscovered volatility  The S P 500 is down nearly 3  so far this year and was down 9  just a few weeks ago  More than ever  investors that want to make money in the stock market need to do their due diligence and find companies with strong economic profits and cheap valuations 
Our past 48 long calls have outperformed the market by an average of 4 percentage points  increasing about 1  compared to a 3  loss for the S P 500  Five of our long calls over the past year stand out for their impressive returns and continued stability  Investors should take another look at these five stocks that are up 10  or more since our original calls and still earn an Attractive or better rating 


Universal Insurance Holdings  N UVE 


We love companies that consistently earn a strong return on invested capital  ROIC  and UVE has an impressive record here  Its current ROIC of 43  ranks highest of the 45 property and casualty insurers we cover  and since 2007 it s only earned an ROIC below 20  once  in 2007  This long term track record of efficiency led us to recommend UVE to investors in mid July 
Since then  the stock has risen by 27  on the back of strong earnings and a  10 million buyback announcement  Over this same time  the market has dropped nearly 6   Nothing has changed about the quality of the company and best of all the valuation remains appealing 
UVE has a price to economic book value  PEBV  of just 1 2  which implies that the market expects the company to grow after tax operating profit  NOPAT  by no more than 20  for the remainder of its corporate life  Given the fact that UVE has more than doubled its NOPAT in just the past two years  we believe it can continue to exceed market expectations 


Foot Locker  N FL 


Foot Locker has ridden the consumer recovery to big time profit growth and outperformance for investors since the recession  Its ROIC has improved from 3  in 2008 to 11  so far this year  and over the past five years the stock is up 387  compared to 70  for the S P 500 
In May  we argued that FL s strong underlying fundamentals and reasonable valuation meant that its streak of outperformance should continue  Sure enough  the stock is up 10  even as the market has dropped by 6  since our initial report  Steady growth in revenues and margin expansion has helped the stock keep rising 
At its current price of  70 share  FL has a PEBV of 2 1  This ratio implies that the market expects the company to grow profits by no more than 20  over the remainder of its corporate life  However  since 2009  FL has grown NOPAT by 20  compounded annually  If Foot Locker can grow NOPAT by 10  compounded annually for the next decade  the stock is worth  99 share today   a 41  upside  Such strong business operations coupled with low expectations make Foot Locker an opportunity worth looking into 


Inteliquent  O IQNT 


The market keeps looking for reasons to doubt IQNT  When the company reported full year earnings for 2014 in February  the market responded by sending shares tumbling 14   This response came despite the fact that the company beat on earnings and revenue and earned an ROIC of 28   its highest since 2009 
We responded to the drop in the share price by urging investors to buy IQNT in early April  Since then  the stock has risen 23  while the market has dropped by 4   IQNT received a big boost in August after landing a big contract with T Mobile  which adds the wireless carrier to its list of major customers along with Verizon and AT T  N T  
Even with this great news  IQNT still has a PEBV of just 1 2  With the new T Mobile deal providing a big boost to revenue  its margins continuing to expand  and plenty of cash on hand with which to invest in growth  we think IQNT can do much better than the market seems to expect 


The Goodyear Tire   Rubber Company  O GT 


Investors in GT need to look beyond the top line  Declining revenues kept the share price low early this year  but that is in part due to GT s strategy of focusing more on its high value added  HVA  tires  which have higher margins  Even as revenue has fallen in each of the past three years  the company has continued to grow NOPAT and improve ROIC 
With increased efficiency offsetting revenue declines  we made GT our stock pick of the week in February  Since then  the stock is up 18  against a 5  decline in the market  Cheap commodity prices mean improved margins for GT  more people driving  and more needing replacement tires  These trends have manifested in strong profit growth so far this year 
Despite its track record of profit growth  GT trades at a PEBV of 0 7  which implies that the market expects the company s NOPAT to permanently decline by 30   There s no reason to believe such a drastic decline is going to happen  If Goodyear can grow NOPAT by just 3  compounded annually for the next decade  the stock is worth  39 share today   a 22  upside from current prices 


Cigna Corporation  N CI 


Like UVE  CI tops its peer group in terms of ROIC  having earned a 13  return on capital last year  With the strong fundamentals  a cheap valuation  and growth opportunities from the Affordable Care Act and an aging population  we made CI one of our two stocks to own in 2015 
We re not the only one to see value in CI  as competitor Anthem  ANTM  announced a deal to acquire it for  54 billion in July  The deal consists of  55  cash and 45  stock and would make the combined company the largest health insurer in the nation  It would be a tie up of two great companies  as ANTM also earns an Attractive rating 
CI is up 37  since our call  but it still trades at a 21  discount to the acquisition price of  175  Concerns about the deal failing to pass regulatory muster have weighed on the share price  but investors shouldn t be worried  The upside if the deal goes through is great  but even if it doesn t CI is still worth the same  175 share price if it can grow NOPAT by 8  compounded annually for the next 10 years  This scenario seems even more realistic given that over the past five years Cigna has grown NOPAT by 10  compounded annually 
Diligence Matters
Making money in a market like this is tough  It requires lots of effort to dig through the footnotes and discover the true profitability and value of companies  That effort pays off when you find stocks like these that earn great returns in a down market  There s still value to be had in this market  it s just going to take more and more work to find 
Disclosure  David Trainer and Sam McBride receive no compensation to write about any specific stock  sector  style  or theme ",2015-10-14,David Trainer,https://www.investing.com/analysis/5-safe-stocks-in-a-dangerous-market-268143,268143
148421,369937,CI,Dow Jones  June 17th  2015,opinion,Dow JonesThe Dow Jones rose 113 31 points or 0 64  to 17 904 48 as the U S  stocks rose on Tuesday following back to back daily declines  with merger activity more than offsetting market concerns as Greece struggles to avoid a default on its debt  Bolstered by M A rumors involving UnitedHealth Group Incorporated  NYSE UNH   its shares spike 2 42 or 2 03  to 121 40 on Tuesday after reports surfaced that it could be considering a merger with Cigna Corporation  NYSE CI  and Aetna Inc  NYSE AET  ,2015-06-17,ICM Brokers,"https://www.investing.com/analysis/dow-jones-:-june-17,-2015-255317",255317
148422,369938,CI,3 Healthcare Stock Buys To Heal Your Portfolio This Summer,opinion,"The Affordable Care Act of 2010  or ObamaCare as it is commonly dubbed  has made the single biggest impact in the American healthcare industry since the introduction of Medicare in the 60s  The new laws have created a whole new world for healthcare providers and investors alike 

Although new regulations have increased operational costs  the ACA also requires every citizen to have a health insurance plan  handing companies millions of potential new customers  In response to the ups and downs of ObamaCare  healthcare providers have been looking to consolidate to improve efficiency and service quality  Buyout rumors have been running rampant in the industry lately 

Here at Zacks  we ve recognized a variety of favorable trends in the healthcare industry resulting from these operational changes  In fact  rising earnings estimates have landed the HMO industry in the top 12  of the Zacks Industry Rank  Furthermore  buyouts and consolidation tend to lead to increases in share prices  underscoring the positive trend in this market segment 

Top HMO Stocks

Below  we have highlighted a trio of  buy  ranked stocks  which look to take advantage of these trends and could make for interesting additions to investor portfolios this summer  Any of the three listed below are seeing impressive industry strength  positive trends in earning estimate revisions  and talks of large scale buyouts to boot making all of them worth a closer look by investors seeking quality exposure in the health care segment right now 

Centene Corporation  NYSE CNC 

Centene Corporation is a healthcare enterprise that provides a wide variety of services to government healthcare programs  With a focus on the uninsured and under insured  Centene works alongside public programs such as Medicaid and Medicare  The company operates local health plans and contracts with other organizations to provide services ranging from behavioral health to dental care 

A Fortune 500 company  Centene does business in 21 states and has a value of over  10 billion  Centene currently holds a Zacks Rank  1  Strong Buy   The company is also showing strong Style Scores  with  B  grade in growth and value  and an  A  in momentum 

Centene s strong Zacks Rank is the result of recent earnings estimate revisions  In the last 7 days alone  9 positive earnings estimate revisions have been made for Centene s current fiscal quarter  With the Zacks Most Accurate Estimate showing growth of  2 77 per share this year  Centene is a stock to look at now 

Aetna  Inc   NYSE AET 

Aetna is one of the nation s largest health benefits  insurance  and financial services organizations  With customers in all 50 states  Aetna provides plans to a range of employers and plan sponsors  Aetna products include full health  dental  and life insurance plans  dental and pharmacy benefits  and group insurance discounts 

Reports from  have highlighted Aetna s interest in buying out competing health insurance company Cigna  NYSE CI   which could lead to a much wider range of customers and services all good news for investors  Additionally  earnings estimate revisions have been looking favorable for Aetna in the long term  In the past 60 days  Aetna has received 13 positive revisions for the current year  The company currently holds a Zacks Ranks  2  Buy   Aetna is also holding solid Style Scores  with  A  grades in both value and growth 

UnitedHealth Group  Inc   NYSE UNH 

UnitedHealth is a diverse healthcare enterprise servicing over 70 million customers nationwide  UnitedHealth Group is the parent of UnitedHealthcare  which is the largest single healthcare provider in the country  UnitedHealth s services include information management  provider contracting  insurance plans  and benefit administration 

Recently  the  reported that UnitedHealth is seeking to buyout smaller rivals  going as far as approaching Aetna about a buyout worth around  40 billion  UnitedHealth currently holds a Zacks Rank  2  Buy   and is showing positive signs based on earnings estimates  The company also boasts impressive Style Scores  holding a  B  in momentum and  A  scores in growth and value 

Bottom Line

Based on the latest trends  Zacks sees these three companies as valuable buys in a strong industry  Investors should be aware of these impressive trends in earnings estimate revisions  while also paying attention to the latest news as well as any updates on buyouts and acquisitions ",2015-06-21,Zacks Investment Research,https://www.investing.com/analysis/3-healthcare-stock-buys-to-heal-your-portfolio-this-summer-255746,255746
148442,369958,CI,Desperate For More ECB Funding  Spain Creates New Type Of Covered Bonds,opinion,Spanish banks are running out of collateral that can be pledged at the ECB  The ECB no longer permits banks  own bonds guaranteed by their government  beyond what s already been pledged  to be used as collateral  see the document in this post   What about using more covered bonds  Unfortunately with unemployment pushing 25  and housing declining quickly  demand for mortgages has dried up  That means mortgage backed covered bonds  Cedulas  can no longer be issued  These bonds were quite popular in the eurozone during the bubble years  but are now mostly sitting at the ECB as collateral   In a desperate attempt to create more covered bonds in order to extract additional lending from the ECB  the Spanish government is about to authorize a new type of securitization structure   Spanish banks are hoping that the new structure   Cedulas de Internacionalizacion  CI    will extend this funding lifeline by allowing collateral  previously excluded  to be used   Under the terms of the new law  export finance credit from high quality financial institutions or guaranteed public sector entities can be used to back a new issue   This would have the added benefit of lowering issuers  funding costs because covered bonds benefit from lower haircut valuations compared with securitisation  Moody s said   The ECB accepts self issued covered bonds as collateral  but not self issued senior unsecured debt  it added  Spanish banks are already borrowing  337bn from the ECB  in practice the banks are borrowing from the Bank of Spain who is funding all that lending via TARGET2 loans from the Eurosystem   With these new bonds in place the central bank lending will increase further  Over time the nation s whole economy will in effect be funded by the central bank and any private credit that can be packaged into covered bonds will be pledged as collateral ,2012-07-23,Sober Look,"https://www.investing.com/analysis/desperate-for-more-ecb-funding,-spain-creates-new-type-of-covered-bonds-130503",130503
148443,369959,CI,Managed Health Care Sector  Vols Rise Into Presidential Election ,opinion,This is a simple vol note on the health care industry    specifically the managed care group  It appears that the election has embedded a risk premium in the front months and I thought it was worth noting Let s jump right into it and look at the front two month skews for Aetna  AET   Cigna  CI   UnitedHealth Group  UNH  and WellPoint  WLP   respectively  below AETCIUNHWLPWe can see across the board the similar shapes of the skews and even more pronounced  the vol diff between the front and second monthly expiries  One mitigating factor for WLP is that earnings are also due out in the Nov cycle  11 7 2012 BMO     so that vol  should  be elevated to Dec  A fair questionis  is it elevated enough  What s even more interesting is that AET and UNH also have weekly options  Check out the vols for the Nov09 weekly options  Nov monthly options and Dec options respectively  below  AET  43 00   35 24   27 91  UNH  40 05   32 32   24 43  So we can see the risk premium is embedded in the near term    the election near term  which is 11 6 2012   There is a monotonic rise in vol from the Nov09 weeklies to the Nov monthlies to the Dec monthlies  I ll skip the Options Tabs and Charts Tabs as my focus here really is the immediate term risk in the large managed health care companies and the extra premium attached to the election  Pretty cool    This is a good time to remind of the article I posted about ObamaCare  which you can read here   This could be another case where an industry specific reaction will dominate any correlation to the overall market  It s also an interesting examination of WLP and its earnings cycle    is that vol priced correctly  Feels like maybe the vol event is getting diluted   Ya know    or not    DISCLAIMER  This is trade analysis  not a recommendation ,2012-11-04,Ophir Gottlieb,https://www.investing.com/analysis/managed-health-care-sector:-vols-rise-into-presidential-election-142197,142197
148444,369960,CI,Enhance Returns In Managed Health Care Sector By Rolling Down The Yield,opinion,Since the Presidential election  managed care health care stocks have been battered on concerns that profit margins will be squeezed  The re election helped clarify the future of health care overhaul which should cover millions of uninsured people and will result in higher fees and coverage restrictions for the insurance providers  Cigna  CI  and Aetna  AET  have fallen 4 and 6 percent  respectively from the November 6 close to Monday  While the stocks in the sector have tanked  the bonds on the other hand have held in  highlighting the difference in risk between the safer vehicle in bonds and the highly volatile equities  Having said this  here we will cover our best picks in the managed health care sector of the corporate bond market  Furthermore  we will illustrate a simple strategy for each bond that total return fund managers employ that can significantly enhance returns beyond a traditional buy and hold approach  In particular  the strategy captures both income and price appreciation by allowing time to pass and Rolling Down the Yield Curve  For more information  please review    Cigna Corporation  CI  is a global health service organization and is one of the largest managed care companies in the country with over 11 million clients  The company s Health Care segment accounts for roughly seventy percent of revenue which totaled close to 22 billion in FY 2011  The remaining segments  International and Disability   Life account for the remaining portion of total revenues  We will focus on their bond that pays a semi annual coupon of 8 5  and matures on May 01  2019  CUSIP 125509BL2   The bond is a senior note and is straight bullet maturity with no embedded early call feature  This bond is rated BBB by Standard   Poor s and Baa2 by Moody s which falls under the Investment Grade part of the credit spectrum  In addition  the bond deal size is just over  250 million outstanding and this bond is actively traded  These senior notes are currently being offered at a dollar price of  133 00 which translates to a yield to maturity of 2 87   Based off of our analysis  this is the steepest part of Cigna yield curve and offers a nice pickup in yield over shorter maturity Cigna bonds  Comparatively  there is a 4 Year Cigna bond which yields significantly less  Cigna 2 75  Coupon Maturing November 15  2016  CUSIP 125509BR9  can be sold at a dollar price of  104 66 which is a yield to maturity of 1 55   So by extending an additional two plus years provides an additional 132 basis points of yield  As for the Cigna 8 5  May 01  2019 at a dollar price of  133 00  an investor will  lock in  that annual return of 2 87  assuming the coupon payments are reinvested and you hold to maturity  All an investor has to do is wait and collect  If you take a total return approach by rolling down the yield curve  an investor can enhance return  This can be achieved by selling the bonds prior to maturity  An investor will purchase that bond at the stated 2 87  yield and will hold the bond for a period of time  While held and collecting coupon  the bond s maturity will shorten  So after two and half years in time  that original 6 5 Year will become a 4 Year bond  Assuming stable interest rates  the yield of that bond will  roll  downward toward the aforementioned current 4 Year Cigna which is yielding 1 55   This rolling will in turn  result in price appreciation  To quantify this  we use horizon analysis shown below  Source  Bloomberg  to determine the gain As you can see  we purchased the Cigna bond at a yield of 2 87  percent or a dollar price of  133 00  Assuming that rates are stable during our time horizon of 2 5 years or ending April 15  2015  we plug in today s 4 Year yield of 1 55   Again we know that in two plus years our original 6 5 Year will become a 4 Year and hence assuming stable interest rates  we can use the aforementioned yield  This yield at this horizon date will correspond to a price of  127 13  This is the dollar price which we plan to monetize by selling in the open markets at our horizon date  Given our reinvestment rate of 0 29 percent for coupon payments earned during that time period  this profit results in a holding period return of 11 05  or 4 38  annualized gain  Now  when we compare this gain to a static Hold to Maturity strategy we can see the effectiveness of Rolling Down the Yield Curve Keep in mind that the main assumption to this strategy is stable interest rates  As we all know  if rates rise  bond prices fall and this approach as described will not work  Having said this  all is not lost  If rates rise and the objective is to avoid a loss  all an investor has to do is hold the bond to maturity as principal will be paid back at par  Problem solved To summarize  Cigna 2 75  Coupon Maturing November 15  2016  CUSIP 125509BR9 6 5 Year Cigna bond can be bought at a price of  133 00 yielding 2 87  and should roll down the curve to the current 4 0 Year Cigna bond at 1 55 Rolling Down the Yield Curve strategy  4 38  Annualized Return  2 5 Years Horizon Buy and Hold to Maturity strategy  2 87  Annualized Return  6 5 Years Horizon Aetna Inc   AET  is another diversified managed care company and is one of the largest in the country with 18 million members  The company has three main operating segments  Healthcare  Group Insurance  and Large Case Pensions  Last year  the company generated over 33 billion in revenues and sports a market capitalization greater than 15 billion  Aetna has a long term contract with CVS Caremark to provide prescription drug benefits to its customer base  The company has several bonds outstanding  We will focus on their 6 Year bond that pays a semi annual coupon of 6 50  and matures on September 15  2018  CUSIP 008117AM5   The total deal size of this bond is  500 million  Standard   Poor s rates these senior notes at A  while Moody s provides a rating of Baa1 and is on negative watch for a possible downgrade  This bond is currently being offered at a dollar price of  125 86  This price translates to a yield to maturity of 1 81  which is one of the steepest parts of the Aetna yield curve  The 4 Year Aetna bond that pays a 6  Coupon Maturing on June 15  2016  CUSIP 00817YAE8  is yielding only 1 23  based off of the bid side price  Hence an investor can pick up an additional 58 basis points on a yield to maturity basis by extending the maturity only a couple of years  To determine return from Rolling Down the Yield Curve strategy  see the horizon analysis in the graphic  Source  Bloomberg  below  To summarize  Aetna 6 5  Coupon Maturing September 15  2018  CUSIP 008117AM5 6 0 Year Aetna bond can be bought at a price of  125 86 00 yielding 1 81  and should roll down the curve to the current 4 0 Year Aetna bond at 1 23 Rolling Down the Yield Curve strategy  2 47  Annualized Return  2  Years Horizon Buy and Hold to Maturity strategy  1 81  Annualized Return  6 0 Years Horizon All of the aforementioned bonds were highlighted by finding the best yield given the dollar price  Some bonds yielded higher but at a cost of a higher dollar premium Furthermore  keep in mind that corporate bonds trade over the counter  So  prices and yields can vary depending on the broker you use  The best suggestion is to use a broker that offers the most visibility and price transparency for the corporate bond market  This can be achieved by comparing the price to buy and the sale price  aka bid ask spread   The closer the differential usually means the better the liquidity Information and market quotes on the bond investments are provided by   unless noted otherwise   As always  every bond investor should perform their own due diligence when making their investment decisions Disclaimer  The above content is provided for educational and informational purposes only  does not constitute a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in such content  and does not represent the opinions of Bondsquawk or its employees ,2012-11-13,Bondsquawk,https://www.investing.com/analysis/enhance-returns-in-managed-health-care-sector-by-rolling-down-the-yield-143302,143302
